

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 30, 2004, 07:12:01 ; Search time 47 Seconds
(without alignments)
702.859 Million cell updates/sec

Title: US-10-027-603-2

Perfect score: 589

Sequence: 1 MRGATRVISIMLLVTVSDCA.....CSRFPDGRVRCMDLKNINF 105

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1297172 seqs, 314612898 residues

Total number of hits satisfying chosen parameters: 634

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 2500 summaries

Database : Published Applications AA:

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query Match	Length	ID	Description
1	589	100.0	105	9	US-09-989-722-371	Sequence 371, App
2	589	100.0	105	9	US-09-989-723-371	Sequence 371, App
3	589	100.0	105	9	US-09-989-279-371	Sequence 371, App
4	589	100.0	105	9	US-09-989-727-371	Sequence 371, App
5	589	100.0	105	9	US-09-989-731-371	Sequence 371, App
6	589	100.0	105	9	US-09-989-732-371	Sequence 371, App
7	589	100.0	105	9	US-09-991-073-371	Sequence 371, App
8	589	100.0	105	9	US-09-990-442-371	Sequence 371, App
9	589	100.0	105	9	US-09-991-163-371	Sequence 371, App
10	589	100.0	105	9	US-09-993-604-371	Sequence 371, App
11	589	100.0	105	9	US-09-990-456-371	Sequence 371, App
12	589	100.0	105	9	US-09-990-721-371	Sequence 371, App
13	589	100.0	105	9	US-09-992-598-371	Sequence 371, App
14	589	100.0	105	9	US-09-986-242A-2	Sequence 2, App11
15	589	100.0	105	9	US-09-989-733A-371	Sequence 371, App

16	589	100.0	105	9	US-09-965-528-11	Sequence 11, App1
17	589	100.0	105	9	US-09-989-735-371	Sequence 371, App
18	589	100.0	105	9	US-09-990-444-371	Sequence 371, App
19	589	100.0	105	9	US-09-991-181-371	Sequence 371, App
20	589	100.0	105	9	US-09-989-730-371	Sequence 371, App
21	589	100.0	105	9	US-09-990-436-371	Sequence 371, App
22	589	100.0	105	9	US-09-993-687-371	Sequence 371, App
23	589	100.0	105	10	US-09-989-734-371	Sequence 371, App
24	589	100.0	105	10	US-09-997-653-371	Sequence 371, App
25	589	100.0	105	10	US-09-993-667-371	Sequence 371, App
26	589	100.0	105	10	US-09-997-428-371	Sequence 371, App
27	589	100.0	105	10	US-09-997-666-371	Sequence 371, App
28	589	100.0	105	10	US-09-990-438-371	Sequence 371, App
29	589	100.0	105	10	US-09-980-562-371	Sequence 371, App
30	589	100.0	105	10	US-09-796-753-64	Sequence 64, App1
31	589	100.0	105	10	US-09-990-711-371	Sequence 371, App
32	589	100.0	105	10	US-09-989-726-371	Sequence 371, App
33	589	100.0	105	10	US-09-998-156-371	Sequence 371, App
34	589	100.0	105	10	US-09-990-437-371	Sequence 371, App
35	589	100.0	105	10	US-09-991-157-371	Sequence 371, App
36	589	100.0	105	10	US-09-997-514-371	Sequence 371, App
37	589	100.0	105	10	US-09-997-573-371	Sequence 371, App
38	589	100.0	105	10	US-09-991-172-371	Sequence 371, App
39	589	100.0	105	10	US-09-990-726-371	Sequence 371, App
40	589	100.0	105	10	US-09-997-559-371	Sequence 371, App
41	589	100.0	105	10	US-09-997-601-371	Sequence 371, App
42	589	100.0	105	10	US-09-990-443-371	Sequence 371, App
43	589	100.0	105	10	US-09-991-854-371	Sequence 371, App
44	589	100.0	105	10	US-09-997-628-371	Sequence 371, App
45	589	100.0	105	10	US-09-997-683-371	Sequence 371, App
46	589	100.0	105	10	US-09-989-739A-371	Sequence 371, App
47	589	100.0	105	10	US-09-997-349-371	Sequence 371, App
48	589	100.0	105	10	US-09-997-440-371	Sequence 371, App
49	589	100.0	105	10	US-09-990-440-371	Sequence 371, App
50	589	100.0	105	10	US-09-993-469-371	Sequence 371, App
51	589	100.0	105	10	US-09-997-542-371	Sequence 371, App
52	589	100.0	105	10	US-09-993-748-371	Sequence 371, App
53	589	100.0	105	10	US-09-990-429-371	Sequence 371, App
54	589	100.0	105	10	US-09-990-427-371	Sequence 371, App
55	589	100.0	105	10	US-09-989-328-371	Sequence 371, App
56	589	100.0	105	10	US-09-993-583-371	Sequence 371, App
57	589	100.0	105	10	US-09-941-992-371	Sequence 371, App
58	589	100.0	105	10	US-09-997-333-371	Sequence 371, App
59	589	100.0	105	10	US-09-997-384-371	Sequence 371, App
60	589	100.0	105	10	US-09-997-585-371	Sequence 371, App
61	589	100.0	105	10	US-09-998-041-371	Sequence 371, App
62	589	100.0	105	10	US-09-997-614-371	Sequence 371, App
63	589	100.0	105	10	US-09-989-862-371	Sequence 371, App
64	589	100.0	105	10	US-09-997-529-371	Sequence 371, App
65	589	100.0	105	10	US-09-989-725-371	Sequence 371, App
66	589	100.0	105	10	US-09-989-733-371	Sequence 371, App
67	589	100.0	105	11	US-09-992-643-371	Sequence 371, App
68	589	100.0	105	11	US-09-992-643-371	Sequence 470, App
69	589	100.0	105	12	US-10-147-493-470	Sequence 470, App
70	589	100.0	105	12	US-10-145-127-470	Sequence 470, App
71	589	100.0	105	12	US-10-160-503-470	Sequence 470, App
72	589	100.0	105	12	US-10-143-118-470	Sequence 470, App
73	589	100.0	105	12	US-10-144-993-470	Sequence 470, App
74	589	100.0	105	12	US-10-158-787-470	Sequence 172, App
75	589	100.0	105	12	US-10-081-056-172	Sequence 166, App
76	589	100.0	105	12	US-10-219-535-166	Sequence 166, App
77	589	100.0	105	12	US-10-232-230-166	Sequence 11, App1
78	589	100.0	105	12	US-09-969-984-11	Sequence 470, App
79	589	100.0	105	12	US-10-140-024-470	Sequence 371, App
80	589	100.0	105	12	US-09-989-724-371	Sequence 371, App
81	589	100.0	105	12	US-09-990-441-371	Sequence 371, App
82	589	100.0	105	12	US-09-990-441-371	Sequence 470, App
83	589	100.0	105	12	US-10-140-808-470	Sequence 371, App
84	589	100.0	105	12	US-09-997-857-371	Sequence 166, App
85	589	100.0	105	12	US-10-232-224-166	Sequence 371, App
86	589	100.0	105	12	US-09-997-641-371	Sequence 371, App
87	589	100.0	105	12	US-09-991-150-371	Sequence 470, App
88	589	100.0	105	12	US-10-152-405-470	Sequence 470, App

89	589	100.0	105	12	US-10-127-852A-470	Sequence 470, App	162	589	100.0	105	14	US-10-121-043-470	Sequence 470, App
90	589	100.0	105	12	US-10-127-900A-470	Sequence 470, App	163	589	100.0	105	14	US-10-121-047-470	Sequence 470, App
91	589	100.0	105	12	US-10-128-685A-470	Sequence 470, App	164	589	100.0	105	14	US-10-123-213-470	Sequence 470, App
92	589	100.0	105	12	US-10-131-820A-470	Sequence 470, App	165	589	100.0	105	14	US-10-123-903-470	Sequence 470, App
93	589	100.0	105	12	US-10-142-886-470	Sequence 470, App	166	589	100.0	105	14	US-10-123-908-470	Sequence 470, App
94	589	100.0	105	12	US-10-146-728-470	Sequence 470, App	167	589	100.0	105	14	US-10-123-909-470	Sequence 470, App
95	589	100.0	105	12	US-10-146-786-470	Sequence 470, App	168	589	100.0	105	14	US-10-123-910-470	Sequence 470, App
96	589	100.0	105	12	US-10-147-499-470	Sequence 470, App	169	589	100.0	105	14	US-10-123-910-470	Sequence 470, App
97	589	100.0	105	12	US-10-157-798-470	Sequence 470, App	170	589	100.0	105	14	US-10-124-813-470	Sequence 470, App
98	589	100.0	105	12	US-10-305-654-172	Sequence 172, App	171	589	100.0	105	14	US-10-124-817-470	Sequence 470, App
99	589	100.0	105	13	US-10-016-481-2	Sequence 2, Appli	172	589	100.0	105	14	US-10-125-922-470	Sequence 470, App
100	589	100.0	105	13	US-10-027-603-2	Sequence 2, Appli	173	589	100.0	105	14	US-10-125-924-470	Sequence 470, App
101	589	100.0	105	14	US-10-028-072-470	Sequence 470, App	174	589	100.0	105	14	US-10-140-860-470	Sequence 470, App
102	589	100.0	105	14	US-10-121-049-470	Sequence 470, App	175	589	100.0	105	14	US-10-142-417-470	Sequence 470, App
103	589	100.0	105	14	US-10-123-904-470	Sequence 470, App	176	589	100.0	105	14	US-10-147-519-470	Sequence 470, App
104	589	100.0	105	14	US-10-140-474-470	Sequence 470, App	177	589	100.0	105	14	US-10-157-782-470	Sequence 470, App
105	589	100.0	105	14	US-10-175-746-470	Sequence 470, App	178	589	100.0	105	14	US-10-152-395-470	Sequence 470, App
106	589	100.0	105	14	US-10-176-918-470	Sequence 470, App	179	589	100.0	105	14	US-10-218-076-166	Sequence 166, App
107	589	100.0	105	14	US-10-178-921-470	Sequence 470, App	180	589	100.0	105	14	US-10-230-434-166	Sequence 166, App
108	589	100.0	105	14	US-10-227-884-166	Sequence 166, App	181	589	100.0	105	14	US-10-125-926A-470	Sequence 470, App
109	589	100.0	105	14	US-10-137-865-470	Sequence 470, App	182	589	100.0	105	14	US-10-125-930A-470	Sequence 470, App
110	589	100.0	105	14	US-10-140-474-470	Sequence 470, App	183	589	100.0	105	14	US-10-127-831A-470	Sequence 470, App
111	589	100.0	105	14	US-10-142-431-470	Sequence 470, App	184	589	100.0	105	14	US-10-127-837A-470	Sequence 470, App
112	589	100.0	105	14	US-10-143-114-470	Sequence 470, App	185	589	100.0	105	14	US-10-127-838B-470	Sequence 470, App
113	589	100.0	105	14	US-10-230-163-166	Sequence 166, App	186	589	100.0	105	14	US-10-127-842A-470	Sequence 470, App
114	589	100.0	105	14	US-10-140-002-470	Sequence 470, App	187	589	100.0	105	14	US-10-127-843A-470	Sequence 470, App
115	589	100.0	105	14	US-10-230-338-166	Sequence 166, App	188	589	100.0	105	14	US-10-127-845A-470	Sequence 470, App
116	589	100.0	105	14	US-10-142-619-470	Sequence 470, App	189	589	100.0	105	14	US-10-127-846A-470	Sequence 470, App
117	589	100.0	105	14	US-10-218-631-166	Sequence 166, App	190	589	100.0	105	14	US-10-127-848A-470	Sequence 470, App
118	589	100.0	105	14	US-10-123-262-470	Sequence 470, App	191	589	100.0	105	14	US-10-127-849A-470	Sequence 470, App
119	589	100.0	105	14	US-10-142-423-470	Sequence 470, App	192	589	100.0	105	14	US-10-127-850A-470	Sequence 470, App
120	589	100.0	105	14	US-10-230-414-166	Sequence 166, App	193	589	100.0	105	14	US-10-127-851A-470	Sequence 470, App
121	589	100.0	105	14	US-10-121-050-470	Sequence 470, App	194	589	100.0	105	14	US-10-128-684A-470	Sequence 470, App
122	589	100.0	105	14	US-10-141-755-470	Sequence 470, App	195	589	100.0	105	14	US-10-128-686A-470	Sequence 470, App
123	589	100.0	105	14	US-10-132-812-16	Sequence 16	196	589	100.0	105	14	US-10-128-690A-470	Sequence 470, App
124	589	100.0	105	14	US-10-143-032-470	Sequence 470, App	197	589	100.0	105	14	US-10-128-691A-470	Sequence 470, App
125	589	100.0	105	14	US-10-123-108-470	Sequence 470, App	198	589	100.0	105	14	US-10-131-819A-470	Sequence 470, App
126	589	100.0	105	14	US-10-123-236-470	Sequence 470, App	199	589	100.0	105	14	US-10-131-829A-470	Sequence 470, App
127	589	100.0	105	14	US-10-123-261-470	Sequence 470, App	200	589	100.0	105	14	US-10-131-836A-470	Sequence 470, App
128	589	100.0	105	14	US-10-140-921-470	Sequence 470, App	201	589	100.0	105	14	US-10-146-729-470	Sequence 470, App
129	589	100.0	105	14	US-10-140-928-470	Sequence 470, App	202	589	100.0	105	14	US-10-147-484-470	Sequence 470, App
130	589	100.0	105	14	US-10-216-059A-166	Sequence 166, App	203	589	100.0	105	14	US-10-147-508-470	Sequence 470, App
131	589	100.0	105	14	US-10-121-045A-470	Sequence 470, App	204	589	100.0	105	14	US-10-147-512-470	Sequence 470, App
132	589	100.0	105	14	US-10-123-292-470	Sequence 470, App	205	589	100.0	105	14	US-10-175-735-470	Sequence 470, App
133	589	100.0	105	14	US-10-123-903-470	Sequence 470, App	206	589	100.0	105	14	US-10-121-040-470	Sequence 470, App
134	589	100.0	105	14	US-10-124-819-470	Sequence 470, App	207	589	100.0	105	14	US-10-121-056-470	Sequence 470, App
135	589	100.0	105	14	US-10-124-822-470	Sequence 470, App	208	589	100.0	105	14	US-10-121-061-470	Sequence 470, App
136	589	100.0	105	14	US-10-140-925-470	Sequence 470, App	209	589	100.0	105	14	US-10-123-235-470	Sequence 470, App
137	589	100.0	105	14	US-10-160-498-470	Sequence 470, App	210	589	100.0	105	14	US-10-124-818-470	Sequence 470, App
138	589	100.0	105	14	US-10-218-849-166	Sequence 166, App	211	589	100.0	105	14	US-10-137-868-470	Sequence 470, App
139	589	100.0	105	14	US-10-227-873-166	Sequence 166, App	212	589	100.0	105	14	US-10-147-492-470	Sequence 470, App
140	589	100.0	105	14	US-10-124-824-470	Sequence 470, App	213	589	100.0	105	14	US-10-158-782-470	Sequence 470, App
141	589	100.0	105	14	US-10-127-833A-166	Sequence 166, App	214	589	100.0	105	14	US-10-123-905-470	Sequence 470, App
142	589	100.0	105	14	US-10-127-825A-470	Sequence 470, App	215	589	100.0	105	14	US-10-123-907-470	Sequence 470, App
143	589	100.0	105	14	US-10-127-829A-470	Sequence 470, App	216	589	100.0	105	14	US-10-124-815-470	Sequence 470, App
144	589	100.0	105	14	US-10-127-835A-470	Sequence 470, App	217	589	100.0	105	14	US-10-125-921A-470	Sequence 470, App
145	589	100.0	105	14	US-10-127-839A-470	Sequence 470, App	218	589	100.0	105	14	US-10-125-928A-470	Sequence 470, App
146	589	100.0	105	14	US-10-127-901A-470	Sequence 470, App	219	589	100.0	105	14	US-10-127-822A-470	Sequence 470, App
147	589	100.0	105	14	US-10-128-693A-470	Sequence 470, App	220	589	100.0	105	14	US-10-127-824A-470	Sequence 470, App
148	589	100.0	105	14	US-10-131-813A-470	Sequence 470, App	221	589	100.0	105	14	US-10-127-826A-470	Sequence 470, App
149	589	100.0	105	14	US-10-131-818A-470	Sequence 470, App	222	589	100.0	105	14	US-10-127-827A-470	Sequence 470, App
150	589	100.0	105	14	US-10-131-823A-470	Sequence 470, App	223	589	100.0	105	14	US-10-127-828A-470	Sequence 470, App
151	589	100.0	105	14	US-10-131-824A-470	Sequence 470, App	224	589	100.0	105	14	US-10-127-830A-470	Sequence 470, App
152	589	100.0	105	14	US-10-131-830A-470	Sequence 470, App	225	589	100.0	105	14	US-10-127-832A-470	Sequence 470, App
153	589	100.0	105	14	US-10-131-837A-470	Sequence 470, App	226	589	100.0	105	14	US-10-127-833A-470	Sequence 470, App
154	589	100.0	105	14	US-10-137-872A-470	Sequence 470, App	227	589	100.0	105	14	US-10-127-836A-470	Sequence 470, App
155	589	100.0	105	14	US-10-147-500-470	Sequence 470, App	228	589	100.0	105	14	US-10-127-841A-470	Sequence 470, App
156	589	100.0	105	14	US-10-147-502-470	Sequence 470, App	229	589	100.0	105	14	US-10-127-844A-470	Sequence 470, App
157	589	100.0	105	14	US-10-147-515-470	Sequence 470, App	230	589	100.0	105	14	US-10-127-847A-470	Sequence 470, App
158	589	100.0	105	14	US-10-147-517-470	Sequence 470, App	231	589	100.0	105	14	US-10-128-687A-470	Sequence 470, App
159	589	100.0	105	14	US-10-147-526-470	Sequence 470, App	232	589	100.0	105	14	US-10-128-688A-470	Sequence 470, App
160	589	100.0	105	14	US-10-147-527-470	Sequence 470, App	233	589	100.0	105	14	US-10-128-689A-470	Sequence 470, App
161	589	100.0	105	14	US-10-121-041-470	Sequence 470, App	234	589	100.0	105	14	US-10-128-689A-470	Sequence 470, App

Query Match 15.0%; Score 88.5; DB 2; Length 640;
Best Local Similarity 31.6%; Pred. No. 0.24;
Matches 24; Conservative 5; Mismatches 24; Indels 23; Gaps 4;
QY 32 CGAGTCCCAISLWLRGCTPLRGEGECHPGSHKVPFRKRKHHTCPCLPNLLCSRF-- 89
Db 498 CTAGRCC-----WM-----TCLPMWGGTWPRLMTP-----SRICACLPFCPSRWLR 533
QY 90 -----PDGRYRCSM 98
Db 534 RWRGWAGPGRWRCGL 549
RESULT 3
Ti6840
Hypothetical protein Ti0E10.4 - *Caenorhabditis elegans*
C:Species: *Caenorhabditis elegans*
C>Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999
C:Accession: Ti6840
R:Geisels, C.
submitted to the EMBL Data Library, October 1995
A:Description: The sequence of *C. elegans* cosmid Ti0E10.
A:Reference number: Z18588
A:Accession: Ti6840
A>Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-1101 <GEI>
A:Cross-references: EMBL:U39644; NID:g1049339; PID:g1049343; PIDN:AAA80360.1; CESP:Ti0E10
A:Experimental source: strain Bristol N2
C:Genetics:
A:Gene: CESP:Ti0E10.4
A:Introns: 93/2; 152/2; 191/3; 209/2; 283/3; 303/1; 399/3; 421/1; 440/1; 465/1; 547/3; 7
Query Match 14.1%; Score 83; DB 2; Length 1101;
Best Local Similarity 24.4%; Pred. No. 1.4;
Matches 32; Conservative 9; Mismatches 40; Indels 50; Gaps 6;
QY 13 LVTYSDCAVINGACERDVQCGAGTCCCAISLWLRG----- 46
Db 749 LMSVORCANGIG-CPPGNQENGVCPPMCCSSGSIASSVCGVANSCTPIGYICERGGCL 807
QY 47 -LRMCTPLGR-----EGEECHPG-----SHKVPFRKRKHHTCPCLPNLLCS 87
Db 808 EPLPLCPNGGRASMRGVRGAECPGVCCTPLGGCCLLSMEPVCTRSNAVCCQSPNWC- 866
QY 88 RPDGRYRCSM 98
Db 867 --PSGA-SCTW 874
RESULT 4
T09059
notch4 - mouse
C:Species: *Mus musculus* (house mouse)
C>Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 08-Sep-2002
C:Accession: T09059
R:Rowen, L.; Mahairas, G.; Qin, S.; Ahearn, M.E.; Dankers, C.; Lasky, S.; Loretz, C.; S
submitted to the EMBL Data Library, October 1997
A:Description: Sequence of the mouse major histocompatibility locus class III region.
A:Reference number: Z16543
A:Accession: T09059
A>Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-1964 <ROW>
A:Cross-references: EMBL:AF030001; NID:g2564945; PID:g2564947
C:Genetics:
A:Gene: notch4
A:Map position: 17
A:Introns: 22/1; 49/2; 148/1; 264/1; 305/1; 384/1; 436/1; 501/1; 539/1; 577/1; 618/1; 67
1679/3; 1729/1; 1761/3
C:Superfamily: notch protein; ankyrin repeat homology; EGF homology
C:Keywords: receptor; signal transduction
F:154-545/Domain: EGF homology <EGF>

Query Match 13.8%; Score 81; DB 2; Length 1964;
Best Local Similarity 30.4%; Pred. No. 3.5;
Matches 24; Conservative 7; Mismatches 22; Indels 26; Gaps 5;
QY 26 CERDVQ-----CGAGTCCCAISLWLRGCTPLRGEGECHPGSHKVPFRKRKH 76
Db 188 CERDINECFLEPGCPQGISCNTL---GSYQCLCPVGQEGPQC-----KLRKG 233
QY 77 TCP----CLPNLLCSRFPDG 92
Db 234 ACPPGSLNGGTQQLVPEG 252
RESULT 5
XLHU
colipase precursor [validated] - human
N:Alternate names: procolipase
C:Species: *Homo sapiens* (man)
C>Date: 04-Dec-1986 #sequence_revision 19-May-1995 #text_change 08-Dec-2000
C:Accession: A42568; A33949; A03163
R:Sims, H.F.; Lowe, M.E.
Biochemistry 31, 7120-7125, 1992
A:Title: The human colipase gene: isolation, chromosomal location, and tissue-specific e
A:Reference number: A42568; MUID:92353041; PMID:1643046
A:Accession: A42568
A:Molecule type: DNA
A:Residues: 1-112 <SIM>
A:Cross-references: GB:M95529; NID:g180842; PIDN:AA05818.1; PID:g1483624
A:Note: sequence extracted from NCBI backbone (NCBIN:110576, NCBIN:110578, NCBI:110580)
R:Lowe, M.E.; Rosenblum, J.L.; McEwen, P.; Strauss, A.W.
Biochemistry 29, 823-828, 1990
A:Title: Cloning and characterization of the human colipase cDNA.
A:Reference number: A33949; MUID:90248429; PMID:2337598
A:Accession: A33949
A:Molecule type: mRNA
A:Residues: 1-112 <LOW>
A:Cross-references: GB:J02883; NID:g180885; PIDN:AAA52054.1; PID:g180886
A:Note: evidence of partial N-glycosylation, possibly at Asn-43
R:Sternby, B.; Engstrom, A.; Hellman, U.; Vihert, A.M.; Sternby, N.H.; Borgstrom, B.
Biochim. Biophys. Acta 784, 75-80, 1984
A:Title: The primary sequence of human pancreatic colipase.
A:Reference number: A90652; MUID:84104937; PMID:6691986
A:Accession: A03163
A:Molecule type: protein
A:Residues: 23-108 <STE>
C:Comment: Colipase, a cofactor of triacylglycerol lipase (EC 3.1.1.3), forms a 1:1 stoic
se the enzyme is washed off by bile salts, which are known to have an inhibitory effect
C:Genetics:
A:Gene: GDB:CLPS
A:Cross-references: GDB:1127277; OMIM:120105
A:Map position: 6pter-6p21.1
A:Introns: 28/3; 69/3
C:Superfamily: colipase
C:Keywords: lipid digestion; lipid hydrolysis; pancreas
F:1-17/Domain: signal sequence #status predicted <SIG>
F:18-22/Domain: amino-terminal propeptide #status predicted <APP>
F:23-108/Product: colipase #status experimental <NAT>
F:109-112/Domain: carboxyl-terminal propeptide #status predicted <CPP>
F:34-104, 40-56, 44-80, 45-78, 66-86/Disulfide bonds: #status predicted
F:69, 72, 75, 76/Binding site: micellar substrate (Lys, Tyr, Tyr) #status predicted
Query Match 13.4%; Score 79; DB 1; Length 112;
Best Local Similarity 28.4%; Pred. No. 0.52;
Matches 31; Conservative 9; Mismatches 45; Indels 24; Gaps 6;
QY 9 IMLLVTVDCAVITG-----ACERDVQCGAGTCCCAISLWLRGCTPLRG 56
Db 5 LILLVGLSVAVAAAPGPGRIIINLENGELCMNSAQC-KSNGCQHSSAL-GLARCTSWAE 62
QY 57 GEECHPGSHKVPFRKRKHHTCPCLPNLLCSRFDPGRYRCSMDLKNINF 105
Db 63 NSEC---SVKTYL---GIYKCPCEGTCTC-----EGDKTIVGSITNTNF 101

A;Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs
A;Reference number: Z14126; MUID:98360089; PMID:9693030
A;Accession: Tl3954
A>Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A;Residues: 1-1574 <NA>
A;Cross-references: EMBL:AB011532; NID:g3449293; PIDN:BAA32462.1; PID:g3449294
A;Experimental source: strain Sprague-Dawley; brain
C;Genetics:
A;Gene: MECF6

Query Match 12.8%; Score 75.5; DB 2; Length 1574;
Best Local Similarity 28.6%; Pred. No. 10;
Matches 24; Conservative 6; Mismatches 33; Indels 21; Gaps 4;

QY 19 CAVITGAC-----BRDVOCAGTCCATSLWLRLRMCTPLRGEGEECHPGSHKVPFFRXR 73
 |::| :||:||||||
Db 755 CHRTVGECLPPGGTGDCGAD--CPGRWGLGCQEICPACHGASCNP-----801
 |::| :||:||||||

QY 74 KHHTPCPLENLCSRFDPDGYRCSS 97
 ||||| |||
Db 802 ETGTCLCLPFVGSRQCD---TCS 822
 :||| :

RESULT 9
JC4861
fertilin beta chain - human
C;Species: Homo sapiens (man)
C;Date: 15-Aug-1996 #sequence_revision 18-Oct-1996 #text_change 21-Jan-2000
C;Accession: JC4861
R;Gupta, S.K.; Alves, K.; O'Neil Palladino, L.; Mark, G.E.; Hollis, G.F.
Biochem. Biophys. Res. Commun. 224, 318-326, 1996
A;Title: Molecular cloning of the human fertilin beta subunit.
A;Reference number: JC4861; MUID:96295488; PMID:8702389
A;Accession: JC4861
A:Molecule type: mRNA
A;Residues: 1-734 <GUP>
A;Cross-references: GB:U38905; NID:g4151118; PIDN:AAD04206.1; PID:g4151119
C;Comment: This protein is an integral sperm membrane glycoprotein, and plays a role in
C;Superfamily: mouse meltrin alpha; disintegrin homology
E;Keywords: Glycoprotein; integrin binding; transmembrane protein
F;382-734/Product: fertilin beta chain #status predicted <NAT>
F;382-467/Domains: disintegrin homology <Dis>
F;448-450/Region: Integrin binding #status predicted
F;686-708/Domain: Transmembrane #status predicted <TM>
F;121,219,352,458,565/Binding site: carbohydate (Asn) (covalent) #status predicted

Query Match 12.7%; Score 75; DB 2; Length 734;
Best Local Similarity 28.8%; Pred. No. 6.2;
Matches 21; Conservative 7; Mismatches 29; Indels 16; Gaps 3;

QY 15 TVSDCAVTTCAC-----BRDVQCAGTAGTCCAISLWLRLRMCTPLRGEGEECHPGSHX 66
 ||||| |||::|::|
Db 401 TEQDCALIGETCCDIATCRFRAGSNCAEGPOCCENCLFMNKERMCRP----SFEEC-----D 452
 |::| |||::|::|

QY 67 VPFFRKRRKHTPPT 79
 ::| ::|
Db 453 LPFYCNSSASACP 465
 ::| ::|

RESULT 10
S45306
notch 3 protein - mouse
C;Species: Mus musculus (house mouse)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 02-Aug-2002
C;Accession: S45306
R;Lardelli, M.; Dahlstrand, J.; Lendahl, U.
Mech. Dev. 46, 123-136, 1994
A;Title: The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-
A;Reference number: S45306; MUID:95001556; PMID:7918097
A;Accession: S45306
A>Status: preliminary
A:Molecule type: mRNA

A;Residues: 1-2318 <LAR>
A;Cross-references: EMBL:X74760; NID:G483580; PIDN:CAA52776.1; PID:G483581
C;Superfamily: notch protein; ankyrin repeat homology; EGF homology
F;163-195/Domain: EGF homology <EGF1>
F;474-505/Domain: EGF homology <EGF>
F;854-885/Domain: EGF homology <EGF2>
F;1839-1871/Domain: ankyrin repeat homology <AN1>
F;1872-1904/Domain: ankyrin repeat homology <AN2>
F;1906-1938/Domain: ankyrin repeat homology <AN3>
F;1939-1971/Domain: ankyrin repeat homology <AN4>
F;1972-2004/Domain: ankyrin repeat homology <AN5>

Query Match 12.7%; Score 75; DB 2; Length 2318;
Best Local Similarity 28.1%; Pred. No. 16;
Matches 25; Conservative 5; Mismatches 25; Indels 34; Gaps 5;
QY 19 CAVITACERDVCGAGTCCCAISLWRLGLRMCTPLGREGEEC-----60
DB 1287 CERVASC-RELQCPVIPCQQT--ARGPRCACPGLSGPSCRVSPSGATNASCASA 1343
QY 61 ---HPGS-----HKVPFRKRKHHTCPLP 82
DB 1344 PCLHGGSCLEPVQGVPPFR-----CVCAP 1366

RESULT 11
T31070
notch homolog - sea urchin (Lytechinus variegatus)
C;Species: Lytechinus variegatus (variegated urchin)
C;Date: 22-Oct-1999 #sequence_revision 22-Oct-1999 #text_change 31-Jan-2000
C;Accession: T31070
R;Sherwood, D.R.; McClay, D.R.
Development 124, 3363-3374, 1997
A;Title: Identification and localization of a sea urchin Notch homologue: insights into
A;Reference number: Z20966; MUID:97454256; PMID:9310331
A;Accession: T31070
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-2531 <SHE>
A;Cross-references: EMBL:AF00634; NID:G2570350; PID:G2570351; PIDN:AAB82088.1
C;Superfamily: notch protein; ankyrin repeat homology; EGF homology

Query Match 12.7%; Score 75; DB 2; Length 2531;
Best Local Similarity 29.9%; Pred. No. 17;
Matches 23; Conservative 8; Mismatches 32; Indels 14; Gaps 5;
QY 22 ITGACERDVCGAGTCCCAISLWRLGLRMCTPLGREGECHPGSKVPFRKRKHHTCP 79
DB 120 DVNVKLEPQNGGTRLTSLWDYEC-FCIP-ANTGENCTDDNHCV-----SNP 168
QY 80 CLPNLLCSRPFDGRYC 96
DB 169 CLNGAVCTSSDG-YSC 184

RESULT 12
I51909
colipase precursor - rat
N;Alternate names: procollipase
C;Species: Rattus norvegicus (Norway rat)
C;Date: 26-Jul-1996 #sequence_revision 26-Jul-1996 #text_change 20-Apr-2000
C;Accession: I51909; A34623
R;Payne, R.M.; Sams, H.F.; Jennens, M.L.; Lowe, M.E.
Am. J. Physiol. 266, G914-G921, 1994
A;Title: Rat pancreatic lipase and two related proteins: enzymatic properties and mRNA
A;Reference number: I51909; MUID:94262798; PMID:8203536
A;Accession: I51909
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-112 <PAY>
A;Cross-references: GB:M58370; NID:G203504; PIDN:AAA0505.1; PID:G203505
R;Wicker, C.; Puigserver, A.
Biochem. Biophys. Res. Commun. 167, 130-136, 1990

A;Title: Rat pancreatic colipase mRNA: nucleotide sequence of a cDNA clone and nutritione
A;Reference number: A34623; MUID:90179738; PMID:2129524
A;Accession: A34623
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-17, 'V', 19-112 <WTC>
A;Cross-references: GB:M33333; NID:G203502; PIDN:AAA40943.1; PID:G203503
C;Superfamily: colipase
C;Keywords: lipid digestion; lipid hydrolysis; pancreas
F;1-17/Domain: signal sequence #status predicted <SIG>
F;18-112/Product: colipase #status predicted <MAT>

Query Match 12.6%; Score 74; DB 2; Length 112;
Best Local Similarity 25.8%; Pred. No. 1.7;
Matches 24; Conservative 10; Mismatches 39; Indels 20; Gaps 4;
QY 6 RVSIMLLLVTVSDCAVITG-----ACERDVCGAGTCCCAISLWRLGLRMCTPL 53
DB 2 KVLVLLVTLVAVAYAAPGRGLFINLEDGEICVNSMQC-KSRCCQHDITL-GIARCTHK 59
QY 54 GREGECHPGSKHVPFRKRKHHTCPLP 86
DB 60 AMENSECSPKTLXGIYVR-----CPCERGLTC 86

RESULT 13
T27283
hypothetical protein Y64G10A.f - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C;Accession: T27283
R;Ainscough, R.
submitted to the EMBL Data Library, September 1999
A;Reference number: Z20336
A;Accession: T27283
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-1620 <WIL>
A;Cross-references: EMBL:AL110498; NID:ei542303; PIDN:CAB54471.1; CESP:Y64G10A.f
A;Experimental source: clone Y64G10A
C;Genetics:
A;Gene: CESP:Y64G10A.f
A;Introns: 77/1; 116/1; 198/1; 282/1; 365/1; 425/1; 466/1; 548/1; 559/1; 601/1; 625/1; 71

Query Match 12.6%; Score 74; DB 2; Length 1620;
Best Local Similarity 27.5%; Pred. No. 15;
Matches 22; Conservative 4; Mismatches 16; Indels 38; Gaps 4;
QY 16 VSDCAVITGACERDVCGAG-----TCCASLWRLGLRMCTPLGREGECHPGSKHVP 68
DB 1114 VARCDHVTGEC---RCPAGWTGPDQOTSC-----PLGRHGECC-----1148
QY 69 FFRKRKHHTCPLP 88
DB 1149 -----RHSCQCSNGASCDR 1162

RESULT 14
A35356
tumor necrosis factor receptor 2 precursor [validated] - human
N;Alternate names: 75K tumor necrosis factor receptor; TNF receptor type 2
C;Species: Homo sapiens (man)
C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 27-Oct-2003
C;Accession: A35356; A36475; A48416; A36007; A32666; B35010; I38094
R;Smith, C.A.; Davis, T.; Anderson, D.; Solam, L.; Beckmann, M.P.; Jerzy, R.; Dower, S.K.
Science 248, 1019-1023, 1990
A;Title: A receptor for tumor necrosis factor defines an unusual family of cellular and
A;Reference number: A35356; MUID:90260639; PMID:2160731
A;Accession: A35356
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-461 <SMI>
A;Cross-references: GB:M32315; NID:G189185; PIDN:AAA59929.1; PID:G189186

R;Kohn, T.; Brewer, M.T.; Baker, S.L.; Schwartz, F.E.; King, M.W.; Hale, K.K.; Squires, Proc. Natl. Acad. Sci. U.S.A. 87, 8331-8335, 1990
 A;Title: A second tumor necrosis factor receptor gene product can shed a naturally occurring
 A;Reference number: A36475; MUID:91045991; PMID:2172983
 A;Accession: A36475
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-195; 'R', 197-461 <KOH>
 A;Cross-references: GB:M55994; GB:M38549; NID:G339757; PIDN:AAA36755.1; PID:G339758
 R;Dembic, Z.; Loetscher, H.; Gubler, U.; Pan, Y.C.; Lahm, H.W.; Gentz, R.; Brockhaus, M. Cytochrome 2, 231-237, 1990
 A;Title: Two human TNF receptors have similar extracellular, but distinct intracellular, A;Reference number: A48416; MUID:91370690; PMID:1966549
 A;Accession: A48416
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 23-461 <DEM>
 A;Cross-references: GB:S63368; NID:G235648; PIDN:AA19824.1; PID:G235649
 A;Note: sequence extracted from NCBI backbone (NCBIN:63368, NCBI:P:63371)
 R;Heiler, R.A.; Song, K.; Onasch, M.A.; Fischer, W.H.; Chang, D.; Ringold, G.M. Proc. Natl. Acad. Sci. U.S.A. 87, 6151-6155, 1990
 A;Title: Complementary DNA cloning of a receptor for tumor necrosis factor and demonstra A;Reference number: A36007; MUID:90349572; PMID:2166946
 A;Accession: A36007
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 116-140, 'P', 142-195, 'R', 197-362, 'T', 364-461 <HEL>
 A;Cross-references: GB:M35857; NID:G339751; PIDN:AA63262.1; PID:G339752
 R;Loetscher, H.; Schlaeger, E.J.; Lahm, H.W.; Pan, Y.C.E.; Lesslauer, W.; Brockhaus, M. J. Biol. Chem. 265, 20131-20138, 1990
 A;Title: Purification and partial amino acid sequence analysis of two distinct tumor nec A;Reference number: A3666; MUID:91056048; PMID:2173696
 A;Accession: A3666
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 23-40; 65-69; 136-141; 300-306 <LOE>
 R;Engelmann, H.; Novick, D.; Wallach, D. J. Biol. Chem. 265, 1531-1536, 1990
 A;Title: Two tumor necrosis factor-binding proteins purified from human urine. Evidence A;Reference number: A35010; MUID:90110215; PMID:2153136
 A;Accession: B35010
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 27-31 <ENG>
 R;Kuhnert, P.; Kemper, O.; Wallach, D. Gene 150, 381-386, 1994
 A;Title: Cloning, sequencing and partial functional characterization of the 5' region of A;Reference number: I38094; MUID:95121834; PMID:7821811
 A;Accession: I38094
 A;Status: preliminary; translated from GB/EMBL/DBJ
 A;Molecule type: DNA
 A;Residues: 1-37 <RES>
 A;Cross-references: EMBL:X80021; NID:G666044; PIDN:CAA56324.1; PID:G825701
 C;Genetics:
 A;Gene: GDB:TNFR2
 A;Cross-references: GDB:I25914; OMIM:191191
 A;Map position: lp36.2-1p36.2
 A;Introns: 26/3
 C;Note: the list of introns is incomplete
 C;Superfamily: tumor necrosis factor receptor type 2 (TNFR2); NGF receptor repeat homolo C;Keywords: duplication; glycoprotein; receptor; transmembrane protein
 F;1-22/Domain: signal sequence #status predicted <SIG>
 F;23-416/Product: tumor necrosis factor receptor 2 #status experimental <MAT>
 F;40-76/Domain: NGF receptor repeat homology <NG1>
 F;78-119/Domain: NGF receptor repeat homology <NG2>
 F;120-162/Domain: NGF receptor repeat homology <NG3>
 F;164-201/Domain: NGF receptor repeat homology <NG4>
 F;262-279/Domain: transmembrane #status predicted <TMN>
 F;280-461/Domain: intracellular #status predicted <INT>
 F;171,193/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 12.4%; Score 73; DB 1; Length 461;
 Best Local Similarity 29.5%; Pred. No. 6.7;

Matches 28; Conservative 8; Mismatches 29; Indels 30; Gaps 6;
 QY 17 SDCA---VITGACERD---VOCGAGTCCALSLWLRGLRMCPTL-----GREGEF- 59
 Db 98 SRCSSDQVETQACTREONRICTRCFGWYCALSK-QEGCRLCAPLRKCRPGFGVAPGTET 156
 QY 60 -----CHPGSHKVPFFRKRKHHTCPLNLLCS 87
 Db 157 SDVVCKPCAPGT-----FSNTTSSDICHPHOICN 186
 RESULT 15
 S14458
 laminin alpha-1 chain precursor - human
 C;Species: Homo sapiens (man)
 C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 19-Jan-2001
 C;Accession: S14458; S14663; A34961
 R;Haaparanta, T.; Uitto, J.; Ruoslahti, E.; Engvall, E. Matrix 11, 151-160, 1991
 A;Title: Molecular cloning of the cDNA encoding human laminin A chain.
 A;Reference number: S14458; MUID:91333420; PMID:1714537
 A;Accession: S14458
 A;Status: not compared with conceptual translation
 A;Molecule type: mRNA
 A;Residues: 1-3075 <HAA>
 E;Nissinen, M.; Vuolteenaho, R.; Boot-Handford, R.; Kallunki, P.; Tryggvason, K. Biochem. J. 276, 369-379, 1991
 A;Title: Primary structure of the human laminin A chain. Limited expression in human tiss A;Reference number: S14663; MUID:91264789; PMID:2049067
 A;Accession: S14663
 A;Molecule type: mRNA
 A;Residues: 1-227, 'FE', 230-251, 'MLP', 255-418, 'E', 420-518, 'L', 520-1022, 'V', 1024-1074, 'V', J A;Cross-references: EMBL:X58531; NID:G34225; PIDN:CAA41418.1; PID:G34226
 R;Olson, D.; Nagayoshi, T.; Fazio, M.; Peltonen, J.; Jaakkola, S.; Sanborn, D.; Sasaki, J Lab. Invest. 60, 772-782, 1989
 A;Title: Human laminin: cloning and sequence analysis of cDNAs encoding A, B1 and B2 cha A;Reference number: A34961; MUID:89280632; PMID:2733383
 A;Accession: A34961
 A;Status: not compared with conceptual translation
 A;Molecule type: mRNA
 A;Residues: 'N', 2397-2745, 'L', 2747-3053, 'L', 3055-3072, 'PSP', <OLS>
 A;Note: the authors translated the codon AGA for residue 2692 as Pro
 C;Genetics:
 A;Gene: GDB:LAMAL; LAMA
 A;Cross-references: GDB:I20135; OMIM:150320
 A;Map position: 18p11.32-18p11.22
 C;Superfamily: laminin alpha-1 chain; laminin G repeat homology; laminin-type EGF-like ho C;Keywords: basement membrane; calcium binding; cell binding; coiled coil; disulfide bonc
 F;1-17/Domain: signal sequence #status predicted <SIG>
 F;18-3075/Product: laminin alpha-1 chain #status predicted <MAT>
 F;18-269/Domain: VI <DOM6>
 F;270-516/Domain: V <DOM5>
 F;270-324/Domain: laminin-type EGF-like homology <LE1>
 F;327-394/Domain: laminin-type EGF-like homology <LE2>
 F;397-451/Domain: laminin-type EGF-like homology <LE3>
 F;454-500/Domain: laminin-type EGF-like homology <LE4>
 F;503-512/Domain: laminin-type EGF-like homology #status atypical <LE5>
 F;517-708/Domain: IVB <DO4B>
 F;709-1159/Domain: IIIB <DO3B>
 F;709-739/Domain: laminin-type EGF-like homology #status atypical <LE6>
 F;742-788/Domain: laminin-type EGF-like homology <LE7>
 F;791-846/Domain: laminin-type EGF-like homology <LE8>
 F;849-899/Domain: laminin-type EGF-like homology <LE9>
 F;902-948/Domain: laminin-type EGF-like homology <LE10>
 F;951-995/Domain: laminin-type EGF-like homology <LE11>
 F;998-1041/Domain: laminin-type EGF-like homology <LE12>
 F;1044-1087/Domain: laminin-type EGF-like homology <LE13>
 F;1090-1109/Domain: laminin-type EGF-like homology #status atypical <LE14>
 F;1111-1147/Domain: laminin-type EGF-like homology #status atypical <LE15>
 F;1150-1159/Domain: laminin-type EGF-like homology #status atypical <LE16>
 F;1160-1361/Domain: IIVa <DO4A>
 F;1362-1553/Domain: IIIB <DO3A>
 F;1362-1400/Domain: laminin-type EGF-like homology #status atypical <LE17>

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 30, 2004, 06:38:38 ; Search time 23 Seconds
(without alignments)
237.712 Million cell updates/sec

Title: US-10-027-603-2

Perfect score: 589

Sequence: 1 MRGATRVISIMLLLVTVSDCA.....CSRFPDGRYRCMDLKNINF 105

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	589	100.0	105	PRK1_HUMAN	P58294 homo sapien
2	545	92.5	105	PRK1_RAT	Q8r414 rattus norv
3	310.5	52.7	81	VPRA_DENPO	P25687 dendroaspis
4	298	50.6	107	PRK2_RAT	Q8r413 rattus norv
5	287.5	48.8	96	BV8_BOWVA	Q9pw66 bombina var
6	282.5	48.0	129	PRX2_HUMAN	Q9hc23 homo sapien
7	277.5	47.1	128	PRX2_MOUSE	Q9qxi7 mus musculu
8	107.5	18.3	224	DKX4_HUMAN	Q9ubt3 homo sapien
9	107.5	18.3	350	DKX3_CHICK	Q90839 gallus gall
10	102	17.3	259	DKX2_HUMAN	Q9ubz2 homo sapien
11	101	17.1	259	DKX2_MOUSE	Q9qy28 mus musculu
12	101	17.1	272	DKX1_MOUSE	O54908 mus musculu
13	100.5	17.1	350	DKX3_HUMAN	Q9ubp4 homo sapien
14	98.5	16.7	349	DKX3_MOUSE	Q9qun9 mus musculu
15	97	16.5	266	DKX1_HUMAN	Q94907 homo sapien
16	90.5	15.4	425	CND0_MOUSE	Q8bu04 mus musculu
17	85	14.4	107	COL_RABIT	P42890 oryctolagus
18	82.5	14.0	425	CND0_HUMAN	Q8r806 homo sapien
19	81	13.8	1964	NTC4_MOUSE	P31695 mus musculu
20	79.5	13.5	704	FBL1_CHICK	O73775 gallus gall
21	78	13.4	112	COL_HUMAN	P04118 homo sapien
22	78	13.2	70	CX2X_CONBE	Q9u323 conus betul
23	77.5	13.2	473	FP2_MYTGA	Q25464 mytilus gal
24	75	12.7	490	TMS2_MOUSE	Q9j1q8 mus musculu
25	75	12.7	735	AD02_HUMAN	Q95965 homo sapien
26	75	12.7	1581	LMG3_MOUSE	Q9r0b6 mus musculu
27	75	12.7	2003	NTC4_HUMAN	Q99466 homo sapien
28	75	12.7	2318	NTC3_MOUSE	Q61982 mus musculu
29	75	12.7	2319	NTC3_RAT	Q9r172 rattus norv
30	74.5	12.6	113	COL_MOUSE	Q9qcq2 mus musculu
31	74	12.6	111	COL_MOUSE	Q9ix17 spermophilu
32	74	12.6	112	COL_RAT	P17084 rattus norv
33	73.5	12.5	2715	MLL4_HUMAN	Q9um66 homo sapien

ALIGNMENTS

RESULT 1

ID	PRK1_HUMAN	STANDARD;	PRT;	105 AA.
AC	P58294;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	16-OCT-2001 (Rel. 40, Last sequence update)			
DT	28-FEB-2003 (Rel. 41, Last annotation update)			
DE	Prokineticin 1 precursor (Endocrine-gland-derived vascular endothelial growth factor) (EG-VEGF) (Mambakine).			
GN	PROK1.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE=21150229; PubMed=11259612;			
RA	Li M., Bullock C.M., Knauer D.J., Ehler F.J., Zhou Q.Y.;			
RT	"Identification of two prokineticin cDNAs: recombinant proteins potentially contract gastrointestinal smooth muscle.";			
RL	Mol. Pharmacol. 59:692-698(2001).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE=21419730; PubMed=11528470;			
RA	Lecouter J., Kowalski J., Foster J., Hass P., Zhang Z.,			
RA	Dillard-Telm L., Frantz G., Rangell L., Deguzman L., Keller G.-A.,			
RA	Peale F., Gurney A., Hillan K.J., Ferrara N.;			
RT	"Identification of an angiogenic mitogen selective for endocrine gland endothelium.";			
RL	Nature 412:877-884(2001).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RA	Fraser C.;			
RT	"Mambakine, a snake venom related endocrine hormone that controls macrophages.";			
RL	Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.			
CC	-!- FUNCTION: Potently contract gastrointestinal (GI) smooth muscle. Induces proliferation, migration and fenestration (the formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. Has little or no effect on a variety of other endothelial and non-endothelial cell types.			
CC	-!- SUBCELLULAR LOCATION: Secreted.			
CC	-!- TISSUE SPECIFICITY: Expressed in the steroidogenic glands, ovary, testis, adrenal and placenta.			
CC	-!- SIMILARITY: Belongs to the prokineticin family.			
CC	-----			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).			
CC	-----			
DR	EMBL; AF333024; AAK49918.1; -			
DR	EMBL; AY029225; AAK33111.1; -			

Q920w1 mus musculu
P20333 homo sapien
Q9tv36 sus scrofa
P25391 bos sapien
P98133 bos taurus
P35555 homo sapien
P15215 drosophila
P28797 cavia porce
P23142 homo sapien
Q95116 bos taurus
P35440 gallus gall
P28799 h granulins

34 73 12.4 417 1 TRI6_MOUSE
35 73 12.4 461 1 TRIB_HUMAN
36 73 12.4 2871 1 FBNI_PIG
37 73 12.4 3075 1 LMA1_HUMAN
38 72.5 12.3 2871 1 FBNI_BOVIN
39 72.5 12.3 2871 1 FBNI_HUMAN
40 72 12.2 1639 1 LMGI_DROME
41 71.5 12.1 591 1 GRN_CAVPO
42 71.5 12.1 703 1 FBNI_HUMAN
43 71.5 12.1 1170 1 TSP2_BOVIN
44 71.5 12.1 1178 1 TSP2_CHICK
45 71 12.1 593 1 GRN_HUMAN

```
DR Genew; HGNC:18454; PROK1.
DR MIM; 606233; -.
KW Mitogen; Growth factor; Signal.
FT SIGNAL 1 19 BY SIMILARITY.
FT CHAIN 20 105 PROKINETICIN 1.
FT DISULFID 26 38 BY SIMILARITY.
FT DISULFID 32 50 BY SIMILARITY.
FT DISULFID 37 78 BY SIMILARITY.
FT DISULFID 60 86 BY SIMILARITY.
FT DISULFID 80 96 BY SIMILARITY.
SQ SEQUENCE 105 AA; 11715 MW; C7B3FDE308FB416A CRC64;

Query Match 100.0%; Score 589; DB 1; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.1e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 2
PRKI_RAT
ID PRKI_RAT STANDARD; PRT; 105 AA.
AC G9R414;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DE Prokineticin 1 precursor (Endocrine-gland-derived vascular endothelial
DE growth factor) (EG-VEGF).
GN PROK1.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]_
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley;
RX MEDLINE=22050031; PubMed=12054613;
RA Masuda Y., Takatsu Y., Terao Y., Kumano S., Ishibashi Y., Suenaga M.,
RA Abe M., Fukusumi S., Watanabe T., Shintani Y., Yamada T., Hinuma S.,
RA Inatomi N., Ohtaki T., Onda H., Fujino M.;
RT "Isolation and identification of EG-VEGF/prokineticins as cognate
RT ligands for two orphan G-protein-coupled receptors.";
RL Biochem. Biophys. Res. Commun. 293:396-402(2002).
CC -!- FUNCTION: Potentially contract gastrointestinal (GI) smooth muscle.
CC Induces proliferation, migration and fenestration (the formation
CC of membrane discontinuities) in capillary endothelial cells
CC derived from endocrine glands. Has little or no effect on a
CC variety of other endothelial and non-endothelial cell types (By
CC similarity).
CC -!- SUBCELLULAR LOCATION: Secreted (By similarity).
CC -!- SIMILARITY: Belongs to the prokinectin family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/ebis-sib.ch/announcement/
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; AF089983; AAM09104.1; -.
KW Mitogen; Growth factor; Signal.
FT SIGNAL 1 19 POTENTIAL.
FT CHAIN 20 105 PROKINETICIN 1.
FT DISULFID 26 38 BY SIMILARITY.
FT DISULFID 32 50 BY SIMILARITY.
FT DISULFID 37 78 BY SIMILARITY.
```

```
FT DISULFID 60 86 BY SIMILARITY.
FT DISULFID 80 96 BY SIMILARITY.
SQ SEQUENCE 105 AA; 11642 MW; 8DF0C42122B1C5B6 CRC64;

Query Match 92.5%; Score 545; DB 1; Length 105;
Best Local Similarity 89.5%; Pred. No. 7.5e-50;
Matches 94; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
Db 1 MRGAVQVFMILLATVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRLLCTPLGREGEC 60

QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRYRCSDMLKNINF 105
Db 61 HPGSHKIPFRKRQHHTCPCLNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 3
VPRA_DENPO
ID VPRA_DENPO STANDARD; PRT; 81 AA.
AC P25687;
DT 01-MAY-1992 (Rel. 22, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Intestinal toxin 1 (MIT 1) (MIT1) (Venom protein A).
OS Dendroaspis polylepsis polylepsis (Black mamba).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
OC Elapidae; Elapinae; Dendroaspis.
OX NCBI_TaxID=8620;
RN [1]_
RP SEQUENCE.
RC TISSUE=Venom;
RX MEDLINE=8115818; PubMed=7461607;
RA Joubert F.J., Strydom D.J.;
RT "Snake venom. The amino acid sequence of protein A from Dendroaspis
RT polylepsis polylepsis (black mamba) venom.";
RL Hoppe-Seyler's Z. Physiol. Chem. 361:1787-1794(1980).
RN [2]_
RP CHARACTERIZATION.
RX MEDLINE=20036442; PubMed=10567694;
RA Schweitz H., Pascaud P., Diochot S., Moinier D., Lazdunski M.;
RT "MIT1, a black mamba toxin with a new and highly potent activity on
RT intestinal contraction.";
RL FEBS Lett. 461:183-188(1998).
RN [3]_
RP STRUCTURE BY NMR.
RC TISSUE=Venom;
RX MEDLINE=98437381; PubMed=9761684;
RA Boissouvier J., Albrand J.-P., Blackledge M., Jaquinod M.,
RA Schweitz H., Lazdunski M., Marion D.;
RT "A structural homologue of colipase in black mamba venom revealed by
RT NMR floating disulphide bridge analysis.";
RL J. Mol. Biol. 283:205-219(1998).
CC -!- FUNCTION: Potentially contract gastrointestinal (GI) smooth muscle.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the prokinectin family.
CC -----
CC Toxin; 3D-structure.
DR PDB; 1MT; 20-APR-99.
KW Toxin; 3D-structure.
FT DISULFID 7 19
FT DISULFID 13 31
FT DISULFID 18 60
FT DISULFID 41 68
FT DISULFID 62 78
FT DISULFID 73 73
FT VARIANT 18 18 C -> Q (IN PROTEIN A').
FT CONFLICT 18 18 C -> S (IN REF. 1).
FT CONFLICT 22 22 S -> C (IN REF. 1).
SQ SEQUENCE 81 AA; 8645 MW; 6C01368841572044 CRC64;

Query Match 52.7%; Score 310.5; DB 1; Length 81;
Best Local Similarity 62.8%; Pred. No. 1.1e-25;
Matches 49; Conservative 14; Mismatches 14; Indels 1; Gaps 1;
```

```
QY 20 AVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECHPGSHKVPFRK-K-HHTC 78
Db 1 AVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECHPGSHKVPFRK-K-HHTC 60
QY 79 PCLEPNLLCSRFPDGRYRC 96
Db 61 PCAPNLACVQTSPPKFKC 78

RESULT 4
PRK2_RAT
ID PRK2_RAT STANDARD; PRT; 107 AA.
AC Q8R413;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DE Prokineticin 2 precursor (PK2).
GN PROK2.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN:Sprague-Dawley;
RX MEDLINE=22050031; PubMed=12054613;
RA Masuda Y., Takatsu Y., Terao Y., Kumano S., Ishibashi Y., Suenaga M.,
RA Abe M., Fukusumi S., Watanabe T., Shintani Y., Yamada T., Hinuma S.,
RA Inatomi N., Ohtaki T., Onda H., Fujino M.;
RT "Isolation and identification of EG-VEGF/prokineticins as cognate
RT ligands for two orphan G-protein-coupled receptors.";
RL Biochem. Biophys. Res. Commun. 293:396-402(2002).
RN [2]
RP EFFECT ON CIRCADIAN LOCOMOTOR ACTIVITY.
RX MEDLINE=22022134; PubMed=12024206;
RA Cheng M.Y., Bullock C.M., Li C., Lee A.G., Bernak J.C., Belluzzi J.,
RA Weaver D.R., Leslie F.M., Zhou Q.-Y.;
RT "Prokineticin 2 transmits the behavioural circadian rhythm of the
RT suprachiasmatic nucleus";
RL Nature 417:405-410(2002).
CC -!- FUNCTION: May function as an output molecule from the
CC suprachiasmatic nucleus (SCN) that transmits behavioral circadian
CC rhythm. May also function locally within the SCN to synchronize
CC output. Potently contracts gastrointestinal (GI) smooth muscle (By
CC similarity).
CC -!- SUBCELLULAR LOCATION: Secreted (By similarity).
CC -!- TISSUE SPECIFICITY: Expressed at high levels in testis and at
CC lower levels in brain, lung, ovary, spleen, thymus and uterus.
CC -!- INDUCTION: Activated by Clock and Bmal heterodimers and light;
CC inhibited by period genes (PER1, PER2 and PER3) and cryptochrome
CC genes (CRY1 and CRY2) (Probable).
CC -!- SIMILARITY: Belongs to the prokineticin family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; AY089984; AA09105.1;
CC SIGNAL 1 26 POTENTIAL.
CC CHAIN 27 107 PROKINETICIN 2.
CC FT DISULFID 33 45 BY SIMILARITY.
CC FT DISULFID 39 57 BY SIMILARITY.
CC FT DISULFID 44 85 BY SIMILARITY.
CC FT DISULFID 67 93 BY SIMILARITY.
CC FT DISULFID 87 103 BY SIMILARITY.
CC SQ SEQUENCE 107 AA; 11594 MW; BDF316DCB5FED0 CRC64;

Query Match 50.6%; Score 298; DB 1; Length 107;
PRK2_HUMAN
```

```
Best Local Similarity 54.0%; Pred. No. 2.8e-24;
Matches 47; Conservative 16; Mismatches 24; Indels 0; Gaps 0;

QY 10 MLLLVTVSCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECHPGSHKVPF 69
Db 17 LLITPPAGDAAVITGACDKDSQCGGMCACCAVSIKIRICTPMGVGSDSCHPLTRKVPF 76
QY 70 FRKXKHTCPCPLNLLCSRFPDGRYRC 96
Db 77 WGRMEHTCPCPLGLACLTSPNRFIC 103

RESULT 5
BV8_BOMVA
ID BV8_BOMVA STANDARD; PRT; 96 AA.
AC Q9PW66;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Protein Bv8 precursor.
OS Bombina variegata (Yellow-bellied toad).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID=8348;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC TISSUE=Skin secretion;
RX MEDLINE=93349621; PubMed=10422759;
RA Molloy C., Wechselsberger C., Mignogna G., Negri L., Melchiorri P.,
RA Barra D., Kreil G.;
RT "Bv8, a small protein from frog skin and its homologue from snake
RT venom induce hyperalgesia in rats.";
RL Eur. J. Pharmacol. 374:189-196(1999).
CC -!- FUNCTION: Potently contract gastrointestinal (GI) smooth muscle.
CC induces hyperalgesia.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the prokineticin family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; AF168790; AAD45816.1;
CC HSSP; P25687; IMT.
CC SIGNAL 1 19
CC CHAIN 20 96 PROTEIN BV8.
CC FT DISULFID 26 38 BY SIMILARITY.
CC FT DISULFID 32 50 BY SIMILARITY.
CC FT DISULFID 37 78 BY SIMILARITY.
CC FT DISULFID 60 86 BY SIMILARITY.
CC FT DISULFID 80 95 BY SIMILARITY.
CC SQ SEQUENCE 96 AA; 10102 MW; A12490A7437609B4 CRC64;

Query Match 48.8%; Score 287.5; DB 1; Length 96;
Best Local Similarity 50.5%; Pred. No. 3.1e-23;
Matches 49; Conservative 18; Mismatches 29; Indels 1; Gaps 1;

QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECH 60
Db 1 MKCPAQIWLVLVIAFSHGAVITGACDKVQCGSGTGCCAAASAWNRIRFCIPLGNSGEDC 60
QY 61 HPGSHKVPFRKXKHTCPCPLNLLCSRFPDGRYRC 97
Db 61 HPASHKVPYDCKRLSSLCPCKSLGTCSEKSE-KFKCS 96

RESULT 6
PRK2_HUMAN
```

ID AC Q9HC23; PRK2 HUMAN STANDARD; PRT; 129 AA.
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Prokineticin 2 precursor (PK2) (Protein Bv8 homolog).
 GN PROK2 OR Bv8.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE OF 5-129 FROM N.A. (ISOFORM 1).
 RC TISSUE=Testis;
 RX MEDLINE=20047850; PubMed=10580115;
 RA Wechselberger C., Puglisi R., Lepperdinger G., Boitani C., Kreil G.;
 RT "The mammalian homologue of Bv8 from frog skin is mainly expressed in
 RT spermatocytes".
 RL FEBS Lett. 462:177-181(1999).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RX MEDLINE=21160229; PubMed=11259612;
 RA Li M., Bullock C.M., Knauer D.J., Ehliert F.J., Zhou Q.-Y.;
 RT "Identification of two prokineticin cDNAs: recombinant proteins
 RT potentially contract gastrointestinal smooth muscle".
 RL Mol. Pharmacol. 59:692-698(2001).
 CC -!- FUNCTION: May function as an output molecule from the
 CC suprachiasmatic nucleus (SCN) that transmits behavioral circadian
 CC rhythm. May also function locally within the SCN to synchronize
 CC output. Potentially contracts gastrointestinal (GI) smooth muscle.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event-Alternative splicing; Named isoforms=2;
 CC Name=1;
 CC IsoId=Q9HC23-1; Sequences=Displayed;
 CC Name=2;
 CC IsoId=Q9HC23-2; Sequences=VSP 005219;
 CC -!- TISSUE SPECIFICITY: Expressed in the testis and, at low levels, in
 CC the small intestine.
 CC -!- INDUCTION: Activated by Clock and Bmal heterodimers and light;
 CC inhibited by period genes (PER1, PER2 and PER3) and cryptochrome
 CC genes (CRY1 and CRY2) (Probable).
 CC -!- SIMILARITY: Belongs to the prokineticin family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: AF182069; AAG16893.2; --
 DR EMBL: AF333025; AAK49919.1; --
 DR HSSP: F25687; IIMT.
 DR MIM: 607002; --
 DR Genew; HGNC:18455; PROK2.
 KW Neuropeptide; Biological rhythms; Signal; Alternative splicing.
 FT SIGNAL 1 27
 FT BY SIMILARITY.
 FT PROKINETICIN 2.
 FT DISULFID 34 46
 FT BY SIMILARITY.
 FT DISULFID 40 58
 FT BY SIMILARITY.
 FT DISULFID 45 107
 FT BY SIMILARITY.
 FT DISULFID 68 115
 FT BY SIMILARITY.
 FT DISULFID 109 125
 FT BY SIMILARITY.
 FT VARSPLC 75 95
 FT Missing (in isoform 2).
 FT /FTId=VSP_005219.
 SEQUENCE 129 AA; 14314 MW; 0487679E8700DA55 CRC64;
 Query Match 48.0%; Score 282.5; DB 1; Length 129;
 Best Local Similarity 44.4%; Pred. No. 1.4e-22;
 Matches 48; Conservative 15; Mismatches 24; Indels 21; Gaps 1;

QY 10 MLLLVTSQCAVITGACERDVOCAGTCCTCAISLWRLGRLMCTPLRGEGEGCHGSHK--- 66
 DB 18 LLITPRAGDAAVITGACRDSQCGGMCACAVSIWKSIRICTPMGKLGDSCHPLTKKNF 77
 QY 67 -----VFFPKRKHKHTCPCLNLLCSRPDPGRYRC 96
 DB 78 GNGRQERRKRSKRKEKVEFFGRVHHTCPCLPLGLACLRLTSFRNPFIC 125
 RESULT 7
 PRK2_MOUSE
 ID PRK2_MOUSE STANDARD; PRT; 128 AA.
 AC Q9QXU7; Q9QXU5; Q9QXU6;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Prokineticin 2 precursor (PK2) (Protein Bv8 homolog).
 GN PROK2 OR Bv8.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
 RC STRAIN=129/Sv;
 RX MEDLINE=20047850; PubMed=10580115;
 RA Wechselberger C., Puglisi R., Lepperdinger G., Boitani C., Kreil G.;
 RT "The mammalian homologue of Bv8 from frog skin is mainly expressed in
 RT spermatocytes".
 RL FEBS Lett. 462:177-181(1999).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
 RC STRAIN=129/Sv;
 RX MEDLINE=20510004; PubMed=11054548;
 RA Gilek A., Engel E., Beier D., Lepperdinger G.;
 RT "Murine Bv8 gene maps near a syntenic breakpoint of mouse chromosome 6
 RT and human 3p21".
 RL Gene 256:189-195(2000).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORM 2), AND FUNCTION.
 RC STRAIN=C57BL/6;
 RX MEDLINE=22022134; PubMed=12024206;
 RA Cheng M.Y., Bullock C.M., Li C., Lee A.G., Bermak J.C., Belluzzi J.,
 RA Weaver D.R., Leslie F.M., Zhou Q.-Y.;
 RT "Prokineticin 2 transmits the behavioural circadian rhythm of the
 RT suprachiasmatic nucleus".
 RL Nature 417:405-410(2002).
 RN [4]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX MEDLINE=21085660; PubMed=11217851;
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamataka I.,
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
 RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Monbaerts P.,
 RA Nordore P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
 RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kotsuki S.,
 RA Hayashizaki Y.;
 RT "Functional annotation of a full-length mouse cDNA collection".
 RL Nature 409:685-690(2001).
 CC -!- FUNCTION: May function as an output molecule from the
 CC suprachiasmatic nucleus (SCN) that transmits behavioral circadian

rhythm. May also function locally within the SCN to synchronize output. Potently contracts gastrointestinal (GI) smooth muscle (By similarity).

-!- SUBCELLULAR LOCATION: Secreted.

-!- ALTERNATIVE PRODUCTS:

Event=Alternative splicing; Named isoforms=3;

Name=1; Synonyms=Bv8-a;

IsoId=Q9XU7-1; Sequences=Displayed;

Name=2; Synonyms=Bv8-b;

IsoId=Q9XU7-2; Sequences=VSP_005220;

Name=3;

IsoId=Q9XU7-3; Sequences=VSP_005221;

-!- TISSUE SPECIFICITY: Expressed in the SCN and among a few other discrete brain areas, including the islands of Calleja, medial preoptic area of the hypothalamus and the shell of the nucleus accumbens. Highly expressed in testis. In the SCN, expression subjected to high amplitude of circadian oscillation.

-!- DEVELOPMENTAL STAGE: Expressed in mid-late pachytene spermatocytes at the stages VII, VIII and IX of the semiferous epithelial cycle.

-!- INDUCTION: Activated by Clock and Small heterodimers and light; inhibited by period genes (PER1, PER2 and PER3) and cryptochrome genes (CRY1 and CRY2).

-!- SIMILARITY: Belongs to the prokinectin family.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL; AF182064; AAF15259.1; -

EMBL; AF182065; AAF15260.1; -

EMBL; AF182066; AAF15261.1; -

EMBL; AF182068; AAG09439.1; -

EMBL; AF182067; AAG09439.1; JOINED.

EMBL; AF487280; AAM49572.1; -

EMBL; AX015462; BAB29857.1; -

HSSP; P25687; 11MT.

MGD; MGI:1354178; Prok2.

GO; GO:0007623; P:circadian rhythm; IDA.

Neuropeptide; Biological rhythms; Signal; Alternative splicing.

SIGNAL 1 26 POTENTIAL.

CHAIN 27 128 PROKINETICIN 2.

DISULFID 33 45 BY SIMILARITY.

DISULFID 39 57 BY SIMILARITY.

DISULFID 44 106 BY SIMILARITY.

DISULFID 67 114 BY SIMILARITY.

DISULFID 108 124 BY SIMILARITY.

VARSPLIC 74 94 Missing (in isoform 2).

/FTId=VSP_005220.

SHVANGQERRAKRRKRKKEVFFWGRMHHTCPCLPLGLAC

LRTSFNRFCILARK -> VSVCTGILGVFESH (in isoform 3).

/FTId=VSP_005221.

5F08BA177FDB58C CRC64;

SEQUENCE 128 AA; 14185 MW; 5F08BA177FDB58C CRC64;

Query Match 47.1%; Score 277.5; DB 1; Length 128;

Best Local Similarity 40.7%; Pred. No. 4.5e-22;

Matches 50; Conservative 19; Mismatches 25; Indels 29; Gaps 2;

3 GATRVSMILLLVTV-----SDCAVITGACERDVQCGAGTCCCAISLWRLGRMCTPLG 54

2 GDFRCAPULLLLLLPULLFTPPAGDAAVITGACDKSQCGGMCVAVSWKSIRICTPWG 61

55 REEECHPGSHK-----VPEFRKRKHTCTCLNLCSPFDOR 93

62 QVDSCHPLTRKSHVANGQERRAKRRKRKKEVFFWGRMHHTCPCLPLGLACLTFSNR 121

94 YRC 96

122 FIC 124

RESULT 8

DKK4 HUMAN

ID DKK4 HUMAN STANDARD; PRT; 224 AA.

AC Q9UBT3; Q9Y4C3;

DT 16-OCT-2001 (Rel. 40, Created)

DT 16-OCT-2001 (Rel. 40, Last sequence update)

DT 15-MAR-2004 (Rel. 43, Last annotation update)

DE Dickkopf related protein-4 precursor (Dkk-4) (Dkk-4).

GN DKK4

OS Homo sapiens (Human)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

[1]

RP SEQUENCE FROM N.A., AND SEQUENCE OF 19-28 AND 134-144.

EX MEDLINE=2003735; PubMed=10570958;

RA Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W.,

RA Amaravadi L., Brown D.B., Guyot D., Mays G., Leiby K., Chang B.,

RA Duong T., Goodearl A.D.J., Gearing D.P., Sokol S.Y., McCarthy S.A.,

RT "Functional and structural diversity of the human Dickkopf gene family,"

RL Gene 238:301-313(1999).

[2]

RP SEQUENCE FROM N.A.

RA Tate G., Mitsuya T.,

RT "Human Dickkopf as well as DAN family members, Cerberus and Gremlin, are preferentially expressed in the epithelial malignant cell lines."

RL J. Biochem. Mol. Biol. Biophys. 3:239-242(1999).

[3]

RP SEQUENCE FROM N.A.

RA Tate G., Mitsuya T.,

RL Submitted (SEP-1998) to the EMBL/GenBank/DBJ databases.

CC -!- FUNCTION: Inhibitor of Wnt signaling pathway.

CC -!- SUBCELLULAR LOCATION: Secreted.

CC -!- TISSUE SPECIFICITY: Expressed in cerebellum, T-cells, esophagus and lung.

CC -!- PTM: APPEARS NOT TO BE GLYCOSYLATED.

CC -!- PTM: CAN ALSO BE PROTEOLYTICALLY PROCESSED BY A FURIN-LIKE PROTEASE.

CC -!- SIMILARITY: Belongs to the dickkopf family.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL; AF177397; AAF02677.1; -

EMBL; AB018005; BAA33475.1; -

EMBL; AB018003; BAA33475.1; JOINED.

EMBL; AB018004; BAA33475.1; JOINED.

EMBL; AB017788; BAA33438.1; -

HSSP; P25687; 11MT.

Genew; HGNC:2894; DKK4.

MIM; 605417; -

GO; GO:00030178; P:negative regulation of Wnt receptor signaling. . .; NAS.

InterPro; IPR006796; dickkopf_N.

Ffam; PF04706; dickkopf_N; 1.

Developmental protein; Signal; Wnt signaling pathway.

SIGNAL 1 18

CHAIN 19 224 DICKKOPF RELATED PROTEIN-4.

FT CHAIN 134 224 DICKKOPF RELATED PROTEIN-4 SHORT FORM.

FT DOMAIN 41 90 DKK-TYPE CVS-1.

FT DOMAIN 145 218 DKK-TYPE CVS-2.

FT CONFLICT 93 93 M -> L (IN REF. 3).

SEQUENCE 224 AA; 24875 MW; 45F8EBC476961357 CRC64;

Query Match 18.3%; Score 107.5; DB 1; Length 224;

Best Local Similarity 35.5%; Pred. No. 0.00031;

Matches 22; Conservative 5; Mismatches 32; Indels 3; Gaps 1;

QY 25 ACERDVQCGAGTCAISLWLRGLRMTCTPLGREGECHPGSHKVPFRKRKHHTCPLNPL 84
 Db 144 SCRTFDCGPGLCARHF---TKICKVLLGQVCSRRGHDKDTAQAPFQFCDCGGL 200
 QY 85 LC 86
 Db 201 LC 202

RESULT 9
 DKK3_CHICK
 ID DKK3_CHICK STANDARD; PRT; 350 AA.
 AC Q30839;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE DICKKOPF related protein-3 precursor (Dkk-3) (Dickkopf-3) (Lens fiber protein CLFEST4).
 DE protein CLFEST4).
 GN DKK3.
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
 OC Gallus.
 OC NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Lens fibers;
 RA MEDLINE=96437509; PubMed=8840185;
 RX Sawada K., Agata K., Eguchi G.;
 RT "Characterization of terminally differentiated cell state by categorizing cDNA clones derived from chicken lens fibers.";
 RL Int. J. Dev. Biol. 40:531-535(1996).
 CC -!- FUNCTION: Inhibitor of Wnt signaling pathway (By similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted (Potential).
 CC -!- TISSUE SPECIFICITY: Expressed in eye lens.
 CC -!- SIMILARITY: Belongs to the dickkopf family.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
 CC
 CC EMBL; D26311; BAA05373.1; -;
 CC HSP; P25687; ILMT.
 CC InterPro; IPR006796; dickkopf_N.
 CC Pfam; PF04706; dickkopf_N; 1.
 CC Developmental protein; Signal; Wnt signaling pathway; Glycoprotein.
 FT SIGNAL 1 29 POTENTIAL.
 FT CHAIN 30 350 DICKKOPF RELATED PROTEIN-3.
 FT DOMAIN 139 187 DKK-TYPE CYS-1.
 FT DOMAIN 200 277 DKK-TYPE CYS-2.
 FT CARBOHYD 88 88 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 98 98 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 113 113 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 196 196 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 282 282 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 350 AA; 39208 MW; 57BE7ED850089DAE CRC64;
 Query Match 18.3%; Score 107.5; DB 1; Length 350;
 Best Local Similarity 35.8%; Pred. No. 0.0049;
 Matches 24; Conservative 5; Mismatches 31; Indels 7; Gaps 2;

QY 26 CERDVQCGAGTCAISLWLRGLRMTCTPLGREGECHPGSHKVPFRKRKHHTCPCP 79
 Db 200 CENQHCNFGTCAFCQKELL-FPVCTPLPEEGPCHDPSNLLNLTWELEPDGVLRCP 258
 QY 80 CLPNLLC 86

Db 259 CASGLIC 265

RESULT 10
 DKK2_HUMAN
 ID DKK2_HUMAN STANDARD; PRT; 259 AA.
 AC Q9UBU2; Q9UIU3;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE DICKKOPF related protein-2 precursor (Dkk-2) (Dickkopf-2).
 GN DKK2.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OC NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Fetal lung;
 RA MEDLINE=20035735; PubMed=10570958;
 RX Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W., Amaravadi L., Brown D.E., Guyot D., Mays G., Leiby K., Chang B., Duong T., Goodearl A.D.J., Gearing D.P., Sokol S.Y., McCarthy S.A.;
 RT "Functional and structural diversity of the human Dickkopf gene family.";
 RL Gene 238:301-313(1999).
 RN [2]
 RP SEQUENCE FROM N.A.
 RA Tanaka S., Sugimachi K., Sugimachi K.;
 RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE OF 75-259 FROM N.A.
 RA Tate G., Suzuki T., Mitsuwa T.;
 RL Submitted (NOV-1999) to the EMBL/GenBank/DBJ databases.
 CC -!- FUNCTION: Inhibitor of Wnt signaling pathway (Potential).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Expressed in heart, brain, skeletal muscle and lung.
 CC -!- PM: MAY BE PROTEOLYTICALLY PROCESSED BY A FURIN-LIKE PROTEASE.
 CC -!- SIMILARITY: Belongs to the dickkopf family.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
 CC
 CC EMBL; AF177395; AAF02675.1; -;
 CC EMBL; AB033208; BAA85465.1; -;
 CC EMBL; AB035181; BAA87056.1; -;
 CC EMBL; AB035180; BAA87056.1; JOINED.
 CC Genew; HGNC:2892; DKK2.
 CC MIM; 605415; -;
 CC GO; GO:0005615; Cytoplasmic space; TAS.
 CC InterPro; IPR006796; dickkopf_N.
 CC Pfam; PF04706; dickkopf_N; 1.
 CC Developmental protein; Signal; Wnt signaling pathway; Glycoprotein.
 FT SIGNAL 1 33 POTENTIAL.
 FT CHAIN 34 259 DICKKOPF RELATED PROTEIN-2.
 FT DOMAIN 78 127 DKK-TYPE CYS-1.
 FT DOMAIN 183 256 DKK-TYPE CYS-2.
 FT CARBOHYD 52 52 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 259 AA; 28447 MW; 39DDA3FA8975E87F CRC64;
 Query Match 17.3%; Score 102; DB 1; Length 259;
 Best Local Similarity 31.5%; Pred. No. 0.0013;
 Matches 23; Conservative 8; Mismatches 30; Indels 12; Gaps 3;

QY 26 CERDVQCGAGTCAISLWLRGLRMTCTPLGREGECHPGSHKVPFRKRKHHTCPCP 81
 Db 183 CLRSSDCIEGFCARHF---TKICKVLLHGEVCTKQKKGSHGLEIFOR-----CDCA 234


```

QY      82 PNLLCSRPDPGRY 94
Db      235 KGLSCKVWKDATY 247

RESULT 11
DKK2_MOUSE
ID DKK2_MOUSE STANDARD; PRT; 259 AA.
AC Q9QY78;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Dickkopf related protein-2 precursor (Dkk-2) (mDkk-2).
GN DKK2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
SEQUENCE FROM N.A.
RX MEDLINE=99425169; PubMed=10495270;
RA Monaghan P.A., Kloschis P., Wu W., Zuniga A., Bock D., Poustka A.,
RA Delius H., Niehrs C.
RT "Dickkopf genes are co-ordinately expressed in mesodermal lineages.";
RL Mech. Dev. 87:45-56 (1999).
CC -!- FUNCTION: Inhibitor of Wnt signaling pathway (Potential).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- PTM: MAY BE PROTEOLYTICALLY PROCESSED BY A FURIN-LIKE PROTEASE.
CC -!- SIMILARITY: Belongs to the dickkopf family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AJ243963; CAB60110.1; -
CC MGD; MGI:1890663; Dkk2.
CC InterPro; IPR006796; dickkopf_N.
CC Pfam; PF04706; dickkopf_N; 1.
CC Developmental protein; Signal; Wnt signaling pathway; Glycoprotein.
CC SIGNAL 1 33 POTENTIAL.
CC CHAIN 34 259 DICKKOPF RELATED PROTEIN-2.
CC DOMAIN 78 127 DKK-TYPE CYS-1.
CC DOMAIN 183 256 DKK-TYPE CYS-2.
CC CARBOHYD 52 52 N-LINKED (GLCNAC...) (POTENTIAL).
CC SEQUENCE 259 AA; 28416 MW; 54AB76P2D2C9780D CRC64;

Query Match 17.1%; Score 101; DB 1; Length 259;
Best Local Similarity 31.5%; Pred. No. 0.0017;
Matches 23; Conservative 8; Mismatches 30; Indels 12; Gaps 3;

QY      26 CERDVQCGAGTCCTCAISLWRLGRLMCTPLGREGEC-----HPGSHKVPFPRKRKHHTCPCL 81
Db      183 CLRSSDCIDGFCARHFW--TKICKPVLFQEVCTKQKKGSHGLEIFOR-----CDCA 234

QY      82 PNLLCSRPDPGRY 94
Db      235 KGLSCKVWKDATY 247

RESULT 12
DKK1_MOUSE
ID DKK1_MOUSE STANDARD; PRT; 272 AA.
AC O54908;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Dickkopf related protein-1 precursor (Dkk-1) (mDkk-1).
GN DKK1.

```

```

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
SEQUENCE FROM N.A.
RX MEDLINE=98111224; PubMed=9450748;
RA Glinka A., Wu W., Delius H., Monaghan A.P., Blumenstock C., Niehrs C.;
RT "Dickkopf-1 is a member of a new family of secreted proteins and
RT functions in head induction.";
RL Nature 391:357-362 (1998).
CC -!- FUNCTION: Inhibitor of Wnt signaling pathway.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the dickkopf family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AF030433; AAC02426.1; -
CC HSP; P25687; IMT.
CC MGD; MGI:1329040; Dkk1.
CC InterPro; IPR006796; dickkopf_N.
CC Pfam; PF04706; dickkopf_N; 1.
CC Developmental protein; Signal; Wnt signaling pathway; Glycoprotein.
CC SIGNAL 1 31 POTENTIAL.
CC CHAIN 32 272 DICKKOPF RELATED PROTEIN-1.
CC DOMAIN 86 141 DKK-TYPE CYS-1.
CC DOMAIN 195 269 DKK-TYPE CYS-2.
CC CARBOHYD 262 262 N-LINKED (GLCNAC...) (POTENTIAL).
CC SEQUENCE 272 AA; 29268 MW; AB9FA35DFAS7D3EE CRC64;

Query Match 17.1%; Score 101; DB 1; Length 272;
Best Local Similarity 33.8%; Pred. No. 0.0018;
Matches 22; Conservative 8; Mismatches 23; Indels 12; Gaps 3;

QY      26 CERDVQCGAGTCCTCAISLWRLGRLMCTPLGREGEC-----HPGSHKVPFPRKRKHHTCPCL 81
Db      195 CLRSSDCAAGLCCARHFW---SKICKPVLFQEVCTKHKRKGSHGLEIFOR-----CYCG 246

QY      82 PNLLC 86
Db      247 EGLAC 251

RESULT 13
DKK3_HUMAN
ID DKK3_HUMAN STANDARD; PRT; 350 AA.
AC Q9UBF4; Q9ULB7;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Dickkopf related protein-3 precursor (Dkk-3) (hDkk-3).
GN DKK3 OR REIC.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RC TISSUE=Fetal brain;
RX MEDLINE=20035735; PubMed=10570958;
RA Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W.,
RA Amaravadi L., Brown D.E., Guyot D., Mays G., Leiby K., Chang B.,
RA Duong T., Goodearl A.D.J., Gearing D.P., Sokol S.Y., McCarthy S.A.;
RT "Functional and structural diversity of the human Dickkopf gene
RT family.";
RL Gene 238:301-313 (1999).
RN [2]

```

SEQUENCE FROM N.A.
RA Tanaka S., Sugimachi K., Sugimachi K.,
RL Submitted (OCT-1999) to the EMBL/GenBank/DBSJ databases.
RN [3]
RX MEDLINE=20119095; PubMed=10652205;
RA Tsuji T., Miyazaki M., Sakauchi M., Inoue Y., Namba M.,
RT "A REIC gene shows down-regulation in human immortalized cells and
RT human tumor-derived cell lines."
RL Biochem. Biophys. Res. Commun. 268:20-24 (2000).
RN [4]
RX MEDLINE=21673998; PubMed=11814687;
RA Kobayashi K., Ouchida M., Tsuji T., Hanafusa H., Miyazaki M.,
RA Namba M., Shimizu N., Shimizu K.,
RT "Reduced expression of the REIC/Dkk-3 gene by promoter-
RT hypermethylation in human tumor cells."
RL Gene 282:151-158 (2002).
RN [6]
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins P.S., Wagner L., Shennan C.M., Schuler G.D.,
RA Altschul S.F., Jordan B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Zeeberg H., Moore T., Max S.I., Wang J., Hsieh L.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustun T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Huiyk S.W.,
RA Villalón D.K., Murthy D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettner M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
CC -!- FUNCTION: Inhibitor of Wnt signaling pathway (Potential).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Highest expression in heart, brain, and spinal
CC cord.
CC -!- PTM: N-glycosylated.
CC -!- SIMILARITY: Belongs to the dickkopf family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AF177396; BAF02676.1; -
CC EMBL; AB033421; BAA85488.1; -
CC EMBL; AB034203; BAA90548.1; -
CC EMBL; AB035182; BAA87044.2; -
CC EMBL; AB045205; BAA87044.2; JOINED.
CC EMBL; AB045206; BAA87044.2; JOINED.
CC EMBL; AB045207; BAA87044.2; JOINED.
CC EMBL; AB045208; BAA87044.2; JOINED.
CC EMBL; AB045209; BAA87044.2; JOINED.
CC EMBL; AB045210; BAA87044.2; JOINED.
CC EMBL; AB057591; BAB84360.1; -
CC EMBL; AB057804; BAB84361.1; -

EMBL; BC007660; AAH07660.1; -
DR Genew; HGNC:2893; DKK3.
DR MIM; 605416; -
DR GO; GO:0005615; C:extracellular space; TAS.
DR GO; GO:0007345; P:embryogenesis and morphogenesis; TAS.
DR InterPro; IPR006796; dickkopf_N.
DR Pfam; PF04706; dickkopf_N_1.
KW Developmental protein; Signal; Wnt signaling pathway; Glycoprotein.
FT SIGNAL 1 16 POTENTIAL.
FT CHAIN 17 350 DICKKOPF RELATED PROTEIN-3.
FT DOMAIN 147 195 DKK-TYPE CYS-1.
FT DOMAIN 208 284 DKK-TYPE CYS-2.
FT DOMAIN 338 343 POLY-ALA.
FT CARBOHYD 96 96 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 106 106 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 121 121 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 204 204 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CONFLICT 335 335 G -> R (IN REF. 4).
SQ SEQUENCE 350 AA; 38291 MW; 72F504122B40AFFE CRC64;
Query Match 17.1%; Score 100.5; DB 1; Length 350;
Best Local Similarity 37.7%; Pred. No. 0.0026; 3; Mismatches 29; Indels 11; Gaps 4;
Matches 26; Conservative
QY 26 CERDVQCGAGTCCAIISLWLRGL--RMCTPLRGEGECH-PGSHKVPFFKRKH-----HT 77
DB 208 CDNRDCQPLCCAFQ--RGLFPVCTPLPVEGELCHDPASRLDLITWELEPDGALDR 264
QY 78 CPCLPNLLC 86
DB 265 CPCASGLLC 273
RESULT 14
DKK3 MOUSE STANDARD; PRT; 349 AA.
ID DKK3_MOUSE
AC Q9QUN9;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Dickkopf related protein-3 precursor (Dkk-3) (mdkx-3).
GN DKK3
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99425169; PubMed=10495270;
RA Monaghan P.A., Kioschis P., Wu W., Zuniga A., Bock D., Poustka A.,
RA Delliuss H., Niehrs C.;
RT "Dickkopf genes are co-ordinately expressed in mesodermal lineages."
RL Mech. Dev. 87:45-56 (1999).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=20035735; PubMed=10570958;
RA Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W.,
RA Anaravadi L., Brown D.E., Guyot D., Mays G., Leiby K., Chang S.,
RA Akawa T., Haza A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gofjorbi T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaudo I., Pesole G., Quackenbush J.,
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Liver;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Haza A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gofjorbi T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaudo I., Pesole G., Quackenbush J.,

RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Guscinich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki J., Sato K., Schoenbach C., Seta T., Shibata Y., Storck K.F.,
RA Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA Hayashizaki Y.,
RA "Functional annotation of a full-length mouse cDNA collection";
RL Nature 409:685-690(2001).
RN [4]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6; TISSUE=Brain, and Retina;
RX MEDLINE=22388257; PubMed=12477932;
RA Klausner R.D., Collins F.S., Wagner L., Shermen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: Inhibitor of Wnt signaling pathway (Potential).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Highest expression in brain, eye and heart.
CC -!- SIMILARITY: Belongs to the dickkopf family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AJ243964; CAB60111.1; -;
DR EMBL; AF177400; RAF02680.1; -;
DR EMBL; AK004853; BAB23617.1; -;
DR EMBL; BC046304; RAH46304.1; -;
DR EMBL; BC050934; RAH50934.1; -;
DR MGD; MGI:1354952; Dkk3.
DR InterPro; IPR006796; dickkopf N.
DR Pfam; PF04706; dickkopf N; 1.
KW Developmental protein; Signal; Wnt signaling pathway; Glycoprotein.
FT SIGNAL 1 22 POTENTIAL.
FT CHAIN 23 349 DICKKOPF RELATED PROTEIN-3.
FT DOMAIN 147 195 DKK-TYPE CVS-1.
FT DOMAIN 208 284 DKK-TYPE CVS-2.
FT CARBOHYD 96 96 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 106 106 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 121 121 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 204 204 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 349 AA; 38387 MW; 564CB3C4FB2EAB98 CRC64;
Query Match 16.7%; Score 98.5; DB 1; Length 349;
Best Local Similarity 37.7%; Pred. No. 0.0042;
Matches 26; Conservative 4; Mismatches 28; Indels 11; Gaps 4;

QY 26 CERDVQCGAGTCCCAISLWRLGL--RMCTPLGRGECH-PGSHKVPFFR-----KPKHHT 77
Db 208 CDNRQDCQPLCCAFQ---RGLLFPVCTPLPVEGELCHDPTSLQLDLITWELEPEGALDR 264
QY 78 CPCPLPILIC 86
Db 265 CPCASGLLC 273
RESULT 15
DKK1_HUMAN
ID DKK1_HUMAN STANDARD; PRT; 266 AA.
AC O94907; HUMAN
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2003 (Rel. 42, Last annotation update)
DE Dkkopf related protein-1 precursor (Dkk-1) (Dkkopf-1) (hDkk-1)
DE (SK)
DE DKK1.
GN Homo sapiens (Human).
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Theria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Leiomysarcoma;
RX MEDLINE=9335900; PubMed=10383463;
RA Fedi P., Barico A., Nieto Soria A., Burgess W.H., Miki T.,
RA Bottaro D.P., Kraus M.H., Aaronson S.A.;
RT "Isolation and biochemical characterization of the human Dkk-1
homologue, a novel inhibitor of mammalian Wnt signaling";
RL J. Biol. Chem. 274:19465-19472(1999).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Fetal kidney;
RX MEDLINE=20035735; PubMed=10570958;
RA Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W.,
RA Amaravadi L., Brown D.E., Guyot D., Mays G., Leiby K., Chang B.,
RA Duong T., Goodearl A.D.J., Gearing D.P., Sokol S.V., McCarthy S.A.;
RT "Functional and structural diversity of the human Dkkopf gene
family";
RL Gene 238:301-313(1999).
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=20422487; PubMed=10965128;
RA Roessler E., Du Y., Glinka A., Dutra A., Niehrs C., Muenke M.;
RT "The genomic structure, chromosome location, and analysis of the human
Dkk1 head inducer gene as a candidate for holoprosencephaly";
RL Cytogenet. Cell Genet. 89:220-224(2000).
RN [5]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shermen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,

```

RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RL human and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: Inhibitor of Wnt signaling pathway.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Placenta.
CC -!- SIMILARITY: Belongs to the dickkopf family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF127563; RAD21087.1; -
DR EMBL; AF177394; AAF02674.1; -
DR EMBL; AB020315; BAA34651.1; -
DR EMBL; AB020314; BAA34651.1; JOINED.
DR EMBL; AF261158; AAG15544.1; -
DR EMBL; AF261157; AAG15544.1; JOINED.
DR EMBL; BC001539; AAO11539.1; -
DR Genew; HGNC:2891; DKX1.
DR MIM; 605189; -
DR GO; GO:0008083; F: growth factor activity; TAS.
DR GO; GO:0004871; F: signal transducer activity; TAS.
DR InterPro; IPR006796; dickkopf_N.
DR Pfam; PF04706; dickkopf_N; 1.
KW Developmental protein; Signal; Wnt signaling pathway; Glycoprotein.
FT SIGNAL; 1 19 POTENTIAL.
FT CHAIN; 20 266 DICKKOPF RELATED PROTEIN-1.
FT DOMAIN; 85 138 DKK-TYPE CYS-1.
FT DOMAIN; 189 263 DKK-TYPE CYS-2.
FT CARBOHYD; 256 256 N-LINKED (GLCNAC...) (POTENTIAL).
SQ SEQUENCE 266 AA; 28671 MW; 5E878B2CCE4236BA CRC64;

Query Match 16.5%; Score 97; DB 1; Length 266;
Best Local Similarity 32.3%; Pred. No. 0.0045;
Matches 21; Conservative 9; Mismatches 23; Indels 12; Gaps 3;

QY 26 CERDVQCGAGTCCATSLMLRLGRLMCTPLRGEEEC----HFGSKHKVPFRRKRKHTCPCL 81
Db 189 CLRSSDCASGLCCARHF--SKICKPVLKEGVCTKRRKXGSHGLEIFQR-----CYCG 240

QY 82 FNLLC 86
Db 241 EGLSC 245

Search completed: August 30, 2004, 06:45:03
Job time : 25 secs

```

OM protein - protein search, using sw model

Run on: August 30, 2004, 06:39:14 ; Search time 115 Seconds
(without alignments)
288.082 Million cell updates/sec

Title: US-10-027-603-2
Perfect score: 589
Sequence: 1 MRGATRVSIMLLLVTVSDCA.....CSRFPDGRVRCSDMLKKNINF 105

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- SPTREMBL 25:*
- 1: sp_archea:*
 - 2: sp_bacteria:*
 - 3: sp_fungi:*
 - 4: sp_human:*
 - 5: sp_invertebrate:*
 - 6: sp_mammal:*
 - 7: sp_mhc:*
 - 8: sp_organelle:*
 - 9: sp_phage:*
 - 10: sp_plant:*
 - 11: sp_rodent:*
 - 12: sp_virus:*
 - 13: sp_vertebrate:*
 - 14: sp_unclassified:*
 - 15: sp_virus:*
 - 16: sp_bacteriap:*
 - 17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	588	99.8	105	4 Q8TC69	Q8TC69 homo sapien
2	432	73.3	81	11 Q8K457	Q8K457 mus musculus
3	218	54.0	108	6 Q863H4	Q863H4 bos taurus
4	298.5	50.7	96	13 Q8JFQ0	Q8JFQ0 bombina max
5	298	50.6	128	6 Q863H5	Q863H5 bos taurus
6	274.5	46.6	96	13 Q8JF86	Q8JF86 bombina max
7	273.5	46.4	96	13 Q8JFX8	Q8JFX8 bombina max
8	273.5	46.4	96	13 Q8JFY1	Q8JFY1 bombina max
9	269.5	45.8	96	13 Q8JFX9	Q8JFX9 bombina max
10	269.5	45.8	96	13 Q8JFY0	Q8JFY0 bombina max
11	266.5	45.2	96	13 Q8JFY2	Q8JFY2 bombina max
12	112	19.0	96	13 Q8CUX3	Q8CUX3 gallus gall
13	108.5	18.4	221	11 Q8VEJ3	Q8VEJ3 mus musculus
14	104	17.7	255	13 Q8DDA4	Q8DDA4 xenopus lae
15	101	17.1	259	11 Q8BFW0	Q8BFW0 mus musculus
16	101	17.1	272	11 Q80UL5	Q80UL5 mus musculus

17	100.5	17.1	171	4	O43532	O43532 homo sapien
18	100.5	17.1	215	4	Q8N294	Q8N294 homo sapien
19	99.5	16.9	277	11	Q9ES33	Q9ES33 rattus norv
20	95.5	16.2	259	13	O57464	O57464 xenopus lae
21	94	16.0	240	13	Q9PMH3	Q9PMH3 brachydanio
22	90.5	15.4	425	11	Q8BU04	Q8BU04 mus musculu
23	88.5	15.0	540	10	Q96397	Q96397 chlamydomon
24	86	14.6	241	13	Q9W6D9	Q9W6D9 brachydanio
25	83	14.1	708	13	P87363	P87363 gallus gall
26	83	14.1	966	5	Q22378	Q22378 caenorhabdi
27	82.5	14.0	423	4	Q86U21	Q86U21 homo sapien
28	82.5	14.0	424	4	Q86UA9	Q86UA9 homo sapien
29	81.5	13.8	425	4	Q8N806	Q8N806 homo sapien
30	81.5	13.8	446	4	Q8N803	Q8N803 homo sapien
31	80.5	13.7	113	11	Q9D2R7	Q9D2R7 mus musculu
32	80.5	13.7	729	11	Q8BNH3	Q8BNH3 mus musculu
33	80.5	13.7	787	11	Q8K061	Q8K061 mus musculu
34	80	13.6	412	5	Q86HY9	Q86HY9 dictyostell
35	79.5	13.5	446	4	Q8N1N5	Q8N1N5 homo sapien
36	79.5	13.5	814	5	Q8IQG6	Q8IQG6 drosophila
37	79	13.4	1664	5	Q9TVQ2	Q9TVQ2 caenorhabdi
38	79	13.4	2447	13	O13149	O13149 figu rubrip
39	78	13.2	1537	4	Q8WY29	Q8WY29 homo sapien
40	78	13.2	4599	4	Q9NZR2	Q9NZR2 homo sapien
41	77.5	13.2	911	13	Q7ZZT0	Q7ZZT0 brachydanio
42	77.5	13.2	2559	11	Q8R4U0	Q8R4U0 mus musculu
43	77	13.1	251	5	Q24774	Q24774 enchytraeus
44	77	13.1	762	5	Q8ML23	Q8ML23 drosophila
45	76.5	13.0	1637	6	Q9XSV8	Q9XSV8 bos taurus

ALIGNMENTS

RESULT 1

Q8TC69 PRELIMINARY; PRT; 105 AA.
ID Q8TC69
AC Q8TC69;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Prokineticin 1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA Strausberg R.;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC025399; AAF25399.1; -;
SQ SEQUENCE 105 AA; 11729 MW; E570FDE30EFB52D2 CRC64;

Query Match 99.8%; Score 588; DB 4; Length 105;
Best Local Similarity 99.0%; Pred.No. 4e-66; 0; Indels 0; Gaps 0;
Matches 104; Conservative 1; Mismatches 0;

Qy	1	MRGATRVSIMLLLVTVSDCAVITGACERDVQCAGTCCCAISLWRLGLRMCTPLGRGEEC	60
Db	1	MRGATRVSIMLLLVTVSDCAVITGACERDVQCAGTCCCAISLWRLGLRMCTPLGRGEEC	60
Qy	61	HPGSHKVPFRKXKHKHTCPCLENLCSRPDQGYRCMDLKNINF	105
Db	61	HPGSHKIPFRKXKHKHTCPCLENLCSRPDQGYRCMDLKNINF	105

RESULT 2

Q8K457 PRELIMINARY; PRT; 81 AA.
ID Q8K457
AC Q8K457;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)

```

DE 01-VAR-2003 (Tremblrel. 23, Last annotation update)
DE Prokineticin 1 (Fragment).
GN PROK1 OR PK1.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RX MEDLINE=2022134; PubMed=12024206;
RA Cheng M.Y., Bullock C.M., Li C., Lee A.G., Bermak J.C., Belluzzi J.,
RA Weaver D.R., Leslie F.M., Zhou Q.Y.;
RT "Prokineticin 2 transmits the behavioural circadian rhythm of the
RT suprachiasmatic nucleus.";
RL Nature 417:405-410 (2002).
DR EMBL; AF487281; AAM49573.1; --
DR MGD; MGI:2180370; Prok1.
FT NON_TER 1
SQ SEQUENCE 81 AA; 9192 MW; 7BBE3EC6B16A8011 CRC64;

Query Match 73.3%; Score 432; DB 11; Length 81;
Best Local Similarity 87.7%; Pred. No. 1.3e-46;
Matches 71; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

QY 25 ACERDVOCAGTCCCAISLWLRGLRMLCTPLGREGCHPGSHKVPFRKXKHTCPLPNL 84
Db 1 ACERDIQAGAGTCCCAISLWLRGLRMLCTPLGREGCHPGSHKIPFRKXKHTCPLP 60
QY 85 LCSRFPDGRYRCMDLNKFN 105
Db 61 LCSRFPDGRYRCFRDLKNANF 81

RESULT 3
Q863H4
ID Q863H4 PRELIMINARY; PRT; 108 AA.
AC Q863H4;
DT 01-JUN-2003 (Tremblrel. 24, Created)
DT 01-JUN-2003 (Tremblrel. 24, Last sequence update)
DT 01-JUN-2003 (Tremblrel. 24, Last annotation update)
DE Bv8/prokineticin 2-like protein splice variant.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RX MEDLINE=22612805; PubMed=12728244;
RA Kaser A., Winklmayr M., Lepperdinger G., Kreil G.;
RT "The AVIT protein family.";
RL EMBO Rep. 4:469-473 (2003).
DR EMBL; AY192558; AAP1907.1; --
SQ SEQUENCE 108 AA; 11672 MW; C00410399A9B215E CRC64;

Query Match 54.0%; Score 318; DB 6; Length 108;
Best Local Similarity 51.9%; Pred. No. 4e-32;
Matches 54; Conservative 15; Mismatches 27; Indels 8; Gaps 1;

QY 1 MRGATRVSIMLLV-----TVSDCAVITGACERDVOCAGTCCCAISLWLRGLRMC 52
Db 1 MRSRCARLLELLLPULLTPAGDAVITGACDRDPQCGGMCACAVLWVKIRICTP 60
QY 53 LGREGCHPGSHKVPFRKXKHTCPLPNLCSRFPGRYRC 96
Db 61 MGKVGDSCHPWTRKVPFLGRMHHTCPLPGLACSRISFN 104

RESULT 4
Q8JFQ0
ID Q8JFQ0 PRELIMINARY; PRT; 96 AA
AC Q8JFQ0;
DT 01-OCT-2002 (Tremblrel. 22, Created)
DT 01-OCT-2002 (Tremblrel. 22, Last sequence update)
DT 01-OCT-2002 (Tremblrel. 22, Last annotation update)
DE Bv8 protein homolog 2.
OS Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID=161274;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin secretion;
RA Lai R., Liu H., Lee W.-H., Zhang Y.;
RT "Characterization and cloning of Bv8 protein homologs from toad
RT Bombina maxima.";
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF411091; AAN03822.1; --
SQ SEQUENCE 96 AA; 10198 MW; EC4EAA5E9FE49B2F0 CRC64;

Query Match 50.7%; Score 298.5; DB 13; Length 96;
Best Local Similarity 53.6%; Pred. No. 1e-29;
Matches 52; Conservative 16; Mismatches 28; Indels 1; Gaps 1;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCPLGREGEC 60
Db 1 MKCFQIVVLLLVIAFSHGAVITGACDRDVOCGSGTCCCAASLWSNRNIRFCVPLGNNGEC 60
QY 61 HPGSHKVPFRKXKHTCPLPNLCSRFPGRYRC 97
Db 61 HPASHKVPYNGKRLSSLCPSKSGLTCSKSGE-KFOCS 96

RESULT 5
Q863H5
ID Q863H5 PRELIMINARY; PRT; 128 AA.
AC Q863H5;
DT 01-JUN-2003 (Tremblrel. 24, Created)
DT 01-JUN-2003 (Tremblrel. 24, Last sequence update)
DT 01-JUN-2003 (Tremblrel. 24, Last annotation update)
DE Bv8/prokineticin 2-like protein.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RX MEDLINE=22612805; PubMed=12728244;
RA Kaser A., Winklmayr M., Lepperdinger G., Kreil G.;
RT "The AVIT protein family.";
RL EMBO Rep. 4:469-473 (2003).
DR EMBL; AY192557; AAP1906.1; --
SQ SEQUENCE 128 AA; 14290 MW; C22CDBDBE40483EC CRC64;

Query Match 50.6%; Score 298; DB 6; Length 128;
Best Local Similarity 43.5%; Pred. No. 1.6e-29;
Matches 54; Conservative 15; Mismatches 27; Indels 28; Gaps 2;

QY 1 MRGATRVSIMLLV-----TVSDCAVITGACERDVOCAGTCCCAISLWLRGLRMC 52
Db 1 MRSRCARLLELLLPULLTPAGDAVITGACDRDPQCGGMCACAVLWVKIRICTP 60
QY 53 LGREGCHPGSHKVPFRKXKHTCPLPNLCSRFPG 92
Db 61 MGKVGDSCHPWTRKXKHTCPLPGLACSRISFN 120
QY 93 RYRC 96
Db 121 RYTC 124

RESULT 6
Q8JFQ0
ID Q8JFQ0 PRELIMINARY; PRT; 96 AA
AC Q8JFQ0;
DT 01-OCT-2002 (Tremblrel. 22, Created)
DT 01-OCT-2002 (Tremblrel. 22, Last sequence update)
DT 01-OCT-2002 (Tremblrel. 22, Last annotation update)
DE Bv8 protein homolog 2.
OS Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID=161274;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin secretion;
RA Lai R., Liu H., Lee W.-H., Zhang Y.;
RT "Characterization and cloning of Bv8 protein homologs from toad
RT Bombina maxima.";
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF411091; AAN03822.1; --
SQ SEQUENCE 96 AA; 10198 MW; EC4EAA5E9FE49B2F0 CRC64;

Query Match 50.7%; Score 298.5; DB 13; Length 96;
Best Local Similarity 53.6%; Pred. No. 1e-29;
Matches 52; Conservative 16; Mismatches 28; Indels 1; Gaps 1;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCPLGREGEC 60
Db 1 MKCFQIVVLLLVIAFSHGAVITGACDRDVOCGSGTCCCAASLWSNRNIRFCVPLGNNGEC 60
QY 61 HPGSHKVPFRKXKHTCPLPNLCSRFPGRYRC 97
Db 61 HPASHKVPYNGKRLSSLCPSKSGLTCSKSGE-KFOCS 96
```

Q8JFE6
ID Q8JFE6 PRELIMINARY; PRT; 96 AA.
AC Q8JFE6
DT 01-OCT-2002 (TReMBLrel. 22, Created)
DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TReMBLrel. 22, Last annotation update)
DE BM8-a protein precursor (Bv8 protein homolog 1).
OS Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID=161274;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RA Chen T., Bjourson A.J., Shaw C.;
RT "Multiple BM8 isoforms from the skin of the Oriental toad, Bombina maxima";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin secretion;
RA Lai R., Liu H., Lee W.-H., Zhang Y.;
RT "Characterization and cloning of Bv8 protein homologs from toad Bombina maxima";
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ440230; CAD29340.1; -
DR EMBL; AF411090; AN03821.1; -
KW Signal.
FT CHAIN 1 19 BM8-A PROTEIN.
FT CHAIN 20 96
SQ SEQUENCE 96 AA; 10117 MW; 2269AAC8654B18A6 CRC64;
Query Match 46.6%; Score 274.5; DB 13; Length 96;
Best Local Similarity 49.5%; Pred. No. 1.4e-26;
Matches 48; Conservative 17; Mismatches 31; Indels 1; Gaps 1;
QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MKCFAQIVLLVLLVIAFSGHGVITGCDRAQCGSGTCCAAAFSRNIRFCVPLNGNGEEC 60
QY 61 HPGSHKVPFPRKRKHHTCPCLPNLLCSFPDGRYRCS 97
Db 61 HPASHKVPYNGKRLSSLCPCNTGLTCSKSGE-KFQCS 96
RESULT 7
Q8JFE8
ID Q8JFE8 PRELIMINARY; PRT; 96 AA.
AC Q8JFE8
DT 01-OCT-2002 (TReMBLrel. 22, Created)
DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TReMBLrel. 22, Last annotation update)
DE BM8-f protein precursor.
OS Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID=161274;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RA Chen T., Bjourson A.J., Shaw C.;
RT "Multiple BM8 isoforms from the skin of the Oriental toad, Bombina maxima";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ440235; CAD29345.1; -
KW Signal.
FT CHAIN 1 19 BM8-F PROTEIN.
FT CHAIN 20 96
SQ SEQUENCE 96 AA; 10057 MW; 2269A070F0F118A6 CRC64;
Query Match 46.4%; Score 273.5; DB 13; Length 96;
Best Local Similarity 50.5%; Pred. No. 1.4e-26;
Matches 49; Conservative 15; Mismatches 32; Indels 1; Gaps 1;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MKCFAQIVLLVLLVIAFSGHGVITGCDRAQCGSGTCCAAAFSRNIRFCVPLNGNGEEC 60
QY 61 HPGSHKVPFPRKRKHHTCPCLPNLLCSFPDGRYRCS 97
Db 61 HPASHKVPDGRKRLSSLCPCNTGLTCSKSGE-KYQCS 96
RESULT 8
Q8JFY1
ID Q8JFY1 PRELIMINARY; PRT; 96 AA.
AC Q8JFY1
DT 01-OCT-2002 (TReMBLrel. 22, Created)
DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TReMBLrel. 22, Last annotation update)
DE BM8-c protein precursor.
OS Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID=161274;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RA Chen T., Bjourson A.J., Shaw C.;
RT "Multiple BM8 isoforms from the skin of the Oriental toad, Bombina maxima";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ440232; CAD29342.1; -
KW Signal.
FT CHAIN 1 19 POTENTIAL.
FT CHAIN 20 96 BM8-C PROTEIN.
SQ SEQUENCE 96 AA; 10103 MW; 227EA1A5C49B18A6 CRC64;
Query Match 46.4%; Score 273.5; DB 13; Length 96;
Best Local Similarity 49.5%; Pred. No. 1.4e-26;
Matches 48; Conservative 17; Mismatches 31; Indels 1; Gaps 1;
QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MKCFAQIVLLVLLVIAFSGHGVITGCDRAQCGSGTCCAAAFSRNIRFCVPLNGNGEEC 60
QY 61 HPGSHKVPFPRKRKHHTCPCLPNLLCSFPDGRYRCS 97
Db 61 HPASHKVPYNGKRLSSLCPCNTGLTCSKSGE-KFQCS 96
RESULT 9
Q8JFX9
ID Q8JFX9 PRELIMINARY; PRT; 96 AA.
AC Q8JFX9
DT 01-OCT-2002 (TReMBLrel. 22, Created)
DT 01-OCT-2002 (TReMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TReMBLrel. 22, Last annotation update)
DE BM8-e protein precursor
OS Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX NCBI_TaxID=161274;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skin;
RA Chen T., Bjourson A.J., Shaw C.;
RT "Multiple BM8 isoforms from the skin of the Oriental toad, Bombina maxima";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ440234; CAD29344.1; -
KW Signal.
FT CHAIN 1 19 BM8-E PROTEIN.
FT CHAIN 20 96
SQ SEQUENCE 96 AA; 10127 MW; 226A65C654B18A6 CRC64;

FT CHAIN 20 96 BMS-8 PROTEIN.
SQ SEQUENCE 96 AA; 10186 MW; D77CAACFF54B020C CRC64;

Query Match 45.2%; Score 266.5; DB 13; Length 96;
Best Local Similarity 49.5%; Pred.No.1.le-25;
Matches 48; Conservative 16; Mismatches 32; Indels 1; Gaps 1;

QY 1 MEGATRVSIIMLVTVSDCAVITGACERDVQCAGTGCCAIISLWRLGLRMCTPLGRGEEC 60
Db :
1 MKCFQIIVLLVIAFSGAVITGVDRDQAQCGSGTCCAASAFSNIRECVPLGNNGEEC 60

QY 61 HPGSHKVPFPFRKKHHTCPCLNLLCSRFEDGYRCS 97
Db :
61 HPASHKVYPNGRRKLSCPCNTGLTCKSKSGE-KYQCS 96

RESULT 12
ID Q8UX3 PRELIMINARY; PRT; 96 AA.

OS Q8UX3;
AC Q8UX3;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2002 (TrEMBLrel. 20, Last annotation update)
DE Dkk-1 (Fragment).
GN DKK-1.
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21559221; PubMed=11702953;
RA Mukhopadhyay M., Shtrom S., Rodriguez-Esteban C., Chen L., Tsukui T.,
RA Gomer L., Dorward D.W., Glinka A., Grinberg A., Huang S.P., Niehrs C.,
RA Belmonte J.C.I., Westphal H.;
RT "Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse."
RD Dev. Cell 1:423-434(2001).
RL EMBL; AY049017; AAL07515.1; -.
RS NON TER 1
SQ SEQUENCE 96 AA; 10756 MW; 043B6A647D5AF4E7 CRC64;

Query Match 19.0%; Score 112; DB 13; Length 96;
Best Local Similarity 33.8%; Pred.No.3.le-06;
Matches 22; Conservative 9; Mismatches 22; Indels 12; Gaps 3;

QY 26 CERDVQCAGTGCCAIISLWRLGLRMCTPLGRGEEC---HPGSHKVPFPFRKKHHTCPCL 81
Db :
20 CLRSSDCAGLCARHFV---SKICKPVLREGQVTRHRKGAHGLEIFQR-----CPCA 71

QY 82 PNLLC 86
Db :
72 EGMAC 76

RESULT 13
Q8VEJ3 PRELIMINARY; PRT; 221 AA.

OS Q8VEJ3;
AC Q8VEJ3;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Similar to dickkopf (Xenopus laevis) homolog 4.
GN DKK4.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RS Strausberg R.;

DR EMBL; BC018400; AAH18400.1; -
DR MGI; MGI:12385299; Dkk4.
DR InterPro; IPR006796; dickkopf_N.
DR Pfam; PF04706; dickkopf_N; 1.
SQ SEQUENCE 221 AA; 24260 MW; 670AD9F750BF1715 CRC64;

Query Match 18.4%; Score 108.5; DB 11; Length 221;
Best Local Similarity 35.5%; Pred. No. 1.9e-05;
Matches 22; Conservative 5; Mismatches 32; Indels 3; Gaps 1;

Qy 25 ACERDVCGAGTCCALSLWLRGRLMCTPLGRGEECHPGSHKVPFRKXKHTCPCLPWL 84
Db 144 SCLRTSDCGPLCCARHFW---TKICKPVLHQGEVCTKLRKKGSHGLEIFQR-----CDCA 200
Qy 85 LC 86
Db 201 TC 202

RESULT 14
Q9DDA4 PRELIMINARY; PRT; 255 AA.
AC Q9DDA4; PRELIMINARY; PRT; 255 AA.
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Dickkopf2 precursor.
GN DKK2.
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RA Wu W., Glinka A., Delius H., Niehrs C.;
RT "Mutual antagonism between dickopf1 and -2 regulates Wnt/beta-catenin signalling.";
RL Submitted (NOV-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ300197; CAC17815.1; -.
DR HSP; P25687; 1INT.
DR InterPro; IPR006796; dickkopf_N.
DR Pfam; PF04706; dickkopf_N; 1.
KW Signal.
FT SIGNAL 1 29 POTENTIAL.
FT CHAIN 30 255 DICKKOPF2.
SQ SEQUENCE 255 AA; 28096 MW; F270B7DD0F4FCD73 CRC64;

Query Match 17.7%; Score 104; DB 13; Length 255;
Best Local Similarity 31.5%; Pred. No. 8.1e-05;
Matches 23; Conservative 8; Mismatches 30; Indels 12; Gaps 3;

Qy 26 CERDVCGAGTCCALSLWLRGRLMCTPLGRGEEC-----HPSGHKVPFRKXKHTCPCL 81
Db 179 CLRSTDCIEGFCARHFW---TKICKPVLHQGEVCTKLRKKGSHGLEIFQR-----CDCA 230
Qy 82 PNLLCSRPDPGRY 94
Db 231 KGLSCKVWKDATY 243

RESULT 15
Q8BFW0 PRELIMINARY; PRT; 259 AA.
AC Q8BFW0;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE DICKKOPF related protein-2 precursor.
GN DKK2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Body, and Head;
RX MEDLINE=22354683; PubMed=12466851;
RA The PANTOM Consortium;
RA The RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs.";
RL Nature 420:563-573(2002).
DR EMBL; AK031749; BAC25824.1; -.
DR EMBL; AK031749; BAC25824.1; -.
DR MGI; MGI:1890663; Dkk2.
DR InterPro; IPR006796; dickkopf_N.
DR Pfam; PF04706; dickkopf_N; 1.
SQ SEQUENCE 259 AA; 28432 MW; E649ED8E3BC7E8E4 CRC64;

Query Match 17.1%; Score 101; DB 11; Length 259;
Best Local Similarity 31.5%; Pred. No. 0.0002;
Matches 23; Conservative 8; Mismatches 30; Indels 12; Gaps 3;

Qy 26 CERDVCGAGTCCALSLWLRGRLMCTPLGRGEEC-----HPSGHKVPFRKXKHTCPCL 81
Db 183 CLRSTDCIEGFCARHFW---TKICKPVLHQGEVCTKLRKKGSHGLEIFQR-----CDCA 234
Qy 82 PNLLCSRPDPGRY 94
Db 235 KGLSCKVWKDATY 247

Search completed: August 30, 2004, 06:47:06
Job time: 119 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 30, 2004, 07:11:56 / Search time 55 Seconds

Perfect score: 589
Sequence: 1 MRGATRVSIMLLVTVSDCA.....CSRFPGDGRVCSMDLKNINF 105
539.409 Million cell updates/sec

Title: US-10-027-603-2

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Scoring table: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 289

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 2500 summaries

Database : A: Geneseq_29Jan04.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	589	100.0	105	3	AAV66745 Membrane-
2	589	100.0	105	3	Aab18453 A human T
3	589	100.0	105	4	Aab70148 Human G p
4	589	100.0	105	4	Aab68427 Amino aci
5	589	100.0	105	4	Aau12406 Human PRO
6	589	100.0	105	4	Aab53096 Human arg
7	589	100.0	105	4	Aab52268 Human PRO
8	589	100.0	105	4	Aab48175 Human PRO
9	589	100.0	105	4	Aab48067 Human ext
10	589	100.0	105	4	Aam50773 Endocrine
11	589	100.0	105	5	AAU83674 Human PRO
12	589	100.0	105	5	ABBB4902 Human PRO
13	589	100.0	105	5	AAOI15527 Human phy
14	589	100.0	105	5	ABBO6308 Human G p
15	589	100.0	105	5	ABE24382 Human pro
16	589	100.0	105	5	ABBS5508 Human PRO
17	589	100.0	105	6	ABUS8083 Human PRO
18	589	100.0	105	6	ABUS9161 Novel hum
19	589	100.0	105	6	ABU82673 Human sec
20	589	100.0	105	6	ABOI17850 Novel hum
21	589	100.0	105	6	ABU60592 Human sec
22	589	100.0	105	6	ABU80821 Human PRO
23	589	100.0	105	6	ABO33787 Novel hum
24	589	100.0	105	6	ABUI3974 Human PRO
25	589	100.0	105	6	ABU08800 Human end

26	589	100.0	105	6	ABU81104	Human PRO
27	589	100.0	105	6	ABU07603	Human ZVE
28	589	100.0	105	6	ABU72559	Novel hum
29	589	100.0	105	6	ABU66804	Human PRO
30	589	100.0	105	6	ABU59885	Novel sec
31	589	100.0	105	6	ABU59308	Human sec
32	589	100.0	105	6	ABO26005	Human PRO
33	589	100.0	105	6	ABO25075	Human sec
34	589	100.0	105	6	ABU82130	Novel hum
35	589	100.0	105	6	ABU59014	Human sec
36	589	100.0	105	6	ABU92392	Novel hum
37	589	100.0	105	6	ABU59457	Novel hum
38	589	100.0	105	6	ABU67080	Human sec
39	589	100.0	105	6	ABU92223	Novel hum
40	589	100.0	105	6	ABU10929	Human PRO
41	589	100.0	105	6	ABU81681	Novel hum
42	589	100.0	105	6	ABU88620	Human sec
43	589	100.0	105	6	ABO34134	Human PRO
44	589	100.0	105	6	ADA45989	Novel hum
45	589	100.0	105	6	ADA76420	Human PRO
46	589	100.0	105	6	ADA76420	Human PRO
47	589	100.0	105	6	ADA72310	Human PRO
48	589	100.0	105	6	ADA19070	Human PRO
49	589	100.0	105	6	ADA61693	Homo sapi
50	589	100.0	105	6	ADB19478	Novel hum
51	589	100.0	105	6	ADB28019	Human PRO
52	589	100.0	105	6	ADA86498	Novel hum
53	589	100.0	105	6	ADA81602	Human PRO
54	589	100.0	105	6	ADA47848	Human PRO
55	589	100.0	105	6	ADA21568	Human sec
56	589	100.0	105	6	ADA10355	Human sec
57	589	100.0	105	6	ADA67643	Human PRO
58	589	100.0	105	6	ADB30650	Human PRO
59	589	100.0	105	6	ADA85946	Novel hum
60	589	100.0	105	6	ADA17899	Human PRO
61	589	100.0	105	6	ADA97158	Human PRO
62	589	100.0	105	6	ADA79462	Human PRO
63	589	100.0	105	6	ADA87601	Novel hum
64	589	100.0	105	6	ADB16803	Human PRO
65	589	100.0	105	6	ADA28007	Human sec
66	589	100.0	105	6	ADA91895	Novel hum
67	589	100.0	105	6	ADB14958	Human PRO
68	589	100.0	105	6	ADB18919	Novel hum
69	589	100.0	105	6	ADA94134	Human PRO
70	589	100.0	105	6	ADB20030	Novel hum
71	589	100.0	105	6	ADB13342	Human PRO
72	589	100.0	105	6	ABO43383	Novel hum
73	589	100.0	105	6	ADA4587	Human sec
74	589	100.0	105	6	ADA74596	Human PRO
75	589	100.0	105	6	ADB24829	Human PRO
76	589	100.0	105	6	ADA82353	Human PRO
77	589	100.0	105	6	ADA75316	Human PRO
78	589	100.0	105	6	ADA85394	Novel hum
79	589	100.0	105	6	ADA84842	Novel hum
80	589	100.0	105	6	ADB30098	Human PRO
81	589	100.0	105	6	ADA80626	Human PRO
82	589	100.0	105	6	ADA75868	Human PRO
83	589	100.0	105	6	ADA38812	Human sec
84	589	100.0	105	6	ADA47093	Human PRO
85	589	100.0	105	6	ADB25389	Human PRO
86	589	100.0	105	6	ADA93565	Human PRO
87	589	100.0	105	6	ADB26915	Human PRO
88	589	100.0	105	6	ADB31202	Human PRO
89	589	100.0	105	6	ABJ72438	Human PRO
90	589	100.0	105	6	ADA92933	Human sec
91	589	100.0	105	6	ADA61130	Homo sapi
92	589	100.0	105	6	ADB24277	Human PRO
93	589	100.0	105	6	ADA96606	Human PRO
94	589	100.0	105	6	ADA81178	Human PRO
95	589	100.0	105	6	ADA96054	Human PRO
96	589	100.0	105	6	ADB26363	Human PRO
97	589	100.0	105	6	ADB21848	Novel hum
98	589	100.0	105	6	ABO34333	Human sec

99	589	100.0	105	7	ADA77627	Human PRO	172	589	100.0	105	7	ADC58621	Novel hum
100	589	100.0	105	7	ADB18367	Human PRO	173	589	100.0	105	7	ADC14671	Novel hum
101	589	100.0	105	7	ADA87050	Novel hum	174	589	100.0	105	7	ADC47238	Novel hum
102	589	100.0	105	7	ADA88153	Novel hum	175	589	100.0	105	7	ADC08203	Novel hum
103	589	100.0	105	7	ADA46541	Novel hum	176	589	100.0	105	7	ADC03295	Novel hum
104	589	100.0	105	7	ADB28571	Human PRO	177	589	100.0	105	7	ADC90287	Novel hum
105	589	100.0	105	7	ADB29123	Human PRO	178	589	100.0	105	7	ADC82028	Human PRO
106	589	100.0	105	7	ABO53220	Human sec	179	589	100.0	105	7	ADC69706	Human PRO
107	589	100.0	105	7	ADA77075	Human PRO	180	589	100.0	105	7	ADC48595	Human PRO
108	589	100.0	105	7	ADA22494	Human sec	181	589	100.0	105	7	ADC10124	Human PRO
109	589	100.0	105	7	ADA88705	Human sec	182	589	100.0	105	7	ADC07670	Novel hum
110	589	100.0	105	7	ADA97710	Human PRO	183	589	100.0	105	7	ADC78113	Novel hum
111	589	100.0	105	7	ADB27467	Human PRO	184	589	100.0	105	7	ADC04699	Novel hum
112	589	100.0	105	7	ABO22590	Human sec	185	589	100.0	105	7	ADC82561	Human PRO
113	589	100.0	105	7	ADA06660	Human sec	186	589	100.0	105	7	ADC08348	Novel hum
114	589	100.0	105	7	ABJ72140	Human mem	187	589	100.0	105	7	ADC80655	Novel hum
115	589	100.0	105	7	ADA33953	Human sec	188	589	100.0	105	7	ADC11162	Human PRO
116	589	100.0	105	7	ADA67091	Human PRO	189	589	100.0	105	7	ADC10461	Human sec
117	589	100.0	105	7	ADB22952	Human PRO	190	589	100.0	105	7	ADC48043	Human PRO
118	589	100.0	105	7	ADB23725	Human PRO	191	589	100.0	105	7	ADC08741	Novel hum
119	589	100.0	105	7	ADA92447	Novel hum	192	589	100.0	105	7	ADC77867	Novel hum
120	589	100.0	105	7	ADB15510	Human PRO	193	589	100.0	105	7	ADC80103	Novel hum
121	589	100.0	105	7	ADB83656	Novel hum	194	589	100.0	105	7	ADC06990	Novel hum
122	589	100.0	105	7	ADB80762	Novel hum	195	589	100.0	105	7	ADC11421	Human sec
123	589	100.0	105	7	ADB73303	Novel hum	196	589	100.0	105	7	ADC09572	Human PRO
124	589	100.0	105	7	ADB38762	Novel hum	197	589	100.0	105	7	ADC83237	Human PRO
125	589	100.0	105	7	ADB96379	Human PRO	198	589	100.0	105	7	ADC50830	Novel hum
126	589	100.0	105	7	ADB78385	Novel hum	199	589	100.0	105	7	ADC11285	Novel hum
127	589	100.0	105	7	ADB38210	Novel hum	200	589	100.0	105	7	ADC52424	Human PRO
128	589	100.0	105	7	ADB66682	Novel hum	201	589	100.0	105	7	ADC51076	Novel hum
129	589	100.0	105	7	ADB85033	Human PRO	202	589	100.0	105	7	ADC53164	Human PRO
130	589	100.0	105	7	ADB89762	Human PRO	203	589	100.0	105	7	ADC53716	Novel hum
131	589	100.0	105	7	ADB90494	Human PRO	204	589	100.0	105	7	ADC55344	Human PRO
132	589	100.0	105	7	ADB39595	Novel hum	205	589	100.0	105	7	ADC69106	Human ZAQ
133	589	100.0	105	7	ADB78139	Novel hum	206	589	100.0	105	7	ADC37214	Human sec
134	589	100.0	105	7	ADB87205	Human PRO	207	589	100.0	105	7	ADC56302	Human PRO
135	589	100.0	105	7	ADB84787	Human PRO	208	589	100.0	105	7	ADC51872	Human PRO
136	589	100.0	105	7	ADB47218	Novel hum	209	589	100.0	105	7	ADC02671	Human PRO
137	589	100.0	105	7	ADB83902	Novel hum	210	589	100.0	105	7	ADC50557	Human PRO
138	589	100.0	105	7	ADB86825	Human PRO	211	589	100.0	105	7	ADC02105	Human PRO
139	589	100.0	105	7	ADB73057	Novel hum	212	589	100.0	105	7	ADC54287	Novel hum
140	589	100.0	105	7	ADB77430	Novel hum	213	589	100.0	105	7	ADC54740	Human PRO
141	589	100.0	105	7	ADB34587	Human PRO	214	589	100.0	105	7	ADC50311	Human PRO
142	589	100.0	105	7	ADB35691	Human PRO	215	589	100.0	105	7	ADC51322	Novel hum
143	589	100.0	105	7	ADB34035	Human PRO	216	589	100.0	105	7	ADC92604	Human PRO
144	589	100.0	105	7	ADB35139	Human PRO	217	589	100.0	105	7	ADC91500	Human PRO
145	589	100.0	105	7	ADB36243	Human PRO	218	589	100.0	105	7	ADC04114	Human PRO
146	589	100.0	105	7	ADB46638	Novel hum	219	589	100.0	105	7	ADC26894	Novel hum
147	589	100.0	105	7	ADC57851	Human PRO	220	589	100.0	105	7	ADC32411	Novel hum
148	589	100.0	105	7	ADC57851	Human PRO	221	589	100.0	105	7	ADC22343	Human PRO
149	589	100.0	105	7	ADC55215	Human PRO	222	589	100.0	105	7	ADC79567	Human PRO
150	589	100.0	105	7	ADC12082	Human sec	223	589	100.0	105	7	ADC42103	Human PRO
151	589	100.0	105	7	ADC56504	Human PRO	224	589	100.0	105	7	ADC17920	Human PRO
152	589	100.0	105	7	ADC07559	Human sec	225	589	100.0	105	7	ADC92052	Human PRO
153	589	100.0	105	7	ADC11549	Human sec	226	589	100.0	105	7	ADC33515	Novel hum
154	589	100.0	105	7	ADC36895	Human PRO	227	589	100.0	105	7	ADC34067	Novel hum
155	589	100.0	105	7	ADC21885	Human PRO	228	589	100.0	105	7	ADC80119	Human PRO
156	589	100.0	105	7	ADC50511	Novel hum	229	589	100.0	105	7	ADC93156	Human PRO
157	589	100.0	105	7	ADC72058	Novel hum	230	589	100.0	105	7	ADC19576	Human PRO
158	589	100.0	105	7	ADC60037	Novel hum	231	589	100.0	105	7	ADC19024	Human PRO
159	589	100.0	105	7	ADC49916	Novel hum	232	589	100.0	105	7	ADC43220	Human PRO
160	589	100.0	105	7	ADC49115	Novel hum	233	589	100.0	105	7	ADC96009	Human PRO
161	589	100.0	105	7	ADC47493	Novel hum	234	589	100.0	105	7	ADC22895	Human PRO
162	589	100.0	105	7	ADC53044	Novel hum	235	589	100.0	105	7	ADC79013	Human PRO
163	589	100.0	105	7	ADC57398	Novel hum	236	589	100.0	105	7	ADC6361	Novel hum
164	589	100.0	105	7	ADC60589	Novel hum	237	589	100.0	105	7	ADC32963	Novel hum
165	589	100.0	105	7	ADC51064	Novel hum	238	589	100.0	105	7	ADC42655	Human PRO
166	589	100.0	105	7	ADC65591	Human PRO	239	589	100.0	105	7	ADC80671	Human PRO
167	589	100.0	105	7	ADC54689	Novel hum	240	589	100.0	105	7	ADC89699	Human PRO
168	589	100.0	105	7	ADC53650	Novel hum	241	589	100.0	105	7	ADC40983	Human PRO
169	589	100.0	105	7	ADC59173	Novel hum	242	589	100.0	105	7	ADC04782	Human PRO
170	589	100.0	105	7	ADC56051	Novel hum	243	589	100.0	105	8	ADC46869	Novel hum
171	589	100.0	105	7	ADC56051	Novel hum	244	589	100.0	105	8	ADC81207	Novel hum

245	589	100.0	105	8	ADE21040	Ade21040	Novel	hum
246	589	100.0	105	8	ADE05884	Ade05884	Human	PRO
247	589	100.0	105	8	ADD76655	Add76655	Human	PRO
248	589	100.0	105	8	ADD75113	Add75113	Human	PRO
249	589	100.0	105	8	ADD75859	Add75859	Novel	hum
250	589	100.0	105	8	ADD85091	Add85091	Novel	hum
251	589	100.0	105	8	ADD86917	Add86917	Novel	hum
252	589	100.0	105	8	ADE20794	Ade20794	Novel	hum
253	589	100.0	105	8	ADE39091	Ade39091	Novel	hum
254	589	100.0	105	8	ADD88019	Add88019	Human	PRO
255	589	100.0	105	8	ADD86423	Add86423	Human	PRO
256	589	100.0	105	8	ADE05638	Ade05638	Human	PRO
257	589	100.0	105	8	ADD73623	Add73623	Human	PRO
258	589	100.0	105	8	ADE75871	Ade75871	Human	PRO
259	589	100.0	105	8	ADD78463	Add78463	Novel	hum
260	589	100.0	105	8	ADE41422	Ade41422	Human	sec
261	589	100.0	105	8	ADE23447	Ade23447	Human	PRO
262	589	100.0	105	8	ADE21286	Ade21286	Novel	hum
263	589	100.0	105	8	ADD77401	Add77401	Novel	hum
264	589	100.0	105	8	ADE20548	Ade20548	Novel	hum
265	589	100.0	105	8	ADD75613	Add75613	Human	PRO
266	589	100.0	105	8	ADD74129	Add74129	Human	PRO
267	589	100.0	105	8	ADD74375	Add74375	Human	PRO
268	589	100.0	105	8	ADD76105	Add76105	Novel	hum
269	589	100.0	105	8	ADD85597	Add85597	Novel	hum
270	589	100.0	105	8	ADE23999	Ade23999	Human	PRO
271	589	100.0	105	8	ADE24642	Ade24642	Human	PRO
272	589	100.0	105	8	ADD87467	Add87467	Human	PRO
273	589	100.0	105	8	ADE05146	Ade05146	Human	PRO
274	589	100.0	105	8	ADD75359	Add75359	Human	PRO
275	589	100.0	105	8	ADD76903	Add76903	Novel	hum
276	589	100.0	105	8	ADD86671	Add86671	Novel	hum
277	589	100.0	105	8	ADE89333	Ade89333	Human	PRO
278	589	100.0	105	8	ADD78139	Add78139	Novel	hum
279	589	100.0	105	8	ADE18472	Ade18472	Human	PRO
280	589	100.0	105	8	ADE88781	Ade88781	Human	PRO
281	589	100.0	105	8	ADD77647	Add77647	Novel	hum
282	589	100.0	105	8	ADD77893	Add77893	Novel	hum
283	589	100.0	105	8	ADD85351	Add85351	Novel	hum
284	589	100.0	105	8	ADD73883	Add73883	Human	PRO
285	589	100.0	105	8	ADD74621	Add74621	Human	PRO
286	589	100.0	105	8	ADD77149	Add77149	Novel	hum
287	589	100.0	105	8	ADD85843	Add85843	Novel	hum
288	589	100.0	105	8	ADE05392	Ade05392	Human	PRO
289	589	100.0	105	8	ADD74867	Add74867	Human	PRO

Search completed: August 30, 2004, 07:13:00
Job time : 57 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 30, 2004, 06:42:29 ; Search time 19 Seconds
(without alignments)
285.301 Million cell updates/sec

Title: US-10-027-603-2

Perfect score: 589
Sequence: 1 MRGATRVSIMLLVTVDCA.....CSRFPDGRYCSMDLKNINF 105

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues.

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents_AA.*

- 1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep.*
- 2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep.*
- 3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep.*
- 4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep.*
- 5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep.*
- 6: /cgn2_6/ptodata/2/iaa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	589	100.0	105	4	US-09-712-529-5
2	577	98.0	105	4	US-09-621-976-5350
3	303	51.4	108	4	US-09-712-529-2
4	107.5	18.3	224	4	US-09-161-241-14
5	102	17.3	207	4	US-09-161-241-13
6	102	17.3	259	4	US-09-161-241-12
7	101	17.1	259	4	US-09-161-241-11
8	100.5	17.1	350	4	US-09-161-241-9
9	100.5	17.1	350	4	US-09-907-794A-236
10	100.5	17.1	350	4	US-09-905-125A-236
11	100.5	17.1	350	4	US-09-902-775A-236
12	98.5	16.7	349	4	US-09-161-241-8
13	97	16.5	266	4	US-09-161-241-10
14	97	16.5	266	4	US-09-976-594-1086
15	82	13.9	1342	4	US-09-561-709B-13
16	81	13.8	1964	4	US-09-467-997-1
17	78.5	13.3	163	2	US-08-219-237B-5
18	78.5	13.3	163	3	US-08-477-347-13
19	78.5	13.3	163	3	US-08-476-862-4
20	78.5	13.3	163	3	US-08-468-560C-5
21	78.5	13.3	163	4	US-09-800-909-4
22	78.5	13.3	163	4	US-09-800-908-13
23	75.5	12.8	1101	4	US-09-561-709B-5
24	75.5	12.8	1761	4	US-09-561-709B-1
25	75	12.7	651	1	US-08-264-101-2
26	75	12.7	651	2	US-08-765-243-2
27	75	12.7	651	5	PCT-US95-07295-2

28	75	12.7	734	2	US-08-765-243-8	Sequence 8, Appli
29	75	12.7	734	5	PCT-US95-07295-8	Sequence 8, Appli
30	75	12.7	3075	2	US-08-460-309-5	Sequence 5, Appli
31	75	12.7	3075	2	US-08-125-077-5	Sequence 5, Appli
32	73	12.4	163	4	US-08-828-683A-13	Sequence 13, Appli
33	73	12.4	163	4	US-09-523-323-54	Sequence 54, Appli
34	73	12.4	164	2	US-08-232-087A-9	Sequence 9, Appli
35	73	12.4	227	3	US-08-974-022-48	Sequence 48, Appli
36	73	12.4	227	3	US-08-795-445A-48	Sequence 48, Appli
37	73	12.4	227	3	US-08-795-447A-48	Sequence 48, Appli
38	73	12.4	227	3	US-08-974-186-48	Sequence 48, Appli
39	73	12.4	227	3	US-08-795-446B-48	Sequence 48, Appli
40	73	12.4	227	3	US-08-706-945D-134	Sequence 134, Appli
41	73	12.4	227	4	US-08-577-789C-48	Sequence 48, Appli
42	73	12.4	235	4	US-09-326-394-4	Sequence 4, Appli
43	73	12.4	235	4	US-09-580-235-2	Sequence 2, Appli
44	73	12.4	235	4	US-09-580-235-4	Sequence 4, Appli
45	73	12.4	235	4	US-09-580-235-6	Sequence 6, Appli

ALIGNMENTS

RESULT 1

US-09-712-529-5
; Sequence 5, Application US/09712529
; Patent No. 6485938
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Bishop, Paul D.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Thompson, Penny P.
; TITLE OF INVENTION: Human Zven Proteins
; FILE REFERENCE: 99-81
; CURRENT APPLICATION NUMBER: US/09/712,529
; CURRENT FILING DATE: 2000-11-14
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5
; TYPE: PRT
; LENGTH: 105
; ORGANISM: Homo sapiens
US-09-712-529-5

Query Match 100.0%; Score 589; DB 4; Length 105;
Best Local Similarity 100.0%; Pred. No. 6.8e-59;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MRGATRVSIMLLVTVDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEC	60
Db	1	MRGATRVSIMLLVTVDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEC	60

Qy 61 HPGSHKVPFRKRKHHTCTCLPNLLCSRFPDGRYCSMDLKNINF 105

Db 61 HPGSHKVPFRKRKHHTCTCLPNLLCSRFPDGRYCSMDLKNINF 105

RESULT 2

US-09-621-976-5350
; Sequence 5350, Application US/09621976
; Patent No. 6639063
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Jobert, S.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: ESTs and Encoded Human Proteins.
; FILE REFERENCE: GENSET.054PR2
; CURRENT APPLICATION NUMBER: US/09/621,976
; CURRENT FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 19335
; SOFTWARE: Patent.pm
; SEQ ID NO 5350
; LENGTH: 105

```
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19...-1
; NAME/KEY: UNSURE
; LOCATION: 38
; OTHER INFORMATION: Xaa = Ala, Gly
US-09-621-976-5350

Query Match      98.0%; Score 577; DB 4; Length 105;
Best Local Similarity 97.1%; Pred. No. 1.5e-57;
Matches 102; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
Db 1 MEGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCCAISLWRLGRLMCTPLGRKXEC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFPPDGRVRCSDMLXNINP 105
Db 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFPPDGRVRCSDMLXNINP 105

RESULT 3
US-09-712-529-2
; Sequence 2, Application US/09712529
; Patent No. 6485938
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Bishop, Paul D.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Thompson, Penny P.
; TITLE OF INVENTION: Human Zven Proteins
; FILE REFERENCE: 99-81
; CURRENT APPLICATION NUMBER: US/09/712,529
; CURRENT FILING DATE: 2000-11-14
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-712-529-2

Query Match      51.4%; Score 303; DB 4; Length 108;
Best Local Similarity 55.2%; Pred. No. 9e-27;
Matches 48; Conservative 15; Mismatches 24; Indels 0; Gaps 0;

QY 10 MLLVTVSDCAVITGACERDVOCGAGTCCCAISLWRLGRLMCTPLGREGECHPGSHKVPF 69
Db 18 LLTPRAGDAVITGACDKDSQCGGMCVSIWKSIRICTPMKLGDSCHPLTRKVPF 77

QY 70 FKRRKHHTCPCLPNLLCSRFPPDGRVRC 96
Db 78 FGRRMHHTCPCLPLGLACLRITSNRFIC 104

RESULT 4
US-09-161-241-14
; Sequence 14, Application US/09161241
; Patent No. 6344541
; GENERAL INFORMATION:
; APPLICANT: Bass, Michael B
; APPLICANT: Sullivan, John K
; APPLICANT: Theill, Lars E
; APPLICANT: Wang, Daguang
; TITLE OF INVENTION: NOVEL DKR POLYPEPTIDES
; FILE REFERENCE: A-548
; CURRENT APPLICATION NUMBER: US/09/161,241
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 14

; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-161-241-14
```

```
; LENGTH: 224
; TYPE: PRT
; ORGANISM: Human
US-09-161-241-14

Query Match      18.3%; Score 107.5; DB 4; Length 224;
Best Local Similarity 35.5%; Pred. No. 0.00018;
Matches 22; Conservative 5; Mismatches 32; Indels 3; Gaps 1;

QY 25 AERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECHPGSHKVPFFRKHKHTCPCLPNL 84
Db 144 SCLRTFDCGFLCCARHFW---TKICKVLLGQVCSRRGHKDTAQAPEIFQRCDCGFL 200

QY 85 LC 86
Db 201 LC 202

RESULT 5
US-09-161-241-13
; Sequence 13, Application US/09161241
; Patent No. 6344541
; GENERAL INFORMATION:
; APPLICANT: Bass, Michael B
; APPLICANT: Sullivan, John K
; APPLICANT: Theill, Lars E
; APPLICANT: Wang, Daguang
; TITLE OF INVENTION: NOVEL DKR POLYPEPTIDES
; FILE REFERENCE: A-548
; CURRENT APPLICATION NUMBER: US/09/161,241
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 207
; TYPE: PRT
; ORGANISM: Human
US-09-161-241-13

Query Match      17.3%; Score 102; DB 4; Length 207;
Best Local Similarity 31.5%; Pred. No. 0.00068;
Matches 23; Conservative 8; Mismatches 30; Indels 12; Gaps 3;

QY 26 CERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECHPGSHKVPFFRKHKHTCPCL 81
Db 131 CLRSSDCIEGFCARHFW---TKICKVLLHOGVCTKORKGSHGLEIFQRCDCGFL 182

QY 82 PNLLCSRFPPDGRY 94
Db 183 KGLSCKVWKDATY 195

RESULT 6
US-09-161-241-12
; Sequence 12, Application US/09161241
; Patent No. 6344541
; GENERAL INFORMATION:
; APPLICANT: Bass, Michael B
; APPLICANT: Sullivan, John K
; APPLICANT: Theill, Lars E
; APPLICANT: Wang, Daguang
; TITLE OF INVENTION: NOVEL DKR POLYPEPTIDES
; FILE REFERENCE: A-548
; CURRENT APPLICATION NUMBER: US/09/161,241
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 12
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Human
US-09-161-241-12
```

Query Match 17.3%; Score 102; DB 4; Length 259;
Best Local Similarity 31.5%; Pred. No. 0.00089;
Matches 23; Conservative 8; Mismatches 30; Indels 12; Gaps 3;
QY 26 CERDVQCGAGTCCCAISLWRLGRLMCTPLRGREGEC-----HPGSHKVPFFRKXKHTCPCL 81
DB 183 CLRSSDCIEGFCARHFW---TKICKPVLHQGEVCTQRKKGSHGLEIFQR-----CDCA 234
QY 82 PNLLCSRFPDGRY 94
DB 235 KGLSCKWKDQATY 247

RESULT 7
US-09-161-241-11
; Sequence 11, Application US/09161241
; Patent No. 6344541
; GENERAL INFORMATION:
; APPLICANT: Bass, Michael B
; APPLICANT: Sullivan, John K
; APPLICANT: Theill, Lars E
; APPLICANT: Wang, Daguang
; TITLE OF INVENTION: NOVEL DKR POLYPEPTIDES
; FILE REFERENCE: A-548
; CURRENT APPLICATION NUMBER: US/09/161.241
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 11
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Mouse
US-09-161-241-11

Query Match 17.1%; Score 101; DB 4; Length 259;
Best Local Similarity 31.5%; Pred. No. 0.0011;
Matches 23; Conservative 8; Mismatches 30; Indels 12; Gaps 3;
QY 26 CERDVQCGAGTCCCAISLWRLGRLMCTPLRGREGEC-----HPGSHKVPFFRKXKHTCPCL 81
DB 183 CLRSSDCIDGFCARHFW---TKICKPVLHQGEVCTQRKKGSHGLEIFQR-----CDCA 234
QY 82 PNLLCSRFPDGRY 94
DB 235 KGLSCKWKDQATY 247

RESULT 8
US-09-161-241-9
; Sequence 9, Application US/09161241
; Patent No. 6344541
; GENERAL INFORMATION:
; APPLICANT: Bass, Michael B
; APPLICANT: Sullivan, John K
; APPLICANT: Theill, Lars E
; APPLICANT: Wang, Daguang
; TITLE OF INVENTION: NOVEL DKR POLYPEPTIDES
; FILE REFERENCE: A-548
; CURRENT APPLICATION NUMBER: US/09/161.241
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 9
; LENGTH: 350
; TYPE: PRT
; ORGANISM: Human
US-09-161-241-9

Query Match 17.1%; Score 100.5; DB 4; Length 350;
Best Local Similarity 37.7%; Pred. No. 0.0018;
Matches 26; Conservative 3; Mismatches 29; Indels 11; Gaps 4;
QY 26 CERDVQCGAGTCCCAISLWRLGRL---RMCTPLRGREGEC-PSHKKVPFFRKXKHT-----HT 77

DB 208 CNQRDCQFGLCCAFQ---RGLFFVCTPLFVEGELCHDPASRLDLITWELEPDGALDR 264
QY 78 CPCLNLLC 86
DB 265 CFCASGLLC 273

RESULT 9
US-09-907-794A-236
; Sequence 236, Application US/09907794A
; Patent No. 6635468
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Aids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,794A
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 236
 ; LENGTH: 350
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-907-794A-236

Query Match 17.1%; Score 100.5; DB 4; Length 350;
 Best Local Similarity 37.7%; Pred. No. 0.0018;
 Matches 26; Conservative 3; Mismatches 29; Indels 11; Gaps 4;
 QY 26 CERDVCCAGTCCATSLWRLG--RMCTPLGREGECH-PGSHKVPFFRKXK-----HT 77
 Db 208 CDNQRCQPGLCAPQ---RGLLFPVCTPLPVEGELCHDPASRLDLITWELEPDGALDR 264
 QY 78 CPCLPNLLC 86
 Db 265 CPCASGLLC 273

RESULT 10
 US-09-905-125A-236
 ; Sequence 236, Application US/09905125A
 ; Patent No. 6664376
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/905,125A
 ; CURRENT FILING DATE: 2001-07-12
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 236
 ; LENGTH: 350
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-905-125A-236

Query Match 17.1%; Score 100.5; DB 4; Length 350;
 Best Local Similarity 37.7%; Pred. No. 0.0018;
 Matches 26; Conservative 3; Mismatches 29; Indels 11; Gaps 4;
 QY 26 CERDVCCAGTCCATSLWRLG--RMCTPLGREGECH-PGSHKVPFFRKXK-----HT 77
 Db 208 CDNQRCQPGLCAPQ---RGLLFPVCTPLPVEGELCHDPASRLDLITWELEPDGALDR 264
 QY 78 CPCLPNLLC 86
 Db 265 CPCASGLLC 273

RESULT 11
 US-09-902-775A-236
 ; Sequence 236, Application US/09902775A
 ; Patent No. 6686451
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14

CURRENT APPLICATION NUMBER: US/09/902.775A
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 236
; LENGTH: 350
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-902-775A-236

Query Match 17.1%; Score 100.5; DB 4; Length 350;
Best Local Similarity 37.7%; Pred. No. 0.0018;
Matches 26; Conservative 3; Mismatches 29; Indels 11; Gaps 4;

QY 26 CERDVQCGAGTCCALSMLRGL--RMCTPLGREGEECH-PGSHKVPFPRKXK-----HT 77
DB 208 CDNRDCQPGGLCCAFQ---RGLLFPVCTPLPVEGELCHDPASRLDLITWELEPDGALDR 264

QY 78 CPCLPMLLC 86
DB 265 CFCASGLLC 273

RESULT 12
US-09-161-241-8
; Sequence 8, Application US/09161241
; Patent No. 6344541
; GENERAL INFORMATION:
; APPLICANT: Bass, Michael B
; APPLICANT: Sullivan, John K
; APPLICANT: Theill, Lars E
; APPLICANT: Wang, Daquang
; TITLE OF INVENTION: NOVEL DKR POLYPEPTIDES
; FILE REFERENCE: A-548
; CURRENT APPLICATION NUMBER: US/09/161,241
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 8
; LENGTH: 349
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-902-775A-236

; TYPE: PRT
; ORGANISM: Mouse
US-09-161-241-8

Query Match 16.7%; Score 98.5; DB 4; Length 349;
Best Local Similarity 37.7%; Pred. No. 0.003;
Matches 26; Conservative 4; Mismatches 28; Indels 11; Gaps 4;

QY 26 CERDVQCGAGTCCALSMLRGL--RMCTPLGREGEECH-PGSHKVPFPR-----KRKHT 77
DB 208 CDNRDCQPGGLCCAFQ---RGLLFPVCTPLPVEGELCHDPASRLDLITWELEPDGALDR 264

QY 78 CPCLPMLLC 86
DB 265 CFCASGLLC 273

RESULT 13
US-09-161-241-10
; Sequence 10, Application US/09161241
; Patent No. 6344541
; GENERAL INFORMATION:
; APPLICANT: Bass, Michael B
; APPLICANT: Sullivan, John K
; APPLICANT: Theill, Lars E
; APPLICANT: Wang, Daquang
; TITLE OF INVENTION: NOVEL DKR POLYPEPTIDES
; FILE REFERENCE: A-548
; CURRENT APPLICATION NUMBER: US/09/161,241
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 10
; LENGTH: 266
; TYPE: PRT
; ORGANISM: Human
US-09-161-241-10

Query Match 16.5%; Score 97; DB 4; Length 266;
Best Local Similarity 32.3%; Pred. No. 0.0033;
Matches 21; Conservative 9; Mismatches 23; Indels 12; Gaps 3;

QY 26 CERDVQCGAGTCCALSMLRGL--RMCTPLGREGEECH-PGSHKVPFPRKXKHTCPL 81
DB 189 CURSSDCASGLCCARHF---SKICKPVLKESQVCTKHKRKGSHGLEIFOR-----CYCG 240

QY 82 PNLLC 86
DB 241 EGLSC 245

RESULT 14
US-09-976-594-1086
; Sequence 1086, Application US/09976594
; Patent No. 6673549
; GENERAL INFORMATION:
; APPLICANT: Furness, Michael
; APPLICANT: Buchbinder, Jenny
; TITLE OF INVENTION: GENES EXPRESSED IN C3A LIVER CELL CULTURES TREATED WITH STEROIDS
; FILE REFERENCE: PA-0041 US
; CURRENT APPLICATION NUMBER: US/09/976,594
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/240,409
; PRIOR FILING DATE: 2000-10-12
; NUMBER OF SEQ ID NOS: 1143
; SOFTWARE: PERL Program
; SEQ ID NO 1086
; LENGTH: 266
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. 6673549 2481150CD1

US-09-976-594-1086

Query Match 16.5%; Score 97; DB 4; Length 266;
 Best Local Similarity 32.3%; Pred. No. 0.0033;
 Matches 21; Conservative 9; Mismatches 23; Indels 12; Gaps 3;
 QY 26 CERDVCGAGTCAISLWRLGRLMCTPLGRGEEC-----HPGSHKVPFRKRKHHCTPCL 81
 Db 189 CLRSSDCASGLCCARFW---SKICKPVLKEGVCTKRRKKGSHGLEIFOR-----CYCG 240
 QY 82 PNLIC 86
 Db 241 EGLSC 245

RESULT 15

US-09-561-709B-13
 ; Sequence 13, Application US/09561709B
 ; Patent No. 6682911
 ; GENERAL INFORMATION:
 ; APPLICANT: Burgeson, Robert
 ; APPLICANT: Champilaud, Marie-France
 ; APPLICANT: Olson, Pamela
 ; APPLICANT: Koch, Manuel
 ; APPLICANT: Brunken, William
 ; TITLE OF INVENTION: LAMININS AND USES THEREOF
 ; FILE REFERENCE: 10287-060001
 ; CURRENT APPLICATION NUMBER: US/09/561,709B
 ; CURRENT FILING DATE: 2000-05-01
 ; PRIOR APPLICATION NUMBER: US 09/168,949
 ; PRIOR FILING DATE: 1998-10-09
 ; PRIOR APPLICATION NUMBER: US 60/061,609
 ; PRIOR FILING DATE: 1997-10-10
 ; NUMBER OF SEQ ID NOS: 13
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 13
 ; LENGTH: 1342
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Consensus sequence
 US-09-561-709B-13

Query Match 13.9%; Score 82; DB 4; Length 1342;
 Best Local Similarity 35.0%; Pred. No. 0.97;
 Matches 28; Conservative 4; Mismatches 36; Indels 12; Gaps 4;
 QY 14 VTVSDCAVITGACERDVCGAGTCAISLWRLGRLMCTPLGRGEE--EHPGSHKVPFR 71
 Db 797 VTDPECRY-TGECURCLHTGACQLKFGHYGSALQTCRCSCAGSPMECPGCLCDPV-- 853
 QY 72 KRKHHTCPCLN---LLCSR 88
 Db 854 ---TGCPCLNVTGLACDR 869

Search completed: August 30, 2004, 06:48:13
 Job time : 21 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 30, 2004, 07:03:21 ; Search time 125 Seconds
(without alignments)
237.340 Million cell updates/sec

Title: US-10-027-603-2

Perfect score: 589

Sequence: 1 MEGATRVSIMLLNTVSDCA.....CSRFPDGRYRCMDLKNINF 105

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 289

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 250 summaries

Database : A_Geneseqp_29Jan04:*

1: Genesep1980s:*

2: Genesep1990s:*

3: Genesep2000s:*

4: Genesep2001s:*

5: Genesep2002s:*

6: Genesep2003as:*

7: Genesep2003bs:*

8: Genesep2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	589	100.0	105	3	AAY66745
2	589	100.0	105	3	AAB18453
3	589	100.0	105	4	AAB70148
4	589	100.0	105	4	AAB68427
5	589	100.0	105	4	AAU12406
6	589	100.0	105	4	AAB53096
7	589	100.0	105	4	AAB65268
8	589	100.0	105	4	AAB48175
9	589	100.0	105	4	AAB48067
10	589	100.0	105	5	AAU50773
11	589	100.0	105	5	AAU83674
12	589	100.0	105	5	ABR84902
13	589	100.0	105	5	AAO15527
14	589	100.0	105	5	ABR06308
15	589	100.0	105	5	ABR24382
16	589	100.0	105	5	ABR95508
17	589	100.0	105	6	ABU58083
18	589	100.0	105	6	ABU59161
19	589	100.0	105	6	ABU82673
20	589	100.0	105	6	ABO17850
21	589	100.0	105	6	ABU60592
22	589	100.0	105	6	ABU80821
23	589	100.0	105	6	ABO33787
24	589	100.0	105	6	ABU13974
25	589	100.0	105	6	ABU08800
26	589	100.0	105	6	ABU81104
27	589	100.0	105	6	ABU07603
28	589	100.0	105	6	ABU72559
29	589	100.0	105	6	ABU66804
30	589	100.0	105	6	ABU59885
31	589	100.0	105	6	ABU59308
32	589	100.0	105	6	ABO26005
33	589	100.0	105	6	ABO25075
34	589	100.0	105	6	ABU82130
35	589	100.0	105	6	ABU59014
36	589	100.0	105	6	ABU92392
37	589	100.0	105	6	ABU59457
38	589	100.0	105	6	ABU67080
39	589	100.0	105	6	ABU92223
40	589	100.0	105	6	ABU10929
41	589	100.0	105	6	ABU81681
42	589	100.0	105	6	ABO88620
43	589	100.0	105	6	ABO34134
44	589	100.0	105	6	ADA45989
45	589	100.0	105	6	ADA76420
46	589	100.0	105	6	ABJ72310
47	589	100.0	105	6	ADA19070
48	589	100.0	105	6	ADA61693
49	589	100.0	105	6	ADL19478
50	589	100.0	105	6	ADB28019
51	589	100.0	105	6	ADA86498
52	589	100.0	105	6	ADB16062
53	589	100.0	105	6	ADA37882
54	589	100.0	105	6	ADA47848
55	589	100.0	105	6	ADA21568
56	589	100.0	105	6	ADA10355
57	589	100.0	105	6	ADA67643
58	589	100.0	105	6	ADB30650
59	589	100.0	105	6	ADA85946
60	589	100.0	105	6	ADA17899
61	589	100.0	105	6	ADA97158
62	589	100.0	105	6	ADA79462
63	589	100.0	105	6	ADA87601
64	589	100.0	105	6	ADB16803
65	589	100.0	105	6	ADA28007
66	589	100.0	105	6	ADA91895
67	589	100.0	105	6	ADB14958
68	589	100.0	105	6	ADB18919
69	589	100.0	105	6	ADA94134
70	589	100.0	105	6	ADB20030
71	589	100.0	105	6	ADB13342
72	589	100.0	105	6	ABO43383
73	589	100.0	105	6	ADA94587
74	589	100.0	105	6	ADA74596
75	589	100.0	105	6	ADB24829
76	589	100.0	105	6	ADA82353
77	589	100.0	105	6	ADA75316
78	589	100.0	105	6	ADA85394
79	589	100.0	105	6	ADA84842
80	589	100.0	105	6	ADB33098
81	589	100.0	105	6	ADA80626
82	589	100.0	105	6	ADA75868
83	589	100.0	105	6	ADA38812
84	589	100.0	105	6	ADA47093
85	589	100.0	105	6	ADB25389
86	589	100.0	105	6	ADA93565
87	589	100.0	105	6	ADB26915
88	589	100.0	105	6	ADB31202
89	589	100.0	105	6	ABJ72438
90	589	100.0	105	6	ADA92933
91	589	100.0	105	6	ADA61130
92	589	100.0	105	6	ADB24277
93	589	100.0	105	6	ADA96606
94	589	100.0	105	6	ADA81178
95	589	100.0	105	6	ADA96054
96	589	100.0	105	6	ADB28363
97	589	100.0	105	6	ADB21848
98	589	100.0	105	6	ABO34333

99	7	ADA77627	Human PRO	172	589	100.0	105	7	ADC58621	Novel hum
100	7	ADB18367	Human PRO	173	589	100.0	105	7	ADC14671	Novel hum
101	7	ADA87050	Novel hum	174	589	100.0	105	7	ADC47238	Novel hum
102	7	ADA88153	Novel hum	175	589	100.0	105	7	ADD08203	Novel hum
103	7	ADA46541	Novel hum	176	589	100.0	105	7	ADD03295	Novel hum
104	7	ADB28571	Human PRO	177	589	100.0	105	7	ADC90287	Novel hum
105	7	ADB22123	Human PRO	178	589	100.0	105	7	ADC82028	Human PRO
106	7	ABO53220	Human PRO	179	589	100.0	105	7	ADC69706	Human PRO
107	7	ADA77075	Human sec	180	589	100.0	105	7	ADC48595	Human PRO
108	7	ADA22494	Human sec	181	589	100.0	105	7	ADC48595	Human PRO
109	7	ADA88705	Novel hum	182	589	100.0	105	7	ADD10124	Human PRO
110	7	ADA97710	Human PRO	183	589	100.0	105	7	ADD07670	Novel hum
111	7	ADB227467	Human PRO	184	589	100.0	105	7	ADD78113	Novel hum
112	7	ADB22400	Novel hum	185	589	100.0	105	7	ADD04699	Novel hum
113	7	ABO22590	Human sec	186	589	100.0	105	7	ADC82561	Human PRO
114	7	ADA06660	Human sec	187	589	100.0	105	7	ADD06348	Novel hum
115	7	ABJ72140	Human mem	188	589	100.0	105	7	ADC80655	Novel hum
116	7	ADA39353	Human sec	189	589	100.0	105	7	ADD11162	Human PRO
117	7	ADA67091	Human PRO	190	589	100.0	105	7	ADD10461	Human sec
118	7	ADB22952	Human PRO	191	589	100.0	105	7	ADC48043	Human PRO
119	7	ADB23725	Human PRO	192	589	100.0	105	7	ADD08741	Novel hum
120	7	ADA92447	Novel hum	193	589	100.0	105	7	ADC77867	Novel hum
121	7	ADB45510	Human PRO	194	589	100.0	105	7	ADC80103	Novel hum
122	7	ADB83656	Novel hum	195	589	100.0	105	7	ADD06990	Novel hum
123	7	ADB80762	Novel hum	196	589	100.0	105	7	ADD11421	Human sec
124	7	ADB73303	Novel hum	197	589	100.0	105	7	ADC09572	Human PRO
125	7	ADB38762	Novel hum	198	589	100.0	105	7	ADC83237	Human PRO
126	7	ADB396379	Human PRO	199	589	100.0	105	7	ADD50830	Novel hum
127	7	ADB78385	Novel hum	200	589	100.0	105	7	ADD41285	Novel hum
128	7	ADB38210	Novel hum	201	589	100.0	105	7	ADD52424	Human PRO
129	7	ADB66682	Novel hum	202	589	100.0	105	7	ADD51076	Novel hum
130	7	ADB85033	Human PRO	203	589	100.0	105	7	ADD53164	Human PRO
131	7	ADB89762	Human PRO	204	589	100.0	105	7	ADD53716	Novel hum
132	7	ADB90494	Human PRO	205	589	100.0	105	7	ADD53344	Human PRO
133	7	ADB39595	Novel hum	206	589	100.0	105	7	ADD69106	Human PRO
134	7	ADB78139	Novel hum	207	589	100.0	105	7	ADD37214	Human sec
135	7	ADB87205	Human PRO	208	589	100.0	105	7	ADD56302	Human PRO
136	7	ADB84787	Human PRO	209	589	100.0	105	7	ADD51872	Human PRO
137	7	ADB47218	Novel hum	210	589	100.0	105	7	ADD02671	Human PRO
138	7	ADB83902	Novel hum	211	589	100.0	105	7	ADD50557	Human PRO
139	7	ADB86825	Novel hum	212	589	100.0	105	7	ADD02105	Human PRO
140	7	ADB73057	Novel hum	213	589	100.0	105	7	ADD54287	Novel hum
141	7	ADB77430	Novel hum	214	589	100.0	105	7	ADD54740	Human PRO
142	7	ADB34587	Human PRO	215	589	100.0	105	7	ADD50311	Human PRO
143	7	ADB35691	Human PRO	216	589	100.0	105	7	ADD51322	Novel hum
144	7	ADB34035	Human PRO	217	589	100.0	105	7	ADD92604	Human PRO
145	7	ADB35139	Human PRO	218	589	100.0	105	7	ADD91500	Human PRO
146	7	ADB36243	Human PRO	219	589	100.0	105	7	ADD04114	Human PRO
147	7	ADB46638	Novel hum	220	589	100.0	105	7	ADE26894	Novel hum
148	7	ADC57851	Human PRO	221	589	100.0	105	7	ADE32411	Novel hum
149	7	ADC57851	Human PRO	222	589	100.0	105	7	ADE22343	Human PRO
150	7	ADCL12082	Human sec	223	589	100.0	105	7	ADD79567	Human PRO
151	7	ADC56504	Human sec	224	589	100.0	105	7	ADE42103	Human PRO
152	7	ADC07559	Human sec	225	589	100.0	105	7	ADE17920	Human PRO
153	7	ADC11549	Human sec	226	589	100.0	105	7	ADD92052	Human PRO
154	7	ADC36895	Human PRO	227	589	100.0	105	7	ADE33515	Novel hum
155	7	ADC36895	Human PRO	228	589	100.0	105	7	ADE34067	Novel hum
156	7	ADC21885	Human PRO	229	589	100.0	105	7	ADD80119	Human PRO
157	7	ADC50511	Novel hum	230	589	100.0	105	7	ADD93156	Human PRO
158	7	ADC72058	Novel hum	231	589	100.0	105	7	ADE19576	Human PRO
159	7	ADC60037	Novel hum	232	589	100.0	105	7	ADE19024	Human PRO
160	7	ADC49916	Novel hum	233	589	100.0	105	7	ADE43220	Human PRO
161	7	ADC49115	Novel hum	234	589	100.0	105	7	ADD96009	Human PRO
162	7	ADC49632	Novel hum	235	589	100.0	105	7	ADE22895	Human PRO
163	7	ADC47493	Novel hum	236	589	100.0	105	7	ADD79013	Human PRO
164	7	ADC53044	Novel hum	237	589	100.0	105	7	ADE26361	Novel hum
165	7	ADC57398	Novel hum	238	589	100.0	105	7	ADE32963	Novel hum
166	7	ADC60589	Novel hum	239	589	100.0	105	7	ADE42655	Human PRO
167	7	ADC51064	Novel hum	240	589	100.0	105	7	ADD80671	Human PRO
168	7	ADC65591	Human PRO	241	589	100.0	105	7	ADD89699	Human PRO
169	7	ADC54689	Novel hum	242	589	100.0	105	7	ADE40983	Human PRO
170	7	ADC53650	Novel hum	243	589	100.0	105	7	ADE04782	Human PRO
171	7	ADC59173	Novel hum	244	589	100.0	105	8	ADC48869	Novel hum
	7	ADC56051	Novel hum	244	589	100.0	105		ADC81207	Novel hum

245 589 100.0 105 8 ADE21040 Ade21040 Novel hum
246 589 100.0 105 8 ADE05884 Ade05884 Human PRO
247 589 100.0 105 8 ADD76655 Add76655 Human PRO
248 589 100.0 105 8 ADD75113 Add75113 Human PRO
249 589 100.0 105 8 ADD75859 Add75859 Novel hum
250 589 100.0 105 8 ADD85091 Add85091 Novel hum

ALIGNMENTS

RESULT 1

AA66745
ID AA66745 standard; protein; 105 AA.

AC AA66745;

DT 05-APR-2000 (first entry)

XX Membrane-bound protein PRO1186.

XX Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW pharmaceutical; receptor immunoadesin; gene mapping.

XX Homo sapiens.

XX WO963088-A2.

XX 09-DEC-1999.

XX 02-JUN-1999; 99WO-US012252.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087609P.

XX 03-JUN-1998; 98US-0087759P.

XX 04-JUN-1998; 98US-0087827P.

XX 04-JUN-1998; 98US-0088021P.

XX 04-JUN-1998; 98US-0088025P.

XX 04-JUN-1998; 98US-0088028P.

XX 04-JUN-1998; 98US-0088029P.

XX 04-JUN-1998; 98US-0088030P.

XX 04-JUN-1998; 98US-0088033P.

XX 04-JUN-1998; 98US-0088326P.

XX 05-JUN-1998; 98US-0088167P.

XX 05-JUN-1998; 98US-0088202P.

XX 05-JUN-1998; 98US-0088212P.

XX 05-JUN-1998; 98US-0088217P.

XX 09-JUN-1998; 98US-0088555P.

XX 10-JUN-1998; 98US-0088722P.

XX 10-JUN-1998; 98US-0088730P.

XX 10-JUN-1998; 98US-0088734P.

XX 10-JUN-1998; 98US-0088738P.

XX 10-JUN-1998; 98US-0088740P.

XX 10-JUN-1998; 98US-0088741P.

XX 10-JUN-1998; 98US-0088742P.

XX 10-JUN-1998; 98US-0088810P.

XX 10-JUN-1998; 98US-0088811P.

XX 10-JUN-1998; 98US-0088824P.

XX 10-JUN-1998; 98US-0088825P.

XX 10-JUN-1998; 98US-0088826P.

XX 11-JUN-1998; 98US-0088858P.

XX 11-JUN-1998; 98US-0088861P.

XX 11-JUN-1998; 98US-0088863P.

XX 11-JUN-1998; 98US-0088876P.

XX 12-JUN-1998; 98US-0089090P.

XX 12-JUN-1998; 98US-0089105P.

XX 16-JUN-1998; 98US-0089440P.

XX 16-JUN-1998; 98US-0089512P.

XX 16-JUN-1998; 98US-0089514P.

XX 17-JUN-1998; 98US-0089532P.

XX 17-JUN-1998; 98US-0089538P.

XX 17-JUN-1998; 98US-0089596P.

XX 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090439P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090538P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090691P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090882P.
PR 26-JUN-1998; 98US-0090883P.
PR 01-JUL-1998; 98US-0091358P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096145P.
PR 12-AUG-1998; 98US-0096325P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096769P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.

17-AUG-1998; 98US-0096897P.
 18-AUG-1998; 98US-0096949P.
 18-AUG-1998; 98US-0096950P.
 18-AUG-1998; 98US-0096959P.
 18-AUG-1998; 98US-0096960P.
 18-AUG-1998; 98US-0097022P.
 19-AUG-1998; 98US-0097141P.
 20-AUG-1998; 98US-0097218P.
 24-AUG-1998; 98US-0097661P.
 26-AUG-1998; 98US-0097951P.
 26-AUG-1998; 98US-0097952P.
 26-AUG-1998; 98US-0097954P.
 26-AUG-1998; 98US-0097955P.
 26-AUG-1998; 98US-0097971P.
 26-AUG-1998; 98US-0097974P.
 26-AUG-1998; 98US-0097978P.
 26-AUG-1998; 98US-0097979P.
 26-AUG-1998; 98US-0097986P.
 31-AUG-1998; 98US-0098014P.
 16-SEP-1998; 98US-0098525P.
 12-JAN-1999; 98US-0100634P.
 99US-0115565P.
 (GETH) GENENTECH INC.
 Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
 Wood WI, Yuan J;
 WPI; 2000-072883/06.
 N-PSDB; AA265091.
 Membrane-bound proteins and related nucleotide sequences.
 Claim 12; Fig 266; 822pp; English.
 The invention provides membrane-bound PRO polypeptides and polynucleotides encoding them. The PRO sequences of the invention were identified based on extracellular domain homology screening. The PRO sequences have homology with proteins including LDL receptors, TIE ligands and various enzymes. The membrane-bound proteins and receptor molecules are useful as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be used as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The PRO encoding sequences are useful as hybridization probes, in chromosome and gene mapping and in the generation of antisense RNA and DNA. PRO nucleic acid sequences will also be useful for the preparation of PRO polypeptides, especially by recombinant techniques
 Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 3; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCAGTCCCAISLWRLGRLMCTPLGREGEC 60
 DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCAGTCCCAISLWRLGRLMCTPLGREGEC 60
 QY 61 HPQSHKVPFRKRRKHTTCCPLNLLCSRPDPGGRYCSMDLKNINF 105
 DB 61 HPQSHKVPFRKRRKHTTCCPLNLLCSRPDPGGRYCSMDLKNINF 105
 RESULT 2
 AAB18453
 ID AAB18453 standard; protein; 105 AA.
 XX
 AC AAB18453;
 XX
 DT 15-JAN-2001 (first entry)
 XX

DE XX A human TANGO 266 polypeptide.
 KW TANGO 266; TANGO 216; TANGO 261; TANGO 262; TANGO 267;
 KW cellular proliferation; cellular differentiation; cellular adhesion;
 KW von Willebrand factor-associated disorder; cell trafficking; cancer;
 KW hematopoietic associated disease; atelectasis; pulmonary congestion;
 KW edema; emphysema; chronic bronchitis; bronchial asthma; bronchiectasis;
 KW intestinal disorder; spleen associated disease; renal disorder;
 KW cardiovascular disorder; ischemic heart disease; hydrocephalus;
 KW brain herniation; iatrogenic disease; inflammation; meningitis;
 KW Alzheimer's Disease; cerebral toxoplasmosis; Parkinson's disease;
 KW multiple sclerosis; hydrocephalus; encephalitis; hepatic disorder.
 XX Homo sapiens.
 OS
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..19
 FT Protein /notes "signal sequence"
 FT 20..106
 FT /note= "mature protein"
 XX WO2000052022-A1.
 XX
 XX 08-SEP-2000.
 XX 01-MAR-2000; 2000WO-US005226.
 XX
 XX 01-MAR-1999; 99US-0122458P.
 XX
 XX (MILL-) MILLENNIUM PHARM INC.
 XX Barnes TM, Holtzman DA, Sharp JD, Fraser CC;
 XX WPI: 2000-579269/54.
 XX N-PSDB; AA75155.
 XX Novel human and murine secreted proteins designated TANGO 216, 261, 262,
 XX 266 and 267 useful as modulating agents of cellular processes, e.g. for
 XX treating cancer.
 XX
 XX Claim 8; Fig 14; 175pp; English.
 XX The present sequence represents a human TANGO 266 polypeptide. The
 XX specification also describes TANGO 262, TANGO 216, TANGO 261, and TANGO
 XX 267. The TANGO polypeptides can be used to modulate cellular
 XX proliferation, modulate cellular differentiation and/or modulate cellular
 XX adhesion. The proteins can be used to treat any von Willebrand factor-
 XX associated disorder, regulate extracellular matrix structuring, cellular
 XX adhesion, and cell trafficking and/or migration, modulate cellular
 XX interactions, modulate cell adhesion in proliferative disorders, such as
 XX cancer, modulate the proliferation, differentiation, and/or function of
 XX cells that appear in the bone marrow, and leukocytes, treat bone marrow,
 XX blood and hematopoietic associated diseases and disorders, atelectasis,
 XX pulmonary congestion or edema, emphysema, chronic bronchitis, bronchial
 XX asthma and bronchiectasis, intestinal disorders, spleen associated
 XX diseases, modulate renal disorders, treat cardiovascular disorders such
 XX as ischemic heart disease, modulate the proliferation, differentiation,
 XX and/or function of bone and cartilage cells and to treat bone and/or
 XX cartilage associated diseases or disorder. They may also be used to treat
 XX disorders associated with the ovaries, cerebral oedema, hydrocephalus,
 XX brain herniations, iatrogenic disease, inflammations, bacterial and viral
 XX meningitis, Alzheimer's Disease, cerebral toxoplasmosis, Parkinson's
 XX disease, multiple sclerosis, brain cancers, hydrocephalus and
 XX encephalitis, and treat hepatic disorders
 XX
 XX Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 3; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCAGTCCCAISLWRLGRLMCTPLGREGEC 60
 |||||
 |||||

Db

1 MRGATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

61 HPGSHKVPFFRKRGKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

61 HPGSHKVPFFRKRGKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

Qy

Db

RESULT 3

AAB70148

ID AAB70148 standard; protein; 105 AA.

XX

AC AAB70148;

XX

DT 29-MAY-2001 (first entry)

XX

DE

XX

DE Human G protein-coupled receptor protein-related sequence #4.

XX

XX Human; G protein-coupled receptor protein; neotropic; neuroprotective;

XX

XX hypotensive; orexigenic; anti-allergic; anti-anginal; antimicrobial;

XX

XX antibacterial; gene therapy; Alzheimer's disease; hypertension; anorexia;

XX

XX allergy; angina pectoris; infection; MRSA;

XX

XX multiple resistant Staphylococcus aureus.

XX

OS Homo sapiens.

XX

XX WO200116309-A1.

PN

XX

XX 08-MAR-2001.

PD

XX

XX 24-AUG-2000; 2000WO-JP005695.

PF

XX

XX 27-AUG-1999; 99JP-00241531.

PR

XX

XX 18-JUL-2000; 2000JP-00217474.

PR

XX

XX (TAKE) TAKEDA CHEM IND LTD.

PA

XX

XX Watanabe T, Terao Y, Shintani Y;

PI

XX

XX WPI; 2001-226684/23.

DR

XX

XX New human brain-originated guanosine triphosphate protein-coupled

PT

XX

XX receptor protein, its salt and encoded gene, useful in (gene) diagnosis

PT

XX

XX and development of preventives and remedies for Alzheimer's disease,

PT

XX

XX hypertension and anorexia.

XX

PS Example 4; Page 113; 119pp; Japanese.

XX

XX The present sequence is provided in a specification relating to a protein

CC

XX or its salt with an amino acid sequence identical or substantially

CC

XX similar to a fully defined sequence of 393 amino acids as given in the

CC

XX specification. The protein is useful in gene diagnosis and development of

CC

XX preventives and remedies for diseases associated with dysfunction of the

CC

XX protein, e.g. Alzheimer's disease, hypertension, anorexia, allergy,

CC

XX angina pectoris and infections (e.g. multiple resistant Staphylococcus

CC

XX aureus). The proteins and DNA encoding the proteins are also useful for

CC

XX the treatment of these diseases by gene therapy

XX

XX

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 4; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

Db 1 MRGATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

Qy 61 HPGSHKVPFFRKRGKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

Db 61 HPGSHKVPFFRKRGKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

RESULT 4

AAB68427

ID AAB68427 standard; protein; 105 AA.

XX

AC AAB68427;

XX

DT 23-JUL-2001 (first entry)

XX

DE

XX

DE Amino acid sequence of a human Zven2 polypeptide.

XX

XX Zven1; 3p21.1; 3p14.3; Zven2; small cell lung cancer; wound healing;

XX

XX antitumour; anti-inflammatory; necrosis; tissue growth; digestive enzyme;

XX

XX cellular differentiation; gastrointestinal cell contractility;

XX

XX gastrointestinal motility; inflammation; hypermotility; diarrhoea;

XX

XX Crohn's disease.

XX

OS Homo sapiens.

XX

XX WO200136465-A2.

PN

XX

XX 25-MAY-2001.

PD

XX

XX 14-NOV-2000; 2000WO-US031278.

PF

XX

XX 16-NOV-1999; 99US-00442164.

PR

XX

XX 25-FEB-2000; 2000US-00511879.

PR

XX

XX 19-APR-2000; 2000US-00552203.

PR

XX

XX 07-JUN-2000; 2000US-0210332P.

PR

XX

XX (ZYMO) ZYMOGENETICS INC.

PA

XX

XX Sheppard PO, Bishop PD, Whitmore TE, Thompson PP;

PI

XX

XX WPI; 2001-355611/37.

DR

XX

XX N-PSDB; AAF95427.

DR

XX

XX Novel isolated Zven polypeptide useful for inhibiting proliferation of

PT

XX

XX tumor cells, for treating small cell cancer of lung, to promote wound

PT

XX

XX healing, and for treating Crohn's disease and diarrhea.

PT

XX

XX Claim 27; Page 4; 98pp; English.

XX

XX The present sequence represents a human Zven2 polypeptide. The

CC

XX specification also describes Zven1. The Zven1 gene is present on

CC

XX chromosome 3p21.1-3p14.3. The specification also describes Zven2. Zven

CC

XX polynucleotides and polypeptides are useful in veterinary and human

CC

XX therapeutics, for treating small cell cancer of the lung, to promote

CC

XX wound healing, to prevent or to treat an adverse reaction of the skin to

CC

XX a skin-sensitizing agent or a skin-irritating agent, to stimulate the

CC

XX immune system of an immunocompromised individual, as antitumour agents,

CC

XX as anti-inflammatory agents, as agents to regulate regeneration or

CC

XX remodeling of tissue, as agents to modulate necrosis or tissue growth

CC

XX developmental arrest, to inhibit proliferation of tumour cells, cellular

CC

XX differentiation and necrosis, to treat disorders associated with

CC

XX gastrointestinal cell contractility, secretion of digestive enzymes and

CC

XX acids, gastrointestinal motility, recruitment of digestive enzymes,

CC

XX inflammation, and conditions associated with hypermotility such as

CC

XX diarrhoea and Crohn's disease

XX

XX

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 4; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

Db 1 MRGATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

Qy 61 HPGSHKVPFFRKRGKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

Db 61 HPGSHKVPFFRKRGKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

RESULT 5
AAU12406
ID AAU12406 standard; protein; 105 AA.
XX
AC AAU12406;
XX
DT 24-OCT-2001 (first entry)
XX
DE Human PRO1186 polypeptide sequence.
XX
KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
KW Prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
KW A-peptide; factor VIIa; Gene therapy.
XX
OS Homo sapiens.
XX
PN WO20010466-A2.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US032678.
XX
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 09-DEC-1999; 99US-0170262P.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030939.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 05-JUN-2000; 2000US-0209832P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030352.
PR 10-NOV-2000; 2000WO-US030873.
XX
FA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2001-408281/43.
DR N-PSDB; AAS21478.
XX
XX Isolated, secretory and transmembrane PRO polypeptide used to detect

PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
PT breast, prostate, cervical.
XX
PS Claim 12; Fig 470; 813pp; English.
XX
CC AAU12172-AAU12446 represent novel human secretory and transmembrane PRO
CC polypeptides. The PRO polypeptides are useful to detect other PRO
CC polypeptides, to link bioactive molecules to cells expressing PRO
CC polypeptides, to modulate biological activities of cells expressing PRO
CC polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample. Some
CC of the 275 sequences are also useful to stimulate the release of tumour
CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
CC differentiation of chondrocytes, the proliferation or gene expression in
CC pericyte cells, the release of proteoglycans from cartilage, the
CC proliferation of inner ear utricular supporting cells or of T-
CC lymphocytes, the release of a cytokine from peripheral blood monocytes
CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO
CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
CC VIIa. The PRO polypeptides can be used in assays to identify molecules
CC involved in binding interactions. The polynucleotides encoding PRO
CC polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 4; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
Db 1 MEGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60

QY 61 HFGSHKVPFFRKHKHTCPLNLLCSRPDPGRYRCSDMLKNINF 105
Db 61 HFGSHKVPFFRKHKHTCPLNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 6
AAB53096
ID AAB53096 standard; protein; 105 AA.
XX
AC AAB53096;
XX
DT 28-FEB-2001 (first entry)
XX
DE Human angiogenesis-associated protein PRO1186, SEQ ID NO:155.
XX
KW Human; angiogenesis-associated protein; PRO; endothelial cell growth;
KW cardiac hypertrophy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; atherosclerosis; osteoporosis; hypertension;
KW myocardial infarction; diabetic retinopathy; rheumatoid arthritis;
KW Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;
KW Alzheimer's disease; Huntington's disease; stroke; drug screening;
KW Gene therapy; transgenic animal.
XX
OS Homo sapiens.
XX
PN WO200053753-A2.
XX
PD 14-SEP-2000.
XX
PF 05-JAN-2000; 2000WO-US000219.
XX
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.

PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Kuo SS, Mark ME, Marsters SA;
PI Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;
XX WPI; 2001-090793/10.
DR N-PSDB; AAC97496.
XX New isolated nucleic acid for producing a PRO polypeptide, analyzing
PT genetic disorders and treating cardiovascular, endothelial or angiogenic
PT disorders, such as atherosclerosis, wounds or cancer.
XX Claim 69; Fig 66; 293pp; English.
XX The invention relates to novel human angiogenesis-associated proteins
CC designated PRO proteins (AAB53064-B53097), and to nucleic acids encoding
CC PRO proteins. The invention also relates to vectors and host cells
CC comprising a PRO nucleic acid, the recombinant production of a PRO
CC protein, PRO antibodies specific for a PRO protein, fusion proteins
CC comprising a PRO protein, agonists or antagonists of a PRO protein, and
CC compounds which inhibit the expression of a PRO gene. The invention
CC additionally encompasses methods of identifying modulators of PRO
CC expression or activity; diagnosing a cardiovascular, endothelial or
CC angiogenic disorder, or a susceptibility to such a disorder by detecting
CC mutations in a PRO gene, or the expression level of a PRO gene within a
CC particular tissue; treating a cardiovascular, endothelial or angiogenic
CC disorder via the administration of a PRO protein, PRO nucleic acid, or
CC PRO agonist or antagonist; a retroviral gene therapy vector comprising a
CC PRO nucleic acid; and methods of inhibiting or stimulating endothelial
CC cell growth, cardiac hypertrophy or PRO-induced angiogenesis via the
CC administration of a PRO protein, or an agonist or antagonist thereof. PRO
CC nucleic acids, PRO proteins, or an agonist or antagonist thereof, PRO
CC agonists and PRO antagonists may be used as therapeutic agents to treat
CC cardiovascular, endothelial or angiogenic disorders, such as
CC atherosclerosis, osteoporosis, myocardial infarction, hypertension,
CC diabetic retinopathy, rheumatoid arthritis, Crohn's disease, psoriasis,
CC endometriosis, ulcers, wounds, cancer, Alzheimer's disease, Huntington's
CC disease, or stroke. PRO nucleic acids are additionally useful in the
CC recombinant production of PRO proteins, as hybridisation probes to screen
CC libraries to isolate cDNAs with sequence identity to PRO proteins, to map
CC genes encoding PRO proteins, to analyse genetic disorders, and in gene
CC therapy. PRO nucleic acids can also be used to produce transgenic animals
CC useful for the development and screening of potential therapeutic agents.
CC The present sequence represents a PRO protein of the invention
XX Sequence 105 AA;
SQ Query Match 100.0%; Score 589; DB 4; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGAATRVSMILLVTVSDCAVITGACERDVCGAGTCCATSLWLRGRLMCTPLGREGEC 60
DB 1 MGAATRVSMILLVTVSDCAVITGACERDVCGAGTCCATSLWLRGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRRKHHTKTCPLPNLILCSRFPDGRYRCSMDLNKINF 105
DB 61 HPGSHKVPFFRRKHHTKTCPLPNLILCSRFPDGRYRCSMDLNKINF 105

RESULT 7
AAB565268
ID AAB565268 standard; protein; 105 AA.
XX
AC AAB565268;
XX
DT 02-APR-2001 (first entry)
XX
DE Human PRO1186 (UNQ600) protein sequence SEQ ID NO:371.
XX
KW Human; secreted and transmembrane protein; PRO; cytostatic; cell death;
KW cancer; chromosomal mapping; gene mapping; tissue typing;
KW diagnostic assay.
XX
OS Homo sapiens.
XX
PN WC2000073454-A1.
XX
PD 07-DEC-2000.
XX
PF 30-MAR-2000; 2000WO-US008439.
XX
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi CJ, Gurney AL, Kijavini JJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart RA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX WPI; 2001-032160/04.
DR N-PSDB; AAF44237.
XX
PT PRO polynucleotides used to produce polypeptides used to target bioactive
PT molecules such as toxins, radiolabels or antibodies, to specific cells,
PT to cause targeted cell death.
XX
PS Claim 12; Fig 266; 935pp; English.
XX
CC The present invention describes human secreted and transmembrane PRO
CC proteins. The PRO proteins have cytostatic activity. The PRO proteins can
CC be used for targeted delivery of bioactive molecules, such as toxins,
CC radiolabels or antibodies, that cause cell death. PRO nucleotide
CC sequences, and their fragments, can be used as hybridisation probes, in
CC chromosomal and gene mapping, and in the generation of anti-sense RNA and
CC DNA. They may also be used to produce transgenic animals which are used
CC to develop and screen therapeutically useful reagents. The PRO nucleotide
CC and protein sequence can be used for tissue typing and in treating

CC cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to
 CC AAF4470 represent PCR primers and hybridisation probes used in the
 CC isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to
 CC AAB65300 represent human PRO polynucleotide and protein sequences given
 CC in the exemplification of the present invention
 XX
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 4; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 DB 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60

QY 61 HPGSHKVPFFRRKRGHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105
 DB 61 HPGSHKVPFFRRKRGHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 8
 AAB48175
 ID AAB48175 standard; protein; 105 AA.
 AC AAB48175;
 DT 02-APR-2001 (first entry)
 XX Human PRO1186 polypeptide.
 DE
 XX
 XX PRO1186; PRO184; neoplastic; cell growth; tumour; cancer; breast;
 KW ovarian; renal; colorectal; uterine; prostate; lung; melanoma;
 KW central nervous system; leukemia; antitumor; cytostatic.
 XX
 OS Homo sapiens.

XX Key Location/Qualifiers
 FH Peptide 1..19
 FT /note= "signal sequence"
 FT Protein 20..105
 FT /note= "mature protein"
 FT Modified-site 33..39
 FT /note= "N-myristoylation site"
 FT Modified-site 35..41
 FT /note= "N-myristoylation site"
 FT Modified-site 46..52
 FT /note= "N-myristoylation site"
 FT Modified-site 88..95
 FT /note= "tyrosine kinase phosphorylation site"

XX
 PN WO200075327-A1.
 PD 14-DEC-2000.
 PF 24-FEB-2000; 2000WO-US004914.
 XX
 PR 02-JUN-1999; 99WO-US012252.
 PR 26-JUL-1999; 99US-0145698P.
 PR 05-JAN-2000; 2000WO-US000219.
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Hillan KJ, Napier MA, Watanabe CK, Wood WI;
 XX WPI; 2001-071078/08.
 DR N-PSDB; AAC84469.
 XX
 XX Compositions for inhibiting neoplastic cell growth and treating tumor, a
 PT cancer, comprises novel PRO1186 or PRO184 polypeptides or its agonist.
 XX
 PS Claim 31; Fig 2; 104pp; English.

CC The invention provides PRO1186 and PRO184 polypeptides that can be used
 CC for the inhibition of neoplastic cell growth and for treating tumours.
 CC The PRO polypeptides can be expressed by standard recombinant
 CC methodology. The PRO polypeptides or their agonists are useful for
 CC inhibition of neoplastic cell growth and for treating tumours, cancers
 CC such as breast, ovarian, renal colorectal, uterine, prostate, lung,
 CC bladder or central nervous system cancers or melanoma and leukemia. The
 CC present sequence represents the human PRO1186 polypeptide (encoding cDNA
 XX clone ID: DNA60621-1516)
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 4; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 DB 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60

QY 61 HPGSHKVPFFRRKRGHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105
 DB 61 HPGSHKVPFFRRKRGHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 9
 AAB48067
 ID AAB48067 standard; protein; 105 AA.
 AC AAB48067;
 DT 19-MAR-2001 (first entry)
 XX Human extracellular signaling molecule (EXCS) (ID 2006548CD1).
 DE
 XX Extracellular signaling molecule; EXCS; anti-inflammatory; human;
 KW immunosuppressive; cytostatic; neuroprotective; gastrointestinal;
 KW virucide; antibacterial; anti-HIV; human immunodeficiency virus;
 KW antiinfertility; cerebroprotective; nootropic; antiulcer; antifungal;
 KW anticonvulsant; tranquilizer; neuroleptic; vasotropic; gynecological;
 KW keratolytic; protozoacide; gene therapy.
 XX
 OS Homo sapiens.
 XX WO200070049-A2.
 XX 23-NOV-2000.
 XX 19-MAY-2000; 2000WO-US013975.
 XX 19-MAY-1999; 99US-0134949P.
 PR 15-JUL-1999; 99US-0144270P.
 PR 30-JUL-1999; 99US-0146700P.
 PR 04-OCT-1999; 99US-0157508P.
 XX
 PA (INCY-) INCYTE GENOMICS INC.
 XX
 PI Tang YT, Yue H, Lal P, Burford N, Bandman O, Baughn MR;
 PI Azimzai Y, Lu DAM, Patterson C;
 XX WPI; 2001-025021/03.
 DR N-PSDB; AAC84303.
 XX
 XX New human extracellular signaling nucleic acids and polypeptides useful
 PT for diagnosing, treating and preventing infections and gastrointestinal,
 PT neurological, reproductive, and autoimmune/inflammatory disorders.
 XX
 PS Claim 1; Page 89; 114pp; English.

CC The invention provides human extracellular signaling molecules (EXCS) and
 CC polynucleotides which identify and encode EXCS. EXCS can be expressed by
 CC standard recombinant methodology. The amino acid and nucleic acid
 CC sequences of EXCS are useful for diagnosing, treating and preventing

CC infections and gastrointestinal (peptic ulcer, dysphagia, pancreatitis),
CC neurological (e.g. epilepsy, ischemic cerebrovascular disease, stroke),
CC reproductive (infertility, ovulatory defects, endometriosis), autoimmune
CC /inflammatory (actinic keratosis, acquired immunodeficiency syndrome
CC (AIDS), Addison's disease), and cell proliferative disorders including
CC cancers (of the breast, adrenal gland, bone). They may also be used to
CC treat fatal familial insomnia, nutritional and metabolic diseases of the
CC nervous system, myopathies, mental disorders (anxiety, schizophrenia,
CC mood), as well as infections caused by parasites (malaria, leishmania,
CC trypanosoma), viral (adenovirus, coronavirus, flavivirus), bacterial
CC (e.g. pneumococcus, staphylococcus, bacillus), and fungal (aspergillus,
CC blastomycetes, dermatophytes) agents. The nucleic acids, polypeptides,
CC antagonists, agonists, pharmaceutical compositions, and antibodies may
CC also be used for treating or preventing disorders associated with
CC increased or decreased expression or activity of EXCS. EXCS
CC polynucleotides may also be used to detect and quantify gene expression
CC in biopsied tissues in which expression of EXCS may be correlated with
CC the disease, to determine presence or excess expression of EXCS, to
CC monitor regulation of EXCS levels during therapeutic intervention, to
CC detect the presence of associated disorders, as targets in microarray, to
CC generate hybridization probes, and to detect differences in gene
CC sequences among normal, carrier or affected individuals. Antibodies may
CC also be used in diagnosing disorders, in monitoring patients being
CC treated with EXCS agonists, antagonists or inhibitors. Sequences AAB48057
CC -B48082 represent the EXCS of the invention
XX
XX Sequence 105 AA;
SQ

Query Match 100.0%; Score 589; DB 4; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105

RESULT 10
AAM50773
ID AAM50773 standard; protein; 105 AA.
XX
XX AAM50773;
XX
XX 23-APR-2002 (first entry)
XX
XX Endocrine gland-derived vascular endothelial growth factor.
XX
XX Endocrine gland-derived vascular endothelial growth factor; EG-VEGF;
KW human; cell proliferation; cell migration; fenestration;
KW cell differentiation; angiogenesis; chemotaxis; endocrine; infertility;
KW fertility; polycystic ovary syndrome; ovarian cyst; cancer; cytostatic;
KW diagnosis; therapy.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH Peptide 1..19 /label= Signal_peptide
FT Protein 20..105 /label= Mature_protein
FT Modified-site 33 /note= "N-myristoylated"
FT Modified-site 35 /note= "N-myristoylated"
FT Modified-site 46 /note= "N-myristoylated"
FT Modified-site 46 /note= "N-myristoylated"
XX
XX WO200200711-A2.
XX

PD 03-JAN-2002.
XX
XX 22-JUN-2001; 2001WO-US020116.
XX
XX 23-JUN-2000; 2000US-0213637P.
PR 07-SEP-2000; 2000US-0230978P.
PR 01-DEC-2000; 2000WO-US032678.
XX
XX (GETH) GENENTECH INC.
XX
XX Ferrara N, Watanabe C, Wood WI;
XX WPI; 2002-130882/17.
DR N-PSDB; ABA91567.
XX
XX New endocrine gland-vascular endothelial growth factor (EG-VEGF)
PT polypeptides, agonists and antagonists, useful for regulating fertility,
PT and for treating cancer of the reproductive organs, e.g. ovarian or
PT prostate cancer.
XX
XX Claim 12; Fig 2; 133pp; English.

XX The present sequence is that of a novel, tissue-restricted, growth and
CC differentiation factor termed endocrine gland-derived vascular
CC endothelial growth factor (EG-VEGF). The sequence is predicted from the
CC open reading frame of a cDNA clone (see ABA91567) obtained from an
CC ovarian tissue library. EG-VEGF induces proliferation, migration and
CC fenestrations in capillary endothelial cells derived from endocrine
CC glands, but has no effect on a variety of other endothelial and non-
CC endothelial cell types tested. The EG-VEGF precursor has a predicted
CC mol.wt. of 11715 and a pI of 9.05. The mature protein (mol.wt. 8600) is
CC cysteine-rich and is predicted to consist of a series of short beta
CC strands with large connecting loops held together by disulfide bonds
CC resulting in a flat fold with finger-like projections that act as
CC interactive surfaces. 80% Homology and 63% identity is shown to venom
CC protein A (VPA) of the black mamba snake, and 76% homology and 58%
CC identity to human protein Bv8. EG-VEGF nucleic acids and polypeptides, as
CC well as agonists and antagonists, can be used in the treatment of
CC conditions associated with hormone-producing tissue, especially ovarian,
CC testicular, cervical, adrenal, placental or prostate tissue. The
CC condition may be polycystic ovary syndrome, cancer, especially ovarian
CC cancer, testicular cancer, prostate cancer or uterine cancer, or ovarian
CC cyst (all claimed). Fertility can be regulated using an EG-VEGF
CC antagonist to inhibit follicle maturation or ovulation. Methods are
CC claimed for identifying compounds that modulate EG-VEGF activity,
CC especially the ability to induce phosphorylation of a kinase involved in
CC cell proliferation or survival, to induce chemotaxis, angiogenesis, or
CC cell differentiation, or to induce endothelial cell proliferation
XX
XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 5; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105

RESULT 11
AAU83674
ID AAU83674 standard; protein; 105 AA.
XX
XX AAU83674;
XX
XX 08-MAY-2002 (first entry)
XX
XX Human PRO protein, Seq ID No 166.
DE

XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha.

XX Homo sapiens.

XX WO200208288-A2.

XX 31-JAN-2002.

XX 29-JUN-2001; 2001WO-US021066.

XX 20-JUL-2000; 2000US-0219556P.

XX 25-JUL-2000; 2000US-0220585P.

XX 25-JUL-2000; 2000US-0220605P.

XX 25-JUL-2000; 2000US-0220607P.

XX 25-JUL-2000; 2000US-0220624P.

XX 25-JUL-2000; 2000US-0220638P.

XX 25-JUL-2000; 2000US-0220664P.

XX 25-JUL-2000; 2000US-0220666P.

XX 26-JUL-2000; 2000US-0220893P.

XX 28-JUL-2000; 2000WO-US020710.

XX 01-AUG-2000; 2000US-0222425P.

XX 23-AUG-2000; 2000US-0227133P.

XX 24-AUG-2000; 2000WO-US023328.

XX 10-NOV-2000; 2000WO-US030873.

XX 28-NOV-2000; 2000US-0253646P.

XX 01-DEC-2000; 2000WO-US032678.

XX 20-DEC-2000; 2000US-00747259.

XX 28-FEB-2001; 2000WO-US034956.

XX 01-MAR-2001; 2001WO-US006520.

XX 22-MAR-2001; 2001WO-US006666.

XX 10-MAY-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854208.

XX 25-MAY-2001; 2001WO-US017092.

(GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2002-172001/22.

XX N-PSDB; ABK33618.

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumors such
PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
PT or liver tumor.

XX Claim 11; Fig 166; 359pp; English.

XX The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumors, especially lung
CC cancer, colon cancer, breast tumor, prostate tumor, rectal tumor or
CC liver tumor. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumor necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal
CC fibroblast cells. The PRO polypeptide may also be used as molecular
CC weight markers and for tissue typing. The PRO nucleic acids have
CC applications in molecular biology, including use as hybridisation probes,
CC and in chromosome and gene mapping. NAU83592-AU83713 represent human PRO
CC protein sequences of the invention

XX Sequence 105 AA;

XX SQ

Query Match 100.0%; Score 589; DB 5; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MFGATRVSIMLLLVTSQCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MFGATRVSIMLLLVTSQCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
QY 61 HFGSHKVPPFRKRKHTCPCLPNLLCSRFDPGRVRCMDLKNINF 105
DB 61 HFGSHKVPPFRKRKHTCPCLPNLLCSRFDPGRVRCMDLKNINF 105

RESULT 12

ABB84902

ID ABB84902 standard; protein; 105 AA.

XX AC ABB84902;

XX DT 16-MAY-2002 (first entry)

XX DE Human PRO1186 protein sequence SEQ ID NO:172.

XX KW Human; angiogenesis; cardiact; cytostatic; angiogenic; hypotensive;
KW vulnary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW age-related macular degeneration; arterial restenosis; angina;
KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW lymphatoid; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW wound healing; chromosome mapping; gene mapping.

XX OS Homo sapiens.

XX FN WO200200690-A2.

XX PD 03-JAN-2002.

XX PF 20-JUN-2001; 2001WO-US019692.

XX PR 23-JUN-2000; 2000US-0213637P.

XX PR 20-JUL-2000; 2000US-0219556P.

XX PR 25-JUL-2000; 2000US-0220624P.

XX PR 25-JUL-2000; 2000US-0220664P.

XX PR 28-JUL-2000; 2000WO-US020710.

XX PR 02-AUG-2000; 2000US-0222695P.

XX PR 17-AUG-2000; 2000US-00643657.

XX PR 23-AUG-2000; 2000WO-US023522.

XX PR 24-AUG-2000; 2000WO-US023328.

XX PR 07-SEP-2000; 2000US-023078P.

XX PR 18-SEP-2000; 2000US-00666350.

XX PR 18-SEP-2000; 2000US-00666350.

XX PR 24-OCT-2000; 2000US-0242922P.

XX PR 08-NOV-2000; 2000US-00709238.

XX PR 08-NOV-2000; 2000WO-US030952.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 20-DEC-2000; 2000US-00747259.

XX PR 20-DEC-2000; 2000WO-US034956.

XX PR 22-JAN-2001; 2001US-00767609.

XX PR 28-FEB-2001; 2001US-00796498.

XX PR 28-FEB-2001; 2001WO-US006520.

XX PR 01-MAR-2001; 2001WO-US006666.

XX PR 09-MAR-2001; 2001US-00802706.

XX PR 14-MAR-2001; 2001US-00808689.

XX PR 22-MAR-2001; 2001US-00816744.

XX PR 05-APR-2001; 2001US-00828366.

XX PR 10-MAY-2001; 2001US-00854208.

XX PR 25-MAY-2001; 2001US-00866028.

XX PR 25-MAY-2001; 2001US-00866034.

XX PR 25-MAY-2001; 2001WO-US017092.

PR 30-MAY-2001; 2001US-00870574.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017800.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen MS, Goddard A,
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF,
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W,
XX
DR WPI; 2002-090516/12.
DR N-PSDB; ABL88157.
XX
XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
PS Claim 11; Fig 172; 565pp; English.
XX
CC ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC activities, and can be used in gene therapy. The PRO polynucleotides,
CC proteins, agonists and antagonists are useful for treating or diagnosing
CC a cardiovascular, endothelial or angiogenic disorder in a mammal, e.g.
CC cardiac hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial stenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The PRO polynucleotides have applications in molecular biology,
CC including use as hybridization probes, and in chromosome and gene
CC mapping. ABL88259 to ABL88267 represent primers and probes used in the
CC exemplification of the present invention
XX
SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 5; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
QY 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPGRVRCSDMLKNINF 105
RESULT 13
AA015527
XX ID AA015527 standard; protein; 105 AA.
XX AC AA015527;
XX
XX 24-OCT-2002 (first entry)
XX
XX Human physiologically-active ZAQ ligand-related protein 3.
XX
XX Human; ZAQ ligand; physiologically-active ZAQ ligand; digestive disease;
XX colitis; diarrhoea.
XX
XX Homo sapiens.
XX
XX WO200257443-A1.
XX
XX 25-JUN-2002.
XX
XX 21-JAN-2002; 2002WO-JP000378.
XX
XX 22-JAN-2001; 2001JP-00013027.
XX
XX 17-MAY-2001; 2001JP-00147759.
XX

PA (TAKE) TAKEDA CHEM IND LTD.
PI Yamada T, Suenaga M, Nishimura O;
XX
XX WPI; 2002-566801/60.
XX
XX Industrial production of physiologically-active ZAQ ligand by expressing
PT in transformant prokaryote and refolding in redox buffer, for use in
PT preventing or treating digestive diseases e.g. colitis and diarrhea.
XX
XX Example 3; Page 76-77; 93pp; Japanese.
XX
XX The invention comprises a method for producing an active peptide that has
CC the same activity as a ZAQ ligand isolated from eukaryotic cells. The
CC method of the invention is useful for the production of a physiologically
CC active ZAQ ligand for use in preventing or treating digestive diseases
CC (e.g. colitis and diarrhea). The present amino acid sequence represents a
CC human physiologically active ZAQ ligand-related protein
XX
SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 5; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
QY 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPGRVRCSDMLKNINF 105
RESULT 14
ABB06308
XX ID ABB06308 standard; protein; 105 AA.
XX AC ABB06308;
XX
XX 27-MAY-2002 (first entry)
XX
XX Human G protein-coupled receptor ZAQ ligand protein SEQ ID NO:23.
XX
XX G protein-coupled receptor; ZAQ ligand; physiologically active peptide;
XX ZAQ; antidiarrheic; laxative; drug development; digestive disease;
XX colitis; diarrhoea; constipation; poor-absorption syndrome; gene therapy.
XX
XX Homo sapiens.
XX
XX WO200206483-A1.
XX
XX 24-JAN-2002.
XX
XX 17-JUL-2001; 2001WO-JP006162.
XX
XX 18-JUL-2000; 2000JP-00217442.
XX
XX 02-FEB-2001; 2001JP-00026779.
XX
XX (TAKE) TAKEDA CHEM IND LTD.
XX
XX Ohtaki T, Masuda Y, Takatsu Y, Watanabe T, Terao Y, Shintani Y;
PI Hinuma S;
XX
XX WPI; 2002-188546/24.
XX
XX N-PSDB; ABL49637.
XX
XX Physiologically-active peptides from cows milk, useful for developing
PT drugs to treat ZAQ-mediated diseases, particularly digestive diseases
PT like colitis, diarrhea, constipation and poor-absorption syndrome, by
XX gene therapy.
XX
XX Claim 5; Page 61; 191pp; Japanese.
PS

XX The present invention describes a peptide containing an amino acid
 CC sequence (I) identical to or substantially similar to that of the
 CC sequences in ABB06305 or ABB06306, or its salt. (I) has antidiarrheic and
 CC laxative activities. The peptides and encoding DNAs from the present
 CC invention are useful for developing drugs to treat digestive diseases
 CC like colitis, diarrhoea, constipation and poor-absorption syndrome,
 CC including gene therapy. The physiologically-active cows milk-originated
 CC peptides are applicable as a specific ligand of brain-originated orphan G
 CC to ABB06315 represent sequences used in the exemplification of the
 CC present invention
 XX
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 5; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 15
 AAEE24382
 ID AAE24382 standard; protein; 105 AA.
 AC AAE24382;
 XX
 DT 04-OCT-2002 (first entry)
 DE Human prokineticin 1 precursor protein.
 KW Human; prokineticin 1; gastrointestinal motility; intestinal cancer;
 KW irritable bowel syndrome; gastrointestinal reflux disease; diarrhoea;
 KW diabetic gastroparesis; chronic constipation; malabsorptive disorder;
 KW inflammatory bowel disorder; analgesic; infectious disease.
 XX
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT Peptide 1..19
 FT Protein /label= Signal_peptide
 FT 20..105
 FT /note= "Mature human prokineticin 1"
 XX
 XX WO200236625-A2.
 XX
 XX 10-MAY-2002.
 XX
 XX 01-NOV-2001; 2001WO-US047969.
 XX
 XX 03-NOV-2000; 2000US-0245882P.
 XX
 XX (REGC) UNIV CALIFORNIA.
 XX
 XX Zhou Q, Ehler FJ;
 XX WPI; 2002-479752/51.
 XX N-PSDB; AAD39321.
 XX
 XX New isolated human prokineticin 1 and 2 polypeptides that stimulate
 PT gastrointestinal smooth muscle contraction, useful for improving impaired
 PT gastrointestinal motility in irritable bowel syndrome, chronic
 PT constipation.
 XX
 XX Example 1; Fig 1; 86pp; English.

CC The invention relates to human prokineticin 1 and 2 polypeptides that
 CC stimulate gastrointestinal smooth muscle contraction and nucleic acid
 CC molecules encoding such polypeptides. Polypeptides of the invention are
 CC useful for treating disorders involving impaired gastrointestinal
 CC motility. They are useful for stimulating gastrointestinal motility in
 CC disorders such as irritable bowel syndrome, diabetic gastroparesis, post-
 CC operational ileus, chronic constipation and gastrointestinal reflux
 CC disease. The prokineticin antagonists are useful for inhibiting
 CC gastrointestinal motility in conditions of diarrhoea, malabsorptive
 CC disorders, inflammatory bowel disorders, infectious diseases and
 CC intestinal cancers. The antagonists also act as analgesics. The present
 CC sequence is human prokineticin 1 precursor protein
 XX
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 5; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 16
 ABB95508
 ID ABB95508 standard; protein; 105 AA.
 AC ABB95508;
 XX
 DT 19-JUL-2002 (first entry)
 DE Human angiogenesis related protein PRO1186 SEQ ID NO: 172.
 KW Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
 KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
 KW cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
 KW antiarteriosclerotic.
 XX
 OS Homo sapiens.
 XX
 XX WO200208284-A2.
 XX
 XX 31-JAN-2002.
 XX
 XX 09-JUL-2001; 2001WO-US021735.
 XX
 XX 20-JUL-2000; 2000US-0219556P.
 XX 25-JUL-2000; 2000US-0220624P.
 XX 25-JUL-2000; 2000US-0220664P.
 XX 28-JUL-2000; 2000WO-US020710.
 XX 02-AUG-2000; 2000US-0222695P.
 XX 17-AUG-2000; 2000US-00643657.
 XX 23-AUG-2000; 2000WO-US023522.
 XX 24-AUG-2000; 2000WO-US023328.
 XX 07-SEP-2000; 2000US-0230978P.
 XX 18-SEP-2000; 2000US-00664610.
 XX 18-SEP-2000; 2000US-00665350.
 XX 24-OCT-2000; 2000US-0242922P.
 XX 08-NOV-2000; 2000US-00709238.
 XX 08-NOV-2000; 2000WO-US030952.
 XX 10-NOV-2000; 2000WO-US030873.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 20-DEC-2000; 2000US-00747259.
 XX 20-DEC-2000; 2000WO-US034956.
 XX 22-JAN-2001; 2001US-00767609.
 XX 28-FEB-2001; 2001US-00796498.
 XX 28-FEB-2001; 2001WO-US006520.
 XX 01-MAR-2001; 2001WO-US006686.

PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 30-MAY-2001; 2001US-00870574.
 PR 30-MAY-2001; 2001US-00870574.
 PR 01-JUN-2001; 2001US-00870574.
 PR 20-JUN-2001; 2001US-00870574.
 PR (GETH) GENENTECH INC.
 PA (BAKE) BAKER K P.
 PA (FERR) FERRARA N.
 PA (GERB) GERBER H.
 PA (GERR) GERRITSEN M E.
 PA (GODD) GODDARD A.
 PA (GODO) GODOWSKI P J.
 PA (GURN) GURNEY A L.
 PA (HILL) HILLAN K J.
 PA (MARS) MARSTERS S A.
 PA (PANJ) PAN J.
 PA (PACN) PACNI N F.
 PA (STEP) STEPHAN J F.
 PA (WATA) WATANABE C K.
 PA (WILL) WILLIAMS P M.
 PA (WOOD) WOOD W I.
 XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A; Paoni NF;
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
 PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
 XX WPI; 2002-171999/22.
 DR N-PSDB; ABL95646.
 XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 PT infarction), endothelial or angiogenic disorders in a mammal.
 XX Claim 11; Fig 172; 567pp; English.
 XX The present invention provides the protein and coding sequences of human
 CC PRO proteins. These are useful for treating or diagnosing a
 CC cardiovascular, endothelial or angiogenic disorder, including cardiac
 CC hypertrophy, trauma, cancer, age-related macular degeneration,
 CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
 CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
 CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
 CC healing. The present sequence is a PRO protein of the invention
 XX Sequence 105 AA;
 SQ
 Query Match 100.0%; Score 589; DB 5; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSCAVITGACERDVQCGAGTCCATSLWLRGIRMCPTLGRGEEC 60
 DB 1 MRGATRVSIMLLVTVSCAVITGACERDVQCGAGTCCATSLWLRGIRMCPTLGRGEEC 60
 QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSDMLKNINF 105
 RESULT 17
 ID ABU58083
 ID ABU58083 standard; protein; 105 AA.
 XX
 AC ABU58083;

XX 14-APR-2003 (first entry)
 DE Human PRO polypeptide #115.
 XX Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
 KW horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
 KW antibody-dependent enzyme mediated prodrug therapy.
 XX Homo sapiens.
 OS
 XX US2003027163-A1.
 XX 06-FEB-2003.
 PD
 XX 15-NOV-2001; 2001US-00997666.
 PF 16-JUN-1997; 97US-0049787P.
 PF 17-OCT-1997; 97US-0062250P.
 PF 05-NOV-1997; 97US-0065186P.
 PF 12-NOV-1997; 97US-0065311P.
 PF 24-NOV-1997; 97US-0066770P.
 PF 25-FEB-1998; 98US-0075945P.
 PF 20-MAR-1998; 98US-0078910P.
 PF 28-APR-1998; 98US-0083222P.
 PF 07-MAY-1998; 98US-0084600P.
 PF 28-MAY-1998; 98US-0087108P.
 PF 02-JUN-1998; 98US-0087607P.
 PF 02-JUN-1998; 98US-0087609P.
 PF 02-JUN-1998; 98US-0087759P.
 PF 03-JUN-1998; 98US-0087827P.
 PF 04-JUN-1998; 98US-0088021P.
 PF 04-JUN-1998; 98US-0088025P.
 PF 04-JUN-1998; 98US-0088026P.
 PF 04-JUN-1998; 98US-0088028P.
 PF 04-JUN-1998; 98US-0088029P.
 PF 04-JUN-1998; 98US-0088030P.
 PF 04-JUN-1998; 98US-0088033P.
 PF 04-JUN-1998; 98US-0088325P.
 PF 05-JUN-1998; 98US-0088167P.
 PF 05-JUN-1998; 98US-0088202P.
 PF 05-JUN-1998; 98US-0088212P.
 PF 05-JUN-1998; 98US-0088217P.
 PF 09-JUN-1998; 98US-0088655P.
 PF 10-JUN-1998; 98US-0088734P.
 PF 10-JUN-1998; 98US-0088738P.
 PF 10-JUN-1998; 98US-0088810P.
 PF 10-JUN-1998; 98US-0088824P.
 PF 10-JUN-1998; 98US-0088826P.
 PF 11-JUN-1998; 98US-0088858P.
 PF 11-JUN-1998; 98US-0088861P.
 PF 11-JUN-1998; 98US-0088876P.
 PF 12-JUN-1998; 98US-00889105P.
 PF 16-JUN-1998; 98US-0089440P.
 PF 16-JUN-1998; 98US-0089512P.
 PF 16-JUN-1998; 98US-0089514P.
 PF 17-JUN-1998; 98US-0089532P.
 PF 17-JUN-1998; 98US-0089538P.
 PF 17-JUN-1998; 98US-0089598P.
 PF 17-JUN-1998; 98US-0089599P.
 PF 17-JUN-1998; 98US-0089600P.
 PF 18-JUN-1998; 98US-0089653P.
 PF 18-JUN-1998; 98US-0089801P.
 PF 18-JUN-1998; 98US-0089907P.
 PF 18-JUN-1998; 98US-0089908P.
 PF 19-JUN-1998; 98US-0089947P.
 PF 19-JUN-1998; 98US-0089948P.
 PF 19-JUN-1998; 98US-0089952P.
 PF 22-JUN-1998; 98US-0090246P.
 PF 22-JUN-1998; 98US-0090252P.
 PF 22-JUN-1998; 98US-0090254P.

```
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090455P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091638P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 10-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095335P.
PR 10-AUG-1998; 98US-0095936P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
```

```
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003376.
PR 18-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US005319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
```

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMCTPLGREGECC 60
Db 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMCTPLGREGECC 60
Qy 61 HPGSHKVPFFFRKRKHHTCPLNLLCSRFPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFFRKRKHHTCPLNLLCSRFPDGRYRCSDMLKNINF 105
```

```
RESULT 18
ABU59161
ID ABU59161 standard; protein; 105 AA.
XX
AC ABU59161;
XX
DT 28-APR-2003 (first entry)
XX
```

DE Novel human secreted or transmembrane protein PRO1186.
XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
OS Homo sapiens.
XX
XX US2002132252-A1.
XX
PD 19-SEP-2002.
XX
XX 14-NOV-2001; 2001US-00990442.
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088036P.
PR 04-JUN-1998; 98US-0088038P.
PR 04-JUN-1998; 98US-0088039P.
PR 04-JUN-1998; 98US-0088040P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Grittisen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
XX WPI; 2003-247083/24.
DR N-PSDB; ABX80360.
XX
XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments.
XX
XX Claim 12; Fig 266; 648pp; English.
XX
XX The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial

CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This is the
CC amino acid sequence of a novel human PRO protein

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCATSLMLRGLRMCTPLGREGEEC 60
DB 1 MEGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCATSLMLRGLRMCTPLGREGEEC 60
QY 61 HPGSHKVPFFRRKRKHTCTCPCLNLLCSRFDPGRYRCSDMLKKNIF 105
DB 61 HPGSHKVPFFRRKRKHTCTCPCLNLLCSRFDPGRYRCSDMLKKNIF 105

RESULT 19

ABU82673

ID ABU82673 standard; protein; 105 AA.

XX AC ABU82673;

XX DT 26-JUN-2003 (first entry)

XX DE Human secreted/transmembrane protein PRO1186.

XX KW Human; PRO; secreted protein; transmembrane protein;
KW cardiac insufficiency disorders; angiogenesis; wound healing;
KW cancerous tumour; immune response; retinal disorder; sight loss;
KW retinitis pigmentosa; age-related macular degeneration; AMD;
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpetiformis;
KW Crohn's disease; sports injury; arthritis.

XX OS Homo sapiens.

XX PN US2003032023-A1.

XX PD 13-FEB-2003.

XX PF 14-NOV-2001; 2001US-00990711.

XX PR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087108P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087609P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088038P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 05-JUN-1998; 98US-0088555P.
PR 09-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088878P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090353P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.

PR 20-JUL-1998; 98US-00933339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 20-AUG-1998; 98US-0097641P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 16-SEP-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100631P.
PR 16-SEP-1998; 98US-0100633P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0101943P.
PR 07-OCT-1998; 98US-0102114P.
PR 01-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0123957P.
PR 12-MAR-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0152154P.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 20-DEC-1999; 98US-0158663P.
PR 05-JAN-2000; 98US-0158663P.
PR 06-JAN-2000; 98US-0158663P.
PR 11-FEB-2000; 98US-0158663P.
PR 18-FEB-2000; 98US-0158663P.
PR 22-FEB-2000; 98US-0158663P.

PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLGRGEGEC 60
|||
Db 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLGRGEGEC 60
|||
QY 61 HPGSHKVPFPRKRKHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105
|||
Db 61 HPGSHKVPFPRKRKHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105
|||

RESULT 20
ABOI7850
ID ABOI7850 standard; protein; 105 AA.
AC ABOI7850;
XX
XX
DT 26-AUG-2003 (first entry)
XX
XX
DE Novel human secreted and transmembrane protein PRO1186.
XX
XX
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing.
XX
XX
OS Homo sapiens.
XX
XX
PN US2003032156-A1.
XX
XX
PD 13-FEB-2003.
XX
XX
PF 06-MAY-2002; 2002US-00140474.
XX
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017889.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010713.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 05-OCT-1999; 99WO-US021547.
 PR 29-NOV-1999; 99WO-US023089.
 PR 30-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000217.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000365.
 PR 18-FEB-2000; 2000WO-US000431.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006894.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808659.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001WO-US017032.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001WO-US017800.
 PR 14-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-341980/32.
 DR N-PSDB; ACD24087.
 XX New secreted and transmembrane PRO nucleic acids, for treating
 PT inflammation, organ failure, atherosclerosis, cardiac injury,
 PT infertility, birth defects, premature aging, acquired immunodeficiency
 PT syndrome (AIDS), or cancer.
 XX Claim 12; Fig 470; 660pp; English.
 PS The invention describes an isolated nucleic acid (I) comprising, or which
 CC has 80 % sequence identity to, or the full-length coding sequence of, one
 CC of 275 nucleotide sequences, and which encodes a corresponding
 CC polypeptide selected from 275 amino acid sequences, where all sequences
 CC are given in the specification. The polypeptide encoded by (I) is used to
 CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
 CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
 CC release of tumor necrosis factor (TNF)-alpha from human blood, modulate
 CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
 CC the proliferation or differentiation of cells or gene expression,
 CC stimulate the release of proteoglycans, stimulate the release of cytokine
 CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
 CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
 CC acid and polypeptide encoded by it, are useful for treating inflammatory
 CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
 CC birth defects, premature aging, acquired immunodeficiency syndrome
 CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
 CC hybridisation probes, in chromosome and gene mapping, and in generating
 CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
 CC This is the amino acid sequence of a novel human secreted and
 CC transmembrane PRO polypeptide
 XX Sequence 105 AA;
 SQ Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred.No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MEGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGREGEC 60
 Db 1 MEGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGREGEC 60
 QY 61 HPGSHKVPFFRKHHHTCPLNLLCSFFPDGRVRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRKHHHTCPLNLLCSFFPDGRVRCSDMLKNINF 105
 RESULT 21
 ABU60592
 ID ABU60592 standard; protein; 105 AA.
 XX ABU60592;
 AC ABU60592;
 XX 01-MAY-2003 (first entry)
 DT

XX DE Human secreted/transmembrane protein, #151.
XX KW Human; PRO: secreted; transmembrane; signal peptide; pharmaceutical;
KW KW diagnostic; therapeutic; gene therapy.
XX OS Homo sapiens.
XX PN US2002160384-A1.
XX PD 31-OCT-2002.
XX PF 14-NOV-2001; 2001US-00992598.
XX PR 16-JUN-1997; 97US-0049787P.
PR PR 17-OCT-1997; 97US-0062250P.
PR PR 05-NOV-1997; 97WO-US020069.
PR PR 12-NOV-1997; 97US-0065186P.
PR PR 13-NOV-1997; 97US-0065311P.
PR PR 24-NOV-1997; 97US-0066770P.
PR PR 25-FEB-1998; 98US-0075945P.
PR PR 20-MAR-1998; 98US-0078910P.
PR PR 28-APR-1998; 98US-0083322P.
PR PR 07-MAY-1998; 98US-0084600P.
PR PR 28-MAY-1998; 98US-0087106P.
PR PR 02-JUN-1998; 98US-0087607P.
PR PR 02-JUN-1998; 98US-0087605P.
PR PR 02-JUN-1998; 98US-0087755P.
PR PR 03-JUN-1998; 98US-0087827P.
PR PR 04-JUN-1998; 98US-0088021P.
PR PR 04-JUN-1998; 98US-0088025P.
PR PR 04-JUN-1998; 98US-0088026P.
PR PR 04-JUN-1998; 98US-0088028P.
PR PR 04-JUN-1998; 98US-0088029P.
PR PR 04-JUN-1998; 98US-0088030P.
PR PR 04-JUN-1998; 98US-0088033P.
PR PR 04-JUN-1998; 98US-0088326P.
PR PR 05-JUN-1998; 98US-0088167P.
PR PR 05-JUN-1998; 98US-0088202P.
PR PR 05-JUN-1998; 98US-0088212P.
PR PR 05-JUN-1998; 98US-0088217P.
PR PR 09-JUN-1998; 98US-0088655P.
PR PR 10-JUN-1998; 98US-0088734P.
PR PR 10-JUN-1998; 98US-0088738P.
PR PR 10-JUN-1998; 98US-0088742P.
PR PR 10-JUN-1998; 98US-0088810P.
PR PR 10-JUN-1998; 98US-0088824P.
PR PR 10-JUN-1998; 98US-0088825P.
PR PR 11-JUN-1998; 98US-0088858P.
PR PR 11-JUN-1998; 98US-0088861P.
PR PR 11-JUN-1998; 98US-0088876P.
PR PR 12-JUN-1998; 98US-0089105P.
PR PR 16-JUN-1998; 98US-0089440P.
PR PR 16-JUN-1998; 98US-0089512P.
PR PR 16-JUN-1998; 98US-0089514P.
PR PR 17-JUN-1998; 98US-0089534P.
PR PR 17-JUN-1998; 98US-0089538P.
PR PR 17-JUN-1998; 98US-0089598P.
PR PR 17-JUN-1998; 98US-0089599P.
PR PR 17-JUN-1998; 98US-0089600P.
PR PR 17-JUN-1998; 98US-0089653P.
PR PR 18-JUN-1998; 98US-0089801P.
PR PR 18-JUN-1998; 98US-0089907P.
PR PR 18-JUN-1998; 98US-0089908P.
PR PR 18-SEP-1998; 98WO-US019330.
PR PR 17-SEP-1998; 98WO-US019437.
PR PR 07-OCT-1998; 98WO-US021141.
PR PR 01-DEC-1998; 98WO-US025108.
PR PR 05-JAN-1999; 99WO-US000106.
PR PR 08-MAR-1999; 99WO-US005028.
PR PR 02-JUN-1999; 99WO-US012252.
PR PR 15-SEP-1999; 99WO-US021090.
PR PR 15-SEP-1999; 99WO-US021547.

PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 20-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020311.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Baton DL;
XX PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX WPI; 2003-288106/28.
DR N-PSDB; ABX90338.
XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX Claim 12; Fig 266; 650pp; English.
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful in gene therapy, in chromosome
CC identification, as chromosome markers, or in generating probes. The PRO
CC polypeptides are useful as molecular markers for protein electrophoresis,
CC and the isolated nucleic acids may be used for recombinantly expressing
CC those markers. The PRO polypeptides and nucleic acids may also be used in
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC PRO, and in affinity purification of PRO from recombinant cell culture or
CC natural sources. The sequences presented in ABU60478-ABU60624 are the PRO
CC polynucleotides of the invention. Note: The sequence data for this patent
CC is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX Sequence 105 AA;
SQ Query Match 100.0%; Score 589; DB 6; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSMILLVTVSDCAVITGACERDVCGAGTCCATSLWLRLGRLMCTPLGREGEEC 60

DB 1 MEGATRVSMILLVTVSDCAVITGACERDVCGAGTCCATSLWLRLGRLMCTPLGREGEEC 60

QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105

DB 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105

RESULT 22

ABU0821

ID ABU0821 standard; protein; 105 AA.

XX AC ABU0821;

DT 23-JUN-2003 (first entry)

DE Human PRO polypeptide #83.

KW Human; PRO polypeptide; secreted and transmembrane protein;

KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.

XX OS Homo sapiens.

XX PN US2003036635-A1.

XX PD 20-FEB-2003.

XX PF 28-AUG-2002; 2002US-00230163.

XX PR 25-JUL-2000; 2000US-0220638P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR N-PSDB; AC66923.

XX DR WPI: 2003-342045/32.

XX DR N-PSDB; AC66923.

XX PT One hundred and twenty two nucleic acids encoding PRO polypeptides,

XX PT useful for the manufacture of a medicament for diagnosing or treating

XX PT tumor.

XX PS Claim 11; Fig 166; 314pp; English.

XX CC The present invention relates to the isolation of novel human PRO

XX CC polypeptides, and the polynucleotide sequences encoding them. The PRO

XX CC polypeptides are secreted and transmembrane proteins. The PRO

XX CC polypeptides and polynucleotides are useful for preparing a medicament

XX CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are

XX CC useful in diagnostic assays for PRO, by detecting its expression in

XX CC specific cells, tissues or serum, and for affinity purification of PRO

XX CC from recombinant cell culture or natural sources. ABU0739-ABU0860

XX CC represent the human PRO polypeptides of the invention. Note: The sequence

XX CC data for this patent was obtained in electronic format directly from the

XX CC USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html.

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105

DB 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRVRCSDMLKNINF 105

RESULT 23

ABO33787

ID ABO33787 standard; protein; 105 AA.

XX AC ABO33787;

XX DT 17-SEP-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.

XX DE Human, secreted and transmembrane protein; PRO; cytostatic;

XX DE antiarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;

XX DE chondrocyte stimulator; pericyte stimulator; fibroblast modulator;

XX DE pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;

XX DE colon tumour; breast tumour; prostate tumour; rectal tumour;

XX DE liver tumour; bone disorder; cartilage disorder; sports injury;

XX DE arthritis; wound.

XX OS Homo sapiens.

XX PN US2003045687-A1.

XX PD 06-MAR-2003.

XX PF 12-AUG-2002; 2002US-00218631.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI: 2003-512315/48.

XX DR N-PSDB; ACD68675.

XX PT New genes, and its encoded secreted and transmembrane polypeptides,

XX PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or

XX PT pericyte proliferation, especially for treating lung tumors, arthritis or

XX PT wounds in a mammal.

XX PS Claim 11; Fig 166; 314pp; English.

XX CC The invention describes an isolated nucleic acid molecule comprising a

XX CC sequence with at least 80% identity to: (a) a nucleotide encoding any of

XX CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are

XX CC fully defined in the specification; or (b) any of 122 nucleotide

XX CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the

XX CC specification; or the full length coding sequence of any these 122

XX CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful

XX CC as pharmaceuticals, diagnostics, biosensors or bioreactors. These are

XX CC particularly useful for detecting tumours (e.g. lung tumour, colon

XX CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)

XX CC in a mammal, for stimulating the release of TNF-alpha from human blood,

XX CC for stimulating the proliferation or differentiation of chondrocyte

XX CC cells, for stimulating proliferation of pericyte cells, or for modulating

XX CC normal human dermal fibroblast proliferation. The PRO nucleic acid or

XX CC polypeptide is also useful for treating tumours or various bone and/or

XX CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The

XX CC PRO polypeptides are useful in drug screening, particularly as targets

XX CC for therapeutic intervention in these diseases, and in the diagnostic

XX CC determination of the presence of these diseases. The PRO polypeptides are

XX CC also useful as molecular weight markers, or for chromosome

XX CC identification. The PRO genes are useful as hybridisation probes, or for

XX CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

XX CC

CC also be used in gene therapy, particularly for replacing a defective
 CC gene. This is the amino acid sequence of a novel human secreted and
 CC transmembrane PRO polypeptide

SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVIMLLVTVSCAVITGACERDVCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
 |||||
 DB 1 MRGATRVIMLLVTVSCAVITGACERDVCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
 |||||

QY 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
 |||||

DB 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
 |||||

RESULT 24

ABU13974
 ID ABU13974 standard; protein; 105 AA.

XX AC ABU13974;

XX DT 26-FEB-2003 (first entry)

XX DE Human PRO186 polypeptide.

XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 XX genetic disorder; antibacterial; immunosuppressive.

XX OS Homo sapiens.

XX PN US2002:03125-A1.

XX PD 01-AUG-2002.

XX PF 20-NOV-2001; 2001US-00989731.

XX PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0065770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087603P.

PR 02-JUN-1998; 98US-0087759P.

PR 02-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 05-JUN-1998; 98US-0088326P.

PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 12-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 02-JUN-1999; 99WO-US012252.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 30-NOV-1999; 99WO-US023313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 06-JAN-2000; 2000WO-US000219.
 PR 08-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 15-MAY-2000; 2000WO-US013358.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US008520.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 08-JUL-2001; 2001WO-US021735.
 PR 28-AUG-2001; 2001US-00941992.

(GETH) GENENTECH LTD.

XX ASKenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
 XX Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;
 XX Zhang Z;

XX WPI; 2003-102117/09.
 XX N-PSDB; ABX64184.

XX Novel secreted and transmembrane polypeptide for modulating biological

PT

PT activity of cell expressing the polypeptide, identifying agonists or
 PS antagonists of polypeptide, and as molecular weight markers.
 XX Claim 12; Fig 266; 649pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for linking
 CC bioactive molecules to cells expressing PRO polypeptides, for modulating
 CC biological activities of cells expressing PRO polypeptides, and for for
 CC identifying agonists or antagonists. The polynucleotide sequences
 CC encoding PRO polypeptides are useful as hybridisation probes, in
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
 CC in the preparation of PRO polypeptides, for generating transgenic animals
 CC or knockout animals, to construct hybridisation probes for mapping the
 CC gene which encodes the PRO polypeptide, and for the genetic analysis of
 CC individuals with genetic disorders, in gene therapy, for chromosome
 CC identification, as chromosome markers, and for generating probes for PCR,
 CC Northern analysis, Southern analysis and Western analysis. ABU3860-
 CC ABU4006 represent the human PRO polypeptides of the invention. Note: The
 CC sequence data for this patent was obtained in electronic format directly
 CC from the USPTO web site at seqdata.uspto.gov/psipdsIDEntry.html
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
 Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
 QY 61 HPGSHKVPFFRRKHKHTCPCLENNLCSRPDPGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRRKHKHTCPCLENNLCSRPDPGRYRCSMDLKNINF 105
 RESULT 25
 ABU08800
 ID ABU08800 standard; protein; 105 AA.
 AC ABU08800;
 XX
 XX
 DT 02-JUN-2003 (first entry)
 XX
 DE Human endocrine gland-derived vascular endothelial growth factor.
 XX
 KW Human; EG-VEGF; sexual maturation; hypogonadotropic hypogonadism;
 KW endocrine gland; vascular endothelial growth factor; ovarian cyst;
 KW cellular proliferation; chemotaxis; congenital adrenal hyperplasia;
 KW precocious puberty; McCune-Albright syndrome; cancer; infertility;
 KW androgen-dependent cancer.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..19
 FT Protein /note= "Signal peptide"
 FT Protein 20..105
 FT Modified-site /note= "Mature EG-VEGF"
 FT Modified-site 33
 FT Modified-site /note= "N-myristoylated"
 FT Modified-site 35
 FT Modified-site /note= "N-myristoylated"
 FT Modified-site 46
 FT Modified-site /note= "N-myristoylated"
 XX
 PN US2002192634-A1.
 XX
 PD 19-DEC-2002.
 XX

PF 19-DEC-2001; 2001US-00027603.
 XX
 PR 11-AUG-1998; 98US-0096146P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 26-JUL-1999; 99US-0145698P.
 PR 25-AUG-1999; 99US-03380137.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 23-JUN-2000; 2000US-0213637P.
 PR 07-SEP-2000; 2000US-0230978P.
 PR 08-NOV-2000; 2000US-00709238.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-JUN-2001; 2001US-00886242.
 XX
 PA (FERR/) FERRARA N.
 PA (WATA/) WATANABE C.
 PA (WOOD/) WOOD W I.
 PA (SHEK/) SHEK T.
 XX
 PI Ferrara N, Watanabe C, Wood WI, Shek T;
 XX WPI; 2003-352707/33.
 DR N-PSDB; ABX93675.
 XX
 PT New anti-endocrine gland-derived vascular endothelial growth factor
 PT monoclonal antibodies IC6, 2A3, 2A8 or 4H9, useful for regulating
 PT cellular proliferation and chemotaxis.
 PS
 PS Example 1; Fig 2; 105pp; English.
 XX
 CC The invention relates to an antibody that binds essentially to the
 CC epitope of endocrine gland-derived vascular endothelial growth factors
 CC (EG-VEGF) and is selected from anti-EG-VEGF monoclonal antibodies IC6,
 CC 2A3, 2A8 and 4H9. The composition and methods are useful in regulating
 CC cellular proliferation and chemotaxis, e.g. in treating conditions
 CC associated with hormone-producing tissue such as congenital adrenal
 CC hyperplasia, sexual maturation, precocious puberty, McCune-Albright
 CC syndrome, hypogonadotropic hypogonadism, ovarian cyst, cancer such as
 CC androgen-dependent cancer or infertility. The present sequence represents
 CC the amino acid sequence of human endocrine gland-derived vascular
 CC endothelial growth factor
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
 Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
 QY 61 HPGSHKVPFFRRKHKHTCPCLENNLCSRPDPGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRRKHKHTCPCLENNLCSRPDPGRYRCSMDLKNINF 105
 RESULT 26
 ABU81104
 ID ABU81104 standard; protein; 105 AA.
 AC ABU81104;
 XX
 XX
 DT 23-JUN-2003 (first entry)
 XX
 DE Human PRO polypeptide #235.
 XX
 KW Human; PRO polypeptide; secreted and transmembrane protein;
 KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
 KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
 KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
 KW hearing loss; coagulation disorder; stroke; heart attack; cardiac;
 KW

KW antidiabetic; anorectic; vulnery; antiarthritic; osteopathic;
KW antirheumatic; auditory; cerebroprotective; angiogenic.

XX Homo sapiens.

XX US2003004311-Al.

XX PD 02-JAN-2003.

XX PF 19-DEC-2001; 2001US-00028072.

XX PR 18-JUN-1997; 97US-0049911P.

XX PR 26-AUG-1997; 97US-0056974P.

XX PR 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059115P.

XX PR 17-SEP-1997; 97US-0059117P.

XX PR 17-SEP-1997; 97US-0059123P.

XX PR 17-SEP-1997; 97US-0059184P.

XX PR 18-SEP-1997; 97US-0059263P.

XX PR 19-SEP-1997; 97US-0059352P.

XX PR 19-SEP-1997; 97US-0059588P.

XX PR 24-SEP-1997; 97US-0059836P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 17-OCT-1997; 97US-0062285P.

XX PR 17-OCT-1997; 97US-0062287P.

XX PR 17-OCT-1997; 97US-0063755P.

XX PR 24-OCT-1997; 97US-0062811P.

XX PR 24-OCT-1997; 97US-0063045P.

XX PR 24-OCT-1997; 97US-0063082P.

XX PR 24-OCT-1997; 97US-0063127P.

XX PR 27-OCT-1997; 97US-0063327P.

XX PR 27-OCT-1997; 97US-0063329P.

XX PR 28-OCT-1997; 97US-0063550P.

XX PR 28-OCT-1997; 97US-0063561P.

XX PR 29-OCT-1997; 97US-0063704P.

XX PR 29-OCT-1997; 97US-0063733P.

XX PR 29-OCT-1997; 97US-0063735P.

XX PR 29-OCT-1997; 97US-0063738P.

XX PR 03-NOV-1997; 97US-0064248P.

XX PR 07-NOV-1997; 97US-0064809P.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 17-NOV-1997; 97US-0065846P.

XX PR 21-NOV-1997; 97US-0066364P.

XX PR 24-NOV-1997; 97US-0066453P.

XX PR 24-NOV-1997; 97US-0066511P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 11-DEC-1997; 97US-0069212P.

XX PR 11-DEC-1997; 97US-0069278P.

XX PR 16-DEC-1997; 97US-0069694P.

XX PR 23-JAN-1998; 98US-0072320P.

XX PR 04-FEB-1998; 98US-0073612P.

XX PR 09-FEB-1998; 98US-0074086P.

XX PR 09-FEB-1998; 98US-0074092P.

XX PR 12-MAR-1998; 98US-0077791P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 25-MAR-1998; 98US-0079294P.

XX PR 27-MAR-1998; 98US-0079663P.

XX PR 27-MAR-1998; 98US-0079728P.

XX PR 31-MAR-1998; 98US-0080165P.

XX PR 12-JUN-1998; 98US-0080245P.

XX PR 14-JUL-1998; 98US-0080455P.

XX PR 28-AUG-1998; 98US-0080788P.

XX PR 10-SEP-1998; 98US-0080824P.

XX PR 14-SEP-1998; 98US-0080909P.

XX PR 14-SEP-1998; 98US-0080917P.

XX PR 16-SEP-1998; 98US-0080930P.

XX PR 17-SEP-1998; 98US-0080943P.

XX PR 17-SEP-1998; 98US-0080943P.

XX PR 29-OCT-1998; 98US-0080991P.

XX PR 29-OCT-1998; 98US-0080991P.

XX PR 29-OCT-1998; 98US-0082299P.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 28-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-352836/33.

XX N-PSDB; ACA67228.

XX New isolated PRO polypeptide useful for treating diabetes, rheumatoid

XX arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or

XX heart attack.

XX Claim 12; Fig 470; 643pp; English.

XX The present invention relates to the isolation of novel human PRO

XX polypeptides, and the polynucleotide sequences encoding them. The PRO

XX polypeptides are secreted and transmembrane proteins. The PRO

XX polypeptides and polynucleotides are useful for preparing a medicament

XX useful in the treatment of diabetes, bone and/or cartilage disorders

XX (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,

XX hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders

XX (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic

XX assays for PRO, by detecting its expression in specific cells, tissues or

XX serum, and for affinity purification of PRO from recombinant cell culture

XX or natural sources. AB08070-AB081144 represent the human PRO

XX polypeptides of the invention. Note: The sequence data for this patent

XX was obtained in electronic format directly from the USPTO web site at

XX seqdata.uspto.gov/psipd/entry.html

XX Sequence 105 AA;

XX Query Match 100.0%; Score 589; DB 6; Length 105;

XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEC 60
 DB 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEC 60
 QY 61 HPGSHKVPFFRRKKHHTCPCLENNLCSRPDPGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKKHHTCPCLENNLCSRPDPGRYRCSDMLKNINF 105

RESULT 27

ABU07603
 ID ABU07603 standard; protein; 105 AA.

XX AC ABU07603;

XX DT 10-MAY-2003 (first entry)

XX DE Human ZVEN2.

XX KW Human; ZVEN2; tumour.

XX OS Homo sapiens.

XX PN US6485938-B1.

XX PD 26-NOV-2002.

XX PF 14-NOV-2000; 2000US-00712529.

XX PR 16-NOV-1999; 99US-0165905P.

XX PR 25-FEB-2000; 2000US-0184875P.

XX PR 19-APR-2000; 2000US-0197750P.

XX PR 07-JUN-2000; 2000US-0210332P.

XX PA (ZYMO) ZYMOGENETICS INC.

XX PI Sheppard PO, Bishop PD;

XX DR WPI; 2003-287426/28.

XX DR N-PSDB; ABX12104, ABX12105.

XX PT Novel isolated nucleic acid molecule that encodes a Zven1 polypeptide, useful for inhibiting the proliferation of tumor cells, or to detect the expression of a Zven1 or Zven2 gene in a biological sample.

XX PS Disclosure; Col 3; 37pp; English.

XX CC The invention relates to an isolated nucleic acid molecule (I) that encodes a Zven1 polypeptide. (I) is useful for inhibiting the proliferation of tumor cells, as probes or primers to clone 5' non-coding regions of a Zven gene, to direct the expression of heterologous gene in tissues of, for example, transgenic animals or patients treated with gene therapy, to detect the expression of a Zven1 or Zven2 gene in a biological sample, to detect activated neutrophils, to identify therapeutic or prophylactic agents that modulate the response of a neutrophil to a pathogen, to determine whether a subject's chromosomes contain a mutation in the Zven gene, or to detect aberrations in Zven1 or Zven2 locus. (II) is useful as educational tools, as laboratory practicum kits for courses related to genetics and molecular biology, protein chemistry and antibody production and analysis. The present sequence represents the amino acid sequence of ZVEN2

XX SQ Sequence 105 AA;

Query Match

Best Local Similarity 100.0%; Score 589; DB 6; Length 105;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEC 60
 DB 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRRKKHHTCPCLENNLCSRPDPGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKKHHTCPCLENNLCSRPDPGRYRCSDMLKNINF 105

RESULT 28

ABU72559
 ID ABU72559 standard; protein; 105 AA.

XX AC ABU72559;

XX DT 17-JUN-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.

XX KW Human; secreted and transmembrane protein; cytostatic; anti-HIV; virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy; PRO; pharmaceutical; diagnostic; biosensor; bioindicator; malignancy; cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia; lymphoma; hepatitis B; multiple sclerosis; Crohn's disease; drug screening.

XX OS Homo sapiens.

XX PN US2003003531-A1.

XX PD 02-JAN-2003.

XX PF 19-NOV-2001; 2001US-00989734.

XX PR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0063250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087609P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

XX PR 04-JUN-1998; 98US-0088028P.

XX PR 04-JUN-1998; 98US-0088029P.

XX PR 04-JUN-1998; 98US-0088030P.

XX PR 04-JUN-1998; 98US-0088033P.

XX PR 04-JUN-1998; 98US-0088326P.

XX PR 05-JUN-1998; 98US-0088167P.

XX PR 05-JUN-1998; 98US-0088202P.

XX PR 05-JUN-1998; 98US-0088212P.

XX PR 05-JUN-1998; 98US-0088217P.

XX PR 09-JUN-1998; 98US-0088655P.

XX PR 10-JUN-1998; 98US-0088734P.

XX PR 10-JUN-1998; 98US-0088738P.

XX PR 10-JUN-1998; 98US-0088742P.

XX PR 10-JUN-1998; 98US-0088810P.

XX PR 10-JUN-1998; 98US-0088824P.

XX PR 10-JUN-1998; 98US-0088826P.

XX PR 11-JUN-1998; 98US-0088858P.

XX PR 11-JUN-1998; 98US-0088861P.

XX PR 12-JUN-1998; 98US-0088876P.

XX PR 12-JUN-1998; 98US-0089105P.

XX PR 16-JUN-1998; 98US-0089440P.

XX PR 16-JUN-1998; 98US-0089512P.

XX PR 16-JUN-1998; 98US-0089514P.

XX PR 17-JUN-1998; 98US-0089532P.

PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028555.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000356.
PR 18-FEB-2000; 2000WO-US000431.
PR 18-FEB-2000; 2000WO-US000434.
PR 22-FEB-2000; 2000WO-US000414.
PR 24-FEB-2000; 2000WO-US000494.
PR 24-FEB-2000; 2000WO-US000504.
PR 01-MAR-2000; 2000WO-US000560.
PR 02-MAR-2000; 2000WO-US000574.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034958.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-332040/31.
DR N-PSDB; ACA03837.
XX New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue
PT typing, and in chromosome identification.
XX Claim 12; Fig 470; 660pp; English.
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for
CC identifying agonists or antagonists. The PRO polypeptides are useful for
CC for stimulating the release of tumour necrosis factor (TNF)-alpha from
CC human blood, for stimulating the proliferation or differentiation of
CC chondrocytes, and detecting the presence of tumours. The polynucleotide
CC sequences encoding PRO polypeptides are useful as hybridisation probes,
CC in chromosome and gene mapping, in the generation of antisense RNA and
CC DNA, in the preparation of PRO polypeptides, for generating transgenic
CC animals or knockout animals, for the genetic analysis of individuals with
CC genetic disorders, and in gene therapy. ABU66570-ABU66844 represent the
CC human PRO polypeptides of the invention. Note: The sequence data for this
CC patent was obtained in electronic format directly from the USPTO web site
CC at seqdata.uspto.gov/psipdb/entry.html.
XX SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSI MLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRLMCTPLRGEGEC 60
Db 1 MRGATRVSI MLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRLMCTPLRGEGEC 60
QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRYRCSMDLKNIF 105
Db 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPDPGRYRCSMDLKNIF 105
RESULT 30
ABUS9885
ID ABUS9885 standard; protein; 105 AA.
XX AC ABUS9885;
XX 13-MAY-2003 (first entry)
XX Novel secreted and transmembrane protein PRO1186.
XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;

KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.

OS Homo sapiens.

XX US2003017563-A1.

XX 23-JAN-2003.

XX 07-MAY-2002; 2002US-00140808.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014532.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019033.

XX 14-SEP-1998; 98WO-US019094.

XX 16-SEP-1998; 98WO-US019177.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022931.

XX 29-OCT-1998; 98WO-US022932.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 98WO-US000106.

XX 08-MAR-1999; 98WO-US005028.

XX 10-MAR-1999; 98WO-US005190.

XX 20-APR-1999; 98WO-US008615.

XX 14-MAY-1999; 98WO-US010733.

XX 02-JUN-1999; 98WO-US012252.

XX 01-SEP-1999; 98WO-US020111.

XX 08-SEP-1999; 98WO-US020594.

XX 13-SEP-1999; 98WO-US020944.

XX 15-SEP-1999; 98WO-US021090.

XX 15-SEP-1999; 98WO-US021547.

XX 05-OCT-1999; 98WO-US023089.

XX 29-NOV-1999; 98WO-US028214.

XX 30-NOV-1999; 98WO-US028313.

XX 30-NOV-1999; 98WO-US028409.

XX 01-DEC-1999; 98WO-US028301.

XX 01-DEC-1999; 98WO-US028634.

XX 02-DEC-1999; 98WO-US028551.

XX 02-DEC-1999; 98WO-US028564.

XX 16-DEC-1999; 98WO-US028565.

XX 20-DEC-1999; 98WO-US030911.

XX 22-DEC-1999; 98WO-US030720.

XX 30-DEC-1999; 98WO-US031243.

PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 03-MAR-2001; 2001WO-US006666.
PR 14-MAR-2001; 2001US-00802706.
PR 22-MAR-2001; 2001US-00808689.
PR 05-APR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 23-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 08-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 08-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-148238/14.

N-PSDB; ABX89375.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.

Claim 12; Fig 470; 659pp; English.

The invention describes an isolated human PRO polypeptide. The PRO
polypeptides are useful in detecting PRO polypeptides in a sample, in
linking a bioactive molecule to a cell expressing a PRO polypeptide, and
in modulating at least one biological activity of a cell expressing a PRO
polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
stimulate adrenal cortical capillary endothelial growth, and PRO536,
PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
useful for treating conditions or disorders where angiogenesis would be
beneficial, e.g. wound healing and antagonist of this polypeptide are
useful for treating cancerous tumours. PRO812 inhibits vascular
endothelial growth factor (VEGF) stimulated proliferation of endothelial
cells and is thus useful for inhibiting endothelial cell growth in
mammals which would be beneficial in inhibiting tumour growth. PRO826,
PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
stimulated T-lymphocytes and are therapeutically useful for enhancing
immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
retinal neurons cells (PRO1132 is also enhances survival/proliferation of

rod photoreceptor cells) and therefore are useful for treating retinal disorders of injuries, e.g. retinitis pigmentosa, AMD, PRO819, PRO813 and PRO1066 induce proliferation of mammalian kidney mesangial cells, and therefore are useful for treating kidney disorders associated with decreased mesangial cell function such as Berger disease or other nephropathies associated with dermatitis, herpeticiformis or Crohn's disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the proliferation and/or redifferentiation of chondrocytes in culture and are thus useful for treating sports injuries, and arthritis. This is the amino acid sequence of a novel human PRO protein

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSMILLVTVSDCAVITGACERDVCGAGTCCATSLWLRGRLMCTPLGREGEC 60
 |||||
 DB 1 MEGATRVSMILLVTVSDCAVITGACERDVCGAGTCCATSLWLRGRLMCTPLGREGEC 60
 |||||

QY 61 HPGSHKVPFFRKRGHTCPCLNLLCSRFPPDGRYRCSDMLKNI 105
 |||||
 DB 61 HPGSHKVPFFRKRGHTCPCLNLLCSRFPPDGRYRCSDMLKNI 105
 |||||

RESULT 31
 ABUS93308
 ID ABUS93308 standard; protein; 105 AA.
 XX AC ABUS93308;
 XX XX
 XX 22-APR-2003 (first entry)
 XX XX
 DE Human secreted/transmembrane protein, #151.
 KW Human; PRO; secreted; transmembrane; pharmaceutical; diagnostic;
 KW biosensor; bioreactor; tumour; therapeutic; gene therapy;
 KW tumour-associated antigenic target; FAT; ABEPT;
 KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
 XX OS Homo sapiens.
 XX XX
 XX US2003027162-A1.
 XX PD 06-FEB-2003.
 XX XX
 XX 15-NOV-2001; 2001US-00937428.
 XX PR 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97MO-US020069.
 PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087108P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0095321P.

05-JUN-1998; 98US-0088202P.
 05-JUN-1998; 98US-0088212P.
 05-JUN-1998; 98US-0088217P.
 09-JUN-1998; 98US-0088655P.
 10-JUN-1998; 98US-0088734P.
 10-JUN-1998; 98US-0088738P.
 10-JUN-1998; 98US-0088744P.
 10-JUN-1998; 98US-0088810P.
 10-JUN-1998; 98US-0088824P.
 10-JUN-1998; 98US-0088826P.
 11-JUN-1998; 98US-0088859P.
 11-JUN-1998; 98US-0088861P.
 11-JUN-1998; 98US-0088876P.
 12-JUN-1998; 98US-0089105P.
 16-JUN-1998; 98US-0089400P.
 16-JUN-1998; 98US-0089512P.
 16-JUN-1998; 98US-0089514P.
 17-JUN-1998; 98US-0089532P.
 17-JUN-1998; 98US-0089538P.
 17-JUN-1998; 98US-0089598P.
 17-JUN-1998; 98US-0089599P.
 17-JUN-1998; 98US-0089600P.
 17-JUN-1998; 98US-0089653P.
 18-JUN-1998; 98US-0089801P.
 18-JUN-1998; 98US-0089907P.
 18-JUN-1998; 98US-0089908P.
 19-JUN-1998; 98US-0089947P.
 19-JUN-1998; 98US-0089948P.
 19-JUN-1998; 98US-0089952P.
 22-JUN-1998; 98US-0090246P.
 22-JUN-1998; 98US-0090252P.
 22-JUN-1998; 98US-0090254P.
 23-JUN-1998; 98US-0090349P.
 23-JUN-1998; 98US-0090355P.
 24-JUN-1998; 98US-0090429P.
 24-JUN-1998; 98US-0090431P.
 24-JUN-1998; 98US-0090435P.
 24-JUN-1998; 98US-0090444P.
 24-JUN-1998; 98US-0090445P.
 24-JUN-1998; 98US-0090472P.
 24-JUN-1998; 98US-0090535P.
 24-JUN-1998; 98US-0090540P.
 24-JUN-1998; 98US-0090542P.
 24-JUN-1998; 98US-0090557P.
 25-JUN-1998; 98US-0090676P.
 25-JUN-1998; 98US-0090678P.
 25-JUN-1998; 98US-0090690P.
 25-JUN-1998; 98US-0090694P.
 25-JUN-1998; 98US-0090695P.
 25-JUN-1998; 98US-0090696P.
 26-JUN-1998; 98US-0090862P.
 26-JUN-1998; 98US-0090863P.
 01-JUL-1998; 98US-0091360P.
 01-JUL-1998; 98US-0091544P.
 02-JUL-1998; 98US-0091478P.
 02-JUL-1998; 98US-0091519P.
 02-JUL-1998; 98US-0091626P.
 02-JUL-1998; 98US-0091628P.
 02-JUL-1998; 98US-0091633P.
 02-JUL-1998; 98US-0091646P.
 02-JUL-1998; 98US-0091673P.
 07-JUL-1998; 98US-0091978P.
 07-JUL-1998; 98US-0091982P.
 09-JUL-1998; 98US-0092182P.
 10-JUL-1998; 98US-0092472P.
 20-JUL-1998; 98US-0093339P.
 30-JUL-1998; 98US-0094651P.
 04-AUG-1998; 98US-0095282P.
 04-AUG-1998; 98US-0095285P.
 04-AUG-1998; 98US-0095301P.
 04-AUG-1998; 98US-0095302P.
 04-AUG-1998; 98US-0095318P.
 04-AUG-1998; 98US-0095321P.

04-AUG-1998; 98US-0095325P.
 PR 10-AUG-1998; 98US-0095916P.
 PR 10-AUG-1998; 98US-0095929P.
 PR 10-AUG-1998; 98US-0096012P.
 PR 11-AUG-1998; 98US-0096143P.
 PR 11-AUG-1998; 98US-0096146P.
 PR 11-AUG-1998; 98US-0096322P.
 PR 17-AUG-1998; 98US-0096757P.
 PR 17-AUG-1998; 98US-0096766P.
 PR 17-AUG-1998; 98US-0096768P.
 PR 17-AUG-1998; 98US-0096773P.
 PR 17-AUG-1998; 98US-0096791P.
 PR 17-AUG-1998; 98US-0096867P.
 PR 17-AUG-1998; 98US-0096891P.
 PR 17-AUG-1998; 98US-0096894P.
 PR 17-AUG-1998; 98US-0096895P.
 PR 17-AUG-1998; 98US-0096897P.
 PR 18-AUG-1998; 98US-0096949P.
 PR 18-AUG-1998; 98US-0096950P.
 PR 18-AUG-1998; 98US-0096959P.
 PR 18-AUG-1998; 98US-0096960P.
 PR 18-AUG-1998; 98US-0097022P.
 PR 19-AUG-1998; 98US-0097141P.
 PR 19-AUG-1998; 98US-0097218P.
 PR 24-AUG-1998; 98US-0097661P.
 PR 26-AUG-1998; 98US-0097952P.
 PR 26-AUG-1998; 98US-0097954P.
 PR 26-AUG-1998; 98US-0097955P.
 PR 26-AUG-1998; 98US-0097971P.
 PR 26-AUG-1998; 98US-0097974P.
 PR 26-AUG-1998; 98US-0097978P.
 PR 26-AUG-1998; 98US-0097979P.
 PR 26-AUG-1998; 98US-0097986P.
 PR 26-AUG-1998; 98US-0098014P.
 PR 31-AUG-1998; 98US-0098525P.
 PR 16-SEP-1998; 98US-0100634P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 01-DEC-1998; 98WO-US025108.
 PR 22-DEC-1998; 98US-0113298P.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 12-MAR-1999; 98US-0123957P.
 PR 02-JUN-1999; 98WO-US012252.
 PR 23-JUN-1999; 98US-0141037P.
 PR 07-JUL-1999; 98US-0143048P.
 PR 20-JUL-1999; 98US-014758P.
 PR 26-JUL-1999; 98US-0145698P.
 PR 28-JUL-1999; 98US-0146222P.
 PR 17-AUG-1999; 98US-0149396P.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 08-OCT-1999; 98US-0158663P.
 PR 30-NOV-1999; 98WO-US028313.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000355.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 15-MAY-2000; 2000WO-US013358.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-JUN-2000; 2000US-0213637P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCAGTGCCATSLMRLGRLMCTPLRGEGEC 60
 DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCAGTGCCATSLMRLGRLMCTPLRGEGEC 60
 QY 61 HPGSHKVPFFRRKHHTCPCLPNLLCSRFDPGRYRCSDMLKKNIF 105
 DB 61 HPGSHKVPFFRRKHHTCPCLPNLLCSRFDPGRYRCSDMLKKNIF 105
 RESULT 32
 ABO26005
 ID ABO26005 standard; protein, 105 AA.
 XX ABO26005;
 AC ABO26005;
 XX
 DT 10-SEP-2003 (first entry)
 XX
 DE Human PRO1186 polypeptide.
 XX
 KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW Genetic disorder; antibacterial; immunosuppressive.
 XX
 OS Homo sapiens.
 XX
 PN US2002127576-A1.
 XX
 PD 12-SEP-2002.
 XX
 PF 14-NOV-2001; 2001US-00991073.
 XX
 PR 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0085186P.
 PR 13-NOV-1997; 97US-0085311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-008759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088172P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-008855P.
 PR 10-JUN-1998; 98US-0088734P.

PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025106.
 PR 05-JAN-1999; 98WO-US000109.
 PR 08-MAR-1999; 98WO-US005038.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012232.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015284.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US0747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006566.
 PR 09-MAR-2001; 2001US-00802786.
 PR 14-MAR-2001; 2001US-00808699.
 PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 FA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-466355/44.
 DR N-PSDB; ACD42029.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 12; Fig 470; 659pp; English.

XX The invention relates to an isolated nucleic acid comprising at least 80%
 CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
 CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
 CC extracellular domain (with or without its associated signal peptide),
 CC which comprises any of the 275 120-850 residue amino acid sequences,
 CC given in the specification; (b) comprising any of the 275 300-3500
 CC nucleotide sequences, given in the specification; or (c) comprising the
 CC full-length coding sequence of the nucleotide sequences given in the
 CC specification, or of the DNA deposited under any of the American Type
 CC Culture Collection (ATCC) Accession Numbers listed in the specification.
 CC Also included are a vector comprising the novel nucleic acid, a host cell
 CC comprising the vector, producing a PRO polypeptide, the isolated PRO
 CC polypeptides detailed above, a chimeric molecule comprising the PRO
 CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
 CC antibody, detecting a PRO polypeptide in a sample suspected of containing
 CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
 CC PRO polypeptide, modulating at least one biological activity of a cell
 CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
 CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
 CC modulating the uptake of glucose or FFA by skeletal muscle cells or
 CC adipocyte cells, stimulating the proliferation or differentiation of
 CC chondrocyte cells (or proliferation of or gene expression in pericyte
 CC cells), stimulating the proliferation of inner ear utricular supporting
 CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
 CC binding of A-peptide to factor VIIA, or differentiation of adipocyte
 CC cells, detecting the presence of a tumour in a mammal and an
 CC oligonucleotide probe derived from any of the nucleotide sequences given
 CC in the specification. The polynucleotide is useful in molecular biology,
 CC including uses as hybridisation probes, in chromosome and gene mapping,
 CC in generating antisense RNA and DNA, and in gene therapy. The
 CC polynucleotide may also be used in preparing PRO polypeptides by
 CC recombinant techniques, and in generating either transgenic animals or
 CC knock-out animals which, in turn, are useful in the development and
 CC screening of therapeutically useful reagents. The PRO polypeptide or the

CC antibody is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The present sequence represents a PRO
CC polypeptide
XX
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKHKHTCPCLNLLCSFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKHKHTCPCLNLLCSFPDGRYRCSMDLKNINF 105

RESULT 34
ABU82130
ID ABU82130 standard; protein; 105 AA.
XX AC ABU82130;
XX DT 25-JUN-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1166.
XX
XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
KW antiangiogenic; hypotensive; vulnenry; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX
XX Homo sapiens.
OS
PN US2003088063-A1.
XX
XX 08-MAY-2003.
XX PD 12-AUG-2002; 2002US-00219003.
XX PF 25-JUL-2000; 2000US-0220664P.
XX PR 01-JUN-2001; 2001MO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;
PI WPI; 2003-393229/37.
XX DR N-PSDB; ACA68579.
XX
XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
XX Claim 11; Fig 166; 314pp; English.
XX
XX The invention describes one hundred and eighty seven nucleic acids
CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating or diagnosing a cardiovascular, endothelial or angiogenic
CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
CC related macular degeneration, atherosclerosis, hypertension, arterial
CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,

CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
CC have applications in molecular biology, including use as hybridisation
CC probes, and in chromosome and gene mapping. This is the amino acid
CC sequence of a novel human secreted and transmembrane PRO polypeptide
XX
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKHKHTCPCLNLLCSFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKHKHTCPCLNLLCSFPDGRYRCSMDLKNINF 105

RESULT 35
ABU59014
ID ABU59014 standard; protein; 105 AA.
XX AC ABU59014;
XX DT 16-APR-2003 (first entry)
XX DE Human secreted/transmembrane protein, #151.
XX
XX Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
KW diagnostic; biosensor; bioreactor; tumour; therapeutic; colon cancer;
KW lung cancer; breast cancer; cancer; gene therapy.
XX
XX Homo sapiens.
OS
PN US2002142961-A1.
XX
XX 03-OCT-2002.
XX
XX 19-NOV-2001; 2001US-00989721.
XX
XX 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 24-NOV-1997; 97US-0066770P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PR 28-MAR-1998; 98US-0078910P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 07-MAY-1998; 98US-0084600P.
XX PR 28-MAY-1998; 98US-0087106P.
XX PR 02-JUN-1998; 98US-0087607P.
XX PR 02-JUN-1998; 98US-0087609P.
XX PR 02-JUN-1998; 98US-0087759P.
XX PR 03-JUN-1998; 98US-0087827P.
XX PR 04-JUN-1998; 98US-0088021P.
XX PR 04-JUN-1998; 98US-0088025P.
XX PR 04-JUN-1998; 98US-0088026P.
XX PR 04-JUN-1998; 98US-0088028P.
XX PR 04-JUN-1998; 98US-0088029P.
XX PR 04-JUN-1998; 98US-0088030P.
XX PR 04-JUN-1998; 98US-0088033P.
XX PR 04-JUN-1998; 98US-0088326P.
XX PR 05-JUN-1998; 98US-0088167P.
XX PR 05-JUN-1998; 98US-0088202P.
XX PR 05-JUN-1998; 98US-0088212P.
XX PR 05-JUN-1998; 98US-0088217P.
XX PR 09-JUN-1998; 98US-0088655P.
XX PR 10-JUN-1998; 98US-0088734P.
XX PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089514P.
PR 16-JUN-1998; 98US-0089512P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089633P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 02-JUN-1999; 98WO-US012252.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004314.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski P;
PI Grimaldi JC, Gurney AL, Kijavini IJ, Rapier MA, Pan J, Paoni NP;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX WPI; 2003-155950/15.

XX New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184, PRO361 or PRO846) useful as targets for therapeutic intervention in cancers (e.g. lung or breast cancers), or for diagnosing these cancers.
XX Claim 12; Fig 266; 647pp; English.
XX The invention discloses isolated PRO secreted/transmembrane polypeptides comprising a sequence without signal peptide and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. The PRO polypeptides or polynucleotides are also useful as pharmaceuticals, diagnostics, biosensors or bioreactors, for detecting or treating e.g. tumours in mammals, e.g. humans, dogs, cats, cattle, horses, sheep, goats or rabbits as targets for therapeutic intervention in certain cancers (e.g. colon, lung or breast cancers) and diagnostic determination of the presence of these cancers. The PRO polypeptides are also useful as molecular weight markers or for chromosome identification. The PRO genes are useful as hybridisation probes or for screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequences presented in ABUS8900-ABUS9046 are the PRO polypeptides of the invention
XX Sequence 105 AA;
SQ
Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0;
QY 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
|||
DB 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
|||
QY 61 HPGSHKVPFRKRKHHTCPCLENLLCSRPDGRYRCSDMLKNINF 105
|||
DB 61 HPGSHKVPFRKRKHHTCPCLENLLCSRPDGRYRCSDMLKNINF 105
|||
RESULT 36
ABUS2392 standard; protein; 105 AA.
XX
XX AC ABUS2392;
XX
DT 16-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1186.
XX
KW Human; secreted and transmembrane protein; PRO; PRO183; PRO184; PRO185;
KW PRO943; PRO1133; PRO331; PRO1387; PRO363; PRO5723; PRO1114; PRO3301;
KW PRO9940; PRO1181; PRO7170; PRO361; PRO846; bioactive molecule; toxin;
KW radiolabel; antibody; cell death; tissue typing; gene therapy;
KW cytostatic; chromosome mapping; gene mapping; transgenic animal;
KW knockout animal; immunohistochemical staining.
XX Homo sapiens.
XX OS
XX US2003022187-A1.
XX
XX PN
XX PD 30-JAN-2003.
XX
XX PF 14-NOV-2001; 2001US-00993667.
XX
XX PR 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 24-NOV-1997; 97US-0066770P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087753P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088032P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089511P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 18-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 22-JUN-1998; 98US-0090282P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 01-JUL-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096945P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0102114P.
PR 01-DEC-1998; 98US-0102510P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0143048P.
PR 20-FEB-1999; 98US-0144758P.
PR 08-MAR-1999; 98US-0145698P.
PR 12-MAR-1999; 98US-0145698P.
PR 02-JUN-1999; 98US-0145698P.
PR 23-JUN-1999; 98US-0145698P.
PR 07-JUL-1999; 98US-0145698P.
PR 20-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0145698P.
PR 17-AUG-1999; 98US-0145698P.
PR 15-SEP-1999; 98US-0145698P.
PR 15-SEP-1999; 98US-0145698P.
PR 08-OCT-1999; 98US-0145698P.
PR 30-NOV-1999; 98US-0145698P.


```

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005094.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60
DB 1 MGRATRVSIMLLVTVSCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60

QY 61 HPGSHKVPFFRKXHTCTCLPCLNLLCSRFPDGRYRCSMDLNKINF 105
DB 61 HPGSHKVPFFRKXHTCTCLPCLNLLCSRFPDGRYRCSMDLNKINF 105

RESULT 37
ABUS9457
ID ABUS9457 standard; protein; 105 AA.
XX
XX ABUS9457;
XX
XX 22-APR-2003 (first entry)
XX
XX Novel human secreted or transmembrane protein PRO1198.
XX
XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
XX cardiac insufficiency disorder; cancer; tumour; immune response;
XX adrenal cortical capillary endothelial growth; c-fos induction;
XX vascular endothelial growth factor inhibition; VEGF inhibition;
XX endothelial cell growth inhibitor; T-lymphocytes stimulation;
XX retinal neurons cell survival; rod photoreceptor cell survival;
XX retinal disorder; retinitis pigmentosa; kidney disease;
XX mammalian kidney mesangial cell proliferation; Berger disease;
XX dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
XX chondrocyte redifferentiation; sports injury; arthritis.
XX
XX Homo sapiens.
XX
XX US2003027985-A1.
XX
XX 06-FEB-2003.
XX
XX 14-NOV-2001; 2001US-00990562.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020089.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.

```

```

PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 03-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088910P.
PR 10-JUN-1998; 98US-0088924P.
PR 10-JUN-1998; 98US-0088926P.
PR 11-JUN-1998; 98US-0088958P.
PR 11-JUN-1998; 98US-0088961P.
PR 11-JUN-1998; 98US-0088976P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-009057P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.

```


PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US000528.
PR 10-MAR-1999; 99WO-US000530.
PR 20-APR-1999; 99WO-US000615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023521.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806899.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866038.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 05-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PI
XX WPI; 2003-331925/31.
DR N-PSDB; ACA04258.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 12; Fig 470; 659pp; English.
XX
XX The invention relates to an isolated nucleic acid comprising, or which is
CC at least 80% identical to, or the full-length coding sequence of, any of
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC (one of 275 secreted or transmembrane proteins). The nucleic acid further
CC comprises the full-length coding sequence of the DNA deposited under
CC American Type Culture Collection (ATCC) accession number in a list given
CC in the specification. Also included are vectors and host cells for
CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO
CC extracellular domains and mature sequences, methods of detecting PRO
CC proteins, methods for stimulating the release of TNF-alpha (tumour
CC necrosis factor alpha) from human blood, (and the proliferation of, or gene
CC differentiation of chondrocyte cells, the proliferation of, or gene
CC expression in pericyte cells, the release or proteoglycans from
CC cartilage, proliferation of inner ear articular supporting cells, the
CC proliferation of T-lymphocyte cells, the release of a cytokine from
CC peripheral blood mononuclear cells (PBMC), or the proliferation of
CC endothelial cells), a method for modulating the uptake of glucose or free
CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the
CC binding of A-peptide to factor VIIA, or the differentiation of adipocyte
CC cells, a method for detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences cited
CC above. The nucleic acids and polypeptides are useful for treating
CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,
CC infertility, birth defects, premature aging, AIDS (acquired
CC immunodeficiency syndrome), cancer, or diabetic complications. The
CC nucleic acids are useful as hybridisation probes, in chromosome and gene
CC mapping, and in generating antisense RNA or DNA. The polypeptides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. Both
CC are useful in tissue typing. The present sequence represents a PRO
CC protein of the invention
XX
SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRGATRVISMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWGLRNMCTPLRGEGEC 60
Db 1 MRGATRVISMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWGLRNMCTPLRGEGEC 60
Qy 61 HPGSHKVPFRKRRKHTCTCLPNLCSRPDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPFRKRRKHTCTCLPNLCSRPDPGRYCSMDLKNINF 105


```
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 200WO-US0000219.
PR 06-JAN-2000; 200WO-US0000376.
PR 11-FEB-2000; 200WO-US003565.
PR 18-FEB-2000; 200WO-US004341.
PR 22-FEB-2000; 200WO-US004414.
PR 24-FEB-2000; 200WO-US004914.
PR 02-MAR-2000; 200WO-US005841.
PR 10-MAR-2000; 200WO-US006319.
PR 15-MAR-2000; 200WO-US006884.
PR 20-MAR-2000; 200WO-US007377.
PR 30-MAR-2000; 200WO-US008439.
PR 15-MAY-2000; 200WO-US013358.
PR 17-MAY-2000; 200WO-US013705.
PR 22-MAY-2000; 200WO-US014042.
PR 30-MAY-2000; 200WO-US014941.
PR 02-JUN-2000; 200WO-US015264.
PR 23-JUN-2000; 200US-0213637P.
PR 28-JUL-2000; 200WO-US020710.
PR 11-AUG-2000; 200WO-US022031.
PR 23-AUG-2000; 200WO-US023522.
PR 24-AUG-2000; 200WO-US023328.

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMCTPLGREGEC 60
DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPPGRYRCSDMLKNINF 105

RESULT 40
ABU10929
```

```
ID ABU10929 standard; protein; 105 AA.
XX
AC ABU10929;
XX
DT 04-FEB-2003 (first entry)
XX
DE Human PRO polypeptide #115.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide; toxin;
KW radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW antibacterial.
XX
XX Homo sapiens.
XX
FN US2002123463-A1.
XX
PD 05-SEP-2002.
XX
PF 19-NOV-2001; 2001US-00989732.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
```

PR 07-OCT-1998; 98WO-US021141.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 02-JUN-1999; 99WO-US012252.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 16-DEC-1999; 99WO-US028634.
 PR 20-DEC-1999; 99WO-US030095.
 PR 06-JAN-2000; 99WO-US030911.
 PR 06-JAN-2000; 2000WO-US000219.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004341.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US005004.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 15-MAY-2000; 2000WO-US013358.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 28-AUG-2001; 2001US-00941992.

(GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Borstein D, Desnoyers L, Eaton DL;
 PI Perrazzi N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kljavin IU, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;

DR WPI; 2003-066810/06.
 DR N-PSDB; ABX17148.

XX Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers.

XX Claim 12; Fig 266; 655pp; English.

XX The invention relates to a secreted and transmembrane polypeptide, termed
 CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
 CC useful for detecting PRO polypeptides and for linking a bioactive
 CC molecule to a cell expressing the above polypeptides, where the bioactive
 CC molecule is a toxin, radiolabel or an antibody. The bioactive material
 CC causes the death of the cell. The polypeptide is useful for identifying
 CC agonists or antagonists of the PRO polypeptide, for preparing variants of
 CC PRO, as a molecular weight marker for protein electrophoresis purposes
 CC and the PRO polynucleotide is useful for recombinantly expressing those
 CC markers. The polynucleotide is also useful as a hybridisation probe, in
 CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
 CC the preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, to construct hybridisation

CC probes for mapping the gene which encodes PRO and for the genetic
 CC analysis of individuals with genetic disorders, in gene therapy, for
 CC chromosome identification, as a chromosome marker and for generating
 CC probes for PCR, Northern analysis, Southern analysis and Western
 CC analysis. This sequence represents a human PRO polypeptide of the
 CC invention
 CC
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred.No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MEGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGRGEEC 60
 Db |||||
 QY 1 MEGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGRGEEC 60
 Db |||||
 QY 61 HPGSHKVPFFRRKRHHTCPLNLLCSFPDGRYRCSMDLKNINF 105
 Db |||||
 QY 61 HPGSHKVPFFRRKRHHTCPLNLLCSFPDGRYRCSMDLKNINF 105
 Db |||||

RESULT 41

ABU81681

ID ABU81681 standard; protein; 105 AA.

XX ABU81681;

XX 24-JUN-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; gene therapy; PRO; PRO943;
 KW PRO183; PRO184; PRO185; PRO331; PRO1133; PRO363; PRO5723; PRO1387;
 KW PRO1114; PRO3301; PRO9940; PRO1181; PRO170; PRO361; PRO846;
 KW bioactive molecule; toxin; radiolabel; antibody; cell death; cancer;
 KW autoimmune disease; chromosome mapping; gene mapping; transgenic animal;
 KW knockout animal; septic shock.

XX Homo sapiens.

XX US2002177164-A1.

XX 28-NOV-2002.

XX 20-NOV-2001; 2001US-00989293.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0056770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 03-JUN-1998; 98US-0087759P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089907P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US021108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941932.
XX (GETH) GENENTECH INC.
PA
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;

PI Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
XX WPI; 2003-328481/31.
DR N-PSDB; ACA68003.
XX
PT New secreted and transmembrane polypeptide, useful for modulating
PT biological activity of cell expressing the polypeptide, for identifying
PT agonists or antagonists of polypeptide, and as molecular weight markers.
XX
XX Claim 12; Fig 266; 654pp; English.
XX
CC The invention describes an isolated, secreted and transmembrane
CC polypeptide (I), termed PRO polypeptide. (I) is useful for detecting
CC PRO943, PRO183, PRO184, PRO185, PRO331, PRO1133, PRO363, PRO5723,
CC PRO1387, PRO1114, PRO3301, PRO9940, PRO1181, PRO7170, PRO361 or PRO846
CC polypeptide comprising contacting the sample with the polypeptide and
CC determining formation of a polypeptide conjugate. (I) is also useful for
CC linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a
CC cell expressing the above polypeptides to cause cell death. (I) is also
CC useful as a therapeutic agent e.g. for treating cancer and autoimmune
CC disease. PRO is useful in assays to identify other proteins or molecules
CC involved in binding interactions. The polynucleotide (II) encoding (I) is
CC useful in chromosome and gene mapping, for generating transgenic animals
CC or knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, and as a chromosome marker. An anti-(I)-antibody is
CC useful in diagnostic assays for PRO, e.g. detecting its expression in
CC specific cells, tissues or serum, for affinity purification of PRO, and
CC for treating septic shock. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO polypeptide
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWRLGRLMCTPLGRGEGEC 60
DB 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWRLGRLMCTPLGRGEGEC 60
QY 61 HPGSHKVPFPRKRKHHTCPCLENLCSRPDGRYCSMDLKNINF 105
DB 61 HPGSHKVPFPRKRKHHTCPCLENLCSRPDGRYCSMDLKNINF 105

RESULT 42
ABU88620
ID ABU88620 standard; protein; 105 AA.
XX AC ABU88620;
XX DT 11-AUG-2003 (first entry)
XX DE Human secreted and transmembrane polypeptide PRO1186.
XX KW Human; gene therapy; cancer; retinal disorder; wound healing;
XX KW kidney disorder.
XX OS Homo sapiens.
XX PN US2002197615-A1.
XX PD 26-DEC-2002.
XX PF 16-NOV-2001; 2001US-00991181.
XX PR 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 30-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083222P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 03-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088023P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088228P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088878P.
 PR 12-JUN-1998; 98US-0088910P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 16-SEP-1998; 98US-00919330.
 PR 17-SEP-1998; 98US-00919437.
 PR 07-OCT-1998; 98US-00921141.
 PR 01-DEC-1998; 98US-00925108.
 PR 05-JAN-1999; 98US-00925108.
 PR 08-MAR-1999; 98US-0095028.
 PR 02-JUN-1999; 98US-0095028.
 PR 15-SEP-1999; 98US-0095028.
 PR 15-SEP-1999; 98US-0095028.
 PR 30-NOV-1999; 98US-0095028.
 PR 01-DEC-1999; 98US-0095028.
 PR 01-DEC-1999; 98US-0095028.
 PR 16-DEC-1999; 98US-0095028.
 PR 20-DEC-1999; 98US-0095028.
 PR 05-JAN-2000; 98US-0095028.
 PR 06-JAN-2000; 98US-0095028.
 PR 11-FEB-2000; 98US-0095028.
 PR 18-FEB-2000; 98US-0095028.
 PR 22-FEB-2000; 98US-0095028.
 PR 24-FEB-2000; 98US-0095028.
 PR 24-FEB-2000; 98US-0095028.
 PR 02-MAR-2000; 98US-0095028.
 PR 10-MAR-2000; 98US-0095028.
 PR 15-MAR-2000; 98US-0095028.
 PR 20-MAR-2000; 98US-0095028.
 PR 30-MAR-2000; 98US-0095028.
 PR 15-MAY-2000; 98US-0095028.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US0202031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 28-AUG-2001; 2001US-00941992.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ,
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF,
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,
 PI Zhang Z;
 XX WPI; 2003-370792/35.
 DR N-PSDB; ACA88452.
 XX
 PT New secreted and transmembrane nucleic acids and polypeptides, designated
 as PRO, useful for the preparation of a medicament for treating a
 condition that is responsive to the PRO polypeptide. e.g., cancer.
 PT
 XX
 PS Claim 12; Fig 266; 647pp; English.
 PS
 CC The invention relates to an isolated nucleic acid encoding a PRO
 polypeptide. The polypeptide, agonist, antagonist and antibody are useful
 for the preparation of a medicament for treating a condition that is
 responsive to the PRO polypeptide. The nucleotide sequence is useful in
 molecular biology including being used as hybridisation probes, in
 chromosome and gene mapping and in the generation of anti-sense RNA and
 DNA. The PRO polypeptides can also be used in the treatment of e.g.
 cancer, retinal disorders, wound healing and kidney disorders. The
 present sequence represents the amino acid sequence of a human secreted
 and transmembrane PRO polypeptide of the present invention. Note: The
 CC sequence data for this patent did not form part of the printed
 CC specification but was obtained in electronic format directly from USPTO
 CC at seqdata.uspto.gov/sequence.html?DocID=20020197615
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 Db 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HFGSHKVPFFRRKRKHTCTPCLENLLCSRRFFDGRYRCSDMLKNINF 105
 Db 61 HFGSHKVPFFRRKRKHTCTPCLENLLCSRRFFDGRYRCSDMLKNINF 105
 RESULT 43
 ABO34134
 ID ABO34134 standard; protein; 105 AA.
 XX
 AC ABO34134;
 XX
 DT 19-SEP-2003 (first entry)
 XX Human PRO186 polypeptide.
 DE
 XX

KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW biosensor; bioreactor; tumour; cancer; diabetes; ALS; ulcer;
KW rheumatoid arthritis; amyotrophic lateral sclerosis; cytostatic;
KW antidiabetic; antiarthritic; antirheumatic; antiulcer.
OS Homo sapiens.
XX US2003017981-A1.
XX 23-JAN-2003.
XX 20-NOV-2001; 2001US-00989728.
XX 16-JUN-1997; 97US-0045787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US0200069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0065770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088026P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088030P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088326P.
XX 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088734P.
XX 10-JUN-1998; 98US-0088738P.
XX 10-JUN-1998; 98US-0088742P.
XX 10-JUN-1998; 98US-0088810P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088828P.
XX 11-JUN-1998; 98US-0088858P.
XX 11-JUN-1998; 98US-0088861P.
XX 12-JUN-1998; 98US-0088876P.
XX 16-JUN-1998; 98US-0089105P.
XX 16-JUN-1998; 98US-0089440P.
XX 16-JUN-1998; 98US-0089512P.
XX 16-JUN-1998; 98US-0089544P.
XX 17-JUN-1998; 98US-0089532P.
XX 17-JUN-1998; 98US-0089538P.
XX 17-JUN-1998; 98US-0089589P.
XX 17-JUN-1998; 98US-0089599P.
XX 17-JUN-1998; 98US-0089600P.
XX 18-JUN-1998; 98US-0089601P.
XX 18-JUN-1998; 98US-0089607P.
XX 18-JUN-1998; 98US-0089908P.
XX 19-JUN-1998; 98US-0089947P.
XX 19-JUN-1998; 98US-0089948P.
XX 22-JUN-1998; 98US-0089952P.
XX 22-JUN-1998; 98US-0090246P.
XX 22-JUN-1998; 98US-0090252P.
XX 22-JUN-1998; 98US-0090254P.
XX 23-JUN-1998; 98US-0090349P.
XX 23-JUN-1998; 98US-0090355P.
XX 24-JUN-1998; 98US-0090439P.
XX 24-JUN-1998; 98US-0090431P.

PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 07-JUL-1998; 98US-0091982P.
PR 08-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 10-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 17-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.

cell proliferation stimulator; cell differentiation stimulator;
cell differentiation inhibitor; cytokine release stimulator; tumour;
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.

Homo sapiens.

US2003022328-A1.

30-JAN-2003.

16-APR-2002; 2002US-00123904.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017886.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

16-SEP-1998; 98WO-US019177.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 98WO-US000106.

08-MAR-1999; 98WO-US005028.

10-MAR-1999; 98WO-US005190.

20-APR-1999; 98WO-US008615.

14-MAY-1999; 98WO-US010733.

02-JUN-1999; 98WO-US012252.

08-SEP-1999; 98WO-US020111.

13-SEP-1999; 98WO-US020944.

15-SEP-1999; 98WO-US021090.

05-OCT-1999; 98WO-US023089.

29-NOV-1999; 98WO-US028214.

30-NOV-1999; 98WO-US028313.

01-DEC-1999; 98WO-US028409.

01-DEC-1999; 98WO-US028301.

01-DEC-1999; 98WO-US028634.

02-DEC-1999; 98WO-US028551.

02-DEC-1999; 98WO-US028564.

KW

KW

KW

KW

XX

OS

XX

XX

PN

XX

PD

XX

PF

XX

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

01-DEC-1998; 98WO-US025108.

22-DEC-1998; 98US-0113296P.

05-JAN-1999; 98WO-US000106.

08-MAR-1999; 98WO-US005028.

12-MAR-1999; 98US-0123957P.

02-JUN-1999; 98WO-US012252.

23-JUN-1999; 98US-0141037P.

07-JUL-1999; 98US-0143048P.

26-JUL-1999; 98US-0144758P.

26-JUL-1999; 98US-0145698P.

28-JUL-1999; 98US-0146222P.

17-AUG-1999; 98US-0149396P.

15-SEP-1999; 98WO-US021190.

15-SEP-1999; 98WO-US021197.

08-OCT-1999; 98US-0158663P.

30-NOV-1999; 98WO-US028313.

01-DEC-1999; 98WO-US028301.

01-DEC-1999; 98WO-US028634.

16-DEC-1999; 98WO-US030095.

20-DEC-1999; 98WO-US030911.

05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000376.

11-FEB-2000; 2000WO-US003565.

18-FEB-2000; 2000WO-US004341.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US005004.

02-MAR-2000; 2000WO-US005841.

10-MAR-2000; 2000WO-US006319.

20-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.

30-MAR-2000; 2000WO-US008439.

15-MAY-2000; 2000WO-US013358.

17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.

30-MAY-2000; 2000WO-US014941.

02-JUN-2000; 2000WO-US015264.

23-JUN-2000; 2000US-0213637P.

28-JUL-2000; 2000WO-US020710.

11-AUG-2000; 2000WO-US022031.

23-AUG-2000; 2000WO-US023522.

24-AUG-2000; 2000WO-US023328.

07-SEP-2000; 2000US-0230978P.

08-NOV-2000; 2000WO-US030952.

01-DEC-2000; 2000WO-US032678.

28-FEB-2001; 2001WO-US006520.

Query Match 100.0%; Score 589; DB 6; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54; Mismatches 0; Indels 0; Gaps 0;

Matches 105; Conservative 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCACCAISLWLRGLRMCTPLGREGEEC 60

Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCACCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFRKRGKHTCTCLNLLCSRPFDGRYCSMDLNKINF 105

Db 61 HPGSHKVPFRKRGKHTCTCLNLLCSRPFDGRYCSMDLNKINF 105

RESULT 44

ADA45989 standard; protein; 105 AA.

XX ADA45989;

AC

XX

DT 20-NOV-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 18-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Bresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-584997/55.
DR N-PSDB; ADA45988.
XX
XX Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
XX Claim 12; Fig 470; 659pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding

interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural
sources. (I) and (II) are useful for tissue typing. This is the amino
acid sequence of a novel human secreted and transmembrane PRO
polypeptide.

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54; Mismatches 0; Gaps 0;
Matches 105; Conservative 0; Indels 0; Gaps 0;
Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGLRMTCTPLGRGEEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGLRMTCTPLGRGEEC 60
Qy 61 HPGSHKVPFRERKEKHTCPCPLNLLCSRPPDGYRCSMDLKNINF 105
Db 61 HPGSHKVPFRERKEKHTCPCPLNLLCSRPPDGYRCSMDLKNINF 105

RESULT 45
ADA76420
ID ADA76420 standard; protein; 105 AA.
XX
XX ADA76420;
AC
XX
XX 20-NOV-2003 (first entry)
XX
XX Human PRO polypeptide #235.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX
XX US2003073212-A1.
PN
XX
XX 17-APR-2003.
PD
XX
XX 16-APR-2002; 2002US-00123903.
PF
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 05-JAN-1999; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.

PR	08-MAR-1999;	99WO-US005028.
PR	10-MAR-1999;	99WO-US005190.
PR	20-APR-1999;	99WO-US006615.
PR	14-MAY-1999;	99WO-US010723.
PR	02-JUN-1999;	99WO-US012252.
PR	01-SEP-1999;	99WO-US020111.
PR	08-SEP-1999;	99WO-US020594.
PR	13-SEP-1999;	99WO-US020944.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	05-OCT-1999;	99WO-US023089.
PR	29-NOV-1999;	99WO-US028214.
PR	30-NOV-1999;	99WO-US028313.
PR	30-NOV-1999;	99WO-US028409.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028564.
PR	02-DEC-1999;	99WO-US028565.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	20-DEC-1999;	99WO-US030929.
PR	22-DEC-1999;	99WO-US030720.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	18-FEB-2000;	2000WO-US004342.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004944.
PR	24-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00865028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001US-00867092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00906827.
PR	08-AUG-2001;	2001US-00924419.
PR	03-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00928072.
XX	(GETH) GENENTECH INC.	
PA	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S; PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; XX WPI; 2003-687639/65. DR N-PSDS; ADA76419.	
XX	New isolated nucleic acid encoding a secreted and transmembrane polypeptide, designated e.g. PRO114 or PRO4978, useful in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.	
PT	Claim 12; Fig 470; 659pp; English.	
XX	The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a	

```

RESULT 46
ABJ72310
ID ABJ72310 standard; protein; 105 AA.
XX
AC ABJ72310;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human PRO1186 protein.
XX
KW PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003050448-A1.
XX
PD 13-MAR-2003.
XX
PF 28-AUG-2002; 2002US-00230414.
XX
PR 01-JUN-2001; 2001WO-US017800.
XX
PR 29-JUN-2001; 2001WO-US021066.
XX
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2003-521818/49.
DE N-PSDB; ABT44308.
XX
XX
PT New nucleic acid encoding for a PRO protein, useful for the manufacture
PT of a medicament for diagnosing or treating tumors or for measuring or
PT detecting expression of an associated gene.
XX
XX
PS Claim 11; Fig 166; 315pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding a fully
CC defined PRO polypeptide. The molecules of the invention may be useful for
CC stimulating proliferation or gene expression in pericyte cells or the
CC release of TNF-alpha from human blood. Other possible uses include the
CC stimulation or inhibition of chondrocyte proliferation or
CC differentiation, the stimulation of human dermal fibroblast cell
CC proliferation and the detection of the presence of a tumour within a
CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
CC of a medicament for diagnosing or treating a tumour within a mammal or
CC for measuring or detecting the expression of an associated gene, as well
CC as during gene therapy. The current sequence is that of the human PRO
CC protein of the invention
XX
XX
SQ Sequence 105 AA;

Query Match      100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWRLGRLMCTPLGREGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFDPDGRYCSMDLKNINF 105
DB 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFDPDGRYCSMDLKNINF 105

RESULT 47
ADA19070
ID ADA19070 standard; protein; 105 AA.
XX

```

```

AC ADA19070;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #235.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
PN US2003054517-A1.
XX
PD 20-MAR-2003.
XX
PF 08-MAY-2002; 2002US-00141755.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022931.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 22-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.

```

02-MAR-2000; 2000WO-US005841.
 10-MAR-2000; 2000WO-US006319.
 15-MAR-2000; 2000WO-US006884.
 20-MAR-2000; 2000WO-US007377.
 21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUN-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030973.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854208.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-521954/49.
 N-PSDB; ADA19069.

New PRO nucleic acid, useful for preparing a composition for treating e.g., tumors.

Claim 12; Fig 470; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. lung, colon, breast, prostate, rectal, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO

CC polypeptides by recombinant techniques and in generating either
 CC transgenic animals or knock-out animals which are useful in the
 CC development and screening of therapeutically useful reagents. The PRO
 CC polypeptides or antibodies are used in preparing a medicament for
 CC treating a condition responsive to the polypeptides or antibodies, such
 CC as tumours, for modulating the uptake of glucose or FFA by adipocyte
 CC cells, for stimulating the proliferation of or gene expression in
 CC pericyte cells, for stimulating the release of proteoglycans from
 CC cartilage, for stimulating the proliferation of inner ear utricular
 CC supporting cells, for stimulating the release of cytokines from BMC
 CC cells, for inhibiting the binding of A-peptide to factor VIIA, for
 CC inhibiting the differentiation of adipocyte cells and for stimulating the
 CC proliferation of endothelial cells. This sequence represents a human PRO
 CC polypeptide of the invention. Note: The sequence data for this patent is
 CC also available in electronic format from USPTO at
 CC seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60
 |||||
 Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60
 |||||

QY 61 HPGSHKVPFFRRKRHHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
 |||||
 Db 61 HPGSHKVPFFRRKRHHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
 |||||

RESULT 48
 ADA61693
 ID ADA61693 standard; protein; 105 AA.

XX AC ADA61693;
 XX AC
 DT 20-NOV-2003 (first entry)
 XX XX
 DE Homo sapiens.

XX Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX Novel.
 OS human.
 OS secreted.
 OS and.
 OS transmembrane.
 OS Protein.
 OS PRO1186.
 XX US2003049816-A1.
 XX 13-MAR-2003.
 XX 15-APR-2002; 2002US-00123262.
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005615.
 PR 20-APR-1999; 98WO-US005130.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012232.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004314.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005941.
 PR 15-MAR-2000; 2000WO-US006319.
 PR 20-MAR-2000; 2000WO-US006384.
 PR 21-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US007532.
 PR 17-MAY-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US013705.
 PR 30-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US014941.
 PR 28-JUL-2000; 2000WO-US015264.
 PR 11-AUG-2000; 2000WO-US020710.
 PR 23-AUG-2000; 2000WO-US022031.
 PR 24-AUG-2000; 2000WO-US023322.
 PR 08-NOV-2000; 2000WO-US023328.
 PR 10-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US030873.
 PR 20-DEC-2000; 2000WO-US032578.
 PR 20-DEC-2000; 2000WO-US047259.
 PR 28-FEB-2001; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-US006520.
 PR 01-MAR-2001; 2001WO-US006566.
 PR 09-MAR-2001; 2001US-US002706.
 PR 14-MAR-2001; 2001US-US008689.
 PR 22-MAR-2001; 2001US-US016744.
 PR 05-APR-2001; 2001US-US028366.
 PR 10-MAY-2001; 2001US-US085420.
 PR 10-MAY-2001; 2001US-US085428.
 PR 18-MAY-2001; 2001US-US0860216.

25-MAY-2001; 2001US-US0866028.
 25-MAY-2001; 2001US-US0866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-US0872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-US0874503.
 14-JUN-2001; 2001US-US0882636.
 19-JUN-2001; 2001US-US0886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-US0887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-US0908827.
 06-AUG-2001; 2001US-US0924419.
 09-AUG-2001; 2001US-US0927796.
 16-AUG-2001; 2001US-US0931836.
 19-DEC-2001; 2001US-US0028072.

XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen WB, Goddard A, Godowski P, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-695892/66.
 DR N-PSDB; ADA61692.
 XX
 PT New PRO nucleic acid and encode polypeptides, are useful for
 PT manufacturing a medicament for diagnosing or treating cancer.
 PS
 PS Claim 12; Fig 470; 660pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMNC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MEGATRVSIMLLLVTVSDCAVITGACRDYOCGAGTCACISLWLRGURMCTPLGRGEEC 60
 DB 1 MEGATRVSIMLLLVTVSDCAVITGACRDYOCGAGTCACISLWLRGURMCTPLGRGEEC 60

Mon Aug 30 07:06:19 2004

QY 61 HPGSHKVPFFKRKHHTCPCPLNLLCSRFPDGYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFKRKHHTCPCPLNLLCSRFPDGYRCSMDLKNINF 105
 RESULT 49
 ADB19478
 ID ADB19478 standard; protein; 105 AA.
 XX AC ADB19478;
 XX DT 20-NOV-2003 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1186.
 XX KW Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release.
 XX OS Homo sapiens.
 XX US2003068796-A1.
 PD 10-APR-2003.
 XX 15-APR-2002; 2002US-00123261.
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 20-APR-1999; 98WO-US005190.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 01-DEC-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028554.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 05-JAN-2000; 98WO-US031274.
 PR 06-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 01-MAR-2001; 2001WO-US006520.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff B, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-695927/66.
 N-PSDB; ADB19477.
 Novel secreted and transmembrane PRO polypeptides useful for stimulating
 the release of tumor necrosis factor alpha and detecting the presence of
 a tumor in a mammal.
 Claim 12; Fig 470; 660pp; English.
 The invention describes 305 nucleic acids encoding PRO (secreted and
 transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte
 XX Sequence 105 AA;
 SQ

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
 Db 1 MGRATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 50
 ADB28019
 ID ADB28019 standard; protein; 105 AA.
 XX
 AC ADB28019;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polypeptide #235.
 XX

Human; PRO; secreted polypeptide; transmembrane polypeptide;
 tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 liver; microvascular endothelial cell; glucose; FFA;
 skeletal muscle cell; adipocyte cell; pericyte cell;
 inner ear utricular supporting cell; T-lymphocyte cell;
 endothelial cell tube formation; bone disorder; cartilage disorder;
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;
 immune system cell infiltration.
 KW Homo sapiens.
 XX
 OS
 PN US2003082704-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 24-APR-2002; 2002US-00131819.
 XX
 PR 09-DEC-1999; 99US-0170262P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-765415/72.
 DR N-PSDB; ADB28018.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor or for tissue typing.
 XX
 PS Claim 12; Fig 470; 637pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
 Db 1 MGRATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 51
 ADA86498
 ID ADA86498 standard; protein; 105 AA.
 XX
 AC ADA86498;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1186.
 XX
 XX Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003082711-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 16-MAY-2002; 2002US-00147508.
 XX
 PR 02-JUL-1998; 98US-0091519P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 07-JUL-1999; 99US-0143048P.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.

PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-786914/74.
DR N-PSDB; ADA86497.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX Claim 12; Fig 470; 637pp; English.
PS The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I) (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMSC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the proliferation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
XX polypeptide.
XX Sequence 105 AA;
XX
XX Query Match 100.0%; Score 589; DB 6; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MEGATRVSMILLVTVSCAVITGACERDVCGAGTCACISLWLRGLMCTPLRGEGEC 60
XX |||||
XX 1 MEGATRVSMILLVTVSCAVITGACERDVCGAGTCACISLWLRGLMCTPLRGEGEC 60
XX |||||
XX 61 HPGSHKVPFRKRKHHTCPCLPNLLCSRPDPGRYRCSMDLNKINF 105
XX |||||
XX 61 HPGSHKVPFRKRKHHTCPCLPNLLCSRPDPGRYRCSMDLNKINF 105
XX |||||
XX
XX RESULT 52
XX ADB16062
XX ID ADB16062 standard; protein; 105 AA.
XX AC ADB16062;
XX XX
XX DT 20-NOV-2003 (first entry)
XX XX
XX DE Human PRO polypeptide #235.
XX XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX US2003087350-A1.
XX 08-MAY-2003.
XX 22-APR-2002; 2002US-00127821.
XX 04-AUG-1998; 98US-0095301P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-786914/74.
XX N-PSDB; ADB16061.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 12; Fig 470; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumor necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.

```
SQ Sequence 105 AA;
Query Match
Best Local Similarity 100.0%; Score 589; DB 6; Length 105;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MRGATRSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGIRMCCTPLGREGEC 60
Db 1 MRGATRSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGIRMCCTPLGREGEC 60
OY 61 HPGSHKVPFFRRKXHTTCCPLNLLCSFFPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRRKXHTTCCPLNLLCSFFPDGRYRCSMDLKNINF 105

RESULT 53
ID ADA37882
AC ADA37882;
DT 20-NOV-2003 (first entry)
DE Human secreted/transmembrane protein PRO1186.
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
OS Homo sapiens.
XX
XX US2003008297-A1.
PD 09-JAN-2003.
XX
XX 15-NOV-2001; 2001US-00997653.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0065770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078940P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 02-JUN-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088035P.
PR 04-JUN-1998; 98US-0088036P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088039P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
```

```
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000213.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020311.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
XX (GETH ) GENENTECH INC.
PA
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Klijavin IJ, Napier MA, Pan J, Paoni NF;
XX Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
XX Zhang Z;
XX WPI; 2003-531419/50.
XX N-PSDB; ADA37881.
DR
```

XX New isolated PRO183, PRO184, PRO361 or PRO846 nucleic acid and secreted
PT transmembrane polypeptides, useful as targets for the diagnosis and
PT treatment of cancers, such as lung and breast cancers.
XX
XX
XX Claim 12; Fig 266; 660pp; English.
XX
XX The invention relates to an isolated nucleic acid molecule comprising the
CC full-length coding sequence of the DNA ATCC Accession Numbers given in
CC the specification, or comprising a sequence with at least 80% identity
CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an
CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide
CC sequences fully defined in the specification. Also included are the PRO
CC proteins (or their extracellular domains) with or without their associated
CC extracellular domains), expression vectors, host cells, PRO chimeric
CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a
CC sample, methods of linking a bioactive molecule to a cell-expressing a
CC polypeptide and methods of modulating at least one biological activity of
CC a cell expressing the polypeptide. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocyte
CC cells, inducing proliferation and/or re-differentiation of chondrocytes,
CC or inducing pancreatic beta-cell precursor differentiation. In
CC particular, these are useful for detecting or treating tumours and
CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,
CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes
CC may also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence represents a PRO protein.
XX
XX Sequence 105 AA;
XX
XX Query Match 100.0%; Score 589; DB 6; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MEGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXHTCPCLNLLCSRPDPGRVRCSDMLKKNIF 105
DB 61 HPGSHKVPFFRKXHTCPCLNLLCSRPDPGRVRCSDMLKKNIF 105
RESULT 54
ADA47848
ID ADA47848 standard; protein; 105 AA.
XX
XX ADA47848;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human PRO polypeptide #235.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
OS Homo sapiens.
XX
XX US2003073215-A1.

XX
PD 17-APR-2003.
XX
XX 07-MAY-2002; 2002US-00140925.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 26-AUG-1998; 98WO-US017888.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 25-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001WO-US0366034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX

PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
DR WPI; 2003-644801/61.
DR N-PSDB; ADA47847.
XX

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX

PS Claim 12; Fig 470; 659pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumor necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear uricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWGLRMCITPLGREGEC 60
Db 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWGLRMCITPLGREGEC 60

Qy 61 HPGSHKVPFFRRKRGKHTCPCLNLLCSRPDPGGRYRCMDLKNINF 105

Db 61 HPGSHKVPFFRRKRGKHTCPCLNLLCSRPDPGGRYRCMDLKNINF 105

RESULT 55

ADA21568

ID ADA21568 standard; protein; 105 AA.

XX ADA21568;

XX 20-NOV-2003 (first entry)

XX Human secreted/transmembrane polypeptide PRO1186.

XX human; tumour; cancer; colorectal cancer; Gene therapy;
XX chondrocyte differentiation; VEGF inhibition;
XX vascular endothelial growth factor; Alzheimer's disease;
XX Parkinson's disease; atherosclerosis; cystic fibrosis;
XX multiple sclerosis; ovarian cancer; tissue typing.

XX Homo sapiens.

XX US2003054404-A1.

XX 20-MAR-2003.

XX 15-NOV-2001; 2001US-00997601.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WC-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066770P.

XX 25-FEB-1998; 98US-0075945P.

XX 20-MAR-1998; 98US-0078910P.

XX 28-APR-1998; 98US-0083222P.

XX 07-MAY-1998; 98US-0084600P.

XX 20-MAY-1998; 98US-0087106P.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087599P.

XX 03-JUN-1998; 98US-0087827P.

XX 04-JUN-1998; 98US-0088021P.

XX 04-JUN-1998; 98US-0088023P.

XX 04-JUN-1998; 98US-0088026P.

XX 04-JUN-1998; 98US-0088028P.

XX 04-JUN-1998; 98US-0088029P.

XX 04-JUN-1998; 98US-0088030P.

XX 04-JUN-1998; 98US-0088033P.

XX 04-JUN-1998; 98US-0088328P.

XX 05-JUN-1998; 98US-0088167P.

XX 05-JUN-1998; 98US-0088202P.


```
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match      100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MCGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCCTPLGREGECC 60
Db      1 MCGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCCTPLGREGECC 60

QY      61 HPGSHKVPFRKPKKHTCCLPNLLCSRFDPDGRYCSMDLKNINF 105
Db      61 HPGSHKVPFRKPKKHTCCLPNLLCSRFDPDGRYCSMDLKNINF 105

RESULT 56
ADAL0355
ID ADAL0355 standard; protein; 105 AA.
XX
AC ADAL0355;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein, PRO1186.
XX
KW PRO; secreted protein; transmembrane protein; human; septic shock;
KW immunogen.
XX
OS Homo sapiens.
XX
PN US2003059831-A1.
XX
PD 27-MAR-2003.
XX
PF 19-NOV-2001; 2001US-00989729.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0068770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 02-JUN-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 12-JUN-1998; 98US-0088876P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090576P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094551P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 10-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
```

```
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096779P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 17-AUG-1998; 98US-0096849P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US03943P.
PR 07-OCT-1998; 98WO-US02114.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 13-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.
Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
QY 61 HPGSHKVPFFRRKXKHTCPCLENLLCSRFPDGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFRRKXKHTCPCLENLLCSRFPDGRYRCMDLKNINF 105
RESULT 57
ADA67643
ID ADA67643 standard; protein; 105 AA.
XX AC ADA67643;
XX 20-NOV-2003 (first entry)
XX Human PRO polypeptide #235.
DE Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; INF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS US2003068795-A1.
DN 10-APR-2003.
XX 15-APR-2002; 2002US-00123236.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017886.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
```


PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 28-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030352.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US047259.
PR 20-DEC-2000; 2000WO-US049566.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882836.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00887879.
PR 21-JUN-2001; 2001WO-US019692.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-695926/66.
DR N-PSDB; ADA67642.
XX Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.
XX Claim 12; Fig 470; 660pp; English.
PS The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSVSCAVITGACEDVCGAGTCCATSLWLRGLRMCTPLGREGEC 60
DB 1 MRGATRVSIMLLLVTSVSCAVITGACEDVCGAGTCCATSLWLRGLRMCTPLGREGEC 60
QY 61 HPGSHKVPFFRRKRKHTKTCPLNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTKTCPLNLLCSRFDPGRYRCSDMLKNINF 105
RESULT 58
ADB30650
ID ADB30650 standard; protein; 105 AA.
XX
AC ADB30650;
XX
DT 20-NOV-2003 (first entry)
XX

PR 01-MAR-2000

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung). The colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKRKHTTCPLNLLCSRFPPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKRKHTTCPLNLLCSRFPPDGRYRCSDMLKNINF 105

RESULT 59

IDA85946

ID ADA85946 standard; protein; 105 AA.

XX ADA85946;

XX 20-NOV-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1186.

Human; secreted and transmembrane protein; PRO;
Tumour necrosis factor alpha release; TNF-alpha release;
glucose uptake modulator; FFA uptake modulator;
cell proliferation stimulator; cell differentiation stimulator;
cell differentiation inhibitor; cytokine release stimulator; tumour;
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082693-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127843.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786907/74.
DR N-PSDB; ADA85945.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
PS Claim 12; Fig 470; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.

Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKRKHTTCPLNLLCSRFPPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKRKHTTCPLNLLCSRFPPDGRYRCSDMLKNINF 105

RESULT 60

ADA17899

ID ADA17899 standard; protein; 105 AA.

XX ADA17899;

XX 20-NOV-2003 (first entry)

DE Human PRO1186 polypeptide.

XX Human; PRO polypeptide; secreted protein; transmembrane protein;
KW transgenic; tumour; cytostatic.

XX Homo sapiens.

XX US2003054987-A1.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
SQ

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGVMCTPLGREGEC 60
Db 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGVMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXHTCTCPLNLLCSRPDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXHTCTCPLNLLCSRPDPGRYCSMDLKNINF 105

RESULT 63

ADA87601
AC ADA87601 standard; protein; 105 AA.

XX ADA87601;

XX 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003087345-A1.

PN

XX

PD 08-MAY-2003.
XX 16-APR-2002; 2002US-00123907.
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028554.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004514.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 15-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.

20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854209.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 09-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-786937/74.
 DR N-PSDB; ADA87600.
 XX
 DR New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 XX
 PS Claim 12; Fig 470; 638pp; English.
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMDM cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping. In generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knocking animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO

CC polypeptide.
 XX Sequence 105 AA;
 SQ
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
 Matches 105; Conservative 0; Mismatches 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
 DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
 QY 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105
 DB 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105
 RESULT 64
 ADB16803
 ID ADB16803 standard; protein; 105 AA.
 XX
 AC ADB16803;
 DT 20-NOV-2003 (first entry)
 XX Human PRO polypeptide #235.
 DE Human; PRO; secreted polypeptide; transmembrane polypeptide;
 XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 XX US2003087349-A1.
 XX 08-MAY-2003.
 XX 19-APR-2002; 2002US-00125928.
 XX 19-JUN-1998; 98US-0089947P.
 XX 02-JUN-1999; 99WO-US012252.
 XX 25-AUG-1999; 99US-00380137.
 XX 02-MAR-2000; 2000WO-US003841.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-786940/74.
 DR N-PSDB; ADB16802.
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 XX Claim 12; Fig 470; 637pp; English.
 PS The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCALSLMRGVMCTPLGREGEC 60

Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCALSLMRGVMCTPLGREGEC 60

QY 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPGRYRCMDLKNIF 105

Db 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPGRYRCMDLKNIF 105

RESULT 65

ADA28007

ID ADA28007 standard; protein; 105 AA.

XX AC ADA28007;

XX DT 20-NOV-2003 (first entry)

XX DE Human secreted/transmembrane protein PRO1186.

XX KW PRO; secreted protein; transmembrane protein;
 KW hypertrophy of neonatal heart; angiogenesis;
 KW vascular endothelial growth factor; VEGF-stimulated proliferation;
 KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
 KW rod photoreceptor cell; c-fos induction; adipocyte cell;
 KW chondrocyte differentiation;

XX KW pancreatic beta-cell precursor differentiation;
 KW cardiac insufficiency disorder; wound; cancerous tumour;
 KW retinal disorders; loss of sight; retinitis pigmentosa; kidney disorder;
 KW obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;
 KW cartilage disorder; sports injury; arthritis; cancer; human.

XX OS Homo sapiens.

XX FN US2003054359-A1.

XX PD 20-MAR-2003.

XX PF 14-NOV-2001; 2001US-00990726.

XX

PR 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 03-JUN-1998; 98US-0087759P.
 PR 04-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 05-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089340P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 22-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.
 PR 23-JUN-1998; 98US-0090254P.
 PR 23-JUN-1998; 98US-0090349P.
 PR 23-JUN-1998; 98US-0090355P.
 PR 24-JUN-1998; 98US-0090423P.
 PR 24-JUN-1998; 98US-0090431P.
 PR 24-JUN-1998; 98US-0090435P.
 PR 24-JUN-1998; 98US-0090444P.
 PR 24-JUN-1998; 98US-0090445P.
 PR 24-JUN-1998; 98US-0090472P.
 PR 24-JUN-1998; 98US-0090535P.
 PR 24-JUN-1998; 98US-0090540P.
 PR 24-JUN-1998; 98US-0090542P.
 PR 24-JUN-1998; 98US-0090557P.
 PR 25-JUN-1998; 98US-0090676P.
 PR 25-JUN-1998; 98US-0090678P.
 PR 25-JUN-1998; 98US-0090690P.
 PR 25-JUN-1998; 98US-0090694P.
 PR 25-JUN-1998; 98US-0090695P.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-786908/74.
 DR N-PSDB; ADB14958.
 XX
 XX
 FT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 FT or a composition for treating e.g., tumor or for tissue typing.
 XX
 PS
 PS Claim 12; Fig 470; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 XX Sequence 105 AA;
 SQ
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSMLRGLRMCTPLGRGEEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSMLRGLRMCTPLGRGEEC 60
 Qy 61 HPGSHKVPFRKRKHHTCPCLNLLCSRFPDGRYRCMDLKNIN 105
 Db 61 HPGSHKVPFRKRKHHTCPCLNLLCSRFPDGRYRCMDLKNIN 105
 RESULT 67
 ADB14958
 ID ADB14958 standard; protein; 105 AA.
 XX
 XX ADB14958;
 AC
 XX
 XX 20-NOV-2003 (first entry)
 DT
 XX
 XX Human PRO polypeptide #235.
 DE
 DE
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 XX Homo sapiens.
 OS
 XX US2003087351-A1.
 PN
 PN 08-MAY-2003.
 PD
 PD 22-APR-2002; 2002US-00127822.
 PF
 PF 17-JUN-1998; 98US-0089532P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-786942/74.
 DR N-PSDB; ADB14957.
 DR
 XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 FT
 PS Claim 12; Fig 470; 637pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 105 AA;
 SQ
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PS Claim 12; Fig 470; 638pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLRGEGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLRGEGEC 60

Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105

RESULT 69
ADA94134
XX ADA94134 standard; protein; 105 AA.
XX ADA94134;
DT 20-NOV-2003 (first entry)
XX Human PRO polypeptide #235.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.

XX Homo sapiens.
XX US2003077722-A1.
XX 24-APR-2003.
XX 03-MAY-2002; 2002US-00137872.
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000MO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;
XX WPI; 2003-755077/71.
XX N-PSDB; ADA94133.
XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the
XX diagnosis, prevention and/or treatment of tumors, such as lung, colon,
XX breast, prostate, rectal, cervical and/or liver tumors.
XX Claim 12; Fig 470; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLRGEGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLRGEGEC 60

Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105

RESULT 70
ADE20030
ID ADE20030 standard; protein; 105 AA.
XX ADE20030;
XX ADE20030;
DT 20-NOV-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO1186.
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003082691-A1.
XX 01-MAY-2003.
XX 22-APR-2002; 2002US-00127838.

PR 17-NOV-1998; 98US-0108802P.
 PR 01-SEP-1999; 99MO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000MO-US004342.
 PR 02-JUN-2000; 2000MO-US015264.
 PR 23-AUG-2000; 2000MO-US023522.
 PR 01-DEC-2000; 2000MO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755108/71.
 DR N-PSDB; ADB20029.
 XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
 PT tumor or for tissue typing.
 PT Claim 12; Fig 470; 637pp; English.
 PS The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MRGATRVISMLLLTVSDCAVITGACERDVQCGAGTCCALSILRLGRLMCTPLRGREGEC 60
 Db 1 MRGATRVISMLLLTVSDCAVITGACERDVQCGAGTCCALSILRLGRLMCTPLRGREGEC 60
 Qy 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
 RESULT 71
 ADB13342
 ID ADB13342 standard; protein; 105 AA.
 XX ADB13342;
 AC

XX 20-NOV-2003 (first entry)
 XX Human PRO polypeptide #235.
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 XX US2003082710-A1.
 XX 01-MAY-2003.
 XX 16-MAY-2002; 2002US-00147484.
 XX 09-DEC-1999; 99US-0170262P.
 XX 01-DEC-2000; 2000MO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI; 2003-786913/74.
 DR N-PSDB; ADB13341.
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 PT preparing a composition for treating e.g., tumor, or for tissue typing.
 XX Claim 12; Fig 470; 637pp; English.
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The

CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.9e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
Db |||||
QY 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPGRYRCSDLNKINF 105
Db |||||
QY 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPGRYRCSDLNKINF 105

RESULT 72

ABO43383
ID ABO43383 standard; protein; 105 AA.

XX ABO43383;

XX 26-SEP-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO; gene therapy;
KW chromosome identification; tissue typing.

XX Homo sapiens.

XX US200304945-A1.

XX 06-MAR-2003.

XX 10-MAY-2002; 2002US-00142419.

XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US014552.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 98WO-US000106.
XX 08-MAR-1999; 98WO-US005028.
XX 10-MAR-1999; 98WO-US005190.
XX 20-APR-1999; 98WO-US008615.
XX 14-MAY-1999; 98WO-US010733.
XX 02-JUN-1999; 98WO-US012252.
XX 01-SEP-1999; 98WO-US020111.
XX 08-SEP-1999; 98WO-US020594.
XX 13-SEP-1999; 98WO-US020944.
XX 15-SEP-1999; 98WO-US021090.
XX 15-SEP-1999; 98WO-US021547.
XX 05-OCT-1999; 98WO-US023089.
XX 29-NOV-1999; 98WO-US028214.
XX 30-NOV-1999; 98WO-US028313.
XX 30-NOV-1999; 98WO-US028409.
XX 01-DEC-1999; 98WO-US028401.
XX 01-DEC-1999; 98WO-US028634.
XX 02-DEC-1999; 98WO-US028551.
XX 02-DEC-1999; 98WO-US028564.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerittsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-492275/46.

Mon Aug 30 07:06:19 2004

us-10-027-603-2.rag

DR N-PSDB; ACD98658.
XX
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
XX
XX Claim 12; Fig 470; 660pp; English.
XX
XX The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
XX Sequence 105 AA;
SQ
Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCALSLMLRGLRMCTPLGRGEEC 60
DB 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCALSLMLRGLRMCTPLGRGEEC 60
QY 61 HPGSHKVPFFPKRKHTCPCPLNLLCSRFDPGRYRCMSDLKNINF 105
DB 61 HPGSHKVPFFPKRKHTCPCPLNLLCSRFDPGRYRCMSDLKNINF 105
RESULT 73
ADA94587
ID ADA94587 standard; protein; 105 AA.
XX
XX ADA94587;
XX
XX
DT 20-NOV-2003 (first entry)
XX
XX Human secreted/transmembrane protein PRO1186.
XX
XX PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW C-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
XX Homo sapiens.
XX
XX US2003059832-A1.
XX
XX 27-MAR-2003.
XX
XX 15-NOV-2001; 2001US-00997349.
XX
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.

07-MAY-1998; 98US-0084600P.
28-MAY-1998; 98US-0087106P.
02-JUN-1998; 98US-0087607P.
02-JUN-1998; 98US-0087609P.
02-JUN-1998; 98US-0087759P.
03-JUN-1998; 98US-0087827P.
04-JUN-1998; 98US-0088021P.
04-JUN-1998; 98US-0088025P.
04-JUN-1998; 98US-0088026P.
04-JUN-1998; 98US-0088028P.
04-JUN-1998; 98US-0088030P.
04-JUN-1998; 98US-0088033P.
04-JUN-1998; 98US-0088036P.
05-JUN-1998; 98US-0088167P.
05-JUN-1998; 98US-0088202P.
05-JUN-1998; 98US-0088212P.
05-JUN-1998; 98US-0088217P.
09-JUN-1998; 98US-0088655P.
10-JUN-1998; 98US-0088734P.
10-JUN-1998; 98US-0088738P.
10-JUN-1998; 98US-0088742P.
10-JUN-1998; 98US-0088810P.
10-JUN-1998; 98US-0088824P.
10-JUN-1998; 98US-0088826P.
11-JUN-1998; 98US-0088858P.
11-JUN-1998; 98US-0088861P.
11-JUN-1998; 98US-0088876P.
12-JUN-1998; 98US-0089105P.
16-JUN-1998; 98US-0089440P.
16-JUN-1998; 98US-0089512P.
16-JUN-1998; 98US-0089514P.
17-JUN-1998; 98US-0089532P.
17-JUN-1998; 98US-0089538P.
17-JUN-1998; 98US-0089598P.
17-JUN-1998; 98US-0089599P.
17-JUN-1998; 98US-0089600P.
17-JUN-1998; 98US-0089653P.
18-JUN-1998; 98US-0089801P.
18-JUN-1998; 98US-0089907P.
18-JUN-1998; 98US-0089908P.
19-JUN-1998; 98US-0089947P.
19-JUN-1998; 98US-0089948P.
19-JUN-1998; 98US-0089952P.
22-JUN-1998; 98US-0090246P.
22-JUN-1998; 98US-0090252P.
22-JUN-1998; 98US-0090254P.
23-JUN-1998; 98US-0090349P.
23-JUN-1998; 98US-0090355P.
24-JUN-1998; 98US-0090429P.
24-JUN-1998; 98US-0090431P.
24-JUN-1998; 98US-0090435P.
24-JUN-1998; 98US-0090444P.
24-JUN-1998; 98US-0090445P.
24-JUN-1998; 98US-0090472P.
24-JUN-1998; 98US-0090535P.
24-JUN-1998; 98US-0090540P.
24-JUN-1998; 98US-0090542P.
24-JUN-1998; 98US-0090557P.
25-JUN-1998; 98US-0090676P.
25-JUN-1998; 98US-0090678P.
25-JUN-1998; 98US-0090690P.
25-JUN-1998; 98US-0090694P.
25-JUN-1998; 98US-0090695P.
25-JUN-1998; 98US-0090696P.
26-JUN-1998; 98US-0090862P.
26-JUN-1998; 98US-0090863P.
01-JUL-1998; 98US-0091360P.
01-JUL-1998; 98US-0091544P.
02-JUL-1998; 98US-0091478P.
02-JUL-1998; 98US-0091519P.
02-JUL-1998; 98US-0091628P.
02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091633P.
 PR 02-JUL-1998; 98US-0091646P.
 PR 02-JUL-1998; 98US-0091673P.
 PR 07-JUL-1998; 98US-0091978P.
 PR 07-JUL-1998; 98US-0091982P.
 PR 09-JUL-1998; 98US-0092182P.
 PR 10-JUL-1998; 98US-0092472P.
 PR 20-JUL-1998; 98US-0093339P.
 PR 30-JUL-1998; 98US-0094651P.
 PR 04-AUG-1998; 98US-0095282P.
 PR 04-AUG-1998; 98US-0095285P.
 PR 04-AUG-1998; 98US-0095301P.
 PR 04-AUG-1998; 98US-0095302P.
 PR 04-AUG-1998; 98US-0095318P.
 PR 04-AUG-1998; 98US-0095321P.
 PR 10-AUG-1998; 98US-0095916P.
 PR 10-AUG-1998; 98US-0095929P.
 PR 10-AUG-1998; 98US-0096012P.
 PR 11-AUG-1998; 98US-0096143P.
 PR 11-AUG-1998; 98US-0096146P.
 PR 12-AUG-1998; 98US-0096329P.
 PR 17-AUG-1998; 98US-0096757P.
 PR 17-AUG-1998; 98US-0096766P.
 PR 17-AUG-1998; 98US-0096768P.
 PR 17-AUG-1998; 98US-0096773P.
 PR 17-AUG-1998; 98US-0096791P.
 PR 17-AUG-1998; 98US-0096867P.
 PR 17-AUG-1998; 98US-0096891P.
 PR 17-AUG-1998; 98US-0096894P.
 PR 17-AUG-1998; 98US-0096895P.
 PR 17-AUG-1998; 98US-0096897P.
 PR 18-AUG-1998; 98US-0096949P.
 PR 18-AUG-1998; 98US-0096950P.
 PR 18-AUG-1998; 98US-0096953P.
 PR 18-AUG-1998; 98US-0096960P.
 PR 19-AUG-1998; 98US-0097022P.
 PR 20-AUG-1998; 98US-0097141P.
 PR 24-AUG-1998; 98US-0097218P.
 PR 26-AUG-1998; 98US-0097661P.
 PR 26-AUG-1998; 98US-0097952P.
 PR 26-AUG-1998; 98US-0097954P.
 PR 26-AUG-1998; 98US-0097955P.
 PR 26-AUG-1998; 98US-0097971P.
 PR 26-AUG-1998; 98US-0097974P.
 PR 26-AUG-1998; 98US-0097978P.
 PR 26-AUG-1998; 98US-0097979P.
 PR 26-AUG-1998; 98US-0098014P.
 PR 31-AUG-1998; 98US-0098525P.
 PR 16-SEP-1998; 98US-0100634P.
 PR 16-SEP-1998; 98US-0101933P.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98US-0101943P.
 PR 07-OCT-1998; 98US-0102114P.
 PR 01-DEC-1998; 98US-0102510P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 05-JAN-1999; 98US-0100106P.
 PR 08-MAR-1999; 98US-0100502P.
 PR 12-MAR-1999; 98US-0123957P.
 PR 02-JUN-1999; 98US-0125252P.
 PR 23-JUN-1999; 98US-0141037P.
 PR 07-JUL-1999; 98US-0143048P.
 PR 20-JUL-1999; 98US-0144758P.
 PR 26-JUL-1999; 98US-0145698P.
 PR 28-JUL-1999; 98US-0146222P.
 PR 17-AUG-1999; 98US-0149336P.
 PR 15-SEP-1999; 98US-015021090P.
 PR 15-SEP-1999; 98US-015021154P.
 PR 08-OCT-1999; 98US-0158663P.
 PR 30-NOV-1999; 98US-02028313.
 PR 01-DEC-1999; 98US-02028301.
 PR 01-DEC-1999; 98US-02028334.

PR 16-DEC-1999; 98US-02030095.
 PR 20-DEC-1999; 98US-02030911.
 PR 05-JAN-2000; 2000US-02000219.
 PR 06-JAN-2000; 2000US-02000376.
 PR 11-FEB-2000; 2000US-020003565.
 PR 18-FEB-2000; 2000US-020004341.
 PR 22-FEB-2000; 2000US-020004414.
 PR 24-FEB-2000; 2000US-020004914.
 PR 24-FEB-2000; 2000US-020005004.
 PR 02-MAR-2000; 2000US-020005841.
 PR 15-MAR-2000; 2000US-020006319.
 PR 30-MAR-2000; 2000US-020006884.
 PR 20-MAR-2000; 2000US-020007377.
 PR 15-MAY-2000; 2000US-020008439.
 PR 17-MAY-2000; 2000US-020013358.
 PR 22-MAY-2000; 2000US-020013705.
 PR 30-MAY-2000; 2000US-020014042.
 PR 02-JUN-2000; 2000US-020014941.
 PR 23-JUN-2000; 2000US-020015264.
 PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRCATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
 |||||
 Db 1 MRCATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
 |||||

Qy 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCMDLKNINF 105
 |||||
 Db 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCMDLKNINF 105
 |||||

RESULT 74
 ADA74596
 ID ADA74596 standard; protein; 105 AA.
 XX ADA74596;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polypeptide #235.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003068798-A1.
 XX
 PD 10-APR-2003.
 XX
 PF 07-MAY-2002; 2002US-00140928.
 XX
 PR 31-MAR-1997; 98US-02005230.
 PR 12-JUN-1998; 98US-02012456.
 PR 14-JUL-1998; 98US-02014552.
 PR 28-AUG-1998; 98US-02017888.
 PR 10-SEP-1998; 98US-02018824.
 PR 14-SEP-1998; 98US-02019093.
 PR 14-SEP-1998; 98US-02019094.
 PR 14-SEP-1998; 98US-02019177.
 PR 16-SEP-1998; 98US-02019330.
 PR 17-SEP-1998; 98US-02019437.

PR	07-OCT-1998;	98WO-US021141.	PR	25-MAY-2001;	2001WO-US017092.
PR	29-OCT-1998;	98WO-US022991.	PR	01-JUN-2001;	2001US-00872035.
PR	29-OCT-1998;	98WO-US022992.	PR	01-JUN-2001;	2001WO-US017800.
PR	29-OCT-1998;	98WO-US024855.	PR	05-JUN-2001;	2001US-00874503.
PR	01-DEC-1998;	98WO-US025108.	PR	14-JUN-2001;	2001US-00882636.
PR	05-JAN-1999;	99WO-US000106.	PR	19-JUN-2001;	2001US-00886342.
PR	08-MAR-1999;	99WO-US005190.	PR	20-JUN-2001;	2001WO-US019692.
PR	10-MAR-1999;	99WO-US008615.	PR	21-JUN-2001;	2001US-00887879.
PR	14-MAY-1999;	99WO-US010733.	PR	22-JUN-2001;	2001WO-US020116.
PR	01-SEP-1999;	99WO-US020111.	PR	29-JUN-2001;	2001WO-US021066.
PR	08-SEP-1999;	99WO-US020594.	PR	09-JUL-2001;	2001WO-US021735.
PR	13-SEP-1999;	99WO-US020944.	PR	18-JUL-2001;	2001US-00908827.
PR	15-SEP-1999;	99WO-US021090.	PR	06-AUG-2001;	2001US-00924419.
PR	15-SEP-1999;	99WO-US021547.	PR	09-AUG-2001;	2001US-00927796.
PR	05-OCT-1999;	99WO-US023089.	PR	16-AUG-2001;	2001US-00931836.
PR	29-NOV-1999;	99WO-US028214.	PR	19-DEC-2001;	2001US-00028072.
PR	30-NOV-1999;	99WO-US028313.	XX		
PR	30-NOV-1999;	99WO-US028409.	XX		
PR	01-DEC-1999;	99WO-US028401.	PI		
PR	01-DEC-1999;	99WO-US028634.	PI		
PR	02-DEC-1999;	99WO-US028551.	XX		
PR	02-DEC-1999;	99WO-US028564.	DR		
PR	02-DEC-1999;	99WO-US028565.	XX		
PR	16-DEC-1999;	99WO-US030095.	XX		
PR	20-DEC-1999;	99WO-US030911.	PT		
PR	20-DEC-1999;	99WO-US030999.	PT		
PR	22-DEC-1999;	99WO-US030720.	PT		
PR	30-DEC-1999;	99WO-US031274.	XX		
PR	05-JAN-2000;	2000WO-US000219.	XX		
PR	06-JAN-2000;	2000WO-US000277.	XX		
PR	11-FEB-2000;	2000WO-US000376.	CC		
PR	18-FEB-2000;	2000WO-US000341.	CC		
PR	18-FEB-2000;	2000WO-US004342.	CC		
PR	24-FEB-2000;	2000WO-US004414.	CC		
PR	24-FEB-2000;	2000WO-US004914.	CC		
PR	01-MAR-2000;	2000WO-US005601.	CC		
PR	02-MAR-2000;	2000WO-US005746.	CC		
PR	02-MAR-2000;	2000WO-US005841.	CC		
PR	15-MAR-2000;	2000WO-US006884.	CC		
PR	21-MAR-2000;	2000WO-US007377.	CC		
PR	30-MAR-2000;	2000WO-US007532.	CC		
PR	17-MAY-2000;	2000WO-US008439.	CC		
PR	22-MAY-2000;	2000WO-US014042.	CC		
PR	22-MAY-2000;	2000WO-US014941.	CC		
PR	28-JUL-2000;	2000WO-US015264.	CC		
PR	11-AUG-2000;	2000WO-US020710.	CC		
PR	23-AUG-2000;	2000WO-US023522.	CC		
PR	24-AUG-2000;	2000WO-US023328.	CC		
PR	08-NOV-2000;	2000WO-US030952.	CC		
PR	10-NOV-2000;	2000WO-US030873.	CC		
PR	01-DEC-2000;	2000WO-US032678.	CC		
PR	20-DEC-2000;	2000WO-US034956.	CC		
PR	28-FEB-2001;	2001WO-US00736498.	CC		
PR	28-FEB-2001;	2001WO-US006520.	CC		
PR	01-MAR-2001;	2001WO-US006666.	CC		
PR	09-MAR-2001;	2001US-00802766.	CC		
PR	14-MAR-2001;	2001US-00808689.	CC		
PR	05-APR-2001;	2001US-00816744.	CC		
PR	10-MAY-2001;	2001US-00854208.	CC		
PR	18-MAY-2001;	2001US-00860216.	CC		
PR	25-MAY-2001;	2001US-00866028.	CC		
PR	25-MAY-2001;	2001US-00866034.	CC		
PR			XX		
PR			SQ		

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-625490/59.
N-PSDB; ADA74595.

Novel secreted and transmembrane PRO polypeptides and polynucleotides
encoding them, useful for treating bone disorders, arthritis, heart
attack, injuries, tumors, and stimulating release of Tumor Necrosis
Factor-alpha from human blood.

Claim 12; Fig 470; 659pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumor necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
the proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
USPTO at seqdata.uspto.gov/sequence.html.

Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60
DB 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRPDPGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRPDPGRVRCSDMLKNINF 105
RESULT 75
ID ADB24829
XX ADB24829 standard; protein; 105 AA.
AC ADB24829;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 470.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US200307713-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127839.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755068/71.
XX N-PSDB; ADB24828.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 470; 637pp; English.
XX
PS The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60
DB 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRPDPGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRPDPGRVRCSDMLKNINF 105
RESULT 76
ADA82353
ID ADA82353 standard; protein; 105 AA.
XX
AC ADA82353;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #235.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082701-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128686.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Deanoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755110/71.
 DR N-PSDB; ADA82352.
 XX
 XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
 PT tumor or for tissue typing.
 XX
 XX Claim 12; Fig 470; 637pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful
 XX reagents. The PRO polypeptides or antibodies are used in preparing a
 XX medicament for treating a condition responsive to the polypeptides or
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation
 XX of human microvascular endothelial cells, for modulating the uptake of
 XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
 XX stimulating differentiation of adipocyte cells, for stimulating
 XX proliferation of or gene expression in pericyte cells, for stimulating
 XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
 XX cells, for inducing endothelial cell tube formation and for treating
 XX various bone and/or cartilage disorders such as sports injuries and
 XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
 XX from cartilage are useful for treating sports-related joint problems, PRO
 XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 XX polypeptides are also useful for treating various mammalian haemoglobin-
 XX associated disorders such as various thalassemias and conditions which
 XX may benefit from enhanced local immune system cell infiltration. This
 XX sequence represents a human PRO polypeptide of the invention. Note: The
 XX sequence data for this patent is also available in electronic format from
 XX USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSMILLVTVSDCAVITGACERDVCGAGTCACISLWLRGLMCTPLRGEEEC 60
 Db 1 MRGATRVSMILLVTVSDCAVITGACERDVCGAGTCACISLWLRGLMCTPLRGEEEC 60
 QY 61 HPGSHKVPFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLNKINF 105
 Db 61 HPGSHKVPFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLNKINF 105
 RESULT 77
 ADA75316
 ID ADA75316 standard; protein; 105 AA.
 XX
 XX AC ADA75316;
 XX
 XX DT 20-NOV-2003. (first entry)
 XX
 XX DE Human PRO polypeptide #235.
 XX
 XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 XX OS Homo sapiens.
 XX
 XX US2003073216-A1.
 XX
 XX 17-APR-2003.
 XX
 XX 30-MAY-2002; 2002US-00160498.
 XX
 XX 31-MAR-1997; 97WO-US005230.
 XX 12-JUN-1998; 98WO-US012456.
 XX 14-JUL-1998; 98WO-US014552.
 XX 28-AUG-1998; 98WO-US017888.
 XX 10-SEP-1998; 98WO-US018824.
 XX 14-SEP-1998; 98WO-US019093.
 XX 14-SEP-1998; 98WO-US019177.
 XX 16-SEP-1998; 98WO-US019330.
 XX 17-SEP-1998; 98WO-US019437.
 XX 07-OCT-1998; 98WO-US021141.
 XX 29-OCT-1998; 98WO-US022991.
 XX 29-OCT-1998; 98WO-US024855.
 XX 20-NOV-1998; 98WO-US025108.
 XX 01-DEC-1998; 98WO-US025106.
 XX 08-MAR-1999; 98WO-US005028.
 XX 10-MAR-1999; 98WO-US005190.
 XX 20-APR-1999; 98WO-US008615.
 XX 14-MAY-1999; 98WO-US010733.
 XX 02-JUN-1999; 98WO-US012252.
 XX 01-SEP-1999; 98WO-US020111.
 XX 08-SEP-1999; 98WO-US020594.
 XX 13-SEP-1999; 98WO-US020944.
 XX 15-SEP-1999; 98WO-US021090.
 XX 05-OCT-1999; 98WO-US021547.
 XX 29-NOV-1999; 98WO-US023089.
 XX 30-NOV-1999; 98WO-US028214.
 XX 30-NOV-1999; 98WO-US028313.
 XX 01-DEC-1999; 98WO-US028409.
 XX 01-DEC-1999; 98WO-US028301.
 XX 01-DEC-1999; 98WO-US028634.
 XX 02-DEC-1999; 98WO-US028551.
 XX 02-DEC-1999; 98WO-US028564.
 XX 02-DEC-1999; 98WO-US028565.
 XX 16-DEC-1999; 98WO-US030095.
 XX 20-DEC-1999; 98WO-US030911.
 XX 22-DEC-1999; 98WO-US030999.
 XX 30-DEC-1999; 98WO-US030720.
 XX 30-DEC-1999; 98WO-US031243.
 XX 05-JAN-2000; 98WO-US031274.
 XX 06-JAN-2000; 2000WO-US000219.
 XX 06-JAN-2000; 2000WO-US000277.
 XX 06-JAN-2000; 2000WO-US000376.
 XX 11-FEB-2000; 2000WO-US003565.
 XX 18-FEB-2000; 2000WO-US004341.
 XX 18-FEB-2000; 2000WO-US004342.
 XX 22-FEB-2000; 2000WO-US004414.
 XX 24-FEB-2000; 2000WO-US004914.
 XX 24-FEB-2000; 2000WO-US005004.
 XX 01-MAR-2000; 2000WO-US005601.
 XX 02-MAR-2000; 2000WO-US005746.
 XX 10-MAR-2000; 2000WO-US005841.
 XX 15-MAR-2000; 2000WO-US006319.
 XX 15-MAR-2000; 2000WO-US006884.

DR WPI: 2003-786909/74.
 DR N-PSDB; ADA85393.
 XX
 PT New nucleic acid encoding a PRO polypeptide, useful for preparing a
 PT composition for treating e.g. tumor by gene therapy, or for tissue
 PT typing.
 XX
 XX Claim 12; Fig 470; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPFDGGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPFDGGRYRCSDMLKNINF 105

RESULT 79

ADA84842
 ID ADA84842 standard; protein; 105 AA.

XX
 AC ADA84842;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1186.
 XX
 KW Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.
 XX US2003082708-A1.
 XX
 PD 01-MAY-2003.
 XX
 XX 15-MAY-2002; 2002US-00146729.
 XX
 XX 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032878.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 PI WPI: 2003-786911/74.
 XX N-PSDB; ADA84841.
 DR
 DR New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g. tumor or for tissue typing.
 PT
 PT Claim 12; Fig 470; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPFDGGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFRKRKHHTCPCLNLLCSRPFDGGRYRCSDMLKNINF 105
 RESULT 80
 ADB30098

ID ADB30098 standard; protein; 105 AA.
 XX ADB30098;
 AC
 XX
 XX
 DT 20-NOV-2003 (first entry)
 XX
 XX Human PRO polypeptide #235.
 DE
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; raxum; kidney; cervix;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003073214-A1.
 PN
 XX
 XX 17-APR-2003.
 PD
 XX
 XX 17-APR-2002; 2002US-00124822.
 PF
 XX
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US024952.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006319.
 PR 20-MAR-2000; 2000WO-US006884.
 PR 21-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US007532.
 PR 17-MAY-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US013705.
 PR 30-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US014941.
 PR 28-JUL-2000; 2000WO-US015264.
 PR 11-AUG-2000; 2000WO-US020710.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 05-APR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866038.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 19-JUN-2001; 2001US-00882636.
 PR 20-JUN-2001; 2001US-00886342.
 PR 21-JUN-2001; 2001WO-US019692.
 PR 22-JUN-2001; 2001US-00887879.
 PR 29-JUN-2001; 2001WO-US020116.
 PR 09-JUL-2001; 2001WO-US021066.
 PR 18-JUL-2001; 2001WO-US021735.
 PR 06-AUG-2001; 2001US-00908827.
 PR 09-AUG-2001; 2001US-00924419.
 PR 16-AUG-2001; 2001US-00927796.
 PR 19-DEC-2001; 2001US-00931836.
 XX
 XX (GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-720081/68.
 N-PSDB; ADB30097.

Novel secreted and transmembrane PRO polypeptides useful for stimulating
 the release of tumor necrosis factor alpha and detecting the presence of
 a tumor in a mammal.

Claim 12; Fig 470; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60

Db 1 MRGATRVSMILLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFRRKXHTTCTPCLENLLCSRPDPGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKXHTTCTPCLENLLCSRPDPGRYRCSMDLKNINF 105

RESULT 81

ADA80626

ID ADA80626 standard; protein; 105 AA.

XX AC

XX AD

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #235.

XX KW

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082761-A1.

XX PD 01-MAY-2003.

XX PF 12-APR-2002; 2002US-00121061.

XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022891.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012452.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 23-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.

PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00803689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	18-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00860028.
PR	25-MAY-2001;	2001US-00866034.
PR	01-JUN-2001;	2001WO-US017992.
PR	01-JUN-2001;	2001US-00872035.
PR	05-JUN-2001;	2001WO-US017800.
PR	14-JUN-2001;	2001US-00874503.
PR	19-JUN-2001;	2001US-00882636.
PR	20-JUN-2001;	2001US-00886342.
PR	21-JUN-2001;	2001WO-US019592.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00908827.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00028072.
XX		
XX	(GETH)	GENENTECH INC.
PA		
XX		
XX	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Grithsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI: 2003-755115/71.	
DR	N-PSDB; ADA80625.	
XX		
XX	New PRO polypeptides useful for treating diabetes, hyper- or hypo-	
PT	insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,	
PT	various coagulation disorders and tumors.	
XX		
PS	Claim 12; Fig 470; 638pp; English.	
XX		
XX	The invention relates to isolated human PRO polypeptides (secreted and	
CC	transmembrane polypeptides) and the polynucleotides encoding them. The	
CC	invention also relates to an antibody which specifically binds to a PRO	
CC	polypeptide, a method for stimulating the release of tumour necrosis	
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the	
CC	proliferation or differentiation of chondrocyte cells and a method for	
CC	detecting the presence of a tumour in a mammal (e.g. adrenal lung,	
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The	
CC	polynucleotides are useful in molecular biology, including uses as	
CC	hybridisation probes, in chromosome and gene mapping, in generating	
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	
CC	be used in preparing PRO polypeptides by recombinant techniques and in	
CC	generating either transgenic animals or knock-out animals which are	
CC	useful in the development and screening of therapeutically useful	
CC	reagents. The PRO polypeptides or antibodies are used in preparing a	
CC	medicament for treating a condition responsive to the polypeptides or	
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation	
CC	of human microvascular endothelial cells, for modulating the uptake of	
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
CC	stimulating differentiation of adipocyte cells, for stimulating	
CC	proliferation of or gene expression in pericyte cells, for stimulating	
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte	
CC	cells, for inducing endothelial cell tube formation and for treating	
CC	various bone and/or cartilage disorders such as sports injuries and	
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans	
CC	from cartilage are useful for treating sports-related joint problems,	
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO	
CC	polypeptides are also useful for treating various mammalian haemoglobin-	
CC	associated disorders such as various thalassemias and conditions which	
CC	may benefit from enhanced local immune system cell infiltration. This	

CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGGAHTRVIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRMCTPLGREGGEC 60
Db 1 MGGAHTRVIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRMCTPLGREGGEC 60
Qy 61 HFGSHKVPFFPRKRKHHTCPCLPNLLCSRFDPGGRYRCSMDLKNINF 105
Db 61 HFGSHKVPFFPRKRKHHTCPCLPNLLCSRFDPGGRYRCSMDLKNINF 105

RESULT 82
ADA75868
ID ADA75868 standard; protein; 105 AA.
XX AC ADA75868;
XX DT 20-NOV-2003 (first entry)
XX Human PRO polypeptide #235.
DE
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal, lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX
XX US2003082703-A1.
PN
XX
XX 01-MAY-2003.
PD
XX
XX 23-APR-2002; 2002US-00128691.
PF
XX
XX 09-DEC-1999; 99US-0170262P.
PR
XX
XX 01-DEC-2000; 2000WO-US032678.
PR
XX
XX 19-DEC-2001; 2001US-00028072.
PR
XX
XX (GETH) GENENTECH INC.
PA
XX
XX Baker KP, Beresini M, DeForge L, Deansoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PI
XX
XX WPI: 2003-765414/72.
DR
XX
XX N-PSDB; ADA75867.
DR
XX
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
FT e.g., tumor or for tissue typing.
FT
XX
XX Claim 12; Fig 470; 637pp; English.
PS
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATVSMILLVTVSDCAVITGACERDVCGAGTCACISLWLRGLRMCTPLGREGEEC 60
Db 1 MRGATVSMILLVTVSDCAVITGACERDVCGAGTCACISLWLRGLRMCTPLGREGEEC 60
QY 61 HPGSHKVPFRKRKHTCTCPCLNLLCSRFPPDGRVCSMDLKNINF 105
Db 61 HPGSHKVPFRKRKHTCTCPCLNLLCSRFPPDGRVCSMDLKNINF 105

RESULT 83

ADA38812
ID ADA38812 standard; protein; 105 AA.

XX
AC ADA38812;

XX
DT 20-NOV-2003 (first entry)

XX
XX Human secreted/transmembrane protein PRO186.

XX
XX PRO; secreted protein; transmembrane protein; gene therapy; tumour;
XX cancer; human; colon cancer; lung cancer; breast cancer.

XX
OS Homo sapiens.

XX
PN US2003059780-A1.

XX
PD 27-MAR-2003.

XX
PF 14-NOV-2001; 2001US-00991854.

XX
XX 16-JUN-1997; 97US-0049787P.

PR
PR 17-OCT-1997; 97US-0062250P.

PR
PR 05-NOV-1997; 97WO-US020069.

PR
PR 12-NOV-1997; 97US-0065186P.

PR
PR 13-NOV-1997; 97US-0065311P.

PR
PR 24-NOV-1997; 97US-0062770P.

PR
PR 25-FEB-1998; 98US-0075943P.

PR
PR 20-MAR-1998; 98US-0078910P.

PR
PR 28-APR-1998; 98US-0083322P.

PR
PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 01-JUL-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.

```
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096148P.
PR 12-AUG-1998; 98US-0096323P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096899P.
PR 18-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0096965P.
PR 19-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025408.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99WO-US012957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 08-OCT-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028633P.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2,5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRCATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLNCTPLGREGEC 60
Db 1 MRCATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLNCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 84
ADA47093
ID ADA47093 standard; protein; 105 AA.
AC ADA47093;
XX
XX
XX 20-NOV-2003 (first entry)
DE Human PRO polypeptide #235.
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
OS Homo sapiens.
XX
XX
XX US2003073210-A1.
PD 17-APR-2003.
XX
XX
XX 11-APR-2002; 2002US-00121045.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
```

PR 14-SEP-1998; 98WO-US015093.
PR 14-SEP-1998; 98WO-US015094.
PR 14-SEP-1998; 98WO-US015177.
PR 16-SEP-1998; 98WO-US015330.
PR 17-SEP-1998; 98WO-US019437.
PR 20-OCT-1998; 98WO-US021141.
PR 20-OCT-1998; 98WO-US022591.
PR 20-OCT-1998; 98WO-US023992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US025106.
PR 08-MAR-1999; 98WO-US025028.
PR 10-MAR-1999; 98WO-US025190.
PR 20-APR-1999; 98WO-US025615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US011252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 23-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000358.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 11-JUL-2000; 2000WO-US020710.
PR 21-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US047259.
PR 20-DEC-2000; 2000WO-US049556.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001WO-US006656.
PR 14-MAR-2001; 2001US-00802706.
PR 22-MAR-2001; 2001US-00806689.
PR 05-APR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019852.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-644800/61.
DR N-PSDB; ADA47092.
XX
New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.
PT
PT
XX
PS Claim 12; Fig 470; 63pp; English.
XX
The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.
Sequence 105 AA;
SQ

```

Query Match          100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTPLGREGEBC 60
DB 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTPLGREGEBC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSFPDPGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSFPDPGRYRCSMDLKNINF 105

RESULT 85
ADB25389
ID ADB25389 standard; protein; 105 AA.
XX
AC ADB25389;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 470.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077715-A1.
XX
PD 24-APR-2003.
XX
PF 23-APR-2002; 2002US-00128693.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032578.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755070/71.
DR N-PSDB; ADB25388.
XX
PT New isolated, secreted and transmembrane PRO nucleic acids, useful for
PT the diagnosis, prevention and/or treatment of tumors, such as lung,
PT colon, breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 12; Fig 470; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

```

```

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 105 AA;

```

```

Query Match          100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTPLGREGEBC 60
DB 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTPLGREGEBC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSFPDPGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSFPDPGRYRCSMDLKNINF 105

```

```

RESULT 86
ADB25389
ID ADA93565 standard; protein; 105 AA.
XX
AC ADA93565;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #235.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077721-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131837.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.

```

PR 19-DEC-2001; 2001US-00029072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755076/71.
XX N-PSDB; ADA93564.
XX New PRO nucleic acid, useful for recombinantly producing a PRO
XX polypeptide and for manufacturing a medicament for diagnosing or treating
XX tumor.
XX
XX Claim 12; Fig 470; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumor necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 105 AA;
XX
XX Query Match
XX Best Local Similarity 100.0%; Score 589; DB 6; Length 105;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVIMLLLVTSVCNITGACERDVCCGAGTCCALSLMRLGLRMTPLRGREGEC 60
Db |||||
QY 1 MEGATRVIMLLLVTSVCNITGACERDVCCGAGTCCALSLMRLGLRMTPLRGREGEC 60
Db |||||
QY 61 HPGSHKVPFFRRKRKHTKTCPLNLLCSRFDPGRVRCSDMLKNINF 105
Db |||||
QY 61 HPGSHKVPFFRRKRKHTKTCPLNLLCSRFDPGRVRCSDMLKNINF 105
Db |||||
XX
XX RESULT 87
XX ADB26915
XX ID ADB26915 standard; protein; 105 AA.
XX
XX ADB26915;
XX
XX 20-NOV-2003 (first entry)

XX DE
XX XX
XX Human PRO polypeptide #235.
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003092147-A1.
XX
XX 15-MAY-2003.
XX
XX 11-APR-2002; 2002US-00121051.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 16-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 22-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US0796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021056.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI: 2003-777249/73.
N-PSDB; ADB26914.
Novel isolated PRO polypeptide useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders, tumors.
Claim 12; Fig 470; 560pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSYMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
Db 1 MEGATRVSYMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRRKXKHTCTPCLENLCSRPDPGRYRCSMDLNINF 105
Db 61 HPGSHKVPFFRRKXKHTCTPCLENLCSRPDPGRYRCSMDLNINF 105

RESULT 88
ADB31202
ID ADB31202 standard; protein; 105 AA.
XX
AC ADB31202;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #235.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
OS Homo sapiens.
XX
PN US2003096386-A1.
XX
PD 22-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121042.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 15-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US023992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US035108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 01-DEC-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 02-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 16-DEC-1999; 98WO-US028564.
 PR 16-DEC-1999; 98WO-US028565.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 98WO-US000219.
 PR 06-JAN-2000; 98WO-US000277.
 PR 11-FEB-2000; 98WO-US000376.
 PR 11-FEB-2000; 98WO-US003565.
 PR 18-FEB-2000; 98WO-US004341.
 PR 18-FEB-2000; 98WO-US004342.
 PR 22-FEB-2000; 98WO-US004414.
 PR 24-FEB-2000; 98WO-US004914.
 PR 24-FEB-2000; 98WO-US005004.
 PR 01-MAR-2000; 98WO-US005601.
 PR 02-MAR-2000; 98WO-US005746.
 PR 10-MAR-2000; 98WO-US005841.
 PR 15-MAR-2000; 98WO-US006319.
 PR 15-MAR-2000; 98WO-US006884.
 PR 20-MAR-2000; 98WO-US007377.
 PR 21-MAR-2000; 98WO-US007532.
 PR 30-MAR-2000; 98WO-US008439.
 PR 17-MAY-2000; 98WO-US013705.
 PR 22-MAY-2000; 98WO-US014042.
 PR 30-MAY-2000; 98WO-US014941.
 PR 02-JUN-2000; 98WO-US015264.
 PR 28-JUL-2000; 98WO-US020710.
 PR 11-AUG-2000; 98WO-US022031.
 PR 23-AUG-2000; 98WO-US023522.
 PR 24-AUG-2000; 98WO-US023328.
 PR 08-NOV-2000; 98WO-US030952.
 PR 10-NOV-2000; 98WO-US030873.
 PR 01-DEC-2000; 98WO-US032678.
 PR 20-DEC-2000; 98WO-US034956.
 PR 28-FEB-2001; 98WO-US037425.
 PR 28-FEB-2001; 98WO-US037425.
 PR 28-FEB-2001; 98WO-US037425.
 PR 01-MAR-2001; 98WO-US006520.
 PR 09-MAR-2001; 98WO-US006566.
 PR 14-MAR-2001; 98WO-US008270.
 PR 22-MAR-2001; 98WO-US008689.
 PR 22-MAR-2001; 98WO-US016744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854308.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00860208.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882536.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001US-00886342.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001US-00887879.
 PR 29-JUN-2001; 2001US-00920116.
 PR 09-JUL-2001; 2001US-00921735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI: 2003-786990/74.
 N-PSDB; ADB31201.
 DR Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
 XX hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
 DR attack, various coagulation disorders, tumors.
 XX
 Claim 12; Fig 470; 638pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polypeptide of the invention. Note: The
 sequence data for this patent is also available in electronic format
 the USPTO website at seqdata.uspto.gov.
 XX
 Sequence 105 AA;
 SQ

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEBC 60

Db 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEBC 60

QY 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 89

ABU72438

ID ABU72438 standard; protein; 105 AA.

XX AC ABU72438;

XX DT 06-NOV-2003 (first entry)

XX DE Human PRO1186 protein.

XX KW .PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;

KW tumour necrosis factor; proliferation; differentiation; gene therapy;
KW dermal fibroblast.

XX OS Homo sapiens.

XX PN US2003027988-A1.

XX PD 06-FEB-2003.

XX PF 26-AUG-2002; 2002US-00227884.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI; 2003-503301/47.

XX DR N-PSDB; ABT44591.

XX PT New PRO protein encoding nucleic acid, useful for preparing PRO

XX PT polypeptides and anti-PRO antibodies for detecting the presence of a

XX PT tumor in a mammal.

XX PS Claim 11; Fig 166; 324pp; English.

XX CC The invention relates to a novel isolated PRO protein encoding nucleic

XX CC acid. The nucleic acid of the invention may be useful for preparing PRO

XX CC polypeptides and anti-PRO antibodies for detecting the presence of a

XX CC tumor in a mammal. Furthermore, the molecules of the invention may be

XX CC useful for stimulating proliferation or gene expression in pericyte

XX CC cells, the release of tumour necrosis factor (TNF)-alpha from human

XX CC blood, the proliferation or differentiation of chondrocyte cells and for

XX CC inhibiting the proliferation of normal human dermal fibroblast cells.

XX CC Finally, the molecules may be utilised during gene therapy. The current

XX CC sequence is that of the human PRO protein of the invention

XX CC Sequence 105 AA;

XX SQ

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEBC 60

Db 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEBC 60

QY 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 90

ADA92933

ID ADA92933 standard; protein; 105 AA.

XX AC ADA92933;

XX DT 20-NOV-2003 (first entry)

XX DE Human secreted/transmembrane protein PRO1186.

XX KW PRO; secreted protein; transmembrane protein;

XX KW hypertrophy of neonatal heart; angiogenesis;

XX KW vascular endothelial growth factor; VEGF-stimulated proliferation;

XX KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

XX KW c-fos induction; adipocyte cell; chondrocyte differentiation;

XX KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;

XX KW cancer; human; colon cancer; lung cancer; breast cancer;

XX KW rod photoreceptor cell.

XX OS Homo sapiens.

XX PN US2003060407-A1.

XX PD 27-MAR-2003.

XX PF 14-NOV-2001; 2001US-00990440.

XX PR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0065770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0075910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087609P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

XX PR 04-JUN-1998; 98US-0088028P.

XX PR 04-JUN-1998; 98US-0088029P.

XX PR 04-JUN-1998; 98US-0088030P.

XX PR 04-JUN-1998; 98US-0088033P.

XX PR 05-JUN-1998; 98US-0088167P.

XX PR 05-JUN-1998; 98US-0088202P.

XX PR 05-JUN-1998; 98US-0088212P.

XX PR 09-JUN-1998; 98US-0088217P.

XX PR 09-JUN-1998; 98US-0088655P.

XX PR 10-JUN-1998; 98US-0088734P.

XX PR 10-JUN-1998; 98US-0088738P.

XX PR 10-JUN-1998; 98US-0088742P.

XX PR 10-JUN-1998; 98US-0088810P.

XX PR 10-JUN-1998; 98US-0088824P.

XX PR 11-JUN-1998; 98US-0088826P.

XX PR 11-JUN-1998; 98US-0088858P.

XX PR 11-JUN-1998; 98US-0088861P.

XX PR 11-JUN-1998; 98US-0088876P.

XX PR 12-JUN-1998; 98US-0089105P.

XX PR 16-JUN-1998; 98US-0089440P.

PR	16-JUN-1998;	98US-0089512P.	PR	17-AUG-1998;	98US-0096895P.
PR	16-JUN-1998;	98US-0089514P.	PR	17-AUG-1998;	98US-0096897P.
PR	17-JUN-1998;	98US-0089532P.	PR	18-AUG-1998;	98US-0096949P.
PR	17-JUN-1998;	98US-0089538P.	PR	18-AUG-1998;	98US-0096950P.
PR	17-JUN-1998;	98US-0089598P.	PR	18-AUG-1998;	98US-0096959P.
PR	17-JUN-1998;	98US-0089599P.	PR	18-AUG-1998;	98US-0096960P.
PR	17-JUN-1998;	98US-0089600P.	PR	18-AUG-1998;	98US-0097022P.
PR	17-JUN-1998;	98US-0089633P.	PR	19-AUG-1998;	98US-0097141P.
PR	18-JUN-1998;	98US-0089801P.	PR	20-AUG-1998;	98US-0097218P.
PR	18-JUN-1998;	98US-0089907P.	PR	24-AUG-1998;	98US-0097661P.
PR	18-JUN-1998;	98US-0089908P.	PR	26-AUG-1998;	98US-0097952P.
PR	19-JUN-1998;	98US-0089947P.	PR	26-AUG-1998;	98US-0097954P.
PR	19-JUN-1998;	98US-0089952P.	PR	26-AUG-1998;	98US-0097955P.
PR	22-JUN-1998;	98US-0090246P.	PR	26-AUG-1998;	98US-0097971P.
PR	22-JUN-1998;	98US-0090252P.	PR	26-AUG-1998;	98US-0097974P.
PR	23-JUN-1998;	98US-0090254P.	PR	26-AUG-1998;	98US-0097978P.
PR	23-JUN-1998;	98US-0090349P.	PR	26-AUG-1998;	98US-0097979P.
PR	23-JUN-1998;	98US-0090355P.	PR	26-AUG-1998;	98US-0097986P.
PR	24-JUN-1998;	98US-0090439P.	PR	26-AUG-1998;	98US-0098014P.
PR	24-JUN-1998;	98US-0090431P.	PR	31-AUG-1998;	98US-0098525P.
PR	24-JUN-1998;	98US-0090435P.	PR	16-SEP-1998;	98US-0100634P.
PR	24-JUN-1998;	98US-0090444P.	PR	17-SEP-1998;	98US-0100858P.
PR	24-JUN-1998;	98US-0090445P.	PR	17-SEP-1998;	98US-0100859P.
PR	24-JUN-1998;	98US-0090472P.	PR	07-OCT-1998;	98US-0100859P.
PR	24-JUN-1998;	98US-0090535P.	PR	01-DEC-1998;	98US-0100859P.
PR	24-JUN-1998;	98US-0090540P.	PR	22-DEC-1998;	98US-0113298P.
PR	24-JUN-1998;	98US-0090542P.	PR	05-JAN-1999;	98US-0113298P.
PR	24-JUN-1998;	98US-0090557P.	PR	08-MAR-1999;	98US-0123957P.
PR	25-JUN-1998;	98US-0090676P.	PR	12-MAR-1999;	98US-0123957P.
PR	25-JUN-1998;	98US-0090678P.	PR	02-JUN-1999;	98US-0141037P.
PR	25-JUN-1998;	98US-0090690P.	PR	07-JUL-1999;	98US-0141037P.
PR	25-JUN-1998;	98US-0090694P.	PR	20-JUL-1999;	98US-0144758P.
PR	25-JUN-1998;	98US-0090695P.	PR	26-JUL-1999;	98US-0145698P.
PR	25-JUN-1998;	98US-0090696P.	PR	28-JUL-1999;	98US-0146222P.
PR	26-JUN-1998;	98US-0090862P.	PR	17-AUG-1999;	98US-0149396P.
PR	26-JUN-1998;	98US-0090863P.	PR	15-SEP-1999;	98US-0149396P.
PR	01-JUL-1998;	98US-0091360P.	PR	15-SEP-1999;	98US-0201090.
PR	02-JUL-1998;	98US-0091478P.	PR	08-OCT-1999;	98US-0158663P.
PR	02-JUL-1998;	98US-0091519P.	PR	30-NOV-1999;	98US-02028313.
PR	02-JUL-1998;	98US-0091626P.	PR	01-DEC-1999;	98US-02028313.
PR	02-JUL-1998;	98US-0091628P.	PR	01-DEC-1999;	98US-02028313.
PR	02-JUL-1998;	98US-0091633P.	PR	16-DEC-1999;	98US-02030911.
PR	02-JUL-1998;	98US-0091646P.	PR	05-JAN-2000;	2000US-02000219.
PR	02-JUL-1998;	98US-0091673P.	PR	06-JAN-2000;	2000US-02000219.
PR	07-JUL-1998;	98US-0091978P.	PR	11-FEB-2000;	2000US-02000219.
PR	09-JUL-1998;	98US-0092182P.	PR	18-FEB-2000;	2000US-02000219.
PR	10-JUL-1998;	98US-0092472P.	PR	22-FEB-2000;	2000US-02000219.
PR	30-JUL-1998;	98US-00924651P.	PR	24-FEB-2000;	2000US-02000219.
PR	04-AUG-1998;	98US-00925282P.	PR	02-MAR-2000;	2000US-02000219.
PR	04-AUG-1998;	98US-00925282P.	PR	10-MAR-2000;	2000US-02000219.
PR	04-AUG-1998;	98US-00925301P.	PR	15-MAR-2000;	2000US-02000219.
PR	04-AUG-1998;	98US-00925302P.	PR	20-MAR-2000;	2000US-02000219.
PR	04-AUG-1998;	98US-00925321P.	PR	30-MAR-2000;	2000US-02000219.
PR	04-AUG-1998;	98US-00925325P.	PR	15-MAY-2000;	2000US-02000219.
PR	10-AUG-1998;	98US-00925292P.	PR	17-MAY-2000;	2000US-02000219.
PR	10-AUG-1998;	98US-00926012P.	PR	22-MAY-2000;	2000US-02000219.
PR	11-AUG-1998;	98US-00926146P.	PR	30-MAY-2000;	2000US-02000219.
PR	12-AUG-1998;	98US-0092629P.	PR	02-JUN-2000;	2000US-02000219.
PR	17-AUG-1998;	98US-0096757P.	PR	23-JUN-2000;	2000US-0213637P.
PR	17-AUG-1998;	98US-0096766P.			
PR	17-AUG-1998;	98US-0096768P.			
PR	17-AUG-1998;	98US-0096773P.			
PR	17-AUG-1998;	98US-0096791P.			
PR	17-AUG-1998;	98US-0096867P.			
PR	17-AUG-1998;	98US-0096891P.			
PR	17-AUG-1998;	98US-0096894P.			

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 MRGATRVISIMLLVTVSDCAVITGACERDVQCCAGTCCCAISLWLRGLRMCTPLGREGEC 60
1 MRGATRVISIMLLVTVSDCAVITGACERDVQCCAGTCCCAISLWLRGLRMCTPLGREGEC 60
61 HPGSHKVPFPRKHKHTCPLNLLCSRFDPDGRYCSMDLNINF 105

Db 61 HFGSHKVPFRKRKHTCPCLNLLCSRPDPGRYCSMDLNINF 105
 RESULT 91
 ADA61130
 ID ADA61130 standard; protein; 105 AA.
 AC ADA61130;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Homo sapiens.
 XX
 KW Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; PFA uptake modulator;
 KW Cell proliferation stimulator; cell differentiation stimulator;
 KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Novel.
 OS human.
 OS secreted.
 OS and.
 OS transmembrane.
 OS protein.
 OS PRO1186.
 XX
 PN US2003049817-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 10-MAY-2002; 2002US-00142423.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 16-SEP-1998; 98WO-US019377.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 20-APR-1999; 99WO-US005190.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012352.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030055.

20-DEC-1999; 99WO-US030911.
 20-DEC-1999; 99WO-US030999.
 22-DEC-1999; 99WO-US030720.
 30-DEC-1999; 99WO-US031243.
 30-DEC-1999; 99WO-US031274.
 05-JAN-2000; 2000WO-US000219.
 06-JAN-2000; 2000WO-US000277.
 08-JAN-2000; 2000WO-US000376.
 11-FEB-2000; 2000WO-US003565.
 18-FEB-2000; 2000WO-US004341.
 18-FEB-2000; 2000WO-US004342.
 22-FEB-2000; 2000WO-US004414.
 24-FEB-2000; 2000WO-US004914.
 24-FEB-2000; 2000WO-US005004.
 01-MAR-2000; 2000WO-US005601.
 02-MAR-2000; 2000WO-US005746.
 02-MAR-2000; 2000WO-US005841.
 15-MAR-2000; 2000WO-US006884.
 20-MAR-2000; 2000WO-US007377.
 21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00806889.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 03-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 10-MAR-2009; 2000WO-US006319.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-695893/66.
 DR N-PSDB; ADA61129.
 XX

PT	New secreted and transmembrane PRO polypeptide and nucleic acid, useful for manufacturing a medicament for diagnosing or treating tumor.	
XX		
PT		
XX		
PS	Claim 12; Fig 470; 658pp; English.	
XX		
CC	The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage cells, stimulating the proliferation of inner ear utricular supporting cells, stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from FMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumor in a mammal. The tumor is lung, colon, breast, prostate, rectal, cervical or liver tumor. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.	
XX		
SQ	Sequence 105 AA;	
	Query Match 100.0%; Score 589; DB 6; Length 105;	
	Best Local Similarity 100.0%; Pred. No. 2.5e-54;	
	Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRMCTPLGREGEC 60	
DB	1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRMCTPLGREGEC 60	
QY	61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPPDGRYRCSDMLKXINF 105	
DB	61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPPDGRYRCSDMLKXINF 105	
RESULT 92		
ADB24277		
ID	ADB24277 standard; protein; 105 AA.	
XX		
AC	ADB24277;	
XX		
DT	20-NOV-2003 (first entry)	
DE	Human PRO polypeptide SEQ ID NO 470.	
XX	Human PRO; secreted polypeptide; transmembrane polypeptide;	
KW	tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumor;	
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW	liver; microvascular endothelial cell; glucose; FFA;	
KW	skeletal muscle cell; adipocyte cell; pericyte cell;	
KW	inner ear utricular supporting cell; T-lymphocyte cell;	
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	
KW	immune system cell infiltration.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003077714-A1.	
XX		
PD	24-APR-2003.	
XX		
PF	22-APR-2002; 2002US-00127901.	
XX		
PR	17-JUN-1998; 98US-0089599P.	
PR	02-JUN-1999; 99WO-US012252.	
PR	25-AUG-1999; 99US-00380137.	
PR	30-NOV-1999; 99WO-US028313.	
PR	30-MAR-2000; 2000WO-US008439.	
PR	01-DEC-2000; 2000WO-US032678.	
PR	19-DEC-2001; 2001US-00028072.	
XX	(GETH) GENENTECH INC.	
PA		
XX	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX	WPI; 2003-755069/71.	
DR	N-PSDB; ADB24276.	
XX		
PT	New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.	
XX		
PS	Claim 12; Fig 470; 637pp; English.	
XX		
CC	The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalasaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html .	
XX		
SQ	Sequence 105 AA;	
	Query Match 100.0%; Score 589; DB 6; Length 105;	
	Best Local Similarity 100.0%; Pred. No. 2.5e-54;	
	Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRMCTPLGREGEC 60	
DB	1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRMCTPLGREGEC 60	

QY 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDPGGRYRCSMDLKNINF 105
 DB 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDPGGRYRCSMDLKNINF 105

RESULT 93
 ADA96606
 ID ADA96606 standard; protein; 105 AA.
 XX
 AC ADA96606;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polypeptide #235.
 XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 FN US2003082590-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127837.
 XX
 PR 01-SEP-1998; 98US-0038750P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPT; 2003-755107/71.
 DR N-PSDB; ADA96605.
 XX

PRO nucleic acid, useful for preparing a composition for treating e.g.,
 tumor or for tissue typing.
 XX
 PS Claim 12; Fig 470; 637pp; English.
 XX

The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or

antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassaemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polypeptide of the invention. Note: The
 sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2,5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIIMLLVTYSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

DB 1 MRGATRVSIIMLLVTYSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDPGGRYRCSMDLKNINF 105

DB 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDPGGRYRCSMDLKNINF 105

RESULT 94

ADA81178

ID ADA81178 standard; protein; 105 AA.

XX

AC ADA81178;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human PRO polypeptide #235.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003082702-A1.

XX

PD 01-MAY-2003.

XX

PF 23-APR-2002; 2002US-00128690.

XX

PR 02-MAR-2000; 2000WO-US005841.

XX

PR 30-MAY-2000; 2000WO-US014941.

XX

PR 01-DEC-2000; 2000WO-US032678.

XX

PR 19-DEC-2001; 2001US-00028072.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-755111/71.
DR N-PSDB; ADA91177.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
XX
PS Claim 12; Fig 470; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSTMLLVTVSDCAVITGACERDVCGAGTCCTCAISLWLRGLMCTPLRGEGEC 60
Db 1 MRGATRVSTMLLVTVSDCAVITGACERDVCGAGTCCTCAISLWLRGLMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRRKKHHTCTCPLENLCSRFPPDGRYRCSMDLNINF 105
Db 61 HPGSHKVPFFRRKKHHTCTCPLENLCSRFPPDGRYRCSMDLNINF 105

RESULT 95
ADA96054
ID ADA96054 standard; protein; 105 AA.
XX
AC ADA96054;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #235.
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS
XX PN US2003082759-A1.
XX PD 01-MAY-2003.
XX PF 11-APR-2002; 2002US-00121040.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030311.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US04956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00806889.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 03-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924413.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
 XX
 XX WPI; 2003-755114/71.
 DR N-PSDB; ADA96053.
 DR
 XX New isolated PRO polypeptides, useful for treating diabetes, hyper- or
 PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
 PT attack, various coagulation disorders and tumors.
 XX
 XX Claim 12; Fig 470; 638pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting Proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 Db |||||
 QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 Db |||||
 QY 61 HPGSHKVPFFRRKHHTCPCLPFLNLLCSRFPPDGRYRCSDMLKNINF 105
 Db |||||
 QY 61 HPGSHKVPFFRRKHHTCPCLPFLNLLCSRFPPDGRYRCSDMLKNINF 105
 Db |||||
 RESULT 96
 AD26363
 ID ADB26363 standard; protein; 105 AA.
 XX
 AC ADB26363;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polypeptide #235.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; liver; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003082760-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 12-APR-2002; 2002US-00121056.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012452.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 16-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020940.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 01-DEC-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 16-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 28-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US003376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US020311.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US030873.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US0796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001WO-US0802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 15-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882836.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 16-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-777204/73.
 DR N-PSDB; ADB26362.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, detecting the presence of tumor in a mammal, or
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle
 PT cells or adipocyte cells.
 XX
 XX Claim 12; Fig 470; 659pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 XX Sequence 105 AA;
 SQ
 Query Match 100.0%; Score 589; DB 6; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCCAGTCCCAISLWRLGRMCTPLGREGEC 60
 DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCCAGTCCCAISLWRLGRMCTPLGREGEC 60

Qy 61 HPGSHKVPFFRRKKHHTCPCLENLCSRRPDDGRYCRSMDLKNINF 105
 Db 61 HPGSHKVPFFRRKKHHTCPCLENLCSRRPDDGRYCRSMDLKNINF 105

RESULT 97

ADB21848
 ID ADB21848 standard; protein; 105 AA.

XX AC ADB21848;
 XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.
 XX KW Human; secreted and transmembrane protein; PRO;

KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; PFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082765-A1.

XX PD 01-MAY-2003.

XX PF 17-MAY-2002; 2002US-00147499.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US024214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 22-DEC-1999; 99WO-US030999.

PR 30-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000356.
 PR 18-FEB-2000; 2000WO-US000431.
 PR 18-FEB-2000; 2000WO-US000432.
 PR 22-FEB-2000; 2000WO-US000414.
 PR 24-FEB-2000; 2000WO-US0004914.
 PR 24-FEB-2000; 2000WO-US0005004.
 PR 01-MAR-2000; 2000WO-US0005601.
 PR 02-MAR-2000; 2000WO-US0005746.
 PR 02-MAR-2000; 2000WO-US0005841.
 PR 10-MAR-2000; 2000WO-US0006319.
 PR 15-MAR-2000; 2000WO-US0006884.
 PR 20-MAR-2000; 2000WO-US0007377.
 PR 21-MAR-2000; 2000WO-US0007532.
 PR 30-MAR-2000; 2000WO-US0008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US020231.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US0006520.
 PR 01-MAR-2001; 2001WO-US0006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-786920/74.
 XX N-PSDB; ADB21847.

New secreted and transmembrane PRO polypeptide useful for detecting the presence of tumor in a mammal, or modulating the uptake of glucose or free fatty acid by skeletal muscle cells or adipocyte cells.

Claim 12; Fig 470; 638pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from BMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (II) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knock-out animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This is the amino
XX acid sequence of a novel human secreted and transmembrane PRO
XX polypeptide.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MRGATVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
QY 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRPDPGRYCSMDLNINF 105
DB 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRPDPGRYCSMDLNINF 105

RESULT 98

ABO34333
ID ABO34333 standard; protein; 105 AA.

XX AC ABO34333;
XX DT 19-SEP-2003 (first entry)
XX DE Human secreted/transmembrane polypeptide PRO 1186.

XX Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
XX human dermal fibroblast stimulation; tumour; tissue typing;
XX affinity purification.

XX Homo sapiens.

XX US2003044934-A1.

XX 06-MAR-2003.

XX 28-AUG-2002; 2002US-00230338.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001NO-US021066.

XX 09-APR-2002; 2002US-00119480.

(GETH) GENENTECH INC.

PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-492274/46.

XX DR N-PSDB; ACD82258.

XX New transmembrane polypeptides and nucleic acids encoding the
XX polypeptides, useful in gene therapy, in chromosome identification, as
XX chromosome markers, or in generating probes.

XX Claim 19; Fig 166; 315pp; English.

XX The invention relates to an isolated nucleic acid encoding a PRO
XX polypeptide. Nucleic acids that encode PRO can be used to generate either
XX transgenic animals or knock-out animals useful in developing and
XX screening of therapeutically useful reagents. The nucleic acids may also
XX be used in gene therapy for replacing defective gene, in chromosome
XX identification, as chromosome markers, or in generating probes to isolate
XX full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
XX stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
XX and for detecting the presence of tumour in a mammal. The PRO
XX polypeptides are useful as molecular markers for protein electrophoresis
XX and the isolated nucleic acids may be used for recombinantly expressing
XX those markers. The PRO polypeptides and nucleic acids may also be used in
XX tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
XX PRO and in affinity purification of PRO from recombinant cell culture or
XX natural sources. The present sequence represents the amino acid sequence
XX of a human secreted/transmembrane PRO polypeptide

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 6; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MRGATVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
QY 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRPDPGRYCSMDLNINF 105
DB 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRPDPGRYCSMDLNINF 105

RESULT 99

ADA77627
ID ADA77627 standard; protein; 105 AA.

XX AC ADA77627;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #235.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
XX immune system cell infiltration.

XX Homo sapiens.

XX US2003068797-A1.

XX 10-APR-2003.

PF XX 07-MAY-2002; 2002US-00140921.
 PR XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028651.
 PR 02-DEC-1999; 99WO-US028654.
 PR 02-DEC-1999; 99WO-US028656.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004514.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030973.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 20-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-625489/59.
 DR N-PSDB; ADA77626.
 DR XX Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801
 PT and PRO114, useful in the preparation of a medicament for treating a
 PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.
 PT vaccines.
 XX Claim 12; Fig 470; 659pp; English.
 PS The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MGRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 Db 1 MGRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 QY 61 HPGSHKVPFFRRKRKHHTCPCLPDLNLCSPDGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRRKRKHHTCPCLPDLNLCSPDGRYRCSMDLKNINF 105

RESULT 100

ADB18367
 ID ADB18367 standard; protein; 105 AA.

AC ADB18367;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #235.

XX Human: PRO; secreted polypeptide; transmembrane polypeptide;
 XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 XX liver; microvascular endothelial cell; glucose; FFA;
 XX skeletal muscle cell; adipocyte cell; pericyte cell;
 XX inner ear utricular supporting cell; T-lymphocyte cell;
 XX endothelial cell tube formation; bone disorder; cartilage disorder;
 XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 XX rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 XX immune system cell infiltration.

XX Homo sapiens.

OS US2003077710-A1.

XX 24-APR-2003.

XX 22-APR-2002; 2002US-00127825.

XX 22-OCT-1998; 98US-0105169P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 30-NOV-1999; 99WO-US028313.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaxoff E, Gao W;

XX Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755065/71.

DR N-PSDB; ADB18366.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
 PT in tissue typing, and in identifying chromosomes.

XX Claim 12; Fig 470; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uss as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60

Db 1 MGRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKRKHHTCPCLPDLNLCSPDGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKRKHHTCPCLPDLNLCSPDGRYRCSMDLKNINF 105

RESULT 101

ADA87050

ID ADA87050 standard; protein; 105 AA.

XX ADA87050;

DT 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003082709-A1.

XX 01-MAY-2003.

```

XX PF 15-MAY-2002; 2002US-00146791.
XX PR 17-AUG-1998; 98US-0096895P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI: 2003-786912/74.
XX DR N-PSDB; ADA87049.
XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX PT for preparing a composition for treating e.g., tumor, or for tissue
XX PT typing.
XX PS Claim 12; Fig 470; 637pp; English.
XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
XX CC transmembrane) polypeptides (I). (I) is useful for stimulating the
XX CC release of TNF-alpha from human blood, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating the proliferation or differentiation of chondrocyte cells,
XX CC for stimulating the proliferation of or gene expression in pericyte
XX CC cells, for stimulating the release of proteoglycans from cartilage, for
XX CC stimulating the proliferation of inner ear utricular supporting cells,
XX CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX CC the release of a cytokine from PMNC cells, for inhibiting the binding of
XX CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX CC cells, for stimulating proliferation of endothelial cells, for detecting
XX CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX CC are useful for isolating genomic and cDNA nucleotide sequences or
XX CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX CC in assays to identify other proteins or molecules involved in binding
XX CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX CC and gene mapping, in generation of antisense RNA and DNA, in the
XX CC preparation of PRO polypeptide, for generating transgenic animals or
XX CC knockout animals which in turn are useful in the development and
XX CC screening of therapeutically useful reagents, in gene therapy, for
XX CC chromosome identification, as chromosome marker, and for generating
XX CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX CC detecting its expression in specific cells, tissues or serum, and for
XX CC affinity purification of PRO from recombinant cell culture or natural
XX CC sources. (I) and (II) are useful for tissue typing. This is the amino
XX CC acid sequence of a novel human secreted and transmembrane PRO
XX CC polypeptide.
XX CC Sequence 105 AA;
XX CC
XX CC Query Match
XX CC Best Local Similarity 100.0%; Score 589; DB 7; Length 105;
XX CC Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX CC
XX CC Qy 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCATSLMLRGLRMTCTPLRGEEEC 60
XX CC Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCATSLMLRGLRMTCTPLRGEEEC 60
XX CC
XX CC Qy 61 HPGSHKVPFFKRKHHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
XX CC Db 61 HPGSHKVPFFKRKHHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
XX CC
XX CC RESULT 102
XX CC ADA88153
XX CC ID ADA88153 standard; protein; 105 AA.

```

```

XX AC ADA88153;
XX DT 20-NOV-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1186.
XX KW Human; secreted and transmembrane protein; PRO;
XX KW Tumour necrosis factor alpha release; TNF-alpha release;
XX KW Glucose uptake modulator; FFA uptake modulator;
XX KW cell proliferation stimulator; cell differentiation stimulator;
XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX FN US2003082700-A1.
XX PD 01-MAY-2003.
XX XX 23-APR-2002; 2002US-00128684.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI: 2003-786910/74.
XX DR N-PSDB; ADA88152.
XX PT New PRO nucleic acid, useful for preparing a composition for treating
XX PT e.g., tumor or for tissue typing.
XX PS Claim 12; Fig 470; 637pp; English.
XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
XX CC transmembrane) polypeptides (I). (I) is useful for stimulating the
XX CC release of TNF-alpha from human blood, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating the proliferation or differentiation of chondrocyte cells,
XX CC for stimulating the proliferation of or gene expression in pericyte
XX CC cells, for stimulating the release of proteoglycans from cartilage, for
XX CC stimulating the proliferation of inner ear utricular supporting cells,
XX CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX CC the release of a cytokine from PMNC cells, for inhibiting the binding of
XX CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX CC cells, for stimulating proliferation of endothelial cells, for detecting
XX CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX CC are useful for isolating genomic and cDNA nucleotide sequences or
XX CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX CC in assays to identify other proteins or molecules involved in binding
XX CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX CC and gene mapping, in generation of antisense RNA and DNA, in the
XX CC preparation of PRO polypeptide, for generating transgenic animals or
XX CC knockout animals which in turn are useful in the development and
XX CC screening of therapeutically useful reagents, in gene therapy, for
XX CC chromosome identification, as chromosome marker, and for generating
XX CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX CC detecting its expression in specific cells, tissues or serum, and for
XX CC affinity purification of PRO from recombinant cell culture or natural
XX CC sources. (I) and (II) are useful for tissue typing. This is the amino
XX CC acid sequence of a novel human secreted and transmembrane PRO
XX CC polypeptide.
XX CC Sequence 105 AA;
XX CC
XX CC Query Match
XX CC Best Local Similarity 100.0%; Score 589; DB 7; Length 105;
XX CC Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX CC
XX CC Qy 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCATSLMLRGLRMTCTPLRGEEEC 60
XX CC Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCATSLMLRGLRMTCTPLRGEEEC 60
XX CC
XX CC Qy 61 HPGSHKVPFFKRKHHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
XX CC Db 61 HPGSHKVPFFKRKHHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
XX CC
XX CC RESULT 102
XX CC ADA88153
XX CC ID ADA88153 standard; protein; 105 AA.

```

us-10-027-603-2.rag

Mon Aug 30 07:06:19 2004

```

Query Match      100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. NO. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVISIMLLVTSDCAVITGACERDVCCGAGTCCTCAISLWGLRMCTPLGREGGEC 60
Db 1 MRGATRVISIMLLVTSDCAVITGACERDVCCGAGTCCTCAISLWGLRMCTPLGREGGEC 60

Qy 61 HPGSHKVPFFRKHKHTPCPLNLLCSRFDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKHKHTPCPLNLLCSRFDPGRYCSMDLKNINF 105

RESULT 103
ADA46541
ID ADA46541 standard; protein: 105 AA.
XX AC ADA46541;
XX DT 20-NOV-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1186.
XX KW Human; secreted and transmembrane protein; PRO;
XX KW Tumour necrosis factor alpha release; TNF-alpha release;
XX KW Glucose uptake modulator; FFA uptake modulator;
XX KW cell proliferation stimulator; cell differentiation stimulator;
XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;
XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003054516-A1.
XX PD 20-MAR-2003.
XX PF 12-APR-2002; 2002US-00121050.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-NAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028311.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.

```

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-521853/49.
 DR N-PSDB; ADA46540.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor.
 XX
 PS Claim 12; Fig 470; 200pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of or proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC and interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGRGEEC 60
 DB 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGRGEEC 60
 QY 61 HPGSHKVPFFRKRRKHTKCPCLPMLCSRFDPGRYRCSDMLKKNIF 105
 DB 61 HPGSHKVPFFRKRRKHTKCPCLPMLCSRFDPGRYRCSDMLKKNIF 105
 RESULT 104
 ADB28571
 ID ADB28571 standard; protein; 105 AA.
 AC ADB28571;
 XX
 XX 20-NOV-2003 (first entry)
 DE Human PRO polypeptide #235.
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

immune system cell infiltration.
 Homo sapiens.
 US2003082699-A1.
 01-MAY-2003.
 22-APR-2002; 2002US-00127851.
 17-JUN-1998; 98US-0089599P.
 02-JUN-1999; 99WO-US012252.
 25-AUG-1999; 99US-00380137.
 30-NOV-1999; 99WO-US028313.
 30-MAR-2000; 2000WO-US008439.
 01-DEC-2000; 2000WO-US022678.
 19-DEC-2000; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-777202/73.
 N-PSDB; ADB28570.
 New PRO nucleic acid, useful for preparing a composition for treating
 e.g., tumor or for tissue typing.
 Claim 12; Fig 470; 637pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassaemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polypeptide of the invention. Note: The
 sequence data for this patent is also available in electronic format from
 the USPTO website at seqdata.uspto.gov.
 Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGRGEEC 60

Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPGGRYRCSMDLNINF 105
 Db 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPGGRYRCSMDLNINF 105

RESULT 105
 ID ADB29123 standard; protein; 105 AA.
 AC ADB29123;
 XX
 XX 20-NOV-2003 (first entry)
 DT
 DE Human PRO polypeptide #235.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 XX Homo sapiens.
 OS
 XX US2003082706-A1.
 PN
 XX 01-MAY-2003.
 PD
 XX 24-APR-2002; 2002US-00131836.
 PF
 XX 09-DEC-1999; 99US-0170262P.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforgre L, Desnoyers L, Filvaroff E;
 PI Cao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-777203/73.
 DR N-PSDB; ADB29122.
 DR
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor or for tissue typing.
 PT
 PS Claim 12; Fig 470; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX Sequence 105 AA;
 SQ

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPGGRYRCSMDLNINF 105
 Db 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPGGRYRCSMDLNINF 105

RESULT 106
 ABO53220
 ID ABO53220 standard; protein; 105 AA.
 XX
 AC ABO53220;
 XX
 XX 14-OCT-2003 (first entry)
 DT
 XX Human secreted/transmembrane protein PRO1186.
 DE
 XX Human; secreted protein; transmembrane protein; PRO;
 KW adrenal cortical capillary endothelial cell; angiogenesis; wound healing;
 KW diabetes; obesity; hyper-insulinaemia; hypo-insulinaemia;
 KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
 KW sports injury; arthritis; kidney mesangial cell proliferation;
 KW kidney disorder; Berger disease; neuropathy; coeliac disease;
 KW dermatitis herpetiformis; Crohn's disease; tumour; cancer.
 XX
 XX Homo sapiens.
 OS
 XX US2003044806-A1.
 PN
 XX 06-MAR-2003.
 PD
 XX 15-NOV-2001; 2001US-00998156.
 PF
 XX 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088203P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088743P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088828P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090698P.
PR 26-JUN-1998; 98US-0090699P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 01-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091656P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091797P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUN-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 24-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097561P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100630P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100943P.
PR 01-OCT-1998; 98US-0101141P.
PR 01-DEC-1998; 98US-0102510P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0123957P.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-0141037P.
PR 20-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-015021090.
PR 15-SEP-1999; 98US-015021547.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 20-DEC-1999; 98US-0158663P.
PR 05-JAN-2000; 98US-0158663P.
PR 06-JAN-2000; 98US-0158663P.
PR 11-FEB-2000; 98US-0158663P.
PR 18-FEB-2000; 98US-0158663P.

us-10-027-603-2.rag

Mon Aug 30 07:06:19 2004

```

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCATSLMRLGRLMCTPLGREGEEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCATSLMRLGRLMCTPLGREGEEC 60

Qy 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 107
ADA77075
ID ADA77075 standard; protein; 105 AA.
XX ADA77075;
AC ADA77075;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #235.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003059909-A1.
XX
PD 27-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00143032.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028584.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030035.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 03-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001WO-US006666.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 23-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.

```

PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-540684/51.
DR N-PSDB; ADA77074.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 12; Fig 470; 660pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear uricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWLRGRLMCTPLGRGEEC 60
Dy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWLRGRLMCTPLGRGEEC 60
Qy 61 HPGSHKVPFFPKRKHHTCPLNLLCSRFDPDGRYRCMDLKNINF 105

Db 61 HPGSHKVPFFPKRKHHTCPLNLLCSRFDPDGRYRCMDLKNINF 105
RESULT 108
ADA22494
ID ADA22494 standard; protein; 105 AA.
XX
AC ADA22494;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human secreted/transmembrane polypeptide PRO1186.
XX human; tumour; cancer; colorectal cancer; gene therapy;
KW chondrocyte differentiation; VEGF inhibition;
KW vascular endothelial growth factor; Alzheimer's disease;
KW Parkinson's disease; atherosclerosis; cystic fibrosis;
KW multiple sclerosis; ovarian cancer; tissue typing.
XX
OS Homo sapiens.
XX
XX US2003040473-A1.
XX
XX 27-FEB-2003.
XX
XX 19-NOV-2001; 2001US-00989726.
XX
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0065770P.
PR 25-FEB-1998; 98US-0075445P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084500P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088653P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 11-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.

61 HPGSHKVPFFRKRKHHTCPCLNLLCSRPDGRYRCSDMLKNI NF 105

61 HPGSHKVPFFRKRKHHTCPCLNLLCSRPDGRYRCSDMDIKNI NF 105

RESULT 109
ADA88705
ID ADA88705 standard; protein; 105 AA.
XX
AC ADA88705;
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1186.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW Gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003073213-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124819.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 23-OCT-1998; 98WO-US022991.
PR 23-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000378.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015284.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00860208.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PI
XX WPI: 2003-743816/70.
DR N-FSDS; ADA88704.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 470; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBM cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.

XX SQ Sequence 105. AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
 DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
 QY 61 HPGSHKVPFFPKRKHHTCPCLPMLCSRPDPGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFPKRKHHTCPCLPMLCSRPDPGRYRCSDMLKNINF 105

RESULT 110

ID ADA97710 standard; protein; 105 AA.

XX AC ADA97710;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #235.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082686-A1.

XX PD 01-MAY-2003.

XX PF 19-APR-2002; 2002US-00125926.

XX PP 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755106/71.

DR N-PSDB; ADA97709.

XX Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

PT PRO4978, useful in molecular biology, chromosome and gene mapping, in

PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 12; Fig 470; 566bp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
 DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
 QY 61 HPGSHKVPFFPKRKHHTCPCLPMLCSRPDPGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFPKRKHHTCPCLPMLCSRPDPGRYRCSDMLKNINF 105

RESULT 111

ADB27467

ID ADB27467 standard; protein; 105 AA.

XX AC ADB27467;

DT 20-NOV-2003 (first entry)
XX Human PRO polypeptide #235.
DE
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endorheial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003022239-A1.
PN
XX
XX
PD 30-JAN-2003.
XX
XX 12-APR-2002; 2002US-00121049.
XX
XX 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 97US-0072320P.
PR 04-FEB-1998; 97US-0073612P.
PR 05-FEB-1998; 97US-0074086P.
PR 09-FEB-1998; 97US-0074092P.
PR 12-MAR-1998; 97US-0077791P.
PR 20-MAR-1998; 97US-0078910P.
PR 25-MAR-1998; 97US-0079294P.
PR 27-MAR-1998; 97US-0079663P.
PR 27-MAR-1998; 97US-0079728P.
PR 31-MAR-1998; 97US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 22-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 11-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089539P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014452.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.

PR 15-SEP-1998; 98US-0100390P.
 PR 16-SEP-1998; 98US-0100634P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98US-0100710P.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 07-OCT-1998; 98US-0103215P.
 PR 07-OCT-1998; 98US-0103328P.
 PR 07-OCT-1998; 98WO-US021141.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 29-OCT-1998; 98WO-US022991.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 20-NOV-1998; 98US-0108925P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98WO-US024855.
 PR 15-DEC-1998; 98US-0112743P.
 PR 16-DEC-1998; 98US-0112850P.
 PR 22-DEC-1998; 98US-0113286P.
 PR 22-DEC-1998; 98US-0113299P.
 PR 22-DEC-1998; 98US-0113300P.
 PR 22-DEC-1998; 98US-0113313P.
 PR 22-DEC-1998; 98US-0113314P.
 PR 22-DEC-1998; 98US-0113315P.
 PR 22-DEC-1998; 98US-0113510P.
 PR 22-DEC-1998; 98US-0113511P.
 PR 23-DEC-1998; 98US-0113605P.
 PR 23-DEC-1998; 98US-0113621P.
 PR 05-JAN-1999; 98WO-US000106.
 PR 12-JAN-1999; 99US-0115549P.
 PR 12-JAN-1999; 99US-0115557P.
 PR 12-JAN-1999; 99US-0115560P.
 PR 12-JAN-1999; 99US-0115562P.
 PR 12-JAN-1999; 99US-0115630P.
 PR 12-JAN-1999; 99US-0115705P.
 PR 12-JAN-1999; 99US-0115733P.

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLWMCPTPLGREGEC 60
 Db 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLWMCPTPLGREGEC 60
 Qy 61 HPGSHKVPFPRKHKHTCTCLPNLLCSRPDPGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFPRKHKHTCTCLPNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 112
 ADB22400
 ID ADB22400 standard; protein; 105 AA.
 XX AC ADB22400;
 XX DT 20-NOV-2003 (first entry);
 XX DE Novel human secreted and transmembrane protein P01186.

XX Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; PFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX Homo sapiens.
 XX US2003087344-A1.
 PN 08-MAY-2003.
 PD 16-APR-2002; 2002US-00123905.
 PF 18-JUN-1997; 97US-0049911P.
 PR 26-AUG-1997; 97US-0056974P.
 PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 18-SEP-1997; 97US-0059184P.
 PR 19-SEP-1997; 97US-0059352P.
 PR 19-SEP-1997; 97US-0059588P.
 PR 24-SEP-1997; 97US-0059836P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 17-OCT-1997; 97US-0063755P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063082P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063561P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063733P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 11-DEC-1997; 97US-0069212P.
 PR 11-DEC-1997; 97US-0069278P.
 PR 11-DEC-1997; 97US-0069334P.
 PR 16-DEC-1997; 97US-0069694P.
 PR 23-JAN-1998; 98US-0072320P.
 PR 04-FEB-1998; 98US-0073612P.
 PR 09-FEB-1998; 98US-0074086P.
 PR 09-FEB-1998; 98US-0074092P.
 PR 12-MAR-1998; 98US-0077791P.
 PR 20-MAR-1998; 98US-0078310P.
 PR 25-MAR-1998; 98US-0079244P.
 PR 27-MAR-1998; 98US-0079663P.
 PR 31-MAR-1998; 98US-0080165P.
 PR 09-APR-1998; 98US-0081229P.
 PR 14-APR-1998; 98US-0081695P.
 PR 15-APR-1998; 98US-0081817P.
 PR 15-APR-1998; 98US-0081818P.
 PR 24-APR-1998; 98US-0082999P.

PR 28-APR-1998; 98US-0083322P;
 PR 29-APR-1998; 98US-0083545P;
 PR 07-MAY-1998; 98US-0084600P;
 PR 07-MAY-1998; 98US-0084627P;
 PR 07-MAY-1998; 98US-0084637P;
 PR 12-MAY-1998; 98US-0085149P;
 PR 13-MAY-1998; 98US-0085323P;
 PR 13-MAY-1998; 98US-0085338P;
 PR 13-MAY-1998; 98US-0085339P;
 PR 15-MAY-1998; 98US-0085579P;
 PR 15-MAY-1998; 98US-0085697P;
 PR 15-MAY-1998; 98US-0085704P;
 PR 22-MAY-1998; 98US-0086414P;
 PR 22-MAY-1998; 98US-0086430P;
 PR 23-MAY-1998; 98US-0087106P;
 PR 04-JUN-1998; 98US-0088026P;
 PR 10-JUN-1998; 98US-0088730P;
 PR 10-JUN-1998; 98US-0088741P;
 PR 10-JUN-1998; 98US-0088810P;
 PR 11-JUN-1998; 98US-0088858P;
 PR 12-JUN-1998; 98WO-US012456;
 PR 17-JUN-1998; 98US-0089532P;
 PR 17-JUN-1998; 98US-0089599P;
 PR 18-JUN-1998; 98US-0089907P;
 PR 19-JUN-1998; 98US-0089947P;
 PR 23-JUN-1998; 98US-0090349P;
 PR 24-JUN-1998; 98US-0090429P;
 PR 24-JUN-1998; 98US-0090445P;
 PR 24-JUN-1998; 98US-0090538P;
 PR 26-JUN-1998; 98US-0090863P;
 PR 01-JUL-1998; 98US-0091360P;
 PR 07-JUL-1998; 98US-0091519P;
 PR 07-JUL-1998; 98US-0091982P;
 PR 14-JUL-1998; 98WO-US014552;
 PR 20-JUL-1998; 98US-0093339P;
 PR 30-JUL-1998; 98US-0094651P;
 PR 04-AUG-1998; 98US-0095285P;
 PR 04-AUG-1998; 98US-0095301P;
 PR 04-AUG-1998; 98US-0095302P;
 PR 04-AUG-1998; 98US-0095325P;
 PR 11-AUG-1998; 98US-0096143P;
 PR 12-AUG-1998; 98US-0096146P;
 PR 12-AUG-1998; 98US-0096329P;
 PR 17-AUG-1998; 98US-0096768P;
 PR 17-AUG-1998; 98US-0096773P;
 PR 17-AUG-1998; 98US-0096791P;
 PR 17-AUG-1998; 98US-0096891P;
 PR 17-AUG-1998; 98US-0096895P;
 PR 18-AUG-1998; 98US-0096960P;
 PR 20-AUG-1998; 98US-0097141P;
 PR 26-AUG-1998; 98US-0097218P;
 PR 26-AUG-1998; 98US-0097951P;
 PR 26-AUG-1998; 98US-0097986P;
 PR 28-AUG-1998; 98WO-US017888;
 PR 31-AUG-1998; 98US-0098525P;
 PR 01-SEP-1998; 98US-0098750P;
 PR 09-SEP-1998; 98US-0099536P;
 PR 09-SEP-1998; 98US-0099598P;
 PR 09-SEP-1998; 98US-0099601P;
 PR 10-SEP-1998; 98US-0099792P;
 PR 10-SEP-1998; 98US-0099803P;
 PR 10-SEP-1998; 98US-0099816P;
 PR 14-SEP-1998; 98WO-US018824;
 PR 14-SEP-1998; 98US-0100262P;
 PR 14-SEP-1998; 98US-0100263P;
 PR 14-SEP-1998; 98WO-US019094;
 PR 14-SEP-1998; 98WO-US019094;
 PR 14-SEP-1998; 98WO-US019177;
 PR 15-SEP-1998; 98US-0100390P;
 PR 16-SEP-1998; 98US-0100634P;
 PR 16-SEP-1998; 98WO-US019330;
 PR 17-SEP-1998; 98US-0100710P;
 PR 17-SEP-1998; 98US-0100858P;

PR 17-SEP-1998; 98WO-US019437;
 PR 23-SEP-1998; 98US-0101474P;
 PR 23-SEP-1998; 98US-0101477P;
 PR 24-SEP-1998; 98US-0101741P;
 PR 07-OCT-1998; 98US-0103315P;
 PR 07-OCT-1998; 98US-0103328P;
 PR 07-OCT-1998; 98WO-US021141;
 PR 13-OCT-1998; 98US-0104080P;
 PR 20-OCT-1998; 98US-0104987P;
 PR 22-OCT-1998; 98US-0105169P;
 PR 28-OCT-1998; 98US-0106030P;
 PR 29-OCT-1998; 98WO-US022951;
 PR 29-OCT-1998; 98WO-US022992;
 PR 30-OCT-1998; 98US-0106464P;
 PR 03-NOV-1998; 98US-0106856P;
 PR 03-NOV-1998; 98US-0106934P;
 PR 10-NOV-1998; 98US-0107783P;
 PR 17-NOV-1998; 98US-0108775P;
 PR 17-NOV-1998; 98US-0108801P;
 PR 17-NOV-1998; 98US-0108802P;
 PR 17-NOV-1998; 98US-0108925P;
 PR 20-NOV-1998; 98US-0109304P;
 PR 20-NOV-1998; 98WO-US024855;
 PR 01-DEC-1998; 98WO-US025108;
 PR 16-DEC-1998; 98US-0112743P;
 PR 16-DEC-1998; 98US-0112850P;
 PR 22-DEC-1998; 98US-0113298P;
 PR 22-DEC-1998; 98US-0113299P;
 PR 22-DEC-1998; 98US-0113300P;
 PR 22-DEC-1998; 98US-0113313P;
 PR 22-DEC-1998; 98US-0113314P;
 PR 22-DEC-1998; 98US-0113315P;
 PR 22-DEC-1998; 98US-0113510P;
 PR 22-DEC-1998; 98US-0113511P;
 PR 23-DEC-1998; 98US-0113605P;
 PR 23-DEC-1998; 98US-0113621P;
 PR 05-JAN-1999; 98WO-US000106;
 PR 12-JAN-1999; 98US-0115549P;
 PR 12-JAN-1999; 98US-0115557P;
 PR 12-JAN-1999; 98US-0115560P;
 PR 12-JAN-1999; 98US-0115562P;
 PR 12-JAN-1999; 98US-0115564P;
 PR 12-JAN-1999; 98US-0115630P;
 PR 12-JAN-1999; 98US-0115705P;
 PR 12-JAN-1999; 98US-0115733P;
 PR 20-JAN-1999; 98US-0116533P;
 PR 01-FEB-1999; 98US-0118210P;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALISLMRLGRLMCTPLGREGEC 60

DB 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALISLMRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFRKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

DB 61 HPGSHKVPFRKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 113

ABO22590

ID ABO22590 standard; protein; 105 AA.

XX ABO22590;

XX 04-SEP-2003 (first entry)

XX Human secreted/transmembrane protein PRO1186.

DE Human; PRO; secreted protein; transmembrane protein; antidiabetic;

KW cytostatic; antirheumatic; antiarthritic; antiulcer; neuroprotective;

KW antiinflammatory; antibacterial; immunosuppressive; gene therapy;
KW diabetes; cancer; rheumatoid arthritis; ulcers;
XX ankyrotrophic lateral sclerosis; inflammatory condition; septic shock.
OS Hemo sapiens.
XX US2003017982-A1.
XX 23-JAN-2003.
XX
XX 15-NOV-2001; 2001US-00990441.
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 05-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096239P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 18-AUG-1998; 98US-0097024P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.

PR	17-SEP-1998;	98US-0100858P.	KW	herpetiform; Crohn's disease; sports injury; arthritis.
PR	17-SEP-1998;	98WO-US019437.	XX	
PR	07-OCT-1998;	98WO-US021141.	OS	Homo sapiens.
PR	01-DEC-1998;	98WO-US025108.	XX	
PR	22-DEC-1998;	98US-0113298P.	XX	US2003049638-A1.
PR	05-JAN-1999;	98WO-US000106.	XX	13-MAR-2003.
PR	08-MAR-1999;	98WO-US005028.	PD	
PR	12-MAR-1999;	98WO-US0123957P.	PD	
PR	02-JUN-1999;	98WO-US012252.	XX	16-NOV-2001; 2001US-00991157.
PR	23-JUN-1999;	98US-0141037P.	XX	
PR	07-JUL-1999;	98US-0143048P.	XX	16-JUN-1997;
PR	26-JUL-1999;	98US-0144758P.	PR	97US-0049787P.
PR	28-JUL-1999;	98US-0145698P.	PR	97US-0062250P.
PR	15-SEP-1999;	98US-0146222P.	PR	97WO-US020069.
PR	17-SEP-1999;	98US-0149396P.	PR	12-NOV-1997;
PR	15-SEP-1999;	98WO-US021090.	PR	97US-0065186P.
PR	08-OCT-1999;	98WO-US021547.	PR	13-NOV-1997;
PR	30-NOV-1999;	98US-0158663P.	PR	97US-0065311P.
PR	01-DEC-1999;	98WO-US028313.	PR	24-NOV-1997;
PR	01-DEC-1999;	98WO-US028301.	PR	97US-0066770P.
PR	16-DEC-1999;	98WO-US028634.	PR	23-FEB-1998;
PR	20-DEC-1999;	98WO-US030095.	PR	98US-0075945P.
PR	05-JAN-2000;	98WO-US030911.	PR	20-MAR-1998;
PR	06-JAN-2000;	2000WO-US000219.	PR	98US-0078910P.
PR	11-FEB-2000;	2000WO-US000376.	PR	28-APR-1998;
PR	18-FEB-2000;	2000WO-US003565.	PR	98US-0083322P.
PR	22-FEB-2000;	2000WO-US004341.	PR	07-MAY-1998;
PR	24-FEB-2000;	2000WO-US004914.	PR	98US-0084600P.
PR	02-MAR-2000;	2000WO-US005004.	PR	28-MAY-1998;
PR	10-MAR-2000;	2000WO-US005841.	PR	98US-0087106P.
PR	15-MAR-2000;	2000WO-US006319.	PR	02-JUN-1998;
PR	20-MAR-2000;	2000WO-US006884.	PR	98US-0087607P.
PR	30-MAR-2000;	2000WO-US007377.	PR	02-JUN-1998;
PR	15-MAY-2000;	2000WO-US008439.	PR	98US-0087759P.
PR	17-MAY-2000;	2000WO-US013358.	PR	03-JUN-1998;
PR	22-MAY-2000;	2000WO-US013705.	PR	98US-0088021P.
PR	30-MAY-2000;	2000WO-US014042.	PR	04-JUN-1998;
PR	02-JUN-2000;	2000WO-US014941.	PR	98US-0088025P.
PR	23-JUN-2000;	2000WO-US015264.	PR	04-JUN-1998;
PR	28-JUL-2000;	2000US-0213637P.	PR	98US-0088028P.
PR	11-AUG-2000;	2000WO-US020710.	PR	04-JUN-1998;
PR	23-AUG-2000;	2000WO-US022031.	PR	98US-0088030P.
PR			PR	04-JUN-1998;
			PR	98US-0088033P.
			PR	05-JUN-1998;
			PR	98US-0088326P.
			PR	05-JUN-1998;
			PR	98US-0088167P.
			PR	05-JUN-1998;
			PR	98US-0088202P.
			PR	05-JUN-1998;
			PR	98US-0088212P.
			PR	09-JUN-1998;
			PR	98US-0088655P.
			PR	10-JUN-1998;
			PR	98US-0088734P.
			PR	10-JUN-1998;
			PR	98US-0088738P.
			PR	10-JUN-1998;
			PR	98US-0088742P.
			PR	10-JUN-1998;
			PR	98US-0088810P.
			PR	10-JUN-1998;
			PR	98US-0088824P.
			PR	10-JUN-1998;
			PR	98US-0088826P.
			PR	11-JUN-1998;
			PR	98US-0088858P.
			PR	11-JUN-1998;
			PR	98US-0088861P.
			PR	11-JUN-1998;
			PR	98US-0088876P.
			PR	12-JUN-1998;
			PR	98US-0089105P.
			PR	16-JUN-1998;
			PR	98US-0089440P.
			PR	16-JUN-1998;
			PR	98US-0089512P.
			PR	16-JUN-1998;
			PR	98US-0089514P.
			PR	17-JUN-1998;
			PR	98US-0089532P.
			PR	17-JUN-1998;
			PR	98US-0089538P.
			PR	17-JUN-1998;
			PR	98US-0089598P.
			PR	17-JUN-1998;
			PR	98US-0089599P.
			PR	17-JUN-1998;
			PR	98US-0089600P.
			PR	17-JUN-1998;
			PR	98US-0089653P.
			PR	18-JUN-1998;
			PR	98US-0089801P.
			PR	18-JUN-1998;
			PR	98US-0089907P.
			PR	18-JUN-1998;
			PR	98US-0089908P.
			PR	19-JUN-1998;
			PR	98US-0089947P.
			PR	19-JUN-1998;
			PR	98US-0089948P.
			PR	19-JUN-1998;
			PR	98US-0089952P.
			PR	22-JUN-1998;
			PR	98US-0090246P.
			PR	22-JUN-1998;
			PR	98US-0090252P.
			PR	22-JUN-1998;
			PR	98US-0090254P.
			PR	23-JUN-1998;
			PR	98US-0090349P.
			PR	23-JUN-1998;
			PR	98US-0090355P.
			PR	24-JUN-1998;
			PR	98US-0090429P.
			PR	24-JUN-1998;
			PR	98US-0090431P.
			PR	24-JUN-1998;
			PR	98US-0090435P.
			PR	24-JUN-1998;
			PR	98US-0090444P.
			PR	24-JUN-1998;
			PR	98US-0090445P.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MEGATRYSIMLLLVTSDCAVITGACERDVQCGAGTCCATSLWRLGLRMCTPLGRGEEC 60
Db 1 MEGATRYSIMLLLVTSDCAVITGACERDVQCGAGTCCATSLWRLGLRMCTPLGRGEEC 60
Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYCSMDLKNINF 105

RESULT 114
ID ADA06660 standard; protein; 105 AA.
XX ADA06660;
AC
XX
XX
DT 29-JAN-2004 (revised)
DT 06-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane PRO polypeptide #115.
XX human; tissue typing; cardiac insufficiency disorder; angiogenesis;
KW wound healing; tumour; immune response; retinal disorder; retinal injury;
KW sight loss; age-related macular degeneration; AMD; kidney disorder;
KW mesangial cell function; Berger disease; nephropathy; dermatitis;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQGAGTCCTCAISIMWGLRMCTPLRGEGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQGAGTCCTCAISIMWGLRMCTPLRGEGEC 60

QY 61 HPGSHKVPFRKRKHHTCPCLNLLCSRFPPDGRYRCSMDLNINF 105
DB 61 HPGSHKVPFRKRKHHTCPCLNLLCSRFPPDGRYRCSMDLNINF 105

RESULT 115
ABJ72140
ID ABJ72140 standard; protein; 105 AA.
XX AC ABJ72140;
XX DT 16-OCT-2003 (first entry)
XX XX Human membrane bound receptor/protein Prol186 amino acid sequence.
DE DE Human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuroptide; hormone; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.
XX OS Homo sapiens.
XX XX

PN US2003065147-A1.
 XX
 PD 03-APR-2003.
 XX
 XX 29-AUG-2002; 2002US-00232224.
 XX
 XX 28-JUL-1999; 99US-0146222P.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021086.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AJ, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-522018/49.
 DR N-PSDB; ABT43964.
 XX
 XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.
 XX
 XX Claim 11; Fig 166; 315pp; English.
 XX
 CC This invention relates to one hundred and twenty two novel nucleic acids
 CC encoding human PRO membrane bound proteins or receptors. Extracellular
 CC proteins play important roles in the formation, differentiation and
 CC maintenance of multicellular organisms. The fate of many individual cells
 CC (for example proliferation, migration or differentiation) is typically
 CC governed by information received from other cells and the immediate
 CC environment. The information is often transmitted by secreted
 CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
 CC factors, differentiation factors, neurotrophins and hormones) which are
 CC received and interpreted by diverse cell receptors or membrane bound
 CC proteins. These membrane bound proteins and receptors may be of use as
 CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
 CC -ligand interactions. The current invention provides the amino acid
 CC sequences of novel human membrane bound receptors and proteins, along
 CC with the cDNA sequences encoding them. The novel proteins of the
 CC invention may have cytostatic activities through the stimulation of
 CC chondrocytes. The nucleic acids of the invention may be useful for the
 CC manufacture of a medicament for diagnosing or treating a tumour in a
 CC mammal. In addition, they may be useful for measuring or detecting the
 CC expression of a tumour associated gene. The present sequence is the amino
 CC acid sequence of a human PRO protein of the invention
 XX
 XX Sequence 105 AA;
 SQ
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. NO. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGWRCTPLRGREGSC 60
 DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGWRCTPLRGREGSC 60
 QY 61 HPGSHKVPFFRKRGHTTCPLNLLCSRFDPDGRYCSMDLKNINF 105
 DB 61 HPGSHKVPFFRKRGHTTCPLNLLCSRFDPDGRYCSMDLKNINF 105
 RESULT 116
 ADA39353
 ID ADA39353 standard; protein; 105 AA.
 XX
 XX ADA39353;
 XX
 XX 20-NOV-2003 (first entry)
 DT
 XX Human secreted/transmembrane protein PRO1186.
 DE

XX PRO; secreted protein; transmembrane protein;
 KW hypertrophy of neonatal heart; angiogenesis;
 KW vascular endothelial growth factor; VEGF-stimulated proliferation;
 KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
 KW c-fos induction; adipocyte cell; chondrocyte differentiation;
 KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
 KW cancer; human; colon cancer; lung cancer; breast cancer;
 KW rod photoreceptor cell.
 XX
 OS Homo sapiens.
 XX
 XX US2003059782-A1.
 PN
 XX 27-MAR-2003.
 PD
 XX 15-NOV-2001; 2001US-00997628.
 XX
 XX 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 03-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 11-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 19-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003068793-A1.

PN 10-APR-2003.

PD 15-APR-2002; 2002US-00123108.

PF 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019033.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 20-NOV-1998; 98WO-US024555.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US010733.

PR 14-MAY-1999; 99WO-US012552.

PR 02-JUN-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030911.

PR 22-DEC-1999; 99WO-US030999.

PR 30-DEC-1999; 99WO-US031070.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US000376.

PR 18-FEB-2000; 2000WO-US000365.

PR 18-FEB-2000; 2000WO-US000431.

PR 24-FEB-2000; 2000WO-US000432.

PR 24-FEB-2000; 2000WO-US000444.

PR 24-FEB-2000; 2000WO-US0004914.

PR 01-MAR-2000; 2000WO-US0005004.

PR 02-MAR-2000; 2000WO-US0005601.

PR 02-MAR-2000; 2000WO-US0005746.

PR 15-MAR-2000; 2000WO-US0005841.

PR 15-MAR-2000; 2000WO-US0006319.

PR 20-MAR-2000; 2000WO-US0006684.

PR 20-MAR-2000; 2000WO-US0007377.

PR 21-MAR-2000; 2000WO-US0007532.
PR 30-MAR-2000; 2000WO-US0008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US023522.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00892636.
PR 19-JUN-2001; 2001US-00896342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-695925/66.

N-PSDB; ADA67090.

Novel secreted and transmembrane PRO polypeptides useful for stimulating
release of tumor necrosis factor-alpha from human blood and detecting the
presence of a tumor in a mammal.

Claim 12; Fig 470; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumor necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 CC SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
 Matches 105; Conservative 0; Mismatches 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMTPLRGEGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMTPLRGEGEC 60
 QY 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRFPPDGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRFPPDGRYRCSMDLKNINF 105

RESULT 118

ID ADB22952
 ID ADB22952 standard; protein; 105 AA.

XX AC ADB22952;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #235.

KW Human; PRO: secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX US2003077711-A1.

PN PD 24-APR-2003.

XX DE 22-APR-2002; 2002US-00127829.

XX FR 22-OCT-1998; 98US-0105169P.

FR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 30-NOV-1999; 99WO-US028313.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-755066/71.
 DR N-PSDB; ADB22951.
 DR New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, as diagnostic markers for the presence of a disease
 PT condition, or as therapeutic targets for treating tumors, diabetes,
 PT obesity or arthritis.
 XX Claim 12; Fig 470; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMTPLRGEGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMTPLRGEGEC 60

QY 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRFPPDGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFPRKXKHTCPCLNLLCSRFPPDGRYRCSMDLKNINF 105

RESULT 119

ADB23725
 ID ADB23725 standard; protein; 105 AA.

XX AC ADB23725;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide SEQ ID NO 470.

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIRA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCALSLMLRGLMCTPLGRGSEC 60
DB 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCALSLMLRGLMCTPLGRGSEC 60
QY 61 HPGSHKVPFFRRKHHTCPCLPNNLLCSRFPDGRYRCSMDLNKINF 105
DB 61 HPGSHKVPFFRRKHHTCPCLPNNLLCSRFPDGRYRCSMDLNKINF 105

RESULT 121
ADB15510

ID ADB15510 standard; protein; 105 AA.

XX ADB15510;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #235.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.

XX Homo sapiens.

XX US2003087352-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127824.

XX 17-AUG-1998; 98US-0096891P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-785943/74.
XX N-PSDB; ADB15509.

XX New PRO nucleic acid, useful for producing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 12; Fig 470; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems. PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCALSLMLRGLMCTPLGRGSEC 60
DB 1 MRGATRVISIMLLVTVSDCAVITGACERDVQCGAGTCCALSLMLRGLMCTPLGRGSEC 60
QY 61 HPGSHKVPFFRRKHHTCPCLPNNLLCSRFPDGRYRCSMDLNKINF 105
DB 61 HPGSHKVPFFRRKHHTCPCLPNNLLCSRFPDGRYRCSMDLNKINF 105

RESULT 122

ADB83656

ID ADB83656 standard; protein; 105 AA.

XX ADB83656;

XX 04-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
antiarthritic; pericyte cell proliferation;
pericyte cell differentiation; chondrocyte cell proliferation;
chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.
Homo sapiens.
US2003073814-A1.
17-APR-2003.
12-AUG-2002; 2002US-00218949.
01-JUN-2001; 2001WO-US017800.
29-JUN-2001; 2001WO-US021066.
09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI; 2003-644806/61.
N-PSDB; ADB83655.
New PRO polypeptides and nucleic acids encoding the polypeptides, useful
in gene therapy, chromosome identification, tissue typing, or as
hybridization probes in chromosome and gene mapping.
Claim 11; Fig 166; 315pp; English.
The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO1478, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1347, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1182, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
PRO1987, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (II) is useful
for generating transgenic animals or knock-out animals which are useful
screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g., arthritis,
sport injuries). This is the amino acid sequence of a human secreted and
transmembrane PRO polypeptide.

SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred No. 2,5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCAGTGCCCAISLWLRGLRMCTPLGREGEEC 60
 DB 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCAGTGCCCAISLWLRGLRMCTPLGREGEEC 60
 QY 61 HPGSHKVPPFRKKKHTCPCLENLCSRPPDGRYRCMDLKNINF 105
 DB 61 HPGSHKVPPFRKKKHTCPCLENLCSRPPDGRYRCMDLKNINF 105
 RESULT 232
 ADB80762
 ID ADB80762 standard; protein; 105 AA.
 XX
 AC ADB80762;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1186.
 XX
 KW Human; secreted and transmembrane protein; PRO; cytotostatic; vulnerary;
 KW antianthratic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 XX Homo sapiens.
 OS
 PN US2003088068-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 13-AUG-2002; 2002US-00219481.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PR (GETH) GENENTECH INC.
 XX
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 WP1: 2003-657982/62.
 DR N-PSDB; ADB80761.
 DR
 DR One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 XX Claim 11; Fig 166; 305pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO326, PRO363, PRO331, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338.
 CC

CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO4383, PRO4343, PRO4344, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (i) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
 CC useful for chromosome and gene mapping or gene therapy. (iii) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 QY 61 HPGSHKVPFFFRKHKHTCTCPLNLLCSRFPPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFFRKHKHTCTCPLNLLCSRFPPDGRYRCSDMLKNINF 105

RESULT 124
 ADB73303
 ID ADB73303 standard; protein; 105 AA.

XX AC ADB73303;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.

XX human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.

XX OS Homo sapiens.

XX PN US2003096968-A1.

XX PD 22-MAY-2003.

XX XX 29-AUG-2002; 2002US-00232223.

XX XX 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 DR WPI: 2003-765525/72.
 DR N-PSDB; ADB73302.

XX New isolated PRO polypeptides useful as molecular weight markers in
 PT protein electrophoresis, useful for tissue typing, and for treating
 XX arthritis and tumors.

XX Claim 11; Fig 166; 308pp; English.

CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (i). PRO982, PRO1160, PRO1197 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO363, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1426, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (i) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
 CC useful for chromosome and gene mapping or gene therapy. (iii) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 QY 61 HPGSHKVPFFFRKHKHTCTCPLNLLCSRFPPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFFRKHKHTCTCPLNLLCSRFPPDGRYRCSDMLKNINF 105

RESULT 125

ADB38762

ID ADB38762 standard; protein; 105 AA.

XX AC ADB38762;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.

XX XX

KW Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW Cell proliferation stimulator; cell differentiation stimulator;
 KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumours; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW Gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003082766-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 30-MAY-2002; 2002US-00158782.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028501.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006319.
 PR 20-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 28-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 18-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019592.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-786921/74.
 DR N-PSDB; ADB38761.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, detecting the presence of tumor in a mammal, or
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle
 PT cells or adipocyte cells.
 XX
 PS Claim 12; Fig 470; 660pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

RESULT, 126	
ADB96379	
ID	ADB96379 standard; protein; 105 AA.
XX	
XX	
ADB96379;	
AC	
XX	
04-DEC-2003	(first entry)
XX	
XX	
Human PRO polypeptide #115.	
DE	
XX	
XX	Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW	insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW	thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW	polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW	cytostatic; cardiant; vulnery; antinflammatory; anorectic.
XX	
XX	
OS	Homo sapiens.
XX	
XX	US2003054403-A1.
PN	
XX	
PD	20-MAR-2003.
XX	
XX	
PF	15-NOV-2001; 2001US-00997559.
XX	
XX	
16-JUN-1997;	97US-0049787P.
PR	
17-OCT-1997;	97US-0062250P.
PR	
05-NOV-1997;	97WO-US020069.
PR	
12-NOV-1997;	97US-0085186P.
PR	
13-NOV-1997;	97US-0085311P.
PR	
24-NOV-1997;	97US-0066770P.
PR	
25-FEB-1998;	98US-0075945P.
PR	
20-MAR-1998;	98US-0078910P.
PR	
28-APR-1998;	98US-0083322P.
PR	
07-MAY-1998;	98US-0084600P.
PR	
28-MAY-1998;	98US-0087106P.
PR	
02-JUN-1998;	98US-0087609P.
PR	
02-JUN-1998;	98US-0087759P.
PR	
03-JUN-1998;	98US-0087827P.
PR	
04-JUN-1998;	98US-0088021P.
PR	
04-JUN-1998;	98US-0088025P.
PR	

```
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 12-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 20-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US045108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000105.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030093.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000375.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSQCAVITGACERDVOCGAGTCCALSLWLRGLRMTCTPLRGEGEC 60
Db 1 MEGATRVSIMLLLVTSQCAVITGACERDVOCGAGTCCALSLWLRGLRMTCTPLRGEGEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105

RESULT 127
AD878385
ID ADB78385 standard; protein; 105 AA.
XX ADB78385;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1186.
KW Human; secreted and transmembrane protein; PRO; cytostatic; vulnary;
KW antarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW Gene therapy.
XX
OS Homo sapiens.
XX
XX US2003092889-A1.
XX
PD 15-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219478.
XX
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH ) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2003-765495/72.
DR N-PSDB; ADB78384.
XX
XX New isolated PRO polypeptide useful for tissue typing, gene therapy, as
PT molecular weight markers in protein electrophoresis, and for treating
PT arthritis and tumors.
XX
```

PS Claim 11; Fig 166; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., CC are useful for detecting the presence of tumour in a mammal which CC involves comparing the level of expression of the above PRO polypeptides CC in a test sample of cells taken from the mammal, and a control sample of CC normal cells of the same cell type, where a higher level of expression of CC the PRO polypeptides in the test sample as compared to the control sample CC is indicative of the presence of tumour in the mammal. The tumour is lung CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or CC liver tumour. (I) is useful as molecular weight markers, for tissue CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is CC useful for chromosome and gene mapping or gene therapy. (II) is useful CC for generating transgenic animals or knock-out animals which are useful CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide CC is useful for treating bone and/or cartilage disorders (e.g., arthritis, CC sport injuries). This is the amino acid sequence of a human secreted and CC transmembrane PRO polypeptide.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

Db 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRKRKHTCTCLNLLCSRPFDGRCYCSMDLNINF 105

Db 61 HPGSHKVPFFRKRKHTCTCLNLLCSRPFDGRCYCSMDLNINF 105

RESULT 128

ADB38210

XX ID ADB38210 standard; protein; 105 AA.

XX AC ADB38210;

XX DT 04-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX PN US2003087347-A1.

XX PD 08-MAY-2003.

XX PF 19-APR-2002; 2002US-00125921.

XX PR 17-AUG-1998; 98US-0096791P.

XX PR 02-JUN-1999; 95WO-US012252.

XX PR 25-AUG-1999; 93US-00380137.

XX PR 30-MAR-2000; 2000WO-US008439.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-786938/74.

XX DR N-PSDB; ADB38209.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 12; Fig 470; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from BMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

Db 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRKRKHTCTCLNLLCSRPFDGRCYCSMDLNINF 105

Db 61 HPGSHKVPFFRKRKHTCTCLNLLCSRPFDGRCYCSMDLNINF 105

RESULT 129
ADB66682
ID ADB66682 standard; protein; 105 AA.
XX AC ADB66682;
XX DT 04-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1186.
XX KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator;
KW lung tumour; colon tumour; breast tumour; rectal tumour;
KW cervical tumour; liver tumour; prostate tumour; gene mapping;
KW Gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003082689-A1.
XX PD 01-MAY-2003.
XX PF 22-APR-2002; 2002US-00127831.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 05-JAN-1999; 98WO-US025108.
PR 08-MAR-1999; 98WO-US000106.
PR 10-MAR-1999; 98WO-US005028.
PR 20-APR-1999; 98WO-US005190.
PR 14-MAY-1999; 98WO-US008615.
PR 02-JUN-1999; 98WO-US010733.
PR 01-SEP-1999; 98WO-US012252.
PR 08-SEP-1999; 98WO-US020111.
PR 13-SEP-1999; 98WO-US020594.
PR 15-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 05-OCT-1999; 98WO-US021547.
PR 29-NOV-1999; 98WO-US023089.
PR 30-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 02-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 16-DEC-1999; 98WO-US028565.
PR 20-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 22-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000356.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808699.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00829366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00897879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WR, Zhang Z;
XX WPI; 2003-786905/74.
DR N-PSDB; ADB66681.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX Claim 12; Fig 470; 637pp; English.
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGLMCTPLGREGEEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRRKHKHTCTCPLNLLCSRFDPDGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKHKHTCTCPLNLLCSRFDPDGRYRCSMDLKNINF 105

RESULT 130

ADB85033
 ID ADB85033 standard; protein; 105 AA.

AC ADB85033;

DT 04-DEC-2003 (first entry)

XX Human PRO polypeptide #83.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour;
 KW cancer; lung; colon; breast; prostate; rectum; liver;
 KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
 KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
 KW arthritis; sports injury; cytostatic; antiarthritic.

OS Homo sapiens.

XX US2003073817-A1.

XX 17-APR-2003.

XX 26-AUG-2002; 2002US-00227883.

XX 01-AUG-2000; 2000US-022425P.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 03-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gezritsen ME, Goddard A, Godowski PU;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI: 2003-730024/59.
 DR N-PSDB; ADB85032.
 XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT e.g. in gene therapy, disease diagnosis, chromosome identification and
 PT tissue typing.

XX Claim 11; Fig 166; 314pp; English.

CC The invention relates to human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
 CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors. They are particularly useful for
 CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
 CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
 CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, for stimulating the proliferation or differentiation of
 CC chondrocyte cells, for stimulating the proliferation of or gene
 CC expression in pericyte cells or for stimulating the proliferation of
 CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
 CC technology, in generating transgenic animals or knock-out animals which
 CC may be used in the development and screening of therapeutically useful
 CC reagents, in gene therapy, in chromosome identification, as chromosome
 CC markers and in generating probes. The PRO polypeptides, or anti-PRO
 CC antibodies, are useful for preparing a medicament for treating a
 CC condition which is responsive to the PRO polypeptides or anti-PRO
 CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
 CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
 CC differentiation of chondrocytes. The PRO polypeptides are useful as
 CC molecular markers for protein electrophoresis, and in tissue typing. This
 CC sequence represents a human PRO polypeptide of the invention.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGLMCTPLGREGEEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCTCAISLWLRGLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRRKHKHTCTCPLNLLCSRFDPDGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKHKHTCTCPLNLLCSRFDPDGRYRCSMDLKNINF 105

RESULT 131

ADB89762
 ID ADB89762 standard; protein; 105 AA.

XX ADB89762;

XX 04-DEC-2003 (first entry)

XX Human PRO polypeptide #235.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; PFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX OS

PN US2003082698-A1.
XX 01-MAY-2003;
XX 22-APR-2002; 2002US-00127850.
XX 20-AUG-1998; 98US-0097218P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 02-MAR-2000; 2000WO-US005841.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-743896/70.
XX N-PSDB; ADB89761.
XX New PRO nucleic acids and encoded polypeptides, useful in the treatment
XX of cancer.
XX Claim 12; Fig 470; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 105 AA;
XX Query Match 100.0%; Score 589; DB 7; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCATSLWRLGLRMCTPLGRGEEC 60
Dd 1 MRGATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCATSLWRLGLRMCTPLGRGEEC 60
QY .61 HPGSHKVPFFRKRKHHHTCPCPLNLLCSRFDPGRYRCSMDLKNINF 105

Db .61 HPGSHKVPFFRKRKHHHTCPCPLNLLCSRFDPGRYRCSMDLKNINF 105
RESULT 132
ADB90494
ID ADB90494 standard; protein; 105 AA.
XX AC ADB90494;
XX DT 04-DEC-2003 (first entry)
XX DE Human PRO polypeptide #235.
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US2003082762-A1.
XX 01-MAY-2003.
XX 15-APR-2002; 2002US-00123235.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 17-SEP-1998; 98WO-US019330.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 05-OCT-1999; 99WO-US021547.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 10-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells and for treating cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0

Qy 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQGAGTCCCAISLWRLGLRMCTPLGRGEBC 60
Db 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQGAGTCCCAISLWRLGLRMCTPLGRGEBC 60
Qy 61 HFGSHKVPFFPKRKHHTCPCLPNLLCSRFPPDGRVRCSDMLKNINF 105
Db 61 HFGSHKVPFFPKRKHHTCPCLPNLLCSRFPPDGRVRCSDMLKNINF 105

RESULT 133
ADB39595
ID ADB39595 standard; protein; 105 AA.
XX AC ADB39595;
XX DT 04-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1186.
XX KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW Cell proliferation stimulator; Cell differentiation stimulator;
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
KW Lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX XX US2003082764-A1.
XX PN

PD 01-MAY-2003. 2002US-00137868. 97WO-US0052230. 98WO-US012456. 98WO-US014552. 98WO-US017888. 98WO-US018824. 98WO-US019093. 98WO-US019094. 98WO-US019177. 98WO-US019094. 98WO-US019330. 98WO-US019437. 98WO-US021141. 98WO-US022931. 98WO-US022932. 98WO-US024855. 98WO-US025108. 98WO-US000106. 98WO-US005028. 98WO-US005190. 98WO-US008615. 98WO-US010733. 98WO-US012252. 98WO-US020111. 98WO-US020944. 98WO-US021090. 98WO-US021547. 98WO-US023089. 98WO-US028214. 98WO-US028313. 98WO-US028409. 98WO-US028631. 98WO-US028634. 98WO-US028851. 98WO-US028564. 98WO-US028565. 98WO-US030095. 98WO-US030911. 98WO-US030999. 98WO-US030720. 98WO-US031243. 98WO-US031274. 98WO-US0300219. 98WO-US030277. 98WO-US030376. 98WO-US033565. 98WO-US004341. 98WO-US004342. 98WO-US004414. 98WO-US004914. 98WO-US005004. 98WO-US005501. 98WO-US005746. 98WO-US005841. 98WO-US006319. 98WO-US006884. 98WO-US007377. 98WO-US007532. 98WO-US008439. 98WO-US013705. 98WO-US014042. 98WO-US014941. 98WO-US020710. 98WO-US020710. 98WO-US020710. 98WO-US022031. 98WO-US023522. 98WO-US023328. 98WO-US030952. 98WO-US030873. 98WO-US032678.

XX 20-DEC-2000; 2000US-00747259. 20-DEC-2000; 2000WO-US034956. 28-FEB-2001; 2001US-00796498. 28-FEB-2001; 2001WO-US008520. 01-MAR-2001; 2001WO-US008566. 09-MAR-2001; 2001US-00802706. 14-MAR-2001; 2001US-00808689. 22-MAR-2001; 2001US-00816744. 05-APR-2001; 2001US-00828366. 10-MAY-2001; 2001US-00854208. 18-MAY-2001; 2001US-00854280. 25-MAY-2001; 2001US-00860216. 25-MAY-2001; 2001US-00866028. 25-MAY-2001; 2001WO-US017092. 01-JUN-2001; 2001US-00872035. 05-JUN-2001; 2001WO-US017800. 05-JUN-2001; 2001US-00874503. 14-JUN-2001; 2001US-00882636. 19-JUN-2001; 2001US-00886342. 20-JUN-2001; 2001WO-US019692. 21-JUN-2001; 2001US-00887879. 22-JUN-2001; 2001WO-US020116. 29-JUN-2001; 2001WO-US021066. 09-JUL-2001; 2001WO-US021735. 18-JUL-2001; 2001US-00908827. 08-AUG-2001; 2001US-00924419. 09-AUG-2001; 2001US-00927796. 16-AUG-2001; 2001US-00931836. 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Garritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-786919/74. N-PSDB; AD39594.

DR New secreted and transmembrane PRO polypeptide useful for detecting the presence of tumor in a mammal, or modulating the uptake of glucose or free fatty acid by skeletal muscle cells or adipocyte cells.

XX Claim 12; Fig 470; 659pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from BMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumor in a mammal. The tumor is lung, colon, breast, prostate, rectal, cervical or liver tumor. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino

CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 QY 61 HPGSHKVPFFRKRKHHTCTCLPCLNLLCSRPDPGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRKRKHHTCTCLPCLNLLCSRPDPGRYRCSMDLKNINF 105
 RESULT 134
 ADB78139
 ID ADB78139 standard; protein; 105 AA.
 XX
 AC ADB78139;
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein Prol186.
 XX
 KW Human; secreted and transmembrane protein; PRO; cytostatic; vulnary;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumor necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
 KW dermal fibroblast cell differentiation inhibitor; tumor; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003092886-A1.
 XX
 XX 15-MAY-2003.
 XX
 XX 09-AUG-2002; 2002US-00216165.
 XX
 XX 25-JUL-2000; 2000US-0220607P.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 XX
 XX 29-JUN-2001; 2001WO-US021066.
 XX
 XX 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CX, Wood WI;
 XX WPI; 2003-765494/72.
 XX
 XX N-PSDB; ADB78139.
 XX
 XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
 PT molecular weight markers in protein electrophoresis, for treating
 PT arthritis, tumor.
 XX
 XX Claim 11; Fig 166; 308pp; English.
 XX
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumor necrosis factor (TNF).
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,

CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4332,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO2229, PRO788, PRO1194, PRO1272, PRO1486, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
 QY 61 HPGSHKVPFFRKRKHHTCTCLPCLNLLCSRPDPGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRKRKHHTCTCLPCLNLLCSRPDPGRYRCSMDLKNINF 105
 RESULT 135
 ADB87205
 ID ADB87205 standard; protein; 105 AA.
 XX
 AC ADB87205;
 XX
 XX 04-DEC-2003 (first entry)
 XX
 XX Human PRO polypeptide #83.
 XX
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour;
 KW cancer; lung; colon; breast; prostate; rectum; liver;
 KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
 KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
 KW arthritis; sports injury; cytostatic; antiarthritic.
 XX
 OS Homo sapiens.
 XX
 XX US2003089067-A1.
 XX
 XX 08-MAY-2003.
 XX
 XX 13-AUG-2002; 2002US-00219479.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 XX
 XX 29-JUN-2001; 2001WO-US021066.
 XX
 XX 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-657981/62.
XX N-PSDB; ADB87204.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 166; 314pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis and in tissue typing. This
XX sequence represents a human PRO polypeptide of the invention.
XX
XX Sequence 105 AA;
XX
XX Query Match 100.0%; Score 589; DB 7; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
XX 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
XX
XX 61 HPGSHKVPFFRRKHHTCPCLPILLCSRFPPDGRVRCSDMLKNINF 105
XX 61 HPGSHKVPFFRRKHHTCPCLPILLCSRFPPDGRVRCSDMLKNINF 105
XX
XX
XX RESULT 136
XX ADB84787
XX ID ADB84787 standard; protein; 105 AA.
XX
XX AC ADB84787;
XX
XX DT 04-DEC-2003 (first entry)
XX
XX DE Human PRO polypeptide #83.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour;
XX cancer; lung; colon; breast; prostate; rectum; liver;
XX tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX arthritis; sports injury; cystostatic; antiarthritic.
XX
XX OS Homo sapiens.
XX
XX XX US2003092890-A1.
XX
XX XX 15-MAY-2003.
XX
XX PD

XX 14-AUG-2002; 2002US-00219536.
XX
XX 28-JUL-1999; 99US-0146222P.
XX 24-FEB-2000; 2000WO-US005004.
XX 02-MAR-2000; 2000WO-US005841.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-777259/73.
XX N-PSDB; ADB84786.
XX
XX New isolated PRO polypeptides, useful for tissue typing, gene therapy, as
XX molecular weight markers in protein electrophoresis, and for treating
XX arthritis and tumours.
XX
XX Claim 11; Fig 166; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis and in tissue typing. This
XX sequence represents a human PRO polypeptide of the invention.
XX
XX Sequence 105 AA;
XX
XX Query Match 100.0%; Score 589; DB 7; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
XX 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
XX
XX 61 HPGSHKVPFFRRKHHTCPCLPILLCSRFPPDGRVRCSDMLKNINF 105
XX 61 HPGSHKVPFFRRKHHTCPCLPILLCSRFPPDGRVRCSDMLKNINF 105
XX
XX
XX RESULT 137
XX ADB47218
XX ID ADB47218 standard; protein; 105 AA.
XX
XX AC ADB47218;
XX
XX XX 04-DEC-2003 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO1186.
XX

XX	Human; secreted and transmembrane protein; PRO;	
KW	Tumour necrosis factor alpha release; TNF-alpha release;	
KW	glucose uptake modulator; FFA uptake modulator;	
KW	cell proliferation stimulator; cell differentiation stimulator;	
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;	
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	
KW	gene therapy; chromosome identification; chromosome marker.	
XX	Homo sapiens.	
XX	US2003062687-A1.	
XX	01-MAY-2003.	
XX	19-APR-2002; 2002US-00125930.	
XX	05-JUN-2000; 2000US-0209832P.	
XX	01-DEC-2000; 2000WO-US032678.	
XX	19-DEC-2001; 2001US-00028072.	
XX	(GETH) GENENTECH INC.	
XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX	WPI; 2003-786904/74.	
DR	N-PSDB; ADB47217.	
XX	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO114 or	
PT	PRO4978, useful in molecular biology, chromosome and gene mapping, in	
PT	generating antisense RNA and DNA, and in gene therapy.	
XX	Claim 12; Fig 470; 627pp; English.	
XX	The invention describes 305 nucleic acids encoding PRO (secreted and	
CC	transmembrane) polypeptides (I). (I) is useful for stimulating the	
CC	release of TNF-alpha from human blood, for modulating the uptake of	
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
CC	stimulating the proliferation or differentiation of chondrocyte cells,	
CC	for stimulating the proliferation of or gene expression in pericyte	
CC	cells, for stimulating the release of proteoglycans from cartilage, for	
CC	stimulating the proliferation of inner ear utricular supporting cells,	
CC	for stimulating the proliferation of T-lymphocyte cells, for stimulating	
CC	the release of a cytokine from PBM cells, for inhibiting the binding of	
CC	A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte	
CC	cells, for stimulating proliferation of endothelial cells, for detecting	
CC	the presence of tumour in a mammal. The tumour is lung, colon, breast,	
CC	prostate, rectal, cervical or liver tumour. The oligonucleotide probes	
CC	are useful for isolating genomic and cDNA nucleotide sequences or	
CC	antisense probes. (I) is also useful as therapeutic agent. PRO is useful	
CC	in assays to identify other proteins or molecules involved in binding	
CC	interaction. A polynucleotide (II) encoding (I) is useful in chromosome	
CC	and gene mapping, in generation of antisense RNA and DNA, in the	
CC	preparation of PRO polypeptide, for generating transgenic animals or	
CC	knockout animals which in turn are useful in the development and	
CC	screening of therapeutically useful reagents, in gene therapy, for	
CC	chromosome identification, as chromosome marker, and for generating	
CC	probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.	
CC	detecting its expression in specific cells, tissues or serum, and for	
CC	affinity purification of PRO from recombinant cell culture or natural	
CC	sources. (I) and (II) are useful for tissue typing. This is the amino	
CC	acid sequence of a novel human secreted and transmembrane PRO	
XX	polypeptide.	
XX	Sequence 105 AA:	
SQ	Query Match 100.0%; Score 589; DB 7; Length 105;	
	Best Local Similarity 100.0%; Pred. No. 2,5e-54;	
	Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	

QY	1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCATSLMLRGLRMCTPLRGEGEC 60	
Db	1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCATSLMLRGLRMCTPLRGEGEC 60	
QY	61 HPGHKVPPFRKRRKHHTCPCLPNLLCSFFDGRVRCSDMLKNINF 105	
Db	61 HPGHKVPPFRKRRKHHTCPCLPNLLCSFFDGRVRCSDMLKNINF 105	
RESULT 138		
ADB83902		
ID	ADB83902 standard; protein; 105 AA.	
XX	AC ADB83902;	
XX	DT 04-DEC-2003 (first entry)	
XX	DE Novel human secreted and transmembrane protein PRO1186.	
XX	human; secreted and transmembrane protein; PRO; cytostatic; vulnery;	
KW	antiarthritic; pericyte cell proliferation;	
KW	pericyte cell differentiation; chondrocyte cell proliferation;	
KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;	
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;	
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;	
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;	
XX	Gene therapy.	
OS	Homo sapiens.	
XX	US2003069397-A1.	
XX	10-APR-2003.	
XX	09-AUG-2002; 2002US-00216159.	
XX	25-JUL-2000; 2000US-0220607P.	
XX	01-JUN-2001; 2001WO-US017800.	
XX	29-JUN-2001; 2001WO-US021086.	
XX	09-APR-2002; 2002US-00119480.	
XX	(GETH) GENENTECH INC..	
XX	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;	
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;	
DR	WPI; 2003-657584/62.	
DR	N-PSDB; ADB83901.	
XX	New isolated polypeptides designated PRO polypeptides including	
PT	polypeptides useful for stimulating the proliferation or differentiation	
PT	of specific cell types, and for diagnosing cancer.	
XX	Claim 11; Fig 166; 314pp; English.	
XX	The invention describes an isolated PRO (secreted and transmembrane)	
CC	polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are	
CC	useful for stimulating the proliferation of or gene expression in	
CC	pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful	
CC	for stimulating the proliferation or differentiation of chondrocyte	
CC	cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide	
CC	are useful for stimulating the release of tumour necrosis factor (TNF)-	
CC	alpha from human blood. PRO363, PRO531, PRO1083, PRO840, PRO1080,	
CC	PRO1478, PRO337, PRO526, PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,	
CC	PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,	
CC	PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,	
CC	PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,	
CC	PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,	
CC	PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,	
CC	PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for	
CC	stimulating the proliferation of normal human dermal fibroblasts cells.	
CC	PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,	

CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.

SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGLRMCTPLGREGSEC 60
 DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGLRMCTPLGREGSEC 60
 QY 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFDPGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 139

ADBE86825
 ID ADB86825 standard; protein; 105 AA.

AC ADB86825;

DT 04-DEC-2003 (first entry)

DE Human PRO polypeptide #235.

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; PFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

OS Homo sapiens.

PN US2003082697-A1.

XX 01-MAY-2003.

PD 22-APR-2002; 2002US-00127849.

PF 20-OCT-1998; 98US-0104987P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-743895/70.
 DR N-PSDB; ADB86824.
 XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis
 PT and treatment of cancer.
 XX Claim 12; Fig 470; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGLRMCTPLGREGSEC 60
 DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGLRMCTPLGREGSEC 60
 QY 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFDPGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 140

ADBE73057
 ID ADB73057 standard; protein; 105 AA.

XX ADB73057;

DT 04-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1186.

XX human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;

KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 FN US2003092887-A1.
 XX
 PD 15-MAY-2003.
 XX
 XX 12-AUG-2002; 2002US-00218956.
 XX
 PF 29-JUN-2001; 2001WO-US021066.
 XX
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR WPI; 2003-777258/73.
 DR N-PSDB; ADB73056.
 XX
 PT Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
 PT molecular weight markers, for treating arthritis, tumor.
 XX
 PS Claim 11; Fig 166; 308pp; English.
 XX

CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC parietal cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO1214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO940, PRO6079, PRO9835 or PRO10095 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.

SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MEGATRVSMILLVTVSDCAVITGACERDVOCAGTCAISLWLRGURMCTPLGREGECC 60
 DB 1 MEGATRVSMILLVTVSDCAVITGACERDVOCAGTCAISLWLRGURMCTPLGREGECC 60
 OY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105
 DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105
 RESULT 141
 ADB77430
 ID ADB77430 standard; protein; 105 AA.
 XX
 AC ADB77430;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 XX Novel human secreted and transmembrane protein PRO1186.
 DE XX
 DE Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 XX US2003082696-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127848.
 XX
 XX 03-NOV-1998; 98US-0106934P.
 PR 26-JUL-1993; 98US-0145688P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI: 2003-755109/71.
 DR N-PSDB; ADB77429.
 XX
 XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
 PT tumor or for tissue typing.
 XX
 PS Claim 12; Fig 470; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCATSLWRLGRLMCTPLGREGEC 60
DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCATSLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFRRKHHTCPCLPNCISFRPDRYRCMDLKNINF 105

DB 61 HPGSHKVPFFRRKHHTCPCLPNCISFRPDRYRCMDLKNINF 105

RESULT 142

ADB34587

ID ADB34587 standard; protein; 105 AA.

XX AC ADB34587;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polypeptide SEQ ID NO 470.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX OS US2003077717-A1.

XX PN 24-APR-2003.

XX PF 24-APR-2002; 2002US-00131818.

XX PR 07-OCT-1998; 98US-0103328P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-755072/71.

XX DR N-PSDB; ADB34586.

XX PT New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

XX PS Claim 12; Fig 470; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCATSLWRLGRLMCTPLGREGEC 60

DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCATSLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFRRKHHTCPCLPNCISFRPDRYRCMDLKNINF 105

DB 61 HPGSHKVPFFRRKHHTCPCLPNCISFRPDRYRCMDLKNINF 105

RESULT 143

ADB35691

ID ADB35691 standard; protein; 105 AA.

XX AC ADB35691;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polypeptide SEQ ID NO 470.

XX DE Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003077719-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131824.
XX
PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755074/71.
DR N-PSDB; ADB35690.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
XX Claim 12; Fig 470; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVOCGAGTCCCAISLWLRGMRMCTPLGREGECC 60
DB 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVOCGAGTCCCAISLWLRGMRMCTPLGREGECC 60
QY 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFDPGRYRCMSMDLKNINF 105
DB 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFDPGRYRCMSMDLKNINF 105
RESULT 144
ADB34035
ID ADB34035 standard; protein; 105 AA.
XX
XX ADB34035;
AC ADB34035;
XX
XX 04-DEC-2003 (first entry)
DT
XX
XX Human PRO polypeptide SEQ ID NO 470.
DE
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003077716-A1.
XX
XX 24-APR-2003.
XX
XX 24-APR-2002; 2002US-00131813.
XX
XX 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755071/71.
DR N-PSDB; ADB34034.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
XX Claim 12; Fig 470; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-34;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCALSLWLRGLRMTPLRGEEEC 60

Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCALSLWLRGLRMTPLRGEEEC 60

QY 61 HPGSHKVPFFRRKHHTCPCLPNLLCSRPDPGRVRCMSDLKNINF 105

Db 61 HPGSHKVPFFRRKHHTCPCLPNLLCSRPDPGRVRCMSDLKNINF 105

RESULT 145

ADB35139

ID ADB35139 standard; protein; 105 AA.

XX AC ADB35139;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polypeptide SEQ ID NO 470.

XX KW

Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003077718-A1.

XX PD 24-APR-2003.

XX PF 24-APR-2002; 2002US-00131823.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 17-SEP-1998; 98WO-US021141.
PR 23-OCT-1998; 98WO-US022991.
PR 23-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 22-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005064.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-0074259.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006656.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001US-00887879.
PR 09-JUL-2001; 2001US-00887879.
PR 18-JUL-2001; 2001US-00887879.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755073/71.
XX N-PSDB; ADB35138.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumors.
XX Claim 12; Fig 470; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;
XX Query Match 100.0%; Score 589; DB 7; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCATSLMRLGRLMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCATSLMRLGRLMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFDPDGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFDPDGRVRCSDMLKNINF 105
RESULT 146
ADB36243
ID ADB36243 standard; protein; 105 AA.
XX AC ADB36243;
XX DT 04-DEC-2003 (first entry)
XX DE Human PRO polypeptide SEQ ID NO 470.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003077720-A1.
XX PD 24-APR-2003.
XX PF 24-APR-2002; 2002US-00131830.
XX PR 09-DEC-1999; 99US-0170262P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755075/71.
XX N-PSDB; ADB36242.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumors.
XX Claim 12; Fig 470; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
SQ Sequence 105 AA;
1 MRGATRVSIMLLLVTSVDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
1 MRGATRVSIMLLLVTSVDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
61 HPGSHKVPFFPKRKHTTCPLNLLCSRFPPDGRYRCSMDLKNINF 105
61 HPGSHKVPFFPKRKHTTCPLNLLCSRFPPDGRYRCSMDLKNINF 105

RESULT 147
ADB46638
ID ADB46638 standard; protein; 105 AA.
AC ADB46638;
DT 04-DEC-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1186.
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS
XX
XX US2003082692-A1.
XX
XX
XX 01-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127842.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786906/74.
DR N-PSDB; ADB46637.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.
PT
PT Claim 12; Fig 470; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from BMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
SQ Sequence 105 AA;
1 MRGATRVSIMLLLVTSVDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
1 MRGATRVSIMLLLVTSVDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGSEC 60
61 HPGSHKVPFFPKRKHTTCPLNLLCSRFPPDGRYRCSMDLKNINF 105
61 HPGSHKVPFFPKRKHTTCPLNLLCSRFPPDGRYRCSMDLKNINF 105
RESULT 148
ADB46638
ID ADC57851 standard; protein; 105 AA.
XX
XX ADC57851;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human PRO polypeptide #115.
XX
XX Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell; insulin deficiency; diabetes mellitus; haemoglobin-associated disorder; thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour; antidiabetic; antianemic; Cystostatic; cardiac; vulnary; antiinflammatory; anorectic.

[illegible]

01-DEC-1998; 98WO-US025108.
22-DEC-1998; 98US-0113296P.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
12-MAR-1999; 98US-0123957P.
02-JUN-1999; 99WO-US012252.
23-JUN-1999; 99US-0141037P.
07-JUL-1999; 99US-0143048P.
20-JUL-1999; 99US-0144758P.
26-JUL-1999; 99US-0145698P.
28-JUL-1999; 99US-0146222P.
17-AUG-1999; 99US-0149396P.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
08-OCT-1999; 99US-0158663P.
30-NOV-1999; 99WO-US028313.
01-DEC-1999; 99WO-US028301.
16-DEC-1999; 99WO-US028634.
20-DEC-1999; 99WO-US030095.
05-JAN-2000; 99WO-US030911.
06-JAN-2000; 2000WO-US000219.
11-FEB-2000; 2000WO-US000376.
18-FEB-2000; 2000WO-US003565.
22-FEB-2000; 2000WO-US004341.
24-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
02-MAR-2000; 2000WO-US005004.
10-MAR-2000; 2000WO-US005841.
15-MAR-2000; 2000WO-US006319.
20-MAR-2000; 2000WO-US006884.
30-MAR-2000; 2000WO-US007377.
15-MAY-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013358.
22-MAY-2000; 2000WO-US013705.
30-MAY-2000; 2000WO-US014042.
02-JUN-2000; 2000WO-US014941.
23-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000US-0213637P.
11-AUG-2000; 2000WO-US020710.
23-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRGATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRSGEC 60
Db 1 MRGATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRSGEC 60
Qy 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYRCMDLKNINF 105
RESULT 149
ADC55215
ID ADC55215 standard; protein; 105 AA.
AC ADC55215;
XX
XX
XX 18-DEC-2003 (first entry)
XX
XX Human PRO polypeptide #115.
XX
XX Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaeamic;
KW cytosolic; cardiac; vulnary; antiinflammatory; anorectic.
XX Homo sapiens.
OS
XX

US2003045463-A1.
06-MAR-2003.
16-NOV-2001; 2001US-00990437.
16-JUN-1997; 97US-0049787P.
17-OCT-1997; 97US-0062250P.
05-NOV-1997; 97WO-US020069.
12-NOV-1997; 97US-0065186P.
13-NOV-1997; 97US-0065311P.
24-NOV-1997; 97US-0066770P.
25-FEB-1998; 98US-0075945P.
28-APR-1998; 98US-0078910P.
07-MAY-1998; 98US-0084600P.
28-MAY-1998; 98US-0087106P.
02-JUN-1998; 98US-0087607P.
02-JUN-1998; 98US-0087609P.
02-JUN-1998; 98US-0087759P.
03-JUN-1998; 98US-0087827P.
04-JUN-1998; 98US-0088021P.
04-JUN-1998; 98US-0088025P.
04-JUN-1998; 98US-0088026P.
04-JUN-1998; 98US-0088028P.
04-JUN-1998; 98US-0088029P.
04-JUN-1998; 98US-0088030P.
04-JUN-1998; 98US-0088033P.
05-JUN-1998; 98US-0088167P.
05-JUN-1998; 98US-0088202P.
05-JUN-1998; 98US-0088212P.
05-JUN-1998; 98US-0088217P.
09-JUN-1998; 98US-0088655P.
10-JUN-1998; 98US-0088734P.
10-JUN-1998; 98US-0088738P.
10-JUN-1998; 98US-0088742P.
10-JUN-1998; 98US-0088810P.
10-JUN-1998; 98US-0088824P.
11-JUN-1998; 98US-0088826P.
11-JUN-1998; 98US-0088858P.
11-JUN-1998; 98US-0088861P.
12-JUN-1998; 98US-0089105P.
16-JUN-1998; 98US-0089440P.
16-JUN-1998; 98US-0089512P.
16-JUN-1998; 98US-0089514P.
17-JUN-1998; 98US-0089532P.
17-JUN-1998; 98US-0089538P.
17-JUN-1998; 98US-0089598P.
17-JUN-1998; 98US-0089599P.
17-JUN-1998; 98US-0089600P.
17-JUN-1998; 98US-0089653P.
18-JUN-1998; 98US-0089801P.
18-JUN-1998; 98US-0089907P.
19-JUN-1998; 98US-0089908P.
19-JUN-1998; 98US-0089947P.
19-JUN-1998; 98US-0089948P.
19-JUN-1998; 98US-0089952P.
22-JUN-1998; 98US-0090246P.
22-JUN-1998; 98US-0090252P.
22-JUN-1998; 98US-0090254P.
23-JUN-1998; 98US-0090349P.
23-JUN-1998; 98US-0090355P.
24-JUN-1998; 98US-0090423P.
24-JUN-1998; 98US-0090431P.
24-JUN-1998; 98US-0090435P.
24-JUN-1998; 98US-0090444P.
24-JUN-1998; 98US-0090445P.
24-JUN-1998; 98US-0090472P.
24-JUN-1998; 98US-0090535P.
24-JUN-1998; 98US-0090540P.
24-JUN-1998; 98US-0090542P.

[illegible]

PR	08-MAR-1999;	99WO-US005028.	PR	16-JUN-1997;	97US-0049787P.
PR	12-MAR-1999;	99US-0123957P.	PR	17-OCT-1997;	97US-0062250P.
PR	02-JUN-1999;	99WO-US012252.	PR	05-NOV-1997;	97WO-US020069.
PR	23-JUN-1999;	99US-0141037P.	PR	12-NOV-1997;	97US-0085186P.
PR	07-JUL-1999;	99US-0143048P.	PR	13-NOV-1997;	97US-0065311P.
PR	20-JUL-1999;	99US-0144758P.	PR	24-NOV-1997;	97US-0066770P.
PR	26-JUL-1999;	99US-0145698P.	PR	25-FEB-1998;	98US-0075945P.
PR	28-JUL-1999;	99US-0146222P.	PR	20-MAR-1998;	98US-0078910P.
PR	17-AUG-1999;	99US-0149396P.	PR	28-APR-1998;	98US-0083322P.
PR	15-SEP-1999;	99WO-US021090.	PR	07-MAY-1998;	98US-0084600P.
PR	15-SEP-1999;	99WO-US0211547.	PR	28-MAY-1998;	98US-0087108P.
PR	08-OCT-1999;	99US-0158663P.	PR	02-JUN-1998;	98US-0087607P.
PR	30-NOV-1999;	99WO-US028313.	PR	02-JUN-1998;	98US-0087609P.
PR	01-DEC-1999;	99WO-US028301.	PR	02-JUN-1998;	98US-0087759P.
PR	01-DEC-1999;	99WO-US028634.	PR	03-JUN-1998;	98US-0087827P.
PR	16-DEC-1999;	99WO-US030095.	PR	04-JUN-1998;	98US-0088021P.
PR	20-DEC-1999;	99WO-US030911.	PR	04-JUN-1998;	98US-0088025P.
PR	05-JAN-2000;	2000WO-US000219.	PR	04-JUN-1998;	98US-0088026P.
PR	11-FEB-2000;	2000WO-US003365.	PR	04-JUN-1998;	98US-0088028P.
PR	18-FEB-2000;	2000WO-US004341.	PR	04-JUN-1998;	98US-0088029P.
PR	22-FEB-2000;	2000WO-US004414.	PR	04-JUN-1998;	98US-0088030P.
PR	24-FEB-2000;	2000WO-US004914.	PR	04-JUN-1998;	98US-0088033P.
PR	24-FEB-2000;	2000WO-US005004.	PR	04-JUN-1998;	98US-00880326P.
PR	02-MAR-2000;	2000WO-US005841.	PR	05-JUN-1998;	98US-0088167P.
PR	10-MAR-2000;	2000WO-US006319.	PR	05-JUN-1998;	98US-0088202P.
PR	15-MAR-2000;	2000WO-US006884.	PR	05-JUN-1998;	98US-0088212P.
PR	20-MAR-2000;	2000WO-US007377.	PR	09-JUN-1998;	98US-0088217P.
PR	30-MAR-2000;	2000WO-US008439.	PR	10-JUN-1998;	98US-0088655P.
PR	15-MAY-2000;	2000WO-US013358.	PR	10-JUN-1998;	98US-0088734P.
PR	17-MAY-2000;	2000WO-US013705.	PR	10-JUN-1998;	98US-0088738P.
PR	22-MAY-2000;	2000WO-US014042.	PR	10-JUN-1998;	98US-0088742P.
PR	30-MAY-2000;	2000WO-US014941.	PR	10-JUN-1998;	98US-0088810P.
PR	02-JUN-2000;	2000WO-US015264.	PR	10-JUN-1998;	98US-0088824P.
PR	23-JUN-2000;	2000US-0213637P.	PR	11-JUN-1998;	98US-0088826P.
Query Match 100.0%; Score 589; DB 7; Length 105;			PR	11-JUN-1998;	98US-0088858P.
Best Local Similarity 100.0%; Pred. No. 2.5e-54;			PR	11-JUN-1998;	98US-0088861P.
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			PR	11-JUN-1998;	98US-0088875P.
			PR	12-JUN-1998;	98US-0088765P.
			PR	12-JUN-1998;	98US-0089105P.
			PR	16-JUN-1998;	98US-0089440P.
			PR	16-JUN-1998;	98US-0089512P.
QY	1 MRGATRSIMLLLVTSVDSCAVITGACERDVCGAGTCCATSLWLRGLRMCTPLGREGECC 60		PR	16-JUN-1998;	98US-0089514P.
DB	1 MRGATRSIMLLLVTSVDSCAVITGACERDVCGAGTCCATSLWLRGLRMCTPLGREGECC 60		PR	17-JUN-1998;	98US-0089532P.
QY	61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYRCSMDLKNINF 105		PR	17-JUN-1998;	98US-0089538P.
DB	61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYRCSMDLKNINF 105		PR	17-JUN-1998;	98US-0089598P.
RESULT 151			PR	17-JUN-1998;	98US-0089599P.
ADC56504			PR	17-JUN-1998;	98US-0089600P.
ID	ADC56504 standard; protein; 105 AA.		PR	17-JUN-1998;	98US-0089653P.
XX	XX		PR	18-JUN-1998;	98US-0089601P.
AC	ADC56504;		PR	18-JUN-1998;	98US-0089907P.
XX	XX		PR	18-JUN-1998;	98US-0089908P.
DT	18-DEC-2003 (first entry)		PR	19-JUN-1998;	98US-0089947P.
XX	XX		PR	19-JUN-1998;	98US-0089948P.
DE	Human PRO polypeptide #15.		PR	19-JUN-1998;	98US-0089952P.
XX	XX		PR	22-JUN-1998;	98US-0090246P.
KW	Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;		PR	22-JUN-1998;	98US-0090252P.
KW	insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;		PR	23-JUN-1998;	98US-0090349P.
KW	thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;		PR	23-JUN-1998;	98US-0090355P.
KW	polycystic kidney disease; renal tumour; antidiabetic; antianaemic;		PR	24-JUN-1998;	98US-0090429P.
KW	cytostatic; cardiant; vulnary; antinflammatory; anorectic.		PR	24-JUN-1998;	98US-0090431P.
OS	Homo sapiens.		PR	24-JUN-1998;	98US-0090435P.
XX	XX		PR	24-JUN-1998;	98US-0090444P.
PN	US2003064375-A1.		PR	24-JUN-1998;	98US-0090445P.
XX	XX		PR	24-JUN-1998;	98US-0090472P.
PD	03-APR-2003.		PR	24-JUN-1998;	98US-0090535P.
XX	XX		PR	24-JUN-1998;	98US-0090540P.
PF	15-NOV-2001; 2001US-00997857.		PR	24-JUN-1998;	98US-0090542P.
XX	XX		PR	25-JUN-1998;	98US-0090557P.
XX	XX		PR	25-JUN-1998;	98US-0090676P.
XX	XX		PR	25-JUN-1998;	98US-0090678P.
XX	XX		PR	25-JUN-1998;	98US-0090690P.
XX	XX		PR	25-JUN-1998;	98US-0090694P.
XX	XX		PR	25-JUN-1998;	98US-0090695P.

```
PR 25-JUN-1998; 98US-0090656P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096772P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US010858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98WO-US013296P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98WO-US012452.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.

PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 05-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004311.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
DB 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
QY 61 HEGSHKVPFRKRKHTCTCLPPLLCSFRPDGRYRCSMDLKNINF 105
DB 61 HEGSHKVPFRKRKHTCTCLPPLLCSFRPDGRYRCSMDLKNINF 105

RESULT 152
ADC07559
ID ADC07559 standard; protein; 105 AA.
XX
AC ADC07559;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1186.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003068647-A1.
XX
PD 10-APR-2003.
XX
PF 15-NOV-2001; 2001US-00997542.
XX
```


PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 17-AUG-1999; 99US-0149396P.
 PR 15-SEP-1999; 99US-0211090.
 PR 15-SEP-1999; 99US-0211547.
 PR 08-OCT-1999; 99US-0158663P.
 PR 30-NOV-1999; 99US-0283113.
 PR 01-DEC-1999; 99US-0283101.
 PR 01-DEC-1999; 99US-028634.
 PR 16-DEC-1999; 99US-030095.
 PR 20-DEC-1999; 99US-030311.
 PR 05-JAN-2000; 2000US-0300219.
 PR 06-JAN-2000; 2000US-0300376.
 PR 11-FEB-2000; 2000US-0303565.
 PR 18-FEB-2000; 2000US-0304341.
 PR 22-FEB-2000; 2000US-0304414.
 PR 24-FEB-2000; 2000US-0304914.
 PR 24-FEB-2000; 2000US-0305004.
 PR 02-MAR-2000; 2000US-0305841.
 PR 10-MAR-2000; 2000US-0306319.
 PR 15-MAR-2000; 2000US-0306884.
 PR 20-MAR-2000; 2000US-0307377.
 PR 30-MAR-2000; 2000US-0308439.
 PR 15-MAY-2000; 2000US-0313358.
 PR 17-MAY-2000; 2000US-0313705.
 PR 22-MAY-2000; 2000US-0314042.
 PR 30-MAY-2000; 2000US-0314941.
 PR 02-JUN-2000; 2000US-0315264.
 PR 23-JUN-2000; 2000US-0313637P.

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGRATRVSIMLLVTVDCAVITGACERDVQCGAGTCCCAISLMLRGLRMCTPLGRGEEC 60

Db 1 MGRATRVSIMLLVTVDCAVITGACERDVQCGAGTCCCAISLMLRGLRMCTPLGRGEEC 60

Qy 61 HPGSHKVPFFRKRRKHTCPCLNLLCSRPDPGRYRCMDLKNINF 105

Db 61 HPGSHKVPFFRKRRKHTCPCLNLLCSRPDPGRYRCMDLKNINF 105

RESULT 153

ADCl1549

ID ADCl1549 standard; protein; 105 AA.

XX AC ADCl1549;

XX DT 18-DEC-2003 (first entry)

XX DE Human secreted/transmembrane protein PRO1186.

XX KW PRO; secreted protein; transmembrane protein;

KW hypertrophy of neonatal heart; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW c-fos induction; adipocyte cell; chondrocyte differentiation;

KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;

KW cancer; human; colon cancer; lung cancer; breast cancer;

KW rod photoreceptor cell.

XX OS Homo sapiens.

XX XX

XX PN US2003069403-A1.

XX FD 10-APR-2003.

XX FF 14-NOV-2001; 2001US-00993748.

XX XX

XX FR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97US-0020069.

PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0065770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088036P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088828P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 19-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.
 PR 22-JUN-1998; 98US-0090254P.
 PR 23-JUN-1998; 98US-0090349P.
 PR 23-JUN-1998; 98US-0090355P.
 PR 24-JUN-1998; 98US-0090429P.
 PR 24-JUN-1998; 98US-0090431P.
 PR 24-JUN-1998; 98US-0090435P.
 PR 24-JUN-1998; 98US-0090444P.
 PR 24-JUN-1998; 98US-0090445P.
 PR 24-JUN-1998; 98US-0090472P.
 PR 24-JUN-1998; 98US-0090535P.
 PR 24-JUN-1998; 98US-0090540P.
 PR 24-JUN-1998; 98US-0090542P.
 PR 24-JUN-1998; 98US-0090557P.
 PR 25-JUN-1998; 98US-0090676P.
 PR 25-JUN-1998; 98US-0090678P.
 PR 25-JUN-1998; 98US-0090690P.
 PR 25-JUN-1998; 98US-0090694P.
 PR 25-JUN-1998; 98US-0090695P.
 PR 25-JUN-1998; 98US-0090696P.
 PR 26-JUN-1998; 98US-0090862P.
 PR 26-JUN-1998; 98US-0090863P.

DR WPI: 2003-657979/62.
DR N-PSDB; ADC36894.
XX
PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful in gene therapy, or for preparing a medicament for treating
PT cancer.
XX
XX
PS Claim 11; Fig 166; 315pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of or gene
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polypeptide of the invention.
XX
XX Sequence 105 AA;
SQ

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
Dd |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dd 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
Qy |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dd 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCMSDLKKNIF 105
Dd |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dd 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCMSDLKKNIF 105
RESULT 155
ADC21885
ID ADC21885 standard; protein; 105 AA.
XX
XX AC ADC21885;
XX
XX 18-DEC-2003 (first entry)
DT
XX
DE Human PRO polypeptide #83.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour;
XX cancer; lung; colon; breast; prostate; rectum; liver;
XX tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
XX US2003096969-A1.
XX
XX 22-MAY-2003.
PD
XX
XX 29-AUG-2002; 2002US-00232225.
PF
XX

PR 02-JUN-2000; 2000WO-US015264.
PR 05-JUN-2000; 2000US-0209832P.
PR 20-JUN-2000; 2000US-0212901P.
PR 22-JUN-2000; 2000US-0213807P.
PR 20-JUL-2000; 2000US-0219256P.
PR 25-JUL-2000; 2000US-0220385P.
PR 25-JUL-2000; 2000US-0220605P.
PR 25-JUL-2000; 2000US-0220607P.
PR 25-JUL-2000; 2000US-0220624P.
PR 25-JUL-2000; 2000US-0220638P.
PR 25-JUL-2000; 2000US-0220664P.
PR 26-JUL-2000; 2000US-0220893P.
PR 01-AUG-2000; 2000US-0222425P.
PR 22-AUG-2000; 2000US-0227133P.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 10-NOV-2000; 2000WO-US030873.
PR 26-NOV-2000; 2000US-0253646P.
PR 01-DEC-2000; 2000WO-US03678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 23-JUN-2001; 2001WO-US021066.
PR 03-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WJ;
XX
XX WPI: 2003-765526/72.
DR N-PSDB; ADC21884.
DR
XX
XX Novel isolated PRO polypeptide useful for tissue typing, as molecular
XX weight markers in protein electrophoresis, for treating arthritis, tumor.
XX
XX Claim 11; Fig 166; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of or gene
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polypeptide of the invention.
XX
XX Sequence 105 AA;
SQ

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
Dd |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dd 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
Qy |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dd 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCMSDLKKNIF 105
Dd |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dd 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCMSDLKKNIF 105
RESULT 155
ADC21885
ID ADC21885 standard; protein; 105 AA.
XX
XX AC ADC21885;
XX
XX 18-DEC-2003 (first entry)
DT
XX
DE Human PRO polypeptide #83.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour;
XX cancer; lung; colon; breast; prostate; rectum; liver;
XX tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
XX US2003096969-A1.
XX
XX 22-MAY-2003.
PD
XX
XX 29-AUG-2002; 2002US-00232225.
PF
XX

Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGSEC 60
 Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 156
 ADC50511
 ID ADC50511 standard; protein; 105 AA.
 AC ADC50511;
 DT 18-DEC-2003 (first entry)
 DE Novel human secreted and transmembrane protein PRO1186.
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage defect;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 OS Homo sapiens.
 XX US2003092106-A1.
 PN 15-MAY-2003.
 PD 24-APR-2002; 2002US-00131822.
 PF 19-AUG-1998; 98US-0097141P;
 PR 02-JUN-1999; 99WO-US012252;
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801171/75.
 DR N-PSDB; ADC50510.
 XX New secreted and transmembrane nucleic acid useful for treating
 PT inflammation, organ failure, atherosclerosis, cardiac injury,
 PT infertility, birth defects, premature aging, acquired immunodeficiency
 PT syndrome or cancer.
 PS Claim 12; Fig 470; 637pp; English.
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX Sequence 105 AA;
 SQ

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGSEC 60
 Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGSEC 60

Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 157
 ADC72058
 ID ADC72058 standard; protein; 105 AA.
 AC ADC72058;
 DT 18-DEC-2003 (first entry)
 DE Novel human secreted and transmembrane protein PRO1186.
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage defect;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 OS Homo sapiens.
 XX US2003092107-A1.
 PN 15-MAY-2003.
 PD 24-APR-2002; 2002US-00131828.
 PF 07-OCT-1998; 98US-0103315P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 16-FEB-2000; 2000WO-US004342.

PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801172/75.
DR N-PSDB; ADC72057.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 12; Fig 470; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 105 AA;
SQ
Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRGATRVSIMLLVTVSDCAVITGACRDVQCGAGTCCALSLWRLGRLMCTPLGRGEEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACRDVQCGAGTCCALSLWRLGRLMCTPLGRGEEC 60
Qy 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105
RESULT 158
ADC60037
ID ADC60037 standard; protein; 105 AA.
XX

AD600037;
18-DEC-2003 (first entry)
Novel human secreted and transmembrane protein PRO1186.
Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.
Homo sapiens.
US2003092105-A1.
15-MAY-2003.
24-APR-2002; 2002US-00131821.
09-DEC-1999; 99US-0170262P.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-801170/75.
N-PSDB; ADC60036.
New secreted and transmembrane nucleic acids and polypeptides, designated
as PRO, useful for treating inflammation, organ failure, atherosclerosis,
cardiac injury, infertility, birth defects, premature aging, AIDS, or
cancer.
Claim 12; Fig 470; 637pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating proliferation of or gene expression in pericyte cells, for
stimulating the proliferation of inner ear utricular supporting cells or
T-lymphocyte cells, for inducing endothelial cell tube formation and for
treating various bone and/or cartilage disorders such as sports injuries
and arthritis. PRO polypeptides which stimulate the release of
proteoglycans from cartilage are useful for treating sports-related joint
problems, articular cartilage defects, osteoarthritis and rheumatoid
arthritis. PRO polypeptides are also useful for treating various
mammalian haemoglobin-associated disorders such as various thalassaemias
and conditions which may benefit from enhanced local immune system cell
infiltration. This sequence represents a human PRO polypeptide of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html.
Sequence 105 AA;
SQ

CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 QY 61 HPGSHKVPFFPRKRKHHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105
 DB 61 HPGSHKVPFFPRKRKHHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105
 RESULT 159
 ADC49916
 ID ADC49916 standard; protein; 105 AA.
 AC ADC49916;
 XX
 XX 18-DEC-2003 (first entry)
 XX Novel human secreted and transmembrane protein PRO1186.
 XX human; secreted and transmembrane protein; PRO; cytostatic; vulnary;
 XX antiarthritic; pericyte cell proliferation;
 XX pericyte cell differentiation; chondrocyte cell proliferation;
 XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
 XX (TNF)-alpha release; dermal fibroblast cell proliferation;
 XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 XX colon tumour; breast tumour; prostate tumour; rectal tumour;
 XX liver tumour; tissue typing; chromosome mapping; gene mapping;
 XX gene therapy.
 XX
 XX Homo sapiens.
 XX US2003088064-A1.
 XX 08-MAY-2003.
 XX 14-AUG-2002; 2002US-00219075.
 XX 25-JUL-2000; 2000US-0220605P.
 XX 01-JUN-2001; 2001WO-US017800.
 XX 29-JUN-2001; 2001WO-US021066.
 XX 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX N-PSDB; ADC49915.
 XX WPI; 2003-801154/75.
 XX New secreted and transmembrane PRO polypeptide useful for preparing a
 XX medicament for treating a condition that is responsive to the PRO
 XX polypeptide or anti-PRO antibody, e.g. cancer.
 XX Claim 11; SEQ ID NO 166; 314pp; English.
 XX The invention describes an isolated PRO (secreted and transmembrane)
 XX polypeptide (1). PRO982, PRO1186, PRO1187 or PRO1329 polypeptide are
 XX useful for stimulating the proliferation of or gene expression in

CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO331, PRO357, PRO725, PRO155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1397, PRO1478, PRO1760, PRO1567,
 CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4332,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.
 XX
 XX Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60
 QY 61 HPGSHKVPFFPRKRKHHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105
 DB 61 HPGSHKVPFFPRKRKHHTCPCLNLLCSRFDPDGRYRCMDLKNINF 105
 RESULT 160
 ADC49115
 ID ADC49115 standard; protein; 105 AA.
 XX
 XX ADC49115;
 XX AC
 XX 18-DEC-2003 (first entry)
 XX Novel human secreted and transmembrane protein PRO1186.
 XX human; secreted and transmembrane protein; PRO; cytostatic; vulnary;
 XX antiarthritic; pericyte cell proliferation;
 XX pericyte cell differentiation; chondrocyte cell proliferation;
 XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
 XX (TNF)-alpha release; dermal fibroblast cell proliferation;
 XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 XX colon tumour; breast tumour; prostate tumour; rectal tumour;
 XX liver tumour; tissue typing; chromosome mapping; gene mapping;
 XX gene therapy.
 XX
 XX Homo sapiens.
 XX OS
 XX US2003088070-A1.
 XX 08-MAY-2003.

XX 28-AUG-2002; 2002US-00230260.
XX
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-801155/75.
XX N-PSDB; ADC49114.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; SEQ ID NO 166; 315pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4332,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO3725, PRO7154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (I) is useful as molecular weight markers, for tissue
XX mapping, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX useful for chromosome and gene mapping or gene therapy. (II) is useful
XX for generating transgenic animals or knock-out animals which are useful
XX screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
XX is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX sport injuries). This is the amino acid sequence of a human secreted and
XX transmembrane PRO polypeptide.
XX
XX Sequence 105 AA;
XX
XX Query Match 100.0%; Score 589; DB 7; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MRGATRVSIMLLVTSDCAVITGACERDVCCAGTCCCAISLWGLRNMCTPLGREGEC 60
XX
XX 1 MRGATRVSIMLLVTSDCAVITGACERDVCCAGTCCCAISLWGLRNMCTPLGREGEC 60
XX
XX 61 HPGSHKVPFRKXKHTCPCPLNLLCSRPDPGRYCSMDLNKINF 105
XX
XX 61 HPGSHKVPFRKXKHTCPCPLNLLCSRPDPGRYCSMDLNKINF 105
XX
XX RESULT 161

ADC49632
ID ADC49632 standard; protein; 105 AA.
XX
XX AC ADC49632;
XX
XX DT 18-DEC-2003 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO1186.
XX
XX human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
XX antiarthritic; pericyte cell proliferation;
XX pericyte cell differentiation; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX (TNF)-alpha release; dermal fibroblast cell proliferation;
XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
XX
XX OS Homo sapiens.
XX
XX PN US2003088071-A1.
XX
XX PD 08-MAY-2003.
XX
XX PF 29-AUG-2002; 2002US-00232231.
XX
XX PR 01-JUN-2001; 2001WO-US017800.
XX
XX PR 29-JUN-2001; 2001WO-US021066.
XX
XX PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-801155/75.
XX
XX DR N-PSDB; ADC49631.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; SEQ ID NO 166; 315pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4332,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO3725, PRO7154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (I) is useful as molecular weight markers, for tissue
XX mapping, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX useful for chromosome and gene mapping or gene therapy. (II) is useful
XX for generating transgenic animals or knock-out animals which are useful
XX screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
XX is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX sport injuries). This is the amino acid sequence of a human secreted and
XX transmembrane PRO polypeptide.
XX
XX Sequence 105 AA;
XX
XX Query Match 100.0%; Score 589; DB 7; Length 105;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-54;
XX Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MRGATRVSIMLLVTSDCAVITGACERDVCCAGTCCCAISLWGLRNMCTPLGREGEC 60
XX
XX 1 MRGATRVSIMLLVTSDCAVITGACERDVCCAGTCCCAISLWGLRNMCTPLGREGEC 60
XX
XX 61 HPGSHKVPFRKXKHTCPCPLNLLCSRPDPGRYCSMDLNKINF 105
XX
XX 61 HPGSHKVPFRKXKHTCPCPLNLLCSRPDPGRYCSMDLNKINF 105
XX
XX RESULT 161

CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLGREGEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLGREGEC 60

QY 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPPDGRYCSMDLKNINF 105

Db 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPPDGRYCSMDLKNINF 105

RESULT 162

ADC47493
 ID ADC47493 standard; protein; 105 AA.

XX AC ADC47493;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.

XX OS Homo sapiens.

XX PN US2003098072-A1.

XX PD 08-MAY-2003.

XX PF 29-AUG-2002; 2002US-00232233.

XX PR 25-JUL-2000; 2000US-0220605P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119460.

XX PA (GETH) GENENTECH INC.

XX PI Baker KF, Desnoyers L, Gerritsen ME, Goddard A, Godowski FJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX DR WPI: 2003-801157/75.

XX DR N-PSDB; ADC47492.

XX PT New PRO polypeptide for use as molecular weight markers for protein

XX PT electrophoresis purposes and for detecting the presence of tumor in a

XX PT mammal.

XX PS Claim 11; Fig 166; 314pp; English.

XX CC The invention describes an isolated PRO (secreted and transmembrane)

XX CC polypeptide (I). PRO982, PRO1186, PRO1187 or PRO1329 polypeptide are

XX CC useful for stimulating the proliferation of or gene expression in

CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO226, PRO363, PRO331, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO572, PRO575, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLGREGEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLGREGEC 60

QY 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPPDGRYCSMDLKNINF 105

Db 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFPPDGRYCSMDLKNINF 105

RESULT 163

ADC53044

ID ADC53044 standard; protein; 105 AA.

XX AC ADC53044;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein Seq ID470.

XX human; PRO; membrane bound protein; membrane bound receptor;

XX cell proliferation; cell migration; cell differentiation;

XX mitogenic factor; survival factor; cytotoxic factor;

XX differentiation factor; neuropeptide; hormone; cell receptor;

XX receptor-ligand interaction; cytostatic; chondrocyte; tumour.

XX OS Homo sapiens.

XX PN US2003087365-A1.

XX PD 08-MAY-2003.

XX PF 23-APR-2002; 2002US-00128689.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US022982.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US024855.
PR 03-JAN-1999; 98WO-US025108.
PR 08-JAN-1999; 98WO-US000106.
PR 10-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US006319.
PR 14-MAY-1999; 98WO-US008615.
PR 02-JUN-1999; 98WO-US010733.
PR 01-SEP-1999; 98WO-US012252.
PR 08-SEP-1999; 98WO-US020111.
PR 13-SEP-1999; 98WO-US020594.
PR 15-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030995.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 15-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US0074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen WE, Goddard A, Godwoski PU, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801150/75.
N-PSDB; ADC53043.

PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.

PS Claim 1; SEQ ID NO 470; 637pp; English.

CC This invention relates to novel nucleic acids encoding human PRO secreted
and transmembrane proteins. Extracellular proteins play important roles
in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells (for example proliferation,
migration or differentiation) is typically governed by information
received from other cells and the immediate environment. The information
is often transmitted by secreted polypeptides (for example mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides and hormones) which are received and interpreted by diverse
cell receptors or membrane bound proteins. These membrane bound proteins
and receptors may be of use as pharmaceutical and diagnostic agents, such
as in the blocking of receptor-ligand interactions. The current invention
provides the amino acid sequences of novel human membrane bound receptors
and proteins, along with the cDNA sequences encoding them. The novel
proteins of the invention may have cytostatic activities through the
stimulation of chondrocytes. The nucleic acids of the invention may be
useful for the manufacture of a medicament for diagnosing or treating a
tumour in a mammal. In addition, they may be useful for measuring or
detecting the expression of a tumour associated gene. The present
sequence is the amino acid sequence of a human PRO protein of the
invention.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCTCAISLWLRGLMCTPLGREGEEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCTCAISLWLRGLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFPRKRKHTTCTCLPCLNLLCSRPDPGRYCSMDLKNINF 105

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 22-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
PA Baker KP, Beresini M, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-801152/75.
DR N-PSDB; ADC60588.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 12; Fig 470; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, kidney and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC treating various cells, for inducing endothelial cell tube formation and for
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSTIMLLLVTVSCAVITGACERDVCGAGTCCCAISILWGLRMCTPLGREGEC 60
DB 1 MEGATRVSTIMLLLVTVSCAVITGACERDVCGAGTCCCAISILWGLRMCTPLGREGEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 166

ADCS1064
ID ADCS1064 standard; protein; 105 AA.

XX ADCS1064;

DT 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;

KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003087361-A1.
XX
XX 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127841.
XX
XX 09-SEP-1998; 98US-0099536P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 18-FEB-2000; 2000WO-US004342.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801146/75.
XX N-PSDB; ADC51063.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 12; Fig 470; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proreglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassaemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polypeptide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGRATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTPLRGEGEEC 60
DB 1 MGRATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTPLRGEGEEC 60
QY 61 HPGSHKVPFFFRKXKHTCPCLPCLNLLCSRFDPGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFFRKXKHTCPCLPCLNLLCSRFDPGRYRCMDLKNINF 105
RESULT 167
ADC65591
ID ADC65591 standard; protein; 105 AA.
XX
XX AC ADC65591;
XX 18-DEC-2003 (first entry)
XX Human PRO polypeptide #235.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX OS
XX US2003087362-A1.
XX
XX 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127844.
XX
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801147/75.
XX N-PSDB; ADC65590.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor.
XX
XX Claim 12; Fig 470; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proreglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassaemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polypeptide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 105 AA;

CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or 1-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX

XX SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGEEC 60
DB 1 MEGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGEEC 60
QY 61 HPGSHKVPFFRRKHHTCTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKHHTCTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 168
ADCS4689
ID ADCS4689 standard; protein; 105 AA.
XX AC ADCS4689;
XX AC ADCS4689;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein Seq ID470.

XX human; PRO; membrane bound protein; membrane bound receptor;
XX cell proliferation; cell migration; cell differentiation;
XX mitogenic factor; survival factor; cytotoxic factor;
XX differentiation factor; neuropeptide; hormone; cell receptor;
XX receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX Homo sapiens.
XX OS
XX US2003087363-A1.
XX PN 08-MAY-2003.
XX PD
XX PF 23-APR-2002; 2002US-00128687.
XX PR 10-SEP-1998; 98US-0099816P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 18-FEB-2000; 2000WO-US004342.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX FA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tunas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801148/75.
XX DR N-PSDB; ADCS4688.
XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 1; SEQ ID NO 470; 637pp; English.
XX CC This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neuropeptides and hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytosolic activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a
XX tumour in a mammal. In addition, they may be useful for measuring or
XX detecting the expression of a tumour associated gene. The present
XX sequence is the amino acid sequence of a human PRO protein of the
XX invention.
XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGEEC 60
DB 1 MEGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGEEC 60
QY 61 HPGSHKVPFFRRKHHTCTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKHHTCTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 169
ADCS3650
ID ADCS3650 standard; protein; 105 AA.
XX AC ADCS3650;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein Seq ID470.
XX human; PRO; membrane bound protein; membrane bound receptor;
XX cell proliferation; cell migration; cell differentiation;
XX mitogenic factor; survival factor; cytotoxic factor;
XX differentiation factor; neuropeptide; hormone; cell receptor;
XX receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX Homo sapiens.
XX OS
XX US2003087364-A1.
XX PN 08-MAY-2003.
XX PD
XX PF 23-APR-2002; 2002US-00128688.
XX PR 09-FEB-1999; 99US-0119341P.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801149/75.
 DR N-PSDB; ADCS3649.
 XX
 PT New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 XX
 PS Claim 1; SEQ ID NO 470; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neurotrophins or hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is the amino acid sequence of a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 QY 61 HPGSHKVPFFRRKHHTCPCLPNLLCSFPPDGRYRCSMDLNKINF 105
 DB 61 HPGSHKVPFFRRKHHTCPCLPNLLCSFPPDGRYRCSMDLNKINF 105
 RESULT 170
 ADCS9173
 ID ADCS9173 standard; protein; 105 AA.
 XX
 AC ADCS9173;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein Seq ID470.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neurotrophin; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
 OS Homo sapiens.
 XX
 PN US2003087359-A1.
 XX

PD 08-MAY-2003.
 XX 22-APR-2002; 2002US-00127834.
 XX 17-SEP-1998; 99US-0100710P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801144/75.
 DR N-PSDB; ADCS9172.
 XX
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 XX
 PS Claim 1; SEQ ID NO 470; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neurotrophins or hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is the amino acid sequence of a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 QY 61 HPGSHKVPFFRRKHHTCPCLPNLLCSFPPDGRYRCSMDLNKINF 105
 DB 61 HPGSHKVPFFRRKHHTCPCLPNLLCSFPPDGRYRCSMDLNKINF 105
 RESULT 171
 ADCS6051
 ID ADCS6051 standard; protein; 105 AA.
 XX
 AC ADCS6051;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein Seq ID470.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW

KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuro peptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

XX US2003087360-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127836.

XX 17-NOV-1998; 98US-0108902P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 18-FEB-2000; 2000WO-US004342.

XX 02-JUN-2000; 2000WO-US015264.

XX 23-AUG-2000; 2000WO-US023522.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801145/75.

XX N-PSDB; ADC56050.

XX New PRO nucleic acid, useful for manufacturing a medicament for

XX diagnosing or treating tumor.

XX Claim 1; SEQ ID NO 470; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted

XX and transmembrane proteins. Extracellular proteins play important roles

XX in the formation, differentiation and maintenance of multicellular

XX organisms. The fate of many individual cells (for example proliferation,

XX migration or differentiation) is typically governed by information

XX received from other cells and the immediate environment. The information

XX is often transmitted by secreted polypeptides (for example mitogenic

XX factors, survival factors, cytotoxic factors, differentiation factors,

XX neuropeptides and hormones) which are received and interpreted by diverse

XX cell receptors or membrane bound proteins. These membrane bound proteins

XX and receptors may be of use as pharmaceutical and diagnostic agents, such

XX as in the blocking of receptor-ligand interactions. The current invention

XX provides the amino acid sequences of novel human membrane bound receptors

XX and proteins, along with the cDNA sequences encoding them. The novel

XX proteins of the invention may have cytostatic activities through the

XX stimulation of chondrocytes. The nucleic acids of the invention may be

XX useful for the manufacture of a medicament for diagnosing or treating a

XX tumour in a mammal. In addition, they may be useful for measuring or

XX detecting the expression of a tumour associated gene. The present

XX sequence is the amino acid sequence of a human PRO protein of the

RESULT 172

ADC58621

ID ADC58621 standard; protein; 105 AA.

XX AC ADC58621;

XX 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein Seq ID470.

XX human; PRO; membrane bound protein; membrane bound receptor;

XX cell proliferation; cell migration; cell differentiation;

XX mitogenic factor; survival factor; cytotoxic factor;

XX differentiation factor; neuro peptide; hormone; cell receptor;

XX receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

XX US2003087346-A1.

XX 08-MAY-2003.

XX 17-APR-2002; 2002US-00124815.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801137/75.

XX N-PSDB; ADC58620.

XX Isolated nucleic acid for use in industrial applications has at least 80

XX percent nucleic acid sequence identity to nucleotide sequence that

XX encodes amino acid sequence selected from amino acid sequence group.

XX Claim 1; SEQ ID NO 470; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted

XX and transmembrane proteins. Extracellular proteins play important roles

XX in the formation, differentiation and maintenance of multicellular

XX organisms. The fate of many individual cells (for example proliferation,

XX migration or differentiation) is typically governed by information

XX received from other cells and the immediate environment. The information

XX is often transmitted by secreted polypeptides (for example mitogenic

XX factors, survival factors, cytotoxic factors, differentiation factors,

XX neuropeptides and hormones) which are received and interpreted by diverse

XX cell receptors or membrane bound proteins. These membrane bound proteins

XX and receptors may be of use as pharmaceutical and diagnostic agents, such

XX as in the blocking of receptor-ligand interactions. The current invention

XX provides the amino acid sequences of novel human membrane bound receptors

XX and proteins, along with the cDNA sequences encoding them. The novel

XX proteins of the invention may have cytostatic activities through the

XX stimulation of chondrocytes. The nucleic acids of the invention may be

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

|||||

QY

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HPGSHKVPFFRRKHHTCPCLPNLLCSFRFPDGRYRCNSDLKNINF 105

|||||

QY

DB 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

|||||

DB

61 HPGSHKVPFFRRKHHTCPCLPNLLCSFRFPDGRYRCNSDLKNINF 105

|||||

DB

Db 1 MRGATRVSIMLLVTNSDCAVITGACERDVQCGAGTCCATSLMLRGLRMCTPLGREGEEC 60
QY 61 HPGSHKVPFFKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 173
ADCI14671
ID ADGI14671 standard; protein; 105 AA.
XX AC ADGI14671;
XX 18-DEC-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1186.
XX human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX OS Homo sapiens.
XX PN US2003082546-A1.
XX PD 01-MAY-2003.
XX PF 28-AUG-2001; 2001US-00941992.
XX 06-NOV-1996; 96US-00743698.
PR 16-JUN-1997; 97US-0049787P.
PR 16-JUN-1997; 97US-00876698.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97US-00965056.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0055186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0086770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095345P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096239P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096894P.

PR	17-AUG-1998;	98US-0096895P.	DB	61	HPGSHKVPFFRKXKHTCPCLPNLLCSRRFPDGRYRCSMDLNINF	105
PR	17-AUG-1998;	98US-0096897P.	DB			
PR	18-AUG-1998;	98US-0096949P.	DB			
PR	18-AUG-1998;	98US-0096950P.	DB			
PR	18-AUG-1998;	98US-0096950P.	DB			
PR	18-AUG-1998;	98US-0096950P.	DB			
PR	18-AUG-1998;	98US-0097022P.	DB			
PR	18-AUG-1998;	98US-0097141P.	DB			
PR	20-AUG-1998;	98US-0097218P.	DB			
PR	20-AUG-1998;	98US-0097661P.	DB			
PR	26-AUG-1998;	98US-0097952P.	DB			
PR	26-AUG-1998;	98US-0097955P.	DB			
PR	26-AUG-1998;	98US-0097971P.	DB			
PR	26-AUG-1998;	98US-0097974P.	DB			
PR	26-AUG-1998;	98US-0097978P.	DB			
PR	26-AUG-1998;	98US-0097979P.	DB			
PR	26-AUG-1998;	98US-0097986P.	DB			
PR	26-AUG-1998;	98US-0098014P.	DB			
PR	31-AUG-1998;	98US-0098525P.	DB			
PR	16-SEP-1998;	98US-0100634P.	DB			
PR	16-SEP-1998;	98WO-US019330.	DB			
PR	17-SEP-1998;	98WO-US019437.	DB			
PR	07-OCT-1998;	98WO-US021141.	DB			
PR	06-NOV-1998;	98US-00187368.	DB			
PR	01-DEC-1998;	98WO-US025108.	DB			
PR	07-DEC-1998;	98US-00202054.	DB			
PR	22-DEC-1998;	98US-00218517.	DB			
PR	22-DEC-1998;	98US-0113296P.	DB			
PR	05-JAN-1999;	99WO-US000106.	DB			
PR	20-FEB-1999;	99WO-US030911.	DB			
PR	03-MAR-1999;	99US-00254311.	DB			
PR	08-MAR-1999;	99WO-US005028.	DB			
PR	09-MAR-1999;	99US-00254460.	DB			
PR	12-MAR-1999;	99US-00267213.	DB			
PR	12-MAR-1999;	99US-0123957P.	DB			
PR	12-APR-1999;	99US-00284291.	DB			
PR	02-JUN-1999;	99WO-US012252.	DB			
PR	23-JUN-1999;	99US-0141037P.	DB			
PR	07-JUL-1999;	99US-0143048P.	DB			
PR	20-JUL-1999;	99US-0144758P.	DB			
PR	26-JUL-1999;	99US-0145698P.	DB			
PR	28-JUL-1999;	99US-0146222P.	DB			
PR	17-AUG-1999;	99US-0149396P.	DB			
PR	25-AUG-1999;	99US-00380137.	DB			
PR	25-AUG-1999;	99US-00380138.	DB			
PR	25-AUG-1999;	99US-00380139.	DB			
PR	15-SEP-1999;	99WO-US021090.	DB			
PR	15-SEP-1999;	99WO-US021547.	DB			
PR	08-OCT-1999;	99US-0158663P.	DB			
PR	18-OCT-1999;	99US-00403296.	DB			
PR	12-NOV-1999;	99US-00423844.	DB			
PR	30-NOV-1999;	99WO-US028313.	DB			
PR	01-DEC-1999;	99WO-US028301.	DB			
PR	01-DEC-1999;	99WO-US028634.	DB			
PR	16-DEC-1999;	99WO-US030095.	DB			
PR	05-JAN-2000;	2000WO-US000219.	DB			
PR	06-JAN-2000;	2000WO-US000376.	DB			
PR	11-FEB-2000;	2000WO-US003565.	DB			
PR	18-FEB-2000;	2000WO-US004341.	DB			
PR	22-FEB-2000;	2000WO-US004414.	DB			
QY	1 MEGATRVSMILLVTSVCADITGACERDVCGAGTCCCAISLWRLGLMCTPLGREGGEC	60	QY	1	HPGSHKVPFFRKXKHTCPCLPNLLCSRRFPDGRYRCSMDLNINF	105
DB	1 MEGATRVSMILLVTSVCADITGACERDVCGAGTCCCAISLWRLGLMCTPLGREGGEC	60	DB			
QY	61 HPGSHKVPFFRKXKHTCPCLPNLLCSRRFPDGRYRCSMDLNINF	105	QY			

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

61 HPGSHKVPFFRKXKHTCPCLPNLLCSRRFPDGRYRCSMDLNINF 105

DB RESULT 174
 ADC47238
 ID ADC47238 standard; protein; 105 AA.
 XX
 AC ADC47238;
 XX
 DI 18-DEC-2003 (first entry)
 DE
 DE Novel human secreted and transmembrane protein PRO1186.
 XX
 KW Human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003105288-A1.
 XX
 PD 05-JUN-2003.
 XX
 XX 13-AUG-2002; 2002US-00219070.
 PF
 XX 25-JUL-2000; 2000US-0220666P.
 PR
 PR 01-JUN-2001; 2001WO-US017800.
 PR
 PR 29-JUN-2001; 2001WO-US021066.
 PR
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 PI WPI; 2003-801246/75.
 DR
 DR N-PSDB; ADC47237.
 XX
 XX New isolated nucleic acid encoding a secreted and transmembrane
 PT polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,
 PT as a hybridization probe, and in gene therapy.
 XX
 XX Claim 11; Fig 166; 308pp; English.
 PS
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO382, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1285, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1266, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5725, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO5004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.
 XX
 XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSMILLVTSVCVITGACERDVCGAGTCCALSLWLRGLRMCTPLGREGEC 60
 Db |||||||
 QY 61 HPGSHKVPFPRKRKHTCPCLNLLCSRFDPGRVRCMSMDLKNINF 105
 Db |||||||
 QY 61 HPGSHKVPFPRKRKHTCPCLNLLCSRFDPGRVRCMSMDLKNINF 105

RESULT 175

ADD08203
 ID ADD08203 standard; protein; 105 AA.

AC
 AC ADD08203;
 DT 01-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted protein; transmembrane protein; PRO;
 KW neonatal heart hypertrophy; angiogenesis;
 KW vascular endothelial growth factor; VEGF-stimulated proliferation;
 KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
 KW rod photoreceptor cell; c-fos induction; adipocyte;
 KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
 KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
 KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
 KW thalassemia; endothelial cell growth; cancer; cystic renal dysplasia;
 KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
 KW Parkinson's disease; Alzheimer's disease; gene therapy;
 KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
 KW antidiabetic; antinaemic; cyostatic; nootropic; neuroprotective;
 KW antiparkinsonian.

OS Homo sapiens.

XX US2003068623-A1.

XX 10-APR-2003.

XX 14-NOV-2001; 2001US-00993469.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066770P.

XX 25-FEB-1998; 98US-0075945P.

XX 20-MAR-1998; 98US-0078910P.

XX 28-APR-1998; 98US-0083322P.

XX 07-MAY-1998; 98US-0084600P.

XX 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088214P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 19-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.
 PR 22-JUN-1998; 98US-0090254P.
 PR 23-JUN-1998; 98US-0090349P.
 PR 23-JUN-1998; 98US-0090355P.
 PR 24-JUN-1998; 98US-0090429P.
 PR 24-JUN-1998; 98US-0090431P.
 PR 24-JUN-1998; 98US-0090435P.
 PR 24-JUN-1998; 98US-0090444P.
 PR 24-JUN-1998; 98US-0090445P.
 PR 24-JUN-1998; 98US-0090472P.
 PR 24-JUN-1998; 98US-0090535P.
 PR 24-JUN-1998; 98US-0090540P.
 PR 24-JUN-1998; 98US-0090542P.
 PR 24-JUN-1998; 98US-0090557P.
 PR 25-JUN-1998; 98US-0090676P.
 PR 25-JUN-1998; 98US-0090678P.
 PR 25-JUN-1998; 98US-0090690P.
 PR 25-JUN-1998; 98US-0090694P.
 PR 25-JUN-1998; 98US-0090695P.
 PR 26-JUN-1998; 98US-0090696P.
 PR 26-JUN-1998; 98US-0090862P.
 PR 26-JUN-1998; 98US-0090863P.
 PR 01-JUL-1998; 98US-0091360P.
 PR 01-JUL-1998; 98US-0091544P.
 PR 02-JUL-1998; 98US-0091478P.
 PR 02-JUL-1998; 98US-0091519P.
 PR 02-JUL-1998; 98US-0091626P.
 PR 02-JUL-1998; 98US-0091628P.
 PR 02-JUL-1998; 98US-0091633P.
 PR 02-JUL-1998; 98US-0091646P.


```
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095923P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097651P.
PR 26-AUG-1998; 98US-0097924P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0101943P.
PR 07-OCT-1998; 98US-0102114P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-0140372P.
PR 07-JUL-1999; 98US-0140372P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0158663P.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-028313P.
PR 01-DEC-1999; 98US-028313P.
PR 16-DEC-1999; 98US-028634P.
PR 20-DEC-1999; 98US-028634P.
PR 20-DEC-1999; 98US-030035P.
PR 20-DEC-1999; 98US-030035P.
PR 05-JAN-1999; 98US-030035P.
PR 05-JAN-1999; 98US-030035P.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMILLVTVDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
Db 1 MEGATRVSIMILLVTVDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSDMLKNINF 105
RESULT 176
ADD03295
ID ADD03295 standard; protein; 105 AA.
XX
AC ADD03295;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1186.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage defect;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW Gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092104-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131817.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
```


CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred No. 2.5e-54; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0;

Qy 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTPLGREGEC 60
Db 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTPLGREGEC 60
Qy 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDGRVCSMDLKNINF 105
Db 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDGRVCSMDLKNINF 105

RESULT 178
ADC82028
ID ADC82028 standard; protein; 105 AA.
XX
AC ADC82028;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #115.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003083461-A1.
XX
PD 01-MAY-2003.
XX
PF 14-NOV-2001; 2001US-00992521.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087753P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.

RESULT 177
ADC90287
ID ADC90287 standard; protein; 105 AA.

XX
AC ADC90287;

XX
DT 01-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO1186.

XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostatic tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX
OS Homo sapiens.

XX
PN US2003087348-A1.

XX
PD 08-MAY-2003.

XX
PF 19-APR-2002; 2002US-00125923.

XX
PR 05-JUN-2000; 2000US-0209832P.

XX
PR 01-DEC-2000; 2000WO-US032678.

XX
PR 19-DEC-2001; 2001US-00028072.

FA (GETH) GENENTECH INC.

XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX
DR WPT; 2003-786939/74.

XX
DR N-PSDB; ABC90286.

XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.

XX
PS Claim 12; SEQ ID NO 470; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from PMC cells, for inhibiting the binding of
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural

us-10-027-603-2.rag

Mon Aug 30 07:06:19 2004

PR 10-JUN-1998;	98US-0088742P.	PR 12-AUG-1998;	98US-0096329P.
PR 10-JUN-1998;	98US-0088810P.	PR 17-AUG-1998;	98US-0096757P.
PR 10-JUN-1998;	98US-0088824P.	PR 17-AUG-1998;	98US-0096766P.
PR 11-JUN-1998;	98US-0088826P.	PR 17-AUG-1998;	98US-0096768P.
PR 11-JUN-1998;	98US-0088858P.	PR 17-AUG-1998;	98US-0096773P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-AUG-1998;	98US-0096791P.
PR 11-JUN-1998;	98US-0088876P.	PR 17-AUG-1998;	98US-0096867P.
PR 12-JUN-1998;	98US-0088910P.	PR 17-AUG-1998;	98US-0096891P.
PR 16-JUN-1998;	98US-0089440P.	PR 17-AUG-1998;	98US-0096894P.
PR 16-JUN-1998;	98US-0089512P.	PR 17-AUG-1998;	98US-0096895P.
PR 16-JUN-1998;	98US-0089514P.	PR 18-AUG-1998;	98US-0096897P.
PR 17-JUN-1998;	98US-0089532P.	PR 18-AUG-1998;	98US-0096949P.
PR 17-JUN-1998;	98US-0089538P.	PR 18-AUG-1998;	98US-0096950P.
PR 17-JUN-1998;	98US-0089559P.	PR 18-AUG-1998;	98US-0096959P.
PR 17-JUN-1998;	98US-0089598P.	PR 18-AUG-1998;	98US-0096960P.
PR 17-JUN-1998;	98US-0089600P.	PR 18-AUG-1998;	98US-0097022P.
PR 17-JUN-1998;	98US-0089653P.	PR 19-AUG-1998;	98US-0097141P.
PR 18-JUN-1998;	98US-0089801P.	PR 20-AUG-1998;	98US-0097218P.
PR 18-JUN-1998;	98US-0089907P.	PR 24-AUG-1998;	98US-0097661P.
PR 18-JUN-1998;	98US-0089908P.	PR 26-AUG-1998;	98US-0097952P.
PR 19-JUN-1998;	98US-0089947P.	PR 26-AUG-1998;	98US-0097954P.
PR 19-JUN-1998;	98US-0089948P.	PR 26-AUG-1998;	98US-0097955P.
PR 19-JUN-1998;	98US-0089952P.	PR 26-AUG-1998;	98US-0097971P.
PR 22-JUN-1998;	98US-0090246P.	PR 26-AUG-1998;	98US-0097974P.
PR 22-JUN-1998;	98US-0090252P.	PR 26-AUG-1998;	98US-0097978P.
PR 23-JUN-1998;	98US-0090349P.	PR 26-AUG-1998;	98US-0097979P.
PR 23-JUN-1998;	98US-0090355P.	PR 26-AUG-1998;	98US-0097986P.
PR 24-JUN-1998;	98US-0090429P.	PR 26-AUG-1998;	98US-0098014P.
PR 24-JUN-1998;	98US-0090431P.	PR 31-AUG-1998;	98US-0098525P.
PR 24-JUN-1998;	98US-0090435P.	PR 31-AUG-1998;	98US-0098525P.
PR 24-JUN-1998;	98US-0090444P.	PR 16-SEP-1998;	98US-0100634P.
PR 24-JUN-1998;	98US-0090445P.	PR 17-SEP-1998;	98US-0100858P.
PR 24-JUN-1998;	98US-0090472P.	PR 17-SEP-1998;	98US-0100859P.
PR 24-JUN-1998;	98US-0090535P.	PR 07-OCT-1998;	98US-0100859P.
PR 24-JUN-1998;	98US-0090540P.	PR 01-DEC-1998;	98US-0100859P.
PR 24-JUN-1998;	98US-0090542P.	PR 22-DEC-1998;	98US-0113296P.
PR 24-JUN-1998;	98US-0090557P.	PR 05-JAN-1999;	98US-0113296P.
PR 25-JUN-1998;	98US-0090676P.	PR 08-MAR-1999;	98US-0113296P.
PR 25-JUN-1998;	98US-0090678P.	PR 12-MAR-1999;	98US-0113296P.
PR 25-JUN-1998;	98US-0090690P.	PR 23-JUN-1999;	98US-0141037P.
PR 25-JUN-1998;	98US-0090694P.	PR 07-JUL-1999;	98US-0143048P.
PR 25-JUN-1998;	98US-0090695P.	PR 20-JUL-1999;	98US-0144758P.
PR 25-JUN-1998;	98US-0090696P.	PR 26-JUL-1999;	98US-0145698P.
PR 26-JUN-1998;	98US-0090862P.	PR 28-JUL-1999;	98US-0146222P.
PR 26-JUN-1998;	98US-0090863P.	PR 17-AUG-1999;	98US-0149396P.
PR 26-JUN-1998;	98US-0091360P.	PR 15-SEP-1999;	98US-0149396P.
PR 01-JUL-1998;	98US-0091544P.	PR 15-SEP-1999;	98US-0154754P.
PR 02-JUL-1998;	98US-0091478P.	PR 08-OCT-1999;	98US-0158663P.
PR 02-JUL-1998;	98US-0091519P.	PR 20-NOV-1999;	98US-0158663P.
PR 02-JUL-1998;	98US-0091626P.	PR 01-DEC-1999;	98US-0202831P.
PR 02-JUL-1998;	98US-0091628P.	PR 01-DEC-1999;	98US-0202831P.
PR 02-JUL-1998;	98US-0091633P.	PR 16-DEC-1999;	98US-0202831P.
PR 02-JUL-1998;	98US-0091646P.	PR 16-DEC-1999;	98US-0202831P.
PR 02-JUL-1998;	98US-0091673P.	PR 20-DEC-1999;	98US-0202831P.
PR 07-JUL-1998;	98US-0091978P.	PR 05-JAN-2000;	98US-0202831P.
PR 07-JUL-1998;	98US-0091982P.	PR 11-FEB-2000;	98US-0202831P.
PR 09-JUL-1998;	98US-0092182P.	PR 18-FEB-2000;	98US-0202831P.
PR 10-JUL-1998;	98US-0092472P.	PR 22-FEB-2000;	98US-0202831P.
PR 20-JUL-1998;	98US-0093339P.	PR 24-FEB-2000;	98US-0202831P.
PR 30-JUL-1998;	98US-0094651P.	PR 24-FEB-2000;	98US-0202831P.
PR 04-AUG-1998;	98US-0095282P.	PR 02-MAR-2000;	98US-0202831P.
PR 04-AUG-1998;	98US-0095285P.	PR 10-MAR-2000;	98US-0202831P.
PR 04-AUG-1998;	98US-0095301P.	PR 15-MAR-2000;	98US-0202831P.
PR 04-AUG-1998;	98US-0095302P.	PR 20-MAR-2000;	98US-0202831P.
PR 04-AUG-1998;	98US-0095318P.	PR 30-MAR-2000;	98US-0202831P.
PR 04-AUG-1998;	98US-0095321P.	PR 15-MAY-2000;	98US-0202831P.
PR 04-AUG-1998;	98US-0095325P.	PR 17-MAY-2000;	98US-0202831P.
PR 10-AUG-1998;	98US-0095916P.	PR 22-MAY-2000;	98US-0202831P.
PR 10-AUG-1998;	98US-0095929P.	PR 30-MAY-2000;	98US-0202831P.
PR 10-AUG-1998;	98US-0096012P.	PR 02-JUN-2000;	98US-0202831P.
PR 11-AUG-1998;	98US-0096143P.	PR 23-JUN-2000;	98US-0202831P.
PR 11-AUG-1998;	98US-0096146P.	PR 28-JUN-2000;	98US-0202831P.

```

PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match      100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLRGEGSEC 60
Db 1 MGRATRVIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLRGEGSEC 60
QY 61 HPGSHKVPFFRKXKHTCPCPLNLLCSRFPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCPLNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 179
ID ADC69706 standard; protein; 105 AA.
AC ADC69706;
XX
DT 01-JAN-2004 (first entry)
DE Human PRO polypeptide #235.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; adipocyte cell; pericyte cell;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194770-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152375.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WP; 2003-844453/78.
DR N-PSDB; ADC69705.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 470; 637pp; English.
XX
SS The invention relates to isolated human PRO polypeptides (secreted and
SS transmembrane polypeptides) and the polynucleotides encoding them. The
SS invention also relates to an antibody which specifically binds to a PRO
SS polypeptide, a method for stimulating the release of tumour necrosis
SS factor-alpha (TNF-alpha) from human blood, a method for stimulating the
SS proliferation or differentiation of chondrocyte cells and a method for
SS detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

```

```

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 105 AA;

```

```

Query Match      100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLRGEGSEC 60
Db 1 MGRATRVIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLMCTPLRGEGSEC 60
QY 61 HPGSHKVPFFRKXKHTCPCPLNLLCSRFPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCPLNLLCSRFPDGRYRCSMDLKNINF 105

```

```

RESULT 180
ADC48595
ID ADC48595 standard; protein; 105 AA.
XX
AC ADC48595;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #235.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194773-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152391.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 30-MAY-2000; 2000WO-US014941.

```

PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 PA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-844455/78.
 DR N-PSDB; ADC48534.
 XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
 PT for detecting a tumor, stimulating the release of tumor necrosis factor
 PT alpha and stimulating the proliferation of endothelial cells.
 XX Claim 12; Fig 470; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX Sequence 105 AA;
 SQ Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MFGATRVSTMLLVVSDCAVITGACERDVCGAGTCCALSLWGLRMCTPLGRGEEC 60
 Db 1 MFGATRVSTMLLVVSDCAVITGACERDVCGAGTCCALSLWGLRMCTPLGRGEEC 60
 QY 61 HFGSHKVPFRKRKHTTCPLNLCSPFDPGRYRCSMDLNKINF 105
 Db 61 HFGSHKVPFRKRKHTTCPLNLCSPFDPGRYRCSMDLNKINF 105
 RESULT 181
 ADD10124
 ID ADD10124 standard; protein; 105 AA.
 XX
 AC ADD10124;
 XX

DT 01-JAN-2004 (first entry)
 XX Human PRO polypeptide #235.
 DE
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS
 XX US2003194776-A1.
 PN
 XX 16-OCT-2003.
 PD
 XX 29-MAY-2002; 2002US-00157785.
 PF
 XX 05-JUN-2000; 2000US-0209832P.
 XX 01-DEC-2000; 2000WO-US032678.
 PR
 XX 19-DEC-2001; 2001US-00028072.
 PR
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-852596/79.
 DR N-PSDB; ADD10123.
 DR
 XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
 PT for detecting a tumor, stimulating the release of proteoglycans from
 PT cartilage and inhibiting the differentiation of adipocyte cells.
 XX Claim 12; Fig 470; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX Sequence 105 AA;
 SQ Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MFGATRVSTMLLVVSDCAVITGACERDVCGAGTCCALSLWGLRMCTPLGRGEEC 60
 Db 1 MFGATRVSTMLLVVSDCAVITGACERDVCGAGTCCALSLWGLRMCTPLGRGEEC 60
 QY 61 HFGSHKVPFRKRKHTTCPLNLCSPFDPGRYRCSMDLNKINF 105
 Db 61 HFGSHKVPFRKRKHTTCPLNLCSPFDPGRYRCSMDLNKINF 105
 RESULT 181
 ADD10124
 ID ADD10124 standard; protein; 105 AA.
 XX
 AC ADD10124;
 XX

CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGRATRVSIMLLLVTSQCAVITGACERDVCGAGTCCCAISLWLRGLRMCPTPLGRGEDEC 60
Db 1 MGRATRVSIMLLLVTSQCAVITGACERDVCGAGTCCCAISLWLRGLRMCPTPLGRGEDEC 60
QY 61 HPGSHKVPFFRRKHHTTCPLPNCILCSFPPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRRKHHTTCPLPNCILCSFPPDGRYRCSMDLKNINF 105

RESULT 182

ADD07670

ID ADD07670 standard; protein; 105 AA.

AC ADD07670;

XX DT 01-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.

XX KW Human; secreted protein; transmembrane protein; PRO;

XX KW neonatal heart hypertrophy; angiogenesis; PRO;

XX KW vascular endothelial growth factor; VEGF-stimulated proliferation;

XX KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

XX KW rod photoreceptor cell; c-fos induction; adipocyte;

XX KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;

XX KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;

XX KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

XX KW thalassemia; endothelial cell growth; cancer; cystic renal dysplasia;

XX KW polycystic kidney disease; renal tumour; cancer; neurodegenerative disorder;

XX KW Parkinson's disease; Alzheimer's disease; gene therapy;

XX KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;

XX KW antidiabetic; antianaemic; cytostatic; neurotropic; neuroprotective;

XX KW antiparkinsonian.

XX OS Homo sapiens.

XX PN US2002193299-A1.

XX XX 19-DEC-2002.

XX XX 19-NOV-2001; 2001US-00989735.

XX XX 16-JUN-1997; 97US-0049787P.

XX XX 17-OCT-1997; 97US-0062250P.

XX XX 03-NOV-1997; 97US-0065186P.

XX XX 12-NOV-1997; 97US-0065311P.

XX XX 13-NOV-1997; 97US-0066770P.

XX XX 24-NOV-1997; 97US-0075945P.

XX XX 25-FEB-1998; 98US-0078310P.

XX XX 20-MAR-1998; 98US-0083322P.

XX XX 28-APR-1998; 98US-0084600P.

XX XX 07-MAY-1998; 98US-0087106P.

XX XX 28-MAY-1998; 98US-0087607P.

XX XX 02-JUN-1998; 98US-0087609P.

XX XX 02-JUN-1998; 98US-0087827P.

XX XX 03-JUN-1998; 98US-0088021P.

XX XX 04-JUN-1998; 98US-0088025P.

XX XX 04-JUN-1998; 98US-0088026P.

XX XX 04-JUN-1998; 98US-0088028P.

XX XX 04-JUN-1998; 98US-0088029P.

XX XX 04-JUN-1998; 98US-0088030P.

XX XX 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98US-00919330.
PR 17-SEP-1998; 98US-00919437.
PR 07-OCT-1998; 98US-00921141.
PR 01-DEC-1998; 98US-00925108.
PR 05-JAN-1999; 98US-00925108.
PR 08-MAR-1999; 98US-00925108.
PR 02-JUN-1999; 98US-00925108.
PR 15-SEP-1999; 98US-00925108.
PR 15-SEP-1999; 98US-00925147.
PR 30-NOV-1999; 98US-00928313.
PR 01-DEC-1999; 98US-00928301.
PR 01-DEC-1999; 98US-00928634.
PR 16-DEC-1999; 98US-00930095.
PR 20-DEC-1999; 98US-00930911.
PR 05-JAN-2000; 2000US-00002119.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-0003565.
PR 18-FEB-2000; 2000US-0004341.
PR 22-FEB-2000; 2000US-0004414.
PR 24-FEB-2000; 2000US-0004914.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 10-MAR-2000; 2000US-0006319.
PR 15-MAR-2000; 2000US-0006884.
PR 30-MAR-2000; 2000US-0007377.
PR 30-MAR-2000; 2000US-0008439.
PR 15-MAY-2000; 2000US-0013358.
PR 17-MAY-2000; 2000US-0013705.
PR 22-MAY-2000; 2000US-0014042.
PR 30-MAY-2000; 2000US-0014941.
PR 02-JUN-2000; 2000US-0015364.
PR 28-JUL-2000; 2000US-0020710.
PR 11-AUG-2000; 2000US-0022031.
PR 23-AUG-2000; 2000US-0023522.
PR 24-AUG-2000; 2000US-0023328.
PR 08-NOV-2000; 2000US-0030952.
PR 01-DEC-2000; 2000US-0032678.
PR 28-FEB-2001; 2001US-0006520.
PR 01-JUN-2001; 2001US-0017800.
PR 20-JUN-2001; 2001US-0019692.
PR 29-JUN-2001; 2001US-0021066.
PR 09-JUL-2001; 2001US-0021735.
PR 28-AUG-2001; 2001US-00941992.
XX PA (GETH) GENENTECH INC.

XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
 PI PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 XX Zhang Z;
 DR WPI: 2003-657230/62.
 DR N-PSDB; ADD07669.
 XX
 FT Isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and
 PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and
 PT are thus therapeutically useful e.g. for enhancing immune response.
 XX
 PS Claim 12; SEQ ID NO 371; 659pp; English.
 XX
 CC The invention relates to human secreted and transmembrane PRO
 CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
 CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
 CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
 CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
 CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
 CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
 CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
 CC fos in endothelial cells, modulating glucose or PFA uptake by adipocytes,
 CC inducing proliferation and/or re-differentiation of chondrocytes, or
 CC inducing pancreatic beta-cell precursor differentiation into mature
 CC pancreatic beta-cells. They may therefore be useful in the treatment of
 CC various insulin deficient states in mammals, including diabetes mellitus,
 CC and in treating undesired endothelial cell growth, e.g., inhibiting
 CC tumour growth. The sequences are also useful for treating mammalian
 CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
 CC renal dysplasia, polycystic kidney disease, renal tumours, and other
 CC cancers such as those of the colon, lung and breast. PRO polypeptides or
 CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
 CC a sample; to link a bioactive molecule to a cell; to modulate a
 CC biological activity of a cell; as molecular weight markers for protein
 CC electrophoresis purposes; for tissue typing; to prepare a medicament for
 CC treating a condition responsive to the polypeptide or antibody, such as
 CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
 CC disease); and in various diagnostic assays. The PRO polynucleotides can
 CC be used as hybridisation probes, in chromosome and gene mapping, in
 CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
 CC may also be used in preparing PRO polypeptides by recombinant techniques,
 CC and in generating either transgenic animals or knock-out animals which,
 CC in turn, are useful in the development and screening of therapeutically
 CC useful reagents. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 105 AA;
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2 5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MGRATRVSMILLVTVSCAVITGACERDVCGAGTCCALSLWLRGURMCTPLRGEGEC 60
 DB 1 MGRATRVSMILLVTVSCAVITGACERDVCGAGTCCALSLWLRGURMCTPLRGEGEC 60
 QY 61 HPGSHKVPFRRKXHTCPCLPNLLCSFPPDGRVRCNSMDLKNINF 105
 DB 61 HPGSHKVPFRRKXHTCPCLPNLLCSFPPDGRVRCNSMDLKNINF 105
 RESULT 183
 ID ADC78113
 XX ADC78113 standard; protein; 105 AA.
 AC ADC78113;
 XX
 DT 01-JAN-2004 (first entry)
 XX

DE XX Novel human secreted and transmembrane protein PRO1186.
 KW Human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX Homo sapiens.
 OS
 XX US2003096972-A1.
 PN
 XX 22-MAY-2003.
 XX
 PD 29-AUG-2002; 2002US-00232234.
 PF
 XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 PR
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 PI WPI: 2003-765529/72.
 DR N-PSDB; ADC78112.
 DR
 XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
 PT molecular weight markers, for treating arthritis and tumor.
 PT
 XX Claim 11; Fig 166; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080.
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO609, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1132, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.
 CC

SQ Sequence 105 AA;

Query March 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLGRGEGEC 60
 DB 1 MRGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLGRGEGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCPLNLLCSRFPDGRVRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRKRKHHTCPCPLNLLCSRFPDGRVRCSDMLKNINF 105

RESULT 184
 ADD04699 standard; protein; 105 AA.
 XX ADD04699;
 XX AC
 XX DT 01-JAN-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1186.
 XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX OS Homo sapiens.
 XX US2003087354-A1.
 XX PD 08-MAY-2003.
 XX FF 22-APR-2002; 2002US-00127827.
 XX PR 17-AUG-1998; 98US-0096891P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith W, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801139/75.
 DR N-PSDB; ADD04698.
 XX PT New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 XX Claim 12; Fig 470; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 105 AA;

Query March 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLGRGEGEC 60
 DB 1 MRGATRVSIMLLLVTSVDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLGRGEGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCPLNLLCSRFPDGRVRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRKRKHHTCPCPLNLLCSRFPDGRVRCSDMLKNINF 105

RESULT 185
 ADC82561
 ID ADC82561 standard; protein; 105 AA.
 XX AC
 AC ADC82561;
 XX DT 01-JAN-2004 (first entry)
 XX DE Human PRO polypeptide #115.
 KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
 KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
 KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
 KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
 KW cytostatic; cardiac; vulnery; antinflammatory; anorectic.
 XX OS Homo sapiens.
 XX US2003059833-A1.
 XX PD 27-MAR-2003.
 XX PF 15-NOV-2001; 2001US-00997440.
 XX PR 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0065188P.
 PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 28-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 28-MAY-1998; 98US-0084600P.
PR 28-JUN-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088023P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 02-JUL-1998; 98US-0091788P.
PR 07-JUL-1998; 98US-0091982P.
PR 07-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096788P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0102114P.
PR 01-DEC-1998; 98US-0102114P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 20-FEB-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0113296P.
PR 12-MAR-1999; 98US-0113296P.
PR 02-JUN-1999; 98US-0113296P.
PR 23-JUN-1999; 98US-0113296P.
PR 07-JUL-1999; 98US-0113296P.
PR 20-JUL-1999; 98US-0113296P.
PR 26-JUL-1999; 98US-0113296P.
PR 28-JUL-1999; 98US-0113296P.
PR 17-AUG-1999; 98US-0113296P.
PR 15-SEP-1999; 98US-0113296P.

PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013558.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000US-0213637P.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWRLGLRMTPLRGEGEC 60
Db 1 MRGATRSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWRLGLRMTPLRGEGEC 60

QY 61 HPGSHKVPFFRRKRKHTTCCPLNLLCSRFPPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRRKRKHTTCCPLNLLCSRFPPDGRYRCSDMLKNINF 105

RESULT 186
ADD06348
ID ADD06348 standard; protein; 105 AA.
XX ADD06348;
XX
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1186.
XX human; secreted and transmembrane protein; PRO; cytostatic; vulnary;
KW aniaarthritic; pericyte cell proliferation;
KW chondrocyte cell differentiation; chondrocyte cell proliferation;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
OS Homo sapiens.
XX
XX US2003073816-A1.
XX
PD 17-APR-2003.
XX
XX 26-AUG-2002; 2002US-00227873.
XX
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX

PA (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-644807/61.
DR N-PSDB; ADD06347.
DR
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Claim 11; SEQ ID NO 166; 314pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080.
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWRLGLRMTPLRGEGEC 60
Db 1 MRGATRSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWRLGLRMTPLRGEGEC 60

QY 61 HPGSHKVPFFRRKRKHTTCCPLNLLCSRFPPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRRKRKHTTCCPLNLLCSRFPPDGRYRCSDMLKNINF 105

RESULT 187
ADC80655
ID ADC80655 standard; protein; 105 AA.
XX
XX ADC80655;
XX
XX
DT 01-JAN-2004 (first entry)
XX

DE Novel human secreted and transmembrane protein PRO1186.
 XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 XX gene therapy; chromosome identification; chromosome marker.
 XX Homo sapiens.
 XX US2003092103-A1.
 XX 15-MAY-2003.
 XX 24-APR-2002; 2002US-00131815.
 XX 22-DEC-1998; 98US-0113511P.
 XX 01-DEC-1999; 99WO-US028634.
 XX 22-FEB-2000; 2000WO-US004414.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801168/75.
 XX N-PSDB; ADC80654.
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
 XX generating antisense RNA and DNA, and in gene therapy.
 XX Claim 12; Fig 470; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful
 XX reagents. The PRO polypeptides or antibodies are used in preparing a
 XX medicament for treating a condition responsive to the polypeptides or
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation
 XX of human microvascular endothelial cells, for modulating the uptake of
 XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 XX cells, for stimulating differentiation of adipocyte cells, for
 XX stimulating proliferation of or gene expression in pericyte cells, for
 XX stimulating the proliferation of inner ear utricular supporting cells or
 XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
 XX treating various bone and/or cartilage disorders such as sports injuries
 XX and arthritis. PRO polypeptides which stimulate the release of
 XX proteoglycans from cartilage are useful for treating sports-related joint
 XX problems, articular cartilage defects, osteoarthritis and rheumatoid
 XX arthritis. PRO polypeptides are also useful for treating various
 XX mammalian haemoglobin-associated disorders such as various thalassaemias

CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX CC
 XX Sequence 105 AA;
 SQ
 Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
 QY 61 HPGSHKVPFFRRKRKHHTCPCLPNNLLCSFPDPGRYRCSDMLKXINF 105
 DB 61 HPGSHKVPFFRRKRKHHTCPCLPNNLLCSFPDPGRYRCSDMLKXINF 105
 RESULT 188
 ADD11162
 ID ADD11162 standard; protein; 105 AA.
 XX
 AC ADD11162;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human PRO polypeptide #235.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003.94774-A1.
 XX 16-OCT-2003.
 XX 21-MAY-2002; 2002US-00152399.
 XX 03-MAR-2000; 2000US-0187202P.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-852594/79.
 XX N-PSDB; ADD11161.
 XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
 XX for detecting a tumor, stimulating the proliferation or differentiation
 XX of chondrocyte cells and stimulating the release of tumor necrosis factor
 XX alpha.
 XX Claim 12; SEQ ID NO 470; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGEGEC 60
Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGEGEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSMDLNINF 105
Db 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSMDLNINF 105

RESULT 189
ADD10461
ID ADD10461 standard; protein; 105 AA.
XX AC ADD10461;
XX DT 01-JAN-2004 (first entry)
XX DE Human secreted/transmembrane PRO polypeptide #86.
XX KW human; secreted protein; transmembrane protein; cardiovascular disorder;
KW endothelial disorder; angiogenic disorder; myocardial infarction;
KW cardiac hypertrophy; trauma; cancer; age-related macular degeneration;
KW angiogenesis; endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.

XX OS Homo sapiens.
XX PN US2003105011-A1.
XX PD 05-JUN-2003.
XX PF 16-AUG-2002; 2002US-00223084.
XX PR 15-SEP-2000; 2000US-0232887P.
PR 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021735.
PR 20-FEB-2002; 2002US-00081056.

XX
PA (GETH) GENENTECH INC.
XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WT, Ye W;
XX WPI; 2003-810831/76.
DR N-PSDB; ADD10460.
XX New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.
XX Claim 11; SEQ ID NO 172; 493pp; English.

CC The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of Pgf-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents the amino acid
CC sequence of a PRO polypeptide of the invention.

XX
SQ Sequence 105 AA;
Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGEGEC 60
Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGEGEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSMDLNINF 105
Db 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSMDLNINF 105

RESULT 190
ADC48043
ID ADC48043 standard; protein; 105 AA.
XX AC ADC48043;
XX DT 01-JAN-2004 (first entry)
XX DE Human PRO polypeptide #235.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.
XX PN US2003194771-A1.
XX

ADD08741 standard; protein; 105 AA.

AC ADD08741;

XX

DT 01-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1186.

XX

XX Human; secreted protein; transmembrane protein; PRO;

KW neonatal heart hypertrophy; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW rod photoreceptor cell; c-fos induction; adipocyte;

KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;

KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;

KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

KW thalassemia; endothelial cell growth; cancer; cystic renal dysplasia;

KW polycystic kidney disease; renal tumour; neurodegenerative disorder;

KW Parkinson's disease; Alzheimer's disease; gene therapy;

KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;

KW antidiabetic; antineoplastic; cytostatic; nontropic; neuroprotective;

KW antiParkinsonian.

XX

OS Homo sapiens.

XX

XX US2003073090-A1.

XX

PD 17-APR-2003.

XX

PF 16-NOV-2001; 2001US-00990439.

XX

PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

```
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091366P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 20-JUL-1998; 98US-0092472P.
PR 30-JUL-1998; 98US-0093339P.
PR 04-AUG-1998; 98US-0094551P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096229P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
```

```
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 16-SEP-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003555.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 15-MAY-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
```

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
    |||||
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGRGEEC 60
    |||||
```

```
QY 61 HPGSHKVPFFPKRKHHTKPCLPNLLCSRFDPGRYRCSMDLKNINF 105
    |||||
DB 61 HPGSHKVPFFPKRKHHTKPCLPNLLCSRFDPGRYRCSMDLKNINF 105
    |||||
```

RESULT 192

ADC77867
ID ADC77867 standard; protein; 105 AA.
XX

AC ADC77867;
XX
XX
XX 01-JAN-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1186.
XX
XX Human; secreted and transmembrane protein; PRO; cytotstatic; vulnerary;
KW antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
XX Homo sapiens.
XX
XX US2003088066-A1.
XX
XX 08-MAY-2003.
XX
XX 13-AUG-2002; 2002US-00219466.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-657980/62.
XX
XX N-PSDB; ADC77866.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
XX useful in gene therapy, or for preparing a medicament for treating a
XX condition that is responsive to the PRO polypeptide or anti-PRO antibody,
XX e.g. cancer.
XX
XX Claim 11; Fig 166; 314pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO7174, PRO5775, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (I) is useful as molecular weight markers, for tissue
XX typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX useful for chromosome and gene mapping or gene therapy. (II) is useful

CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX
XX Sequence 105 AA;
SQ
Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCALSLMLRGLRMTPLRGEGEC 60
DB 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCALSLMLRGLRMTPLRGEGEC 60
QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105
RESULT 193
ADC80103
ID ADC80103 standard; protein; 105 AA.
XX
XX AC ADC80103;
XX
XX DT 01-JAN-2004 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO1186.
XX
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
XX
XX OS US2003087358-A1.
XX
XX PN 08-MAY-2003.
XX
XX PD 22-APR-2002; 2002US-00127833.
XX
XX PF 01-SEP-1998; 98US-0098750P.
XX
XX PR 01-SEP-1999; 99WO-US020111.
XX
XX PR 18-OCT-1999; 99US-00403297.
XX
XX PR 18-FEB-2000; 2000WO-US004342.
XX
XX PR 08-NOV-2000; 2000WO-US030952.
XX
XX PR 01-DEC-2000; 2000WO-US032678.
XX
XX PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801143/75.
XX
XX DR N-PSDB; ADC80102.
XX
XX DR New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor.
XX
XX PS Claim 12; Fig 470; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVISIMLLTVSDCAVITGACRDVCCAGTCCCAISLWRLGRLMCTPLGRGEEC 60
Dy 1 MRGATRVISIMLLTVSDCAVITGACRDVCCAGTCCCAISLWRLGRLMCTPLGRGEEC 60
Qy 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPGRVRCSDMLKNTNF 105
Dy 61 HPGSHKVPFFPKRKHHTCPCLNLLCSRFDPGRVRCSDMLKNTNF 105

RESULT 194
ADD06990
ID ADD06990 standard; protein; 105 AA.
XX
AC ADD06990;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1186.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianemic; cytostatic; nootropic; neuroprotective;

KW antiparkinsonian.
XX
OS Homo sapiens.
XX
PN US2002193300-A1.
XX
PD 19-DEC-2002.
XX
XX 14-NOV-2001; 2001US-00990444.
XX
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020089.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087108P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088875P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021030.
PR 30-NOV-1999; 99WO-US021547.
PR 01-DEC-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US0303911.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US0003565.
 PR 18-FEB-2000; 2000WO-US0004341.
 PR 22-FEB-2000; 2000WO-US0004414.
 PR 24-FEB-2000; 2000WO-US0004914.
 PR 24-FEB-2000; 2000WO-US0005004.
 PR 02-MAR-2000; 2000WO-US0005841.
 PR 10-MAR-2000; 2000WO-US0006319.
 PR 15-MAR-2000; 2000WO-US0006884.
 PR 20-MAR-2000; 2000WO-US0007377.
 PR 30-MAR-2000; 2000WO-US0008439.
 PR 15-MAY-2000; 2000WO-US013358.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030352.
 PR 01-DEC-2000; 2000WO-US032578.
 PR 28-DEC-2000; 2001WO-US006520.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 28-AUG-2001; 2001US-00941992.
 XX (GETH) GENENTECH INC.
 XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Klavin IJ, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;
 XX WPI: 2003-657231/62.
 DR N-PSDB; ADD06989.
 XX
 PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
 PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
 PT and are thus therapeutically useful for enhancing immune response.
 XX
 PS Claim 12; SEQ ID NO 371; 653pp; English.
 XX
 CC The invention relates to human secreted and transmembrane PRO
 CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
 CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
 CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
 CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
 CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
 CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
 CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
 CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,
 CC inducing proliferation and/or re-differentiation of chondrocytes, or
 CC inducing pancreatic beta-cell precursor differentiation into mature
 CC pancreatic beta-cells. They may therefore be useful in the treatment of
 CC various insulin deficient states in mammals, including diabetes mellitus,
 CC and in treating undesired endothelial cell growth, e.g., inhibiting
 CC tumour growth. The sequences are also useful for treating mammalian
 CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
 CC renal dysplasia, polycystic kidney disease, renal tumours, and other
 CC cancers such as those of the colon, lung and breast. PRO polypeptides or
 CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
 CC a sample; to link a bioactive molecule to a cell; to modulate a
 CC biological activity of a cell; as molecular weight markers for protein
 CC electrophoresis purposes; for tissue typing; to prepare a medicament for
 CC treating a condition responsive to the polypeptide or antibody, such as
 CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
 CC disease); and in various diagnostic assays. The PRO polynucleotides can

CC be used as hybridisation probes, in chromosome and gene mapping, in
 CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
 CC may also be used in preparing PRO polypeptides by recombinant techniques,
 CC and in generating either transgenic animals or knock-out animals which,
 CC in turn, are useful in the development and screening of therapeutically
 CC useful reagents. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.5e-54;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
 |||||||

DB 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
 |||||||

QY 61 HPGSHKVPFFPRKRKHTCPCLPNLLCSRFPDGRYRCMDLNINF 105
 |||||||

DB 61 HPGSHKVPFFPRKRKHTCPCLPNLLCSRFPDGRYRCMDLNINF 105
 |||||||

RESULT 195

ID ADD11421 standard; protein; 105 AA.

XX AC ADD11421;

XX DT 01-JAN-2004 (first entry)

XX DE Human secreted/transmembrane PRO polypeptide #86.

XX human; secreted protein; transmembrane protein; cardiovascular disorder;
 KW endothelial disorder; angiogenic disorder; myocardial infarction;
 KW cardiac hypertrophy; trauma; cancer; age-related macular degeneration;
 KW angiogenesis; endothelial cell apoptosis; smooth muscle cell growth;
 KW endothelial cell tube formation.

XX OS Homo sapiens.

XX US2003105013-A1.

XX PD 05-JUN-2003.

XX PF 16-AUG-2002; 2002US-00223090.

XX PR 20-JUN-2001; 2001WO-US019692.

XX PR 09-JUL-2001; 2001WO-US021735.

XX PR 20-FEB-2002; 2002US-00081056.

XX (GETH) GENENTECH INC.

PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
 PI Watanabe CK, Williams PM, Wood WI, Ye W;

XX WPI: 2003-801242/75.

XX DR N-PSDB; ADD11420.

XX New isolated nucleic acid encoding a secreted and transmembrane
 PT polypeptide, useful for treating a cardiovascular, endothelial, or
 PT angiogenic disorder in a mammal, such as cancer or age-related macular
 PT degeneration.

XX PS Claim 11; SEQ ID NO 172; 493pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
 CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
 CC by the nucleic acid, or an agonist or antagonist, is used to treat a
 CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
 CC preferably a human. The human may have suffered a myocardial infarction

CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGR-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO1376 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents the amino acid
CC sequence of a PRO polypeptide of the invention.

XX Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60

DB 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60

QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPPDGRVRCSDMLKNINF 105

DB 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPPDGRVRCSDMLKNINF 105

RESULT 196

ID ADD09572 standard; protein; 105 AA.

XX AC ADD09572;

XX DT 01-JAN-2004 (first entry)

XX DE Human PRO polypeptide #235.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX KW liver; microvascular endothelial cell; glucose; PFA;
XX KW skeletal muscle cell; adipocyte cell; pericyte cell;
XX KW inner ear utricular supporting cell; T-lymphocyte cell;
XX KW endothelial cell tube formation; bone disorder; cartilage disorder;
XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003194775-A1.

XX PD 16-OCT-2003.

XX PF 28-MAY-2002; 2002US-00156948.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-852595/79.

XX DR N-PSDB; ADD09571.

XX PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
XX PT for detecting a tumor, stimulating the release of tumor necrosis factor
XX PT alpha from blood and stimulating the release of proteoglycans from
XX PT cartilage.

XX Claim 12; Fig 470; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or PFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60

DB 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGGEC 60

QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPPDGRVRCSDMLKNINF 105

DB 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPPDGRVRCSDMLKNINF 105

RESULT 197

ID ADC83237

XX ID ADC83237 standard; protein; 105 AA.

XX AC ADC83237;

XX DT 01-JAN-2004 (first entry)

XX DE Human PRO polypeptide #115.

XX KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
XX KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
XX KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
XX KW polycystic kidney disease; renal tumour; antidiabetic; antianemic;
XX KW cytostatic; cardiant; vulnery; antiinflammatory; anorectic.

XX OS Homo sapiens.

XX PN US2003059783-A1.

XX PD 27-MAR-2003.

XX	15-NOV-2001;	2001US-00997683.	
PF	16-JUN-1997;	97US-0049787P.	
XX	17-OCT-1997;	97US-0062250P.	
PR	05-NOV-1997;	97WO-US020069.	
PR	12-NOV-1997;	97US-0065186P.	
PR	13-NOV-1997;	97US-0065311P.	
PR	24-NOV-1997;	97US-0066770P.	
PR	25-FEB-1998;	98US-0075945P.	
PR	20-MAR-1998;	98US-0078910P.	
PR	28-APR-1998;	98US-0083332P.	
PR	07-MAY-1998;	98US-0084600P.	
PR	28-MAY-1998;	98US-0087106P.	
PR	02-JUN-1998;	98US-0087607P.	
PR	02-JUN-1998;	98US-0087609P.	
PR	02-JUN-1998;	98US-0087759P.	
PR	03-JUN-1998;	98US-0087827P.	
PR	04-JUN-1998;	98US-0088021P.	
PR	04-JUN-1998;	98US-0088025P.	
PR	04-JUN-1998;	98US-0088036P.	
PR	04-JUN-1998;	98US-0088028P.	
PR	04-JUN-1998;	98US-0088029P.	
PR	04-JUN-1998;	98US-0088030P.	
PR	04-JUN-1998;	98US-0088033P.	
PR	04-JUN-1998;	98US-0088326P.	
PR	05-JUN-1998;	98US-0088167P.	
PR	05-JUN-1998;	98US-0088202P.	
PR	05-JUN-1998;	98US-0088212P.	
PR	05-JUN-1998;	98US-0088217P.	
PR	09-JUN-1998;	98US-0088655P.	
PR	10-JUN-1998;	98US-0088734P.	
PR	10-JUN-1998;	98US-0088738P.	
PR	10-JUN-1998;	98US-0088742P.	
PR	10-JUN-1998;	98US-0088810P.	
PR	10-JUN-1998;	98US-0088824P.	
PR	10-JUN-1998;	98US-0088826P.	
PR	11-JUN-1998;	98US-0088858P.	
PR	11-JUN-1998;	98US-0088861P.	
PR	11-JUN-1998;	98US-0088876P.	
PR	12-JUN-1998;	98US-0089105P.	
PR	16-JUN-1998;	98US-0089144P.	
PR	16-JUN-1998;	98US-0089512P.	
PR	16-JUN-1998;	98US-0089514P.	
PR	17-JUN-1998;	98US-0089532P.	
PR	17-JUN-1998;	98US-0089538P.	
PR	17-JUN-1998;	98US-0089598P.	
PR	17-JUN-1998;	98US-0089599P.	
PR	17-JUN-1998;	98US-0089600P.	
PR	17-JUN-1998;	98US-0089653P.	
PR	18-JUN-1998;	98US-0089801P.	
PR	18-JUN-1998;	98US-0089907P.	
PR	18-JUN-1998;	98US-0089908P.	
PR	19-JUN-1998;	98US-0089947P.	
PR	19-JUN-1998;	98US-0089952P.	
PR	19-JUN-1998;	98US-0089952P.	
PR	22-JUN-1998;	98US-0090246P.	
PR	22-JUN-1998;	98US-0090252P.	
PR	23-JUN-1998;	98US-0090254P.	
PR	23-JUN-1998;	98US-0090349P.	
PR	23-JUN-1998;	98US-0090355P.	
PR	24-JUN-1998;	98US-0090429P.	
PR	24-JUN-1998;	98US-0090431P.	
PR	24-JUN-1998;	98US-0090435P.	
PR	24-JUN-1998;	98US-0090444P.	
PR	24-JUN-1998;	98US-0090445P.	
PR	24-JUN-1998;	98US-0090472P.	
PR	24-JUN-1998;	98US-0090535P.	
PR	24-JUN-1998;	98US-0090540P.	
PR	24-JUN-1998;	98US-0090542P.	
PR	24-JUN-1998;	98US-0090557P.	
PR	25-JUN-1998;	98US-0090676P.	
PR	25-JUN-1998;	98US-0090678P.	
PR	25-JUN-1998;	98US-0090690P.	
PR	25-JUN-1998;	98US-0090694P.	
PR	25-JUN-1998;	98US-0090695P.	
PR	25-JUN-1998;	98US-0090696P.	
PR	26-JUN-1998;	98US-0090862P.	
PR	26-JUN-1998;	98US-0090863P.	
PR	01-JUL-1998;	98US-0091360P.	
PR	01-JUL-1998;	98US-0091544P.	
PR	02-JUL-1998;	98US-0091478P.	
PR	02-JUL-1998;	98US-0091519P.	
PR	02-JUL-1998;	98US-0091626P.	
PR	02-JUL-1998;	98US-0091628P.	
PR	02-JUL-1998;	98US-0091633P.	
PR	02-JUL-1998;	98US-0091646P.	
PR	02-JUL-1998;	98US-0091673P.	
PR	07-JUL-1998;	98US-0091978P.	
PR	07-JUL-1998;	98US-0091982P.	
PR	09-JUL-1998;	98US-0092182P.	
PR	10-JUL-1998;	98US-0092472P.	
PR	20-JUL-1998;	98US-0093339P.	
PR	30-JUL-1998;	98US-0094651P.	
PR	04-AUG-1998;	98US-0095282P.	
PR	04-AUG-1998;	98US-0095285P.	
PR	04-AUG-1998;	98US-0095301P.	
PR	04-AUG-1998;	98US-0095302P.	
PR	04-AUG-1998;	98US-0095318P.	
PR	04-AUG-1998;	98US-0095321P.	
PR	04-AUG-1998;	98US-0095325P.	
PR	10-AUG-1998;	98US-0095916P.	
PR	10-AUG-1998;	98US-0095929P.	
PR	11-AUG-1998;	98US-0096012P.	
PR	11-AUG-1998;	98US-0096143P.	
PR	11-AUG-1998;	98US-0096146P.	
PR	12-AUG-1998;	98US-0096329P.	
PR	17-AUG-1998;	98US-0096757P.	
PR	17-AUG-1998;	98US-0096766P.	
PR	17-AUG-1998;	98US-0096768P.	
PR	17-AUG-1998;	98US-0096773P.	
PR	17-AUG-1998;	98US-0096781P.	
PR	17-AUG-1998;	98US-0096867P.	
PR	17-AUG-1998;	98US-0096891P.	
PR	17-AUG-1998;	98US-0096894P.	
PR	17-AUG-1998;	98US-0096895P.	
PR	17-AUG-1998;	98US-0096897P.	
PR	18-AUG-1998;	98US-0096949P.	
PR	18-AUG-1998;	98US-0096950P.	
PR	18-AUG-1998;	98US-0096959P.	
PR	18-AUG-1998;	98US-0096960P.	
PR	18-AUG-1998;	98US-0097022P.	
PR	19-AUG-1998;	98US-0097141P.	
PR	20-AUG-1998;	98US-0097218P.	
PR	24-AUG-1998;	98US-0097661P.	
PR	26-AUG-1998;	98US-0097952P.	
PR	26-AUG-1998;	98US-0097954P.	
PR	26-AUG-1998;	98US-0097955P.	
PR	26-AUG-1998;	98US-0097971P.	
PR	26-AUG-1998;	98US-0097974P.	
PR	26-AUG-1998;	98US-0097978P.	
PR	26-AUG-1998;	98US-0097979P.	
PR	26-AUG-1998;	98US-0097986P.	
PR	26-AUG-1998;	98US-0098014P.	
PR	31-AUG-1998;	98US-0098525P.	
PR	16-SEP-1998;	98US-0100634P.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98US-0100858P.	
PR	17-SEP-1998;	98WO-US019437.	
PR	07-OCT-1998;	98WO-US021141.	
PR	01-DEC-1998;	98WO-US025108.	
PR	22-DEC-1998;	98US-0113296P.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	12-MAR-1999;	99US-0123957P.	
PR	02-JUN-1999;	99WO-US012252.	

PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005941.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006984.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 198
ADD50830
ID ADD50830 standard; protein; 105 AA.
XX AC ADD50830;
XX DT 15-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1186.
XX Human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
XX antiarthritic; pericyte cell proliferation;
XX pericyte cell differentiation; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX (TNF)-alpha release; dermal fibroblast cell proliferation;
XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX liver tumour; tissue typing; chromosome mapping; gene therapy;
XX Homo sapiens.
OS US2003105291-A1.
PN
XX

PD 05-JUN-2003.
XX 26-AUG-2002; 2002US-00227877.
XX 29-JUN-2001; 2001WO-US021086.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-829361/77.
DR N-PSDB; ADD50829.
XX New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,
PT as a hybridization probe, and in gene therapy.
XX Claim 11; Fig 166; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1185, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1517, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX Sequence 105 AA;
SQ

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 199

ADD41285

ID ADD41285 standard; protein; 105 AA.

XX AC ADD41285;

XX DT 15-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1186.

XX KW Human; secreted and transmembrane protein; PRO;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX FN US2003203438-A1.

XX PD 30-OCT-2003.

XX PF 15-MAY-2002; 2002US-00146786.

XX PR 24-NOV-1997; 97US-0066511P.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 25-AUG-1999; 99US-00380139.

XX PR 22-FEB-2000; 2000WO-US004414.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX FI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-875645/81.

XX DR N-PSDB; ADD41284.

XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in

XX PT generating antisense RNA and DNA, and in gene therapy.

XX PS Claim 12; SEQ ID NO 470; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and

XX CC transmembrane) polypeptides (i). (i) is useful for stimulating the

XX CC release of TNF-alpha from human blood, for modulating the uptake of

XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX CC stimulating the proliferation or differentiation of chondrocyte cells,

XX CC for stimulating the proliferation of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

XX CC cells, for stimulating the release of or gene expression in pericyte

CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (i) and (ii) are useful for tissue typing. This is the amino

CC acid sequence of a novel human secreted and transmembrane PRO

CC polypeptide.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.5e-54;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTVSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCPTLGRGEEC 60

Db 1 MEGATRVSIMLLLVTVSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCPTLGRGEEC 60

QY 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFPPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFPPDGRYRCSDMLKNINF 105

RESULT 200

ADD52424

ID ADD52424 standard; protein; 105 AA.

XX AC ADD52424;

XX DT 15-JAN-2004 (first entry)

XX DE Human PRO polypeptide #235.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX US2003194769-A1.

XX PD 16-OCT-2003.

XX PF 21-MAY-2002; 2002US-00152374.

XX PR 09-DEC-1999; 99US-0170262P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-852593/79.

XX DR N-PSDB; ADD52423.

XX PT New isolated, secreted and transmembrane PRO polypeptides and nucleic

XX PT acids, useful for detection of tumors, modulating the uptake of glucose

XX PT or free fatty acids and stimulating the release of proteoglycans from

XX PT cartilage.

XX PS Claim 12; Fig 470; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and

XX CC transmembrane polypeptides) and the polynucleotides encoding them. The

XX CC invention also relates to an antibody which specifically binds to a PRO

XX CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or RFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 105 AA;

Query Match 100.0%; Score 589; DB 7; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.5e-54;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSILWRLGRLMCTPLGREGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSILWRLGRLMCTPLGREGEC 60
Qy 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYCSMDLKNINF 105

Search completed: August 30, 2004, 07:05:53
Job time : 146 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 30, 2004, 07:03:21 ; Search time 47 Seconds

(without alignments)
702.859 Million cell updates/sec

Title: US-10-027-603-2

Perfect score: 589

Sequence: 1 MRGATRVSIMLLLVTSDCA.....CSRFPDGRYRCMDLKNIF 105

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1297172 seqs, 314612898 residues

Total number of hits satisfying chosen parameters: 634

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 250 summaries

Database : Published Applications AA.*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PTCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PTCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	589	100.0	105	9	US-09-989-722-371
2	589	100.0	105	9	US-09-989-723-371
3	589	100.0	105	9	US-09-989-279-371
4	589	100.0	105	9	US-09-989-727-371
5	589	100.0	105	9	US-09-989-731-371
6	589	100.0	105	9	US-09-989-732-371
7	589	100.0	105	9	US-09-991-073-371
8	589	100.0	105	9	US-09-990-442-371
9	589	100.0	105	9	US-09-991-163-371
10	589	100.0	105	9	US-09-993-604-371
11	589	100.0	105	9	US-09-990-456-371
12	589	100.0	105	9	US-09-989-721-371
13	589	100.0	105	9	US-09-992-598-371
14	589	100.0	105	9	US-09-886-242A-2
15	589	100.0	105	9	US-09-989-293A-371

16	589	100.0	105	9	US-09-965-528-11	Sequence 11, Appl
17	589	100.0	105	9	US-09-989-735-371	Sequence 371, App
18	589	100.0	105	9	US-09-990-444-371	Sequence 371, App
19	589	100.0	105	9	US-09-991-181-371	Sequence 371, App
20	589	100.0	105	9	US-09-989-730-371	Sequence 371, App
21	589	100.0	105	9	US-09-990-436-371	Sequence 371, App
22	589	100.0	105	9	US-09-993-687-371	Sequence 371, App
23	589	100.0	105	10	US-09-989-734-371	Sequence 371, App
24	589	100.0	105	10	US-09-997-653-371	Sequence 371, App
25	589	100.0	105	10	US-09-993-667-371	Sequence 371, App
26	589	100.0	105	10	US-09-997-428-371	Sequence 371, App
27	589	100.0	105	10	US-09-997-666-371	Sequence 371, App
28	589	100.0	105	10	US-09-990-438-371	Sequence 371, App
29	589	100.0	105	10	US-09-990-562-371	Sequence 371, App
30	589	100.0	105	10	US-09-796-753-64	Sequence 64, Appl
31	589	100.0	105	10	US-09-990-711-371	Sequence 371, App
32	589	100.0	105	10	US-09-989-728-371	Sequence 371, App
33	589	100.0	105	10	US-09-998-156-371	Sequence 371, App
34	589	100.0	105	10	US-09-990-437-371	Sequence 371, App
35	589	100.0	105	10	US-09-991-157-371	Sequence 371, App
36	589	100.0	105	10	US-09-997-514-371	Sequence 371, App
37	589	100.0	105	10	US-09-997-573-371	Sequence 371, App
38	589	100.0	105	10	US-09-991-172-371	Sequence 371, App
39	589	100.0	105	10	US-09-990-728-371	Sequence 371, App
40	589	100.0	105	10	US-09-997-559-371	Sequence 371, App
41	589	100.0	105	10	US-09-997-601-371	Sequence 371, App
42	589	100.0	105	10	US-09-990-443-371	Sequence 371, App
43	589	100.0	105	10	US-09-991-854-371	Sequence 371, App
44	589	100.0	105	10	US-09-997-628-371	Sequence 371, App
45	589	100.0	105	10	US-09-997-683-371	Sequence 371, App
46	589	100.0	105	10	US-09-989-729A-371	Sequence 371, App
47	589	100.0	105	10	US-09-997-349-371	Sequence 371, App
48	589	100.0	105	10	US-09-997-440-371	Sequence 371, App
49	589	100.0	105	10	US-09-990-440-371	Sequence 371, App
50	589	100.0	105	10	US-09-993-469-371	Sequence 371, App
51	589	100.0	105	10	US-09-997-543-371	Sequence 371, App
52	589	100.0	105	10	US-09-993-748-371	Sequence 371, App
53	589	100.0	105	10	US-09-990-438-371	Sequence 371, App
54	589	100.0	105	10	US-09-990-427-371	Sequence 371, App
55	589	100.0	105	10	US-09-989-328-371	Sequence 371, App
56	589	100.0	105	10	US-09-993-583-371	Sequence 371, App
57	589	100.0	105	10	US-09-941-993-371	Sequence 371, App
58	589	100.0	105	10	US-09-992-521-371	Sequence 371, App
59	589	100.0	105	10	US-09-997-333-371	Sequence 371, App
60	589	100.0	105	10	US-09-997-384-371	Sequence 371, App
61	589	100.0	105	10	US-09-998-041-371	Sequence 371, App
62	589	100.0	105	10	US-09-997-585-371	Sequence 371, App
63	589	100.0	105	10	US-09-997-614-371	Sequence 371, App
64	589	100.0	105	10	US-09-989-863-371	Sequence 371, App
65	589	100.0	105	10	US-09-997-529-371	Sequence 371, App
66	589	100.0	105	10	US-09-989-723-371	Sequence 371, App
67	589	100.0	105	11	US-09-989-733-371	Sequence 371, App
68	589	100.0	105	11	US-09-992-643-371	Sequence 371, App
69	589	100.0	105	12	US-10-147-493-470	Sequence 470, App
70	589	100.0	105	12	US-10-145-127-470	Sequence 470, App
71	589	100.0	105	12	US-10-160-503-470	Sequence 470, App
72	589	100.0	105	12	US-10-143-113-470	Sequence 470, App
73	589	100.0	105	12	US-10-144-993-470	Sequence 470, App
74	589	100.0	105	12	US-10-158-787-470	Sequence 470, App
75	589	100.0	105	12	US-10-081-056-172	Sequence 172, App
76	589	100.0	105	12	US-10-219-535-166	Sequence 166, App
77	589	100.0	105	12	US-10-232-230-166	Sequence 166, App
78	589	100.0	105	12	US-09-969-984-11	Sequence 11, Appl
79	589	100.0	105	12	US-10-140-024-470	Sequence 470, App
80	589	100.0	105	12	US-09-989-724-371	Sequence 371, App
81	589	100.0	105	12	US-09-989-728-371	Sequence 371, App
82	589	100.0	105	12	US-09-990-441-371	Sequence 371, App
83	589	100.0	105	12	US-10-140-808-470	Sequence 470, App
84	589	100.0	105	12	US-09-997-857-371	Sequence 371, App
85	589	100.0	105	12	US-10-232-224-166	Sequence 166, App
86	589	100.0	105	12	US-09-997-641-371	Sequence 371, App
87	589	100.0	105	12	US-09-991-150-371	Sequence 371, App
88	589	100.0	105	12	US-10-152-405-470	Sequence 470, App

235 589 100.0 105 14 US-10-128-694A-470 Sequence 470, App
236 589 100.0 105 14 US-10-131-825A-470 Sequence 470, App
237 589 100.0 105 14 US-10-230-417-470 Sequence 470, App
238 589 100.0 105 14 US-10-219-003-166 Sequence 166, App
239 589 100.0 105 14 US-10-219-075-166 Sequence 166, App
240 589 100.0 105 14 US-10-219-464-166 Sequence 166, App
241 589 100.0 105 14 US-10-219-466-166 Sequence 166, App
242 589 100.0 105 14 US-10-219-479-166 Sequence 166, App
243 589 100.0 105 14 US-10-219-481-166 Sequence 166, App
244 589 100.0 105 14 US-10-230-260-166 Sequence 166, App
245 589 100.0 105 14 US-10-232-231-166 Sequence 166, App
246 589 100.0 105 14 US-10-232-233-166 Sequence 166, App
247 589 100.0 105 14 US-10-131-815A-470 Sequence 470, App
248 589 100.0 105 14 US-10-131-817A-470 Sequence 470, App
249 589 100.0 105 14 US-10-131-821A-470 Sequence 470, App
250 589 100.0 105 14 US-10-131-822A-470 Sequence-470, App

ALIGNMENTS

RESULT 1

US-09-989-722-371
; Sequence 371, Application US/09989722
; Patent No. US20020072067A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PIC63
; CURRENT APPLICATION NUMBER: US/09/989,722
; PRIOR FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653

; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07

; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMCTPLGREGEEC 60
DB 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSKVPPFFRRKRKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSKVPPFFRRKRKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 2

US-09-989-723-371
; Sequence 371, Application US/09989723
; Patent No. US20020072092A1

GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730PIC62
; CURRENT APPLICATION NUMBER: US/09/989,723
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-08-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607

PRIOR APPLICATION NUMBER:	60/089907
PRIOR FILING DATE:	1998-06-18
PRIOR APPLICATION NUMBER:	60/089908
PRIOR FILING DATE:	1998-06-18
PRIOR APPLICATION NUMBER:	60/089947
PRIOR FILING DATE:	1998-06-19
PRIOR APPLICATION NUMBER:	60/089948
PRIOR FILING DATE:	1998-06-19
PRIOR APPLICATION NUMBER:	60/089952
PRIOR FILING DATE:	1998-06-19
PRIOR APPLICATION NUMBER:	60/090246
PRIOR FILING DATE:	1998-06-22
PRIOR APPLICATION NUMBER:	60/090252
PRIOR FILING DATE:	1998-06-22
PRIOR APPLICATION NUMBER:	60/090254
PRIOR FILING DATE:	1998-06-22
PRIOR APPLICATION NUMBER:	60/090349
PRIOR FILING DATE:	1998-06-23
PRIOR APPLICATION NUMBER:	60/090355
PRIOR FILING DATE:	1998-06-23
PRIOR APPLICATION NUMBER:	60/090429
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090431
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090435
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090444
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090445
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090472
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090557
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090540
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090542
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090557
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090676
PRIOR FILING DATE:	1998-06-25
PRIOR APPLICATION NUMBER:	60/090678
PRIOR FILING DATE:	1998-06-25
PRIOR APPLICATION NUMBER:	60/090690
PRIOR FILING DATE:	1998-06-25
PRIOR APPLICATION NUMBER:	60/090694
PRIOR FILING DATE:	1998-06-25
PRIOR APPLICATION NUMBER:	60/090695
PRIOR FILING DATE:	1998-06-25
PRIOR APPLICATION NUMBER:	60/090696
PRIOR FILING DATE:	1998-06-25
PRIOR APPLICATION NUMBER:	60/090862
PRIOR FILING DATE:	1998-06-26
PRIOR APPLICATION NUMBER:	60/090863
PRIOR FILING DATE:	1998-06-26
PRIOR APPLICATION NUMBER:	60/091360
PRIOR FILING DATE:	1998-07-01
PRIOR APPLICATION NUMBER:	60/091478
PRIOR FILING DATE:	1998-07-02
PRIOR APPLICATION NUMBER:	60/091544
PRIOR FILING DATE:	1998-07-01
PRIOR APPLICATION NUMBER:	60/091519
PRIOR FILING DATE:	1998-07-02
PRIOR APPLICATION NUMBER:	60/091626
PRIOR FILING DATE:	1998-07-02
PRIOR APPLICATION NUMBER:	60/091633
PRIOR FILING DATE:	1998-07-02
PRIOR APPLICATION NUMBER:	60/091978
PRIOR FILING DATE:	1998-07-07
PRIOR APPLICATION NUMBER:	60/091982
PRIOR FILING DATE:	1998-07-07
PRIOR APPLICATION NUMBER:	60/092182

```
; PRIOR FILING DATE: 1998-07-09
Query Match      100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVISMLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGMRCTPLGREGESC 60
Db 1 MRGATRVISMLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGMRCTPLGREGESC 60

Qy 61 HPGSHKVPFFKRKHHTCPCLNLLCSRFDPDGYRCSMDLKNINF 105
Db 61 HPGSHKVPFFKRKHHTCPCLNLLCSRFDPDGYRCSMDLKNINF 105

RESULT 3
US-09-989-279-371
; Sequence 371, Application US/09989279
; Patent No. US20020072496A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gottard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C56
; CURRENT APPLICATION NUMBER: US/09/989,279
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
```

;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090696
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090862
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/090863
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/091360
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091478
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091544
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09

Query Match

100.08; Score 589; DB 9; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLMLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLMLRGLRMCTPLGREGEEC 60
QY 61 HPGSHKVPFFRKRAHHTCPCLNLLCSRRFPDGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRAHHTCPCLNLLCSRRFPDGRYRCSDMLKNINF 105

RESULT 4

US-09-989-727-371
; Sequence 371, Application US/09989727
; Patent No. US20020072497A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Pacini, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C65
; CURRENT APPLICATION NUMBER: US/09/989, 727
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827

1	PRIOR FILING DATE: 1998-06-03	60/089944
2	PRIOR APPLICATION NUMBER: 60/088021	60/089952
3	PRIOR FILING DATE: 1998-06-04	60/089952
4	PRIOR APPLICATION NUMBER: 60/088025	60/090246
5	PRIOR FILING DATE: 1998-06-04	60/090246
6	PRIOR APPLICATION NUMBER: 60/088026	60/090252
7	PRIOR FILING DATE: 1998-06-04	60/090252
8	PRIOR APPLICATION NUMBER: 60/088028	60/090254
9	PRIOR FILING DATE: 1998-06-04	60/090254
10	PRIOR APPLICATION NUMBER: 60/088029	60/090349
11	PRIOR FILING DATE: 1998-06-04	60/090349
12	PRIOR APPLICATION NUMBER: 60/088030	60/090355
13	PRIOR FILING DATE: 1998-06-04	60/090355
14	PRIOR APPLICATION NUMBER: 60/088033	60/090429
15	PRIOR FILING DATE: 1998-06-04	60/090429
16	PRIOR APPLICATION NUMBER: 60/088036	60/090431
17	PRIOR FILING DATE: 1998-06-04	60/090431
18	PRIOR APPLICATION NUMBER: 60/088167	60/090435
19	PRIOR FILING DATE: 1998-06-05	60/090435
20	PRIOR APPLICATION NUMBER: 60/088202	60/090444
21	PRIOR FILING DATE: 1998-06-05	60/090444
22	PRIOR APPLICATION NUMBER: 60/088212	60/090445
23	PRIOR FILING DATE: 1998-06-05	60/090445
24	PRIOR APPLICATION NUMBER: 60/088217	60/090472
25	PRIOR FILING DATE: 1998-06-05	60/090472
26	PRIOR APPLICATION NUMBER: 60/088655	60/090535
27	PRIOR FILING DATE: 1998-06-09	60/090535
28	PRIOR APPLICATION NUMBER: 60/088734	60/090540
29	PRIOR FILING DATE: 1998-06-10	60/090540
30	PRIOR APPLICATION NUMBER: 60/088738	60/090557
31	PRIOR FILING DATE: 1998-06-10	60/090557
32	PRIOR APPLICATION NUMBER: 60/088742	60/090676
33	PRIOR FILING DATE: 1998-06-10	60/090676
34	PRIOR APPLICATION NUMBER: 60/088810	60/090678
35	PRIOR FILING DATE: 1998-06-10	60/090678
36	PRIOR APPLICATION NUMBER: 60/088824	60/090690
37	PRIOR FILING DATE: 1998-06-11	60/090690
38	PRIOR APPLICATION NUMBER: 60/088826	60/090694
39	PRIOR FILING DATE: 1998-06-11	60/090694
40	PRIOR APPLICATION NUMBER: 60/088858	60/090695
41	PRIOR FILING DATE: 1998-06-11	60/090695
42	PRIOR APPLICATION NUMBER: 60/088861	60/090696
43	PRIOR FILING DATE: 1998-06-11	60/090696
44	PRIOR APPLICATION NUMBER: 60/088876	60/090862
45	PRIOR FILING DATE: 1998-06-11	60/090862
46	PRIOR APPLICATION NUMBER: 60/089105	60/090863
47	PRIOR FILING DATE: 1998-06-12	60/091360
48	PRIOR APPLICATION NUMBER: 60/089440	60/091478
49	PRIOR FILING DATE: 1998-06-15	60/091478
50	PRIOR APPLICATION NUMBER: 60/089512	60/091544
51	PRIOR FILING DATE: 1998-06-16	60/091544
52	PRIOR APPLICATION NUMBER: 60/089514	60/091549
53	PRIOR FILING DATE: 1998-06-16	60/091549
54	PRIOR APPLICATION NUMBER: 60/089532	60/091626
55	PRIOR FILING DATE: 1998-06-17	60/091626
56	PRIOR APPLICATION NUMBER: 60/089538	60/091633
57	PRIOR FILING DATE: 1998-06-17	60/091633
58	PRIOR APPLICATION NUMBER: 60/089598	60/091978
59	PRIOR FILING DATE: 1998-06-17	60/091978
60	PRIOR APPLICATION NUMBER: 60/089599	60/091982
61	PRIOR FILING DATE: 1998-06-17	60/091982
62	PRIOR APPLICATION NUMBER: 60/089600	60/092182
63	PRIOR FILING DATE: 1998-06-17	60/092182
64	PRIOR APPLICATION NUMBER: 60/089653	60/092182
65	PRIOR FILING DATE: 1998-06-17	60/092182
66	PRIOR APPLICATION NUMBER: 60/089801	60/092182
67	PRIOR FILING DATE: 1998-06-18	60/092182
68	PRIOR APPLICATION NUMBER: 60/089807	60/092182
69	PRIOR FILING DATE: 1998-06-18	60/092182
70	PRIOR APPLICATION NUMBER: 60/089807	60/092182
71	PRIOR FILING DATE: 1998-06-18	60/092182
72	PRIOR APPLICATION NUMBER: 60/089807	60/092182
73	PRIOR FILING DATE: 1998-06-18	60/092182
74	PRIOR APPLICATION NUMBER: 60/089807	60/092182
75	PRIOR FILING DATE: 1998-06-18	60/092182
76	PRIOR APPLICATION NUMBER: 60/089807	60/092182
77	PRIOR FILING DATE: 1998-06-18	60/092182
78	PRIOR APPLICATION NUMBER: 60/089807	60/092182
79	PRIOR FILING DATE: 1998-06-18	60/092182
80	PRIOR APPLICATION NUMBER: 60/089807	60/092182
81	PRIOR FILING DATE: 1998-06-18	60/092182
82	PRIOR APPLICATION NUMBER: 60/089807	60/092182
83	PRIOR FILING DATE: 1998-06-18	60/092182
84	PRIOR APPLICATION NUMBER: 60/089807	60/092182
85	PRIOR FILING DATE: 1998-06-18	60/092182
86	PRIOR APPLICATION NUMBER: 60/089807	60/092182
87	PRIOR FILING DATE: 1998-06-18	60/092182
88		

```
Query Match      100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels
```


QY 1 MRGATVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLGRLMCTPLGREGSEC 60
Db 1 MRGATVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLGRLMCTPLGREGSEC 60
QY 61 HPGSHKVPFFRRKHKHTCTCLNLLCSRPDPGRYRCSDMLKKNINF 105
Db 61 HPGSHKVPFFRRKHKHTCTCLNLLCSRPDPGRYRCSDMLKKNINF 105

RESULT 5

US-09-989-731-371
; Sequence 371, Application US/09989731
; Patent No. US20020103125A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deshoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730PIC70
; CURRENT APPLICATION NUMBER: US/09/989,731
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952

1 PRIOR FILING DATE: 1998-06-19
 1 PRIOR APPLICATION NUMBER: 60/090246
 1 PRIOR FILING DATE: 1998-06-22
 1 PRIOR APPLICATION NUMBER: 60/090252
 1 PRIOR FILING DATE: 1998-06-22
 1 PRIOR APPLICATION NUMBER: 60/090254
 1 PRIOR FILING DATE: 1998-06-22
 1 PRIOR APPLICATION NUMBER: 60/090349
 1 PRIOR FILING DATE: 1998-06-23
 1 PRIOR APPLICATION NUMBER: 60/090355
 1 PRIOR FILING DATE: 1998-06-23
 1 PRIOR APPLICATION NUMBER: 60/090429
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090431
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090435
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090444
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090445
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090472
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090557
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090676
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090678
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090690
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090694
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090695
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090696
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090862
 1 PRIOR FILING DATE: 1998-06-26
 1 PRIOR APPLICATION NUMBER: 60/090863
 1 PRIOR FILING DATE: 1998-06-26
 1 PRIOR APPLICATION NUMBER: 60/091360
 1 PRIOR FILING DATE: 1998-07-01
 1 PRIOR APPLICATION NUMBER: 60/091478
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091544
 1 PRIOR FILING DATE: 1998-07-01
 1 PRIOR APPLICATION NUMBER: 60/091519
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091626
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091633
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091978
 1 PRIOR FILING DATE: 1998-07-07
 1 PRIOR APPLICATION NUMBER: 60/091982
 1 PRIOR FILING DATE: 1998-07-07
 1 PRIOR APPLICATION NUMBER: 60/092182
 1 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2,6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCALSILWRLGRLMCTPLGREGECC 60
 1 MRGATRVSIMLLLVTVSDCAVITGACERDVCGAGTCCALSILWRLGRLMCTPLGREGECC 60

QY 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFDPGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFDPGRYRCSDMLKNINF 105
 RESULT 6
 US-09-989-732-371
 ; Sequence 371, Application US/09989732
 ; Patent No. US20020123463A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: P27301C57
 ; CURRENT APPLICATION NUMBER: US/09/989,732
 ; CURRENT FILING DATE: 2001-11-19
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/087106
 ; PRIOR FILING DATE: 1998-05-28
 ; PRIOR APPLICATION NUMBER: 60/087607
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087609
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087759
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087827
 ; PRIOR FILING DATE: 1998-06-03
 ; PRIOR APPLICATION NUMBER: 60/088021
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088025
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088026

;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088028
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088029
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088030
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088033
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088326
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088167
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088202
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088212
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088217
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088655
;; PRIOR FILING DATE: 1998-06-09
;; PRIOR APPLICATION NUMBER: 60/088734
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088738
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088742
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088810
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088824
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088826
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088858
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088861
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088876
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/089105
;; PRIOR FILING DATE: 1998-06-12
;; PRIOR APPLICATION NUMBER: 60/089440
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089512
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089514
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089598
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089599
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089600
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089653
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089801
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089907
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089908
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22

;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090696
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090862
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/090863
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/091360
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091478
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091544
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTSDCAVITGACERDVQCCAGTCCATSLMRLGRLMCTPLGRGEEC 60
Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCCAGTCCATSLMRLGRLMCTPLGRGEEC 60
Qy 61 HPGSHKVPFRKRKHHTCPCLPNLLCSRPDPGRYCSMDLKNINF 105

Db 61 HPGSHKVFPRKXKHTCPCLPNLLCSRFDPGRVRCSDMLKNINF 105

RESULT 7

US-09-991-073-371

; Sequence 371, Application US/09991073

; Patent No. US20020127576A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: P273P1C15

; CURRENT APPLICATION NUMBER: US/09/991,073

; CURRENT FILING DATE: 2001-11-14

; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/075945

; PRIOR FILING DATE: 1998-02-25

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/084600

; PRIOR FILING DATE: 1998-05-07

; PRIOR APPLICATION NUMBER: 60/087106

; PRIOR FILING DATE: 1998-05-28

; PRIOR APPLICATION NUMBER: 60/087607

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087609

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087759

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087827

; PRIOR FILING DATE: 1998-06-03

; PRIOR APPLICATION NUMBER: 60/088021

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088025

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088026

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088028

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088029

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088030

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088033

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088326

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088167

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088202

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088212

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088217

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088655

; PRIOR FILING DATE: 1998-06-09

; PRIOR APPLICATION NUMBER: 60/088734

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088738

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088742

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088810

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088824

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088826

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088858

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/088861

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/088876

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/089105

; PRIOR FILING DATE: 1998-06-12

; PRIOR APPLICATION NUMBER: 60/089440

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089512

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089514

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089532

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089538

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089598

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089599

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089600

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089653

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089801

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089907

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089908

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089947

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/089948

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/089952

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/090246

; PRIOR FILING DATE: 1998-06-22

; PRIOR APPLICATION NUMBER: 60/090252

; PRIOR FILING DATE: 1998-06-22

; PRIOR APPLICATION NUMBER: 60/090254

RESULT 8
US/09-990-442-371
Sequence 371, Application US/09990442
Patent No. US20020132252A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Denoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Raphaelene
APPLICANT: Fong, Sherma
APPLICANT: Gerber, Hanspeter
APPLICANT: Grietsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secrypted and Transmem
TITLE OF INVENTION: Acids Encoding the S
FILE REFERENCE: P2730PlC8
CURRENT APPLICATION NUMBER: US/09/990,442
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030

	Query Match	100.0%	Score 589	DB 9	Length 105
	Best Local Similarity	100.0%	Pred. No. 2.6e-55		
	Matches 105	Conservative 0	Mismatches 0	Indels 0	Gaps 0
Qy	1	MRGATRVISIMLLLVTSDDCAVITGACERDVOCGAGTCCAI	SLMWLRLGIMCTPLRGSEEC	60	
Db	1	MRGATRVISIMLLLVTSDDCAVITGACERDVOCGAGTCCAI	SLMWLRLGIMCTPLRGSEEC	60	
Qy	61	HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF		105	
Db	61	HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF		105	

Patent No. US20020132253A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P17
CURRENT APPLICATION NUMBER: US/09/991,163
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429

; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2,6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MGRATRVSIMLLVTSVSDCAVITGACERDVQCGAGTCCALSLMLRGLRMCTPLGRGEEC 60
 Db 1 MGRATRVSIMLLVTSVSDCAVITGACERDVQCGAGTCCALSLMLRGLRMCTPLGRGEEC 60
 Qy 61 HPGSHKVPFFKRRKHTCPCLPNLLCSRFDPGRVRCSDMLKNINF 105
 Db 61 HPGSHKVPFFKRRKHTCPCLPNLLCSRFDPGRVRCSDMLKNINF 105

RESULT 10
 US-09-993-604-371
 ; Sequence 371, Application US/09993604
 ; Patent No. US20020137075A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kijavir, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: P2730P1C25
 ; CURRENT APPLICATION NUMBER: US/09/993,604
 ; PRIOR FILING DATE: 2001-11-14
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/087106
 ; PRIOR FILING DATE: 1998-05-28
 ; PRIOR APPLICATION NUMBER: 60/087607
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087609
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087759
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087827
 ; PRIOR FILING DATE: 1998-06-03
 ; PRIOR APPLICATION NUMBER: 60/088021
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088025
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088026
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088028
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088029
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088030
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088033
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088326
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088167

PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088555
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24

PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCATSLMRLGLRMCTPLGRGEEC 60
Db 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCATSLMRLGLRMCTPLGRGEEC 60
Qy 61 HPGSHKVPFFPRKXKHTCPCLPNLLCSRPDPGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFPRKXKHTCPCLPNLLCSRPDPGRYRCMDLKNINF 105

RESULT 11
US-09-990-456-371
Sequence 371, Application US/09990456
Patent No. US20020137890A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc

APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Godard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C22
CURRENT APPLICATION NUMBER: US/09/990,456
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088036
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444

APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P27301C55
CURRENT APPLICATION NUMBER: US/09/989,721
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55; Mismatches 0; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSVCAGTTCACERDVCGAGTCCATISLWLRGLRMCTPLGREGEEC 60
DB 1 MEGATRVSIMLLLVTSVCAGTTCACERDVCGAGTCCATISLWLRGLRMCTPLGREGEEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPFGYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPFGYRCSMDLKNINF 105

RESULT 12

US-09-989-721-371
Sequence 371, Application US/09989721
Patent No. US20020142961A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman

1	PRIOR FILING DATE: 1998-06-05
2	PRIOR APPLICATION NUMBER: 60/088555
3	PRIOR FILING DATE: 1998-06-09
4	PRIOR APPLICATION NUMBER: 60/088734
5	PRIOR FILING DATE: 1998-06-10
6	PRIOR APPLICATION NUMBER: 60/088738
7	PRIOR FILING DATE: 1998-06-10
8	PRIOR APPLICATION NUMBER: 60/088742
9	PRIOR FILING DATE: 1998-06-10
10	PRIOR APPLICATION NUMBER: 60/088810
11	PRIOR FILING DATE: 1998-06-10
12	PRIOR APPLICATION NUMBER: 60/088824
13	PRIOR FILING DATE: 1998-06-10
14	PRIOR APPLICATION NUMBER: 60/088826
15	PRIOR FILING DATE: 1998-06-10
16	PRIOR APPLICATION NUMBER: 60/088858
17	PRIOR FILING DATE: 1998-06-11
18	PRIOR APPLICATION NUMBER: 60/088861
19	PRIOR FILING DATE: 1998-06-11
20	PRIOR APPLICATION NUMBER: 60/088876
21	PRIOR FILING DATE: 1998-06-11
22	PRIOR APPLICATION NUMBER: 60/089105
23	PRIOR FILING DATE: 1998-06-12
24	PRIOR APPLICATION NUMBER: 60/089440
25	PRIOR FILING DATE: 1998-06-16
26	PRIOR APPLICATION NUMBER: 60/089512
27	PRIOR FILING DATE: 1998-06-16
28	PRIOR APPLICATION NUMBER: 60/089514
29	PRIOR FILING DATE: 1998-06-16
30	PRIOR APPLICATION NUMBER: 60/089532
31	PRIOR FILING DATE: 1998-06-17
32	PRIOR APPLICATION NUMBER: 60/089538
33	PRIOR FILING DATE: 1998-06-17
34	PRIOR APPLICATION NUMBER: 60/089598
35	PRIOR FILING DATE: 1998-06-17
36	PRIOR APPLICATION NUMBER: 60/089599
37	PRIOR FILING DATE: 1998-06-17
38	PRIOR APPLICATION NUMBER: 60/089600
39	PRIOR FILING DATE: 1998-06-17
40	PRIOR APPLICATION NUMBER: 60/089653
41	PRIOR FILING DATE: 1998-06-17
42	PRIOR APPLICATION NUMBER: 60/089801
43	PRIOR FILING DATE: 1998-06-18
44	PRIOR APPLICATION NUMBER: 60/089907
45	PRIOR FILING DATE: 1998-06-18
46	PRIOR APPLICATION NUMBER: 60/089908
47	PRIOR FILING DATE: 1998-06-18
48	PRIOR APPLICATION NUMBER: 60/089947
49	PRIOR FILING DATE: 1998-06-19
50	PRIOR APPLICATION NUMBER: 60/089948
51	PRIOR FILING DATE: 1998-06-19
52	PRIOR APPLICATION NUMBER: 60/089952
53	PRIOR FILING DATE: 1998-06-19
54	PRIOR APPLICATION NUMBER: 60/090246
55	PRIOR FILING DATE: 1998-06-22
56	PRIOR APPLICATION NUMBER: 60/090252
57	PRIOR FILING DATE: 1998-06-22
58	PRIOR APPLICATION NUMBER: 60/090254
59	PRIOR FILING DATE: 1998-06-22
60	PRIOR APPLICATION NUMBER: 60/090349
61	PRIOR FILING DATE: 1998-06-23
62	PRIOR APPLICATION NUMBER: 60/090355
63	PRIOR FILING DATE: 1998-06-23
64	PRIOR APPLICATION NUMBER: 60/090429
65	PRIOR FILING DATE: 1998-06-24
66	PRIOR APPLICATION NUMBER: 60/090431
67	PRIOR FILING DATE: 1998-06-24
68	PRIOR APPLICATION NUMBER: 60/090435
69	PRIOR FILING DATE: 1998-06-24
70	PRIOR APPLICATION NUMBER: 60/090444
71	PRIOR FILING DATE: 1998-06-24
72	PRIOR APPLICATION NUMBER: 60/090445
73	PRIOR FILING DATE: 1998-06-24

1	PRIOR APPLICATION NUMBER: 60/090472
2	PRIOR FILING DATE: 1998-06-24
3	PRIOR APPLICATION NUMBER: 60/090535
4	PRIOR FILING DATE: 1998-06-24
5	PRIOR APPLICATION NUMBER: 60/090540
6	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090542
8	PRIOR FILING DATE: 1998-06-24
9	PRIOR APPLICATION NUMBER: 60/090557
10	PRIOR FILING DATE: 1998-06-24
11	PRIOR APPLICATION NUMBER: 60/090676
12	PRIOR FILING DATE: 1998-06-25
13	PRIOR APPLICATION NUMBER: 60/090678
14	PRIOR FILING DATE: 1998-06-25
15	PRIOR APPLICATION NUMBER: 60/090690
16	PRIOR FILING DATE: 1998-06-25
17	PRIOR APPLICATION NUMBER: 60/090694
18	PRIOR FILING DATE: 1998-06-25
19	PRIOR APPLICATION NUMBER: 60/090695
20	PRIOR FILING DATE: 1998-06-25
21	PRIOR APPLICATION NUMBER: 60/090696
22	PRIOR FILING DATE: 1998-06-25
23	PRIOR APPLICATION NUMBER: 60/090862
24	PRIOR FILING DATE: 1998-06-26
25	PRIOR APPLICATION NUMBER: 60/090863
26	PRIOR FILING DATE: 1998-06-26
27	PRIOR APPLICATION NUMBER: 60/091360
28	PRIOR FILING DATE: 1998-07-01
29	PRIOR APPLICATION NUMBER: 60/091478
30	PRIOR FILING DATE: 1998-07-02
31	PRIOR APPLICATION NUMBER: 60/091544
32	PRIOR FILING DATE: 1998-07-01
33	PRIOR APPLICATION NUMBER: 60/091519
34	PRIOR FILING DATE: 1998-07-02
35	PRIOR APPLICATION NUMBER: 60/091626
36	PRIOR FILING DATE: 1998-07-02
37	PRIOR APPLICATION NUMBER: 60/091633
38	PRIOR FILING DATE: 1998-07-02
39	PRIOR APPLICATION NUMBER: 60/091978
40	PRIOR FILING DATE: 1998-07-07
41	PRIOR APPLICATION NUMBER: 60/091982
42	PRIOR FILING DATE: 1998-07-07
43	PRIOR APPLICATION NUMBER: 60/092182
44	PRIOR FILING DATE: 1998-07-09

Query Match	100.0%;	Score 589;	DB 9;	Length 105;
Best Local Similarity	100.0%;	Pred. No. 2.6e-55;		
Matches 105;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	1	MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCAI	SLWRLGLRMCPTLQREGEC	60
Db	1	MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCAI	SLWRLGLRMCPTLQREGEC	60
QY	61	HFGSHKVPPFRKRGKHTCPCPLNLLCSFFPDGRYRCSMDLNINF	105	
Db	61	HFGSHKVPPFRKRGKHTCPCPLNLLCSFFPDGRYRCSMDLNINF	105	

RESULT 13
US-09-992-598-371
; Sequence 371, Application US/09992598
; Patent No. US20020160384A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoves, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Grittsen, Mary E.
; APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Rapier, Mary A.
APPLICANT: Fan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C20
CURRENT APPLICATION NUMBER: US/09/992,598
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09

PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535

PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55; Mismatches 0; Indels 0; Gaps 0;
Matches 105; Conservative 0;
QY 1 MRGATRVSIMLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMTCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMTCTPLGREGEEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCPLNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCPLNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 14
US-09-886-242A-2
Sequence 2, Application US/09886242A
Patent No. US20020172678A1
GENERAL INFORMATION:
APPLICANT: Ferrara, Napoleone
APPLICANT: Watanabe, Colin
APPLICANT: Wood, William I.
TITLE OF INVENTION: EG-VSGF NUCLEIC ACIDS AND POLYPEPTIDES
TITLE OF INVENTION: AND METHODS OF USE
FILE REFERENCE: GENENT.1516A
CURRENT APPLICATION NUMBER: US/09/886,242A
CURRENT FILING DATE: 2001-06-20
PRIOR APPLICATION NUMBER: US 60/230,978
PRIOR FILING DATE: 2000-09-07
PRIOR APPLICATION NUMBER: US 60/213,637
PRIOR FILING DATE: 2000-06-23
PRIOR APPLICATION NUMBER: US 60/145,698

PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/096,146
PRIOR FILING DATE: 1998-08-11
PRIOR APPLICATION NUMBER: PCT/US00/32678
PRIOR FILING DATE: 2000-12-01
PRIOR APPLICATION NUMBER: PCT/US00/08439
PRIOR FILING DATE: 2000-03-30
PRIOR APPLICATION NUMBER: PCT/US00/04914
PRIOR FILING DATE: 2000-02-24
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
PRIOR APPLICATION NUMBER: PCT/US99/12252
PRIOR FILING DATE: 1999-06-02
PRIOR APPLICATION NUMBER: US 09/709,238
PRIOR FILING DATE: 2000-11-08
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 18
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2

LENGTH: 105
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
US-09-886-242A-2

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55; Mismatches 0; Indels 0; Gaps 0;
Matches 105; Conservative 0;
QY 1 MRGATRVSIMLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMTCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMTCTPLGREGEEC 60
QY 61 HPGSHKVPFFRRKRKHTCPCPLNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCPLNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 15
US-09-989-293A-371
Sequence 371, Application US/09989293A
Patent No. US20020177164A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730PIC66
CURRENT APPLICATION NUMBER: US/09/989,293A
CURRENT FILING DATE: 2001-11-20
PRIOR APPLICATION NUMBER: 60/049787

PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089800
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862

; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60
 DB 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

 QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
 DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 16

US-09-965-528-11
 ; Sequence 11, Application US/09965528
 ; Publication No. US20020187523A1
 ; GENERAL INFORMATION:
 ; APPLICANT: INCYTE GENOMICS, INC.
 ; APPLICANT: TANG, Y. Tom
 ; APPLICANT: YUE, Henry
 ; APPLICANT: LAL, Preeti
 ; APPLICANT: BURFORD, Neil
 ; APPLICANT: BANDMAN, Olga
 ; APPLICANT: BAUGHN, Mariah R.
 ; APPLICANT: AZIMZAI, Valda
 ; APPLICANT: LU, Dzung Aina M.
 ; APPLICANT: PATTERSON, Chandra
 ; TITLE OF INVENTION: EXTRACELLULAR SIGNALING MOLECULES
 ; FILE REFERENCE: PP-0701 USA
 ; CURRENT APPLICATION NUMBER: US/09/965,528
 ; CURRENT FILING DATE: 2001-09-26
 ; PRIOR APPLICATION NUMBER: 60/134,949
 ; PRIOR FILING DATE: 1999-05-19
 ; PRIOR APPLICATION NUMBER: 60/144,270
 ; PRIOR FILING DATE: 1999-07-15
 ; PRIOR APPLICATION NUMBER: 60/146,700
 ; PRIOR FILING DATE: 1999-07-30
 ; PRIOR APPLICATION NUMBER: 60/157,508
 ; PRIOR FILING DATE: 1999-10-04
 ; NUMBER OF SEQ ID NOS: 55
 ; SOFTWARE: PERL Program
 ; SEQ ID NO 11
 ; LENGTH: 105
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: misc feature
 ; OTHER INFORMATION: Incyte ID No. US20020187523A1 2006548CD1
 ; US-09-965-528-11

Query Match 100.0%; Score 589; DB 9; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60
 DB 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

 QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
 DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 17

US-09-989-735-371
 ; Sequence 371, Application US/09989735
 ; Publication No. US20020193299A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Geritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaudo, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tamas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: P2730PIC61
 ; CURRENT APPLICATION NUMBER: US/09/989,735
 ; CURRENT FILING DATE: 2001-11-19
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/087106
 ; PRIOR FILING DATE: 1998-05-28
 ; PRIOR APPLICATION NUMBER: 60/087607
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087609
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087759
 ; PRIOR FILING DATE: 1998-06-02

1	PRIOR APPLICATION NUMBER: 60/087821
2	PRIOR FILING DATE: 1998-06-03
3	PRIOR APPLICATION NUMBER: 60/088021
4	PRIOR FILING DATE: 1998-06-04
5	PRIOR APPLICATION NUMBER: 60/088025
6	PRIOR FILING DATE: 1998-06-04
7	PRIOR APPLICATION NUMBER: 60/088026
8	PRIOR FILING DATE: 1998-06-04
9	PRIOR APPLICATION NUMBER: 60/088028
10	PRIOR FILING DATE: 1998-06-04
11	PRIOR APPLICATION NUMBER: 60/088029
12	PRIOR FILING DATE: 1998-06-04
13	PRIOR APPLICATION NUMBER: 60/088030
14	PRIOR FILING DATE: 1998-06-04
15	PRIOR APPLICATION NUMBER: 60/088033
16	PRIOR FILING DATE: 1998-06-04
17	PRIOR APPLICATION NUMBER: 60/088326
18	PRIOR FILING DATE: 1998-06-04
19	PRIOR APPLICATION NUMBER: 60/088167
20	PRIOR FILING DATE: 1998-06-05
21	PRIOR APPLICATION NUMBER: 60/088202
22	PRIOR FILING DATE: 1998-06-05
23	PRIOR APPLICATION NUMBER: 60/088212
24	PRIOR FILING DATE: 1998-06-05
25	PRIOR APPLICATION NUMBER: 60/088217
26	PRIOR FILING DATE: 1998-06-05
27	PRIOR APPLICATION NUMBER: 60/088655
28	PRIOR FILING DATE: 1998-06-09
29	PRIOR APPLICATION NUMBER: 60/088734
30	PRIOR FILING DATE: 1998-06-10
31	PRIOR APPLICATION NUMBER: 60/088738
32	PRIOR FILING DATE: 1998-06-10
33	PRIOR APPLICATION NUMBER: 60/088742
34	PRIOR FILING DATE: 1998-06-10
35	PRIOR APPLICATION NUMBER: 60/088910
36	PRIOR FILING DATE: 1998-06-10
37	PRIOR APPLICATION NUMBER: 60/088924
38	PRIOR FILING DATE: 1998-06-10
39	PRIOR APPLICATION NUMBER: 60/088926
40	PRIOR FILING DATE: 1998-06-10
41	PRIOR APPLICATION NUMBER: 60/088958
42	PRIOR FILING DATE: 1998-06-11
43	PRIOR APPLICATION NUMBER: 60/088961
44	PRIOR FILING DATE: 1998-06-11
45	PRIOR APPLICATION NUMBER: 60/088976
46	PRIOR FILING DATE: 1998-06-11
47	PRIOR APPLICATION NUMBER: 60/089105
48	PRIOR FILING DATE: 1998-06-12
49	PRIOR APPLICATION NUMBER: 60/089440
50	PRIOR FILING DATE: 1998-06-16
51	PRIOR APPLICATION NUMBER: 60/089512
52	PRIOR FILING DATE: 1998-06-16
53	PRIOR APPLICATION NUMBER: 60/089514
54	PRIOR FILING DATE: 1998-06-16
55	PRIOR APPLICATION NUMBER: 60/089532
56	PRIOR FILING DATE: 1998-06-17
57	PRIOR APPLICATION NUMBER: 60/089538
58	PRIOR FILING DATE: 1998-06-17
59	PRIOR APPLICATION NUMBER: 60/089598
60	PRIOR FILING DATE: 1998-06-17
61	PRIOR APPLICATION NUMBER: 60/089599
62	PRIOR FILING DATE: 1998-06-17
63	PRIOR APPLICATION NUMBER: 60/089600
64	PRIOR FILING DATE: 1998-06-17
65	PRIOR APPLICATION NUMBER: 60/089653
66	PRIOR FILING DATE: 1998-06-17
67	PRIOR APPLICATION NUMBER: 60/089801
68	PRIOR FILING DATE: 1998-06-18
69	PRIOR APPLICATION NUMBER: 60/089907
70	PRIOR FILING DATE: 1998-06-18
71	PRIOR APPLICATION NUMBER: 60/089908
72	PRIOR FILING DATE: 1998-06-18
73	PRIOR APPLICATION NUMBER: 60/089947

1	PRIOR FILING DATE: 1998-06-19	
2	PRIOR APPLICATION NUMBER: 60/089948	
3	PRIOR FILING DATE: 1998-06-19	
4	PRIOR APPLICATION NUMBER: 60/089952	
5	PRIOR FILING DATE: 1998-06-19	
6	PRIOR APPLICATION NUMBER: 60/090246	
7	PRIOR FILING DATE: 1998-06-22	
8	PRIOR APPLICATION NUMBER: 60/090252	
9	PRIOR FILING DATE: 1998-06-22	
10	PRIOR APPLICATION NUMBER: 60/090254	
11	PRIOR FILING DATE: 1998-06-22	
12	PRIOR APPLICATION NUMBER: 60/090349	
13	PRIOR FILING DATE: 1998-06-23	
14	PRIOR APPLICATION NUMBER: 60/090355	
15	PRIOR FILING DATE: 1998-06-23	
16	PRIOR APPLICATION NUMBER: 60/090429	
17	PRIOR FILING DATE: 1998-06-24	
18	PRIOR APPLICATION NUMBER: 60/090433	
19	PRIOR FILING DATE: 1998-06-24	
20	PRIOR APPLICATION NUMBER: 60/090435	
21	PRIOR FILING DATE: 1998-06-24	
22	PRIOR APPLICATION NUMBER: 60/090444	
23	PRIOR FILING DATE: 1998-06-24	
24	PRIOR APPLICATION NUMBER: 60/090445	
25	PRIOR FILING DATE: 1998-06-24	
26	PRIOR APPLICATION NUMBER: 60/090472	
27	PRIOR FILING DATE: 1998-06-24	
28	PRIOR APPLICATION NUMBER: 60/090535	
29	PRIOR FILING DATE: 1998-06-24	
30	PRIOR APPLICATION NUMBER: 60/090540	
31	PRIOR FILING DATE: 1998-06-24	
32	PRIOR APPLICATION NUMBER: 60/090542	
33	PRIOR FILING DATE: 1998-06-24	
34	PRIOR APPLICATION NUMBER: 60/090557	
35	PRIOR FILING DATE: 1998-06-24	
36	PRIOR APPLICATION NUMBER: 60/090676	
37	PRIOR FILING DATE: 1998-06-25	
38	PRIOR APPLICATION NUMBER: 60/090678	
39	PRIOR FILING DATE: 1998-06-25	
40	PRIOR APPLICATION NUMBER: 60/090690	
41	PRIOR FILING DATE: 1998-06-25	
42	PRIOR APPLICATION NUMBER: 60/090694	
43	PRIOR FILING DATE: 1998-06-25	
44	PRIOR APPLICATION NUMBER: 60/090695	
45	PRIOR FILING DATE: 1998-06-25	
46	PRIOR APPLICATION NUMBER: 60/090696	
47	PRIOR FILING DATE: 1998-06-25	
48	PRIOR APPLICATION NUMBER: 60/090862	
49	PRIOR FILING DATE: 1998-06-26	
50	PRIOR APPLICATION NUMBER: 60/090863	
51	PRIOR FILING DATE: 1998-06-26	
52	PRIOR APPLICATION NUMBER: 60/091360	
53	PRIOR FILING DATE: 1998-07-01	
54	PRIOR APPLICATION NUMBER: 60/091478	
55	PRIOR FILING DATE: 1998-07-02	
56	PRIOR APPLICATION NUMBER: 60/091544	
57	PRIOR FILING DATE: 1998-07-01	
58	PRIOR APPLICATION NUMBER: 60/091519	
59	PRIOR FILING DATE: 1998-07-02	
60	PRIOR APPLICATION NUMBER: 60/091626	
61	PRIOR FILING DATE: 1998-07-02	
62	PRIOR APPLICATION NUMBER: 60/091633	
63	PRIOR FILING DATE: 1998-07-02	
64	PRIOR APPLICATION NUMBER: 60/091978	
65	PRIOR FILING DATE: 1998-07-07	
66	PRIOR APPLICATION NUMBER: 60/091982	
67	PRIOR FILING DATE: 1998-07-07	
68	PRIOR APPLICATION NUMBER: 60/092182	
69	PRIOR FILING DATE: 1998-07-09	

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels

Qy 1 MRGATRVISIMLLVTSDCAVITGACERDVQCGAGTCCATSLWLRGIMCTPLGRSGEEC 60
Db 1 MRGATRVISIMLLVTSDCAVITGACERDVQCGAGTCCATSLWLRGIMCTPLGRSGEEC 60
Qy 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPDGRYRCSMDLKNINF 105

RESULT 18

US-09-990-444-371
; Sequence 371, Application US/09990444
; Publication No. US20020193300A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertschen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C19
; CURRENT APPLICATION NUMBER: US/09/990,444
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021

; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19

1 PRIOR APPLICATION NUMBER: 60/089952
2 PRIOR FILING DATE: 1998-06-19
3 PRIOR APPLICATION NUMBER: 60/090246
4 PRIOR FILING DATE: 1998-06-22
5 PRIOR APPLICATION NUMBER: 60/090252
6 PRIOR FILING DATE: 1998-06-22
7 PRIOR APPLICATION NUMBER: 60/090254
8 PRIOR FILING DATE: 1998-06-22
9 PRIOR APPLICATION NUMBER: 60/090349
10 PRIOR FILING DATE: 1998-06-23
11 PRIOR APPLICATION NUMBER: 60/090355
12 PRIOR FILING DATE: 1998-06-23
13 PRIOR APPLICATION NUMBER: 60/090429
14 PRIOR FILING DATE: 1998-06-24
15 PRIOR APPLICATION NUMBER: 60/090431
16 PRIOR FILING DATE: 1998-06-24
17 PRIOR APPLICATION NUMBER: 60/090435
18 PRIOR FILING DATE: 1998-06-24
19 PRIOR APPLICATION NUMBER: 60/090444
20 PRIOR FILING DATE: 1998-06-24
21 PRIOR APPLICATION NUMBER: 60/090445
22 PRIOR FILING DATE: 1998-06-24
23 PRIOR APPLICATION NUMBER: 60/090472
24 PRIOR FILING DATE: 1998-06-24
25 PRIOR APPLICATION NUMBER: 60/090535
26 PRIOR FILING DATE: 1998-06-24
27 PRIOR APPLICATION NUMBER: 60/090540
28 PRIOR FILING DATE: 1998-06-24
29 PRIOR APPLICATION NUMBER: 60/090542
30 PRIOR FILING DATE: 1998-06-24
31 PRIOR APPLICATION NUMBER: 60/090557
32 PRIOR FILING DATE: 1998-06-24
33 PRIOR APPLICATION NUMBER: 60/090676
34 PRIOR FILING DATE: 1998-06-25
35 PRIOR APPLICATION NUMBER: 60/090678
36 PRIOR FILING DATE: 1998-06-25
37 PRIOR APPLICATION NUMBER: 60/090690
38 PRIOR FILING DATE: 1998-06-25
39 PRIOR APPLICATION NUMBER: 60/090694
40 PRIOR FILING DATE: 1998-06-25
41 PRIOR APPLICATION NUMBER: 60/090695
42 PRIOR FILING DATE: 1998-06-25
43 PRIOR APPLICATION NUMBER: 60/090696
44 PRIOR FILING DATE: 1998-06-25
45 PRIOR APPLICATION NUMBER: 60/090862
46 PRIOR FILING DATE: 1998-06-26
47 PRIOR APPLICATION NUMBER: 60/090863
48 PRIOR FILING DATE: 1998-06-26
49 PRIOR APPLICATION NUMBER: 60/091360
50 PRIOR FILING DATE: 1998-07-01
51 PRIOR APPLICATION NUMBER: 60/091478
52 PRIOR FILING DATE: 1998-07-02
53 PRIOR APPLICATION NUMBER: 60/091544
54 PRIOR FILING DATE: 1998-07-01
55 PRIOR APPLICATION NUMBER: 60/091519
56 PRIOR FILING DATE: 1998-07-02
57 PRIOR APPLICATION NUMBER: 60/091626
58 PRIOR FILING DATE: 1998-07-02
59 PRIOR APPLICATION NUMBER: 60/091633
60 PRIOR FILING DATE: 1998-07-02
61 PRIOR APPLICATION NUMBER: 60/091978
62 PRIOR FILING DATE: 1998-07-07
63 PRIOR APPLICATION NUMBER: 60/091982
64 PRIOR FILING DATE: 1998-07-07
65 PRIOR APPLICATION NUMBER: 60/092182
66 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCALISLWRLGRLMCTPLGREGEC 60

QY

Db 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCALISLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFRKRGHTCPCLPNLLCSRPPDGRYRCMDLKNINF 105
Db 61 HPGSHKVPFRKRGHTCPCLPNLLCSRPPDGRYRCMDLKNINF 105

RESULT 19

US-09-991-181-371
; Sequence 371. Application US/09991181
; Publication No. US20020197615A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C53
; CURRENT APPLICATION NUMBER: US/09/991.181
; CURRENT FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04

Db 61 HPGSHKVPFRKRRKHTCTCLPCLNLLCSFFDGRYRCMSDLKINF 105

RESULT 20

US-09-989-730-371
Sequence 371, Application US/09989730

Publication No. US20020197674A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730PIC69
CURRENT APPLICATION NUMBER: US/09/989,730
CURRENT FILING DATE: 2001-11-20
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-03-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028

PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22

1 PRIOR APPLICATION NUMBER: 60/090254
2 PRIOR FILING DATE: 1998-06-22
3 PRIOR APPLICATION NUMBER: 60/090349
4 PRIOR FILING DATE: 1998-06-23
5 PRIOR APPLICATION NUMBER: 60/090355
6 PRIOR FILING DATE: 1998-06-23
7 PRIOR APPLICATION NUMBER: 60/090429
8 PRIOR FILING DATE: 1998-06-24
9 PRIOR APPLICATION NUMBER: 60/090431
10 PRIOR FILING DATE: 1998-06-24
11 PRIOR APPLICATION NUMBER: 60/090435
12 PRIOR FILING DATE: 1998-06-24
13 PRIOR APPLICATION NUMBER: 60/090444
14 PRIOR FILING DATE: 1998-06-24
15 PRIOR APPLICATION NUMBER: 60/090445
16 PRIOR FILING DATE: 1998-06-24
17 PRIOR APPLICATION NUMBER: 60/090472
18 PRIOR FILING DATE: 1998-06-24
19 PRIOR APPLICATION NUMBER: 60/090535
20 PRIOR FILING DATE: 1998-06-24
21 PRIOR APPLICATION NUMBER: 60/090540
22 PRIOR FILING DATE: 1998-06-24
23 PRIOR APPLICATION NUMBER: 60/090542
24 PRIOR FILING DATE: 1998-06-24
25 PRIOR APPLICATION NUMBER: 60/090557
26 PRIOR FILING DATE: 1998-06-24
27 PRIOR APPLICATION NUMBER: 60/090676
28 PRIOR FILING DATE: 1998-06-25
29 PRIOR APPLICATION NUMBER: 60/090678
30 PRIOR FILING DATE: 1998-06-25
31 PRIOR APPLICATION NUMBER: 60/090690
32 PRIOR FILING DATE: 1998-06-25
33 PRIOR APPLICATION NUMBER: 60/090694
34 PRIOR FILING DATE: 1998-06-25
35 PRIOR APPLICATION NUMBER: 60/090695
36 PRIOR FILING DATE: 1998-06-25
37 PRIOR APPLICATION NUMBER: 60/090696
38 PRIOR FILING DATE: 1998-06-25
39 PRIOR APPLICATION NUMBER: 60/090862
40 PRIOR FILING DATE: 1998-06-26
41 PRIOR APPLICATION NUMBER: 60/090863
42 PRIOR FILING DATE: 1998-06-26
43 PRIOR APPLICATION NUMBER: 60/091360
44 PRIOR FILING DATE: 1998-07-01
45 PRIOR APPLICATION NUMBER: 60/091478
46 PRIOR FILING DATE: 1998-07-02
47 PRIOR APPLICATION NUMBER: 60/091544
48 PRIOR FILING DATE: 1998-07-01
49 PRIOR APPLICATION NUMBER: 60/091519
50 PRIOR FILING DATE: 1998-07-02
51 PRIOR APPLICATION NUMBER: 60/091626
52 PRIOR FILING DATE: 1998-07-02
53 PRIOR APPLICATION NUMBER: 60/091633
54 PRIOR FILING DATE: 1998-07-02
55 PRIOR APPLICATION NUMBER: 60/091978
56 PRIOR FILING DATE: 1998-07-07
57 PRIOR APPLICATION NUMBER: 60/091982
58 PRIOR FILING DATE: 1998-07-07
59 PRIOR APPLICATION NUMBER: 60/092182
60 PRIOR FILING DATE: 1998-07-09

Query Match 100.08; Score 589; DB 9; Length 105;
Best Local Similarity 100.08; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSMILLLVTSVCVITGACERDVCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MRGATRVSMILLLVTSVCVITGACERDVCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKHKHTKTCPLNLLCSRFPPGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKHKHTKTCPLNLLCSRFPPGRVRCSDMLKNINF 105

RESULT 21
US-09-990-436-371
Sequence 371, Application US/09990436
Publication No. US20020198148A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Bousteins, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Klijavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C14
CURRENT APPLICATION NUMBER: US/09/990.436
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349

PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIIMLLVTYSDCAVITGACERDVQCGAGTCCALSLWRLGLRMCTPLGREGEC 60
Db 1 MRGATRVSIIMLLVTYSDCAVITGACERDVQCGAGTCCALSLWRLGLRMCTPLGREGEC 60
Qy 61 HPGSHKVPFFRKHKHTCPLNLGSRFPDGYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRKHKHTCPLNLGSRFPDGYRCSMDLKNINF 105

RESULT 22
US-09-993-687-371

Sequence 371, Application US/09993687
Publication No. US20020198149A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C11
CURRENT APPLICATION NUMBER: US/09/993,687
CURRENT FILING DATE: 2002-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088126
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23

PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Dd |||||
QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Dd |||||
QY 61 HPGSHKVPFRRKRKHTCPCLPNLICSRFPDGRYCSMDLNINF 105
Dd |||||
QY 61 HPGSHKVPFRRKRKHTCPCLPNLICSRFPDGRYCSMDLNINF 105
Dd |||||

RESULT 23
US-09-989-734-371
Sequence 371, Application US/09989734
Publication No. US2003000331A1
GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Geider, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pal, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C64
CURRENT APPLICATION NUMBER: US/09/989,734
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04

;
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431

;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSVCNITGACERDVQCGAGTCCCAISILWLRGLMCTPLGREGSEC 60
Db 1 MRGATRVSIMLLLVTSVCNITGACERDVQCGAGTCCCAISILWLRGLMCTPLGREGSEC 60
QY 61 HPGSHKVPFFRKXKHTCPLNLLCSRFPPDGRYVCSMDLNKINF 105
Db 61 HPGSHKVPFFRKXKHTCPLNLLCSRFPPDGRYVCSMDLNKINF 105

RESULT 24
US-09-997-653-371
; Sequence 371, Application US/09997653
; Publication No. US20030008297A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC38
CURRENT APPLICATION NUMBER: US/09/997,553
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202

PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24

PRIOR APPLICATION NUMBER: 60/090444
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090445
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090472
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090535
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090540
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090542
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090557
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090690
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090694
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred No. 2,6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVISMLLVTSDCAVITGACERDVQCGAGTCCALISLWRLGRLMCTPLGRSGEEC 60
 Db 1 MRGATRVISMLLVTSDCAVITGACERDVQCGAGTCCALISLWRLGRLMCTPLGRSGEEC 60
 QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRRFPDGRYCSMDLKNINF 105
 Db 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRRFPDGRYCSMDLKNINF 105

RESULT 25
 US-09-993-667-371
 Sequence 371, Application US/09993667
 Publication No US20030022187A1
 GENERAL INFORMATION:
 APPLICANT: Ashkenazi, Avi J.
 APPLICANT: Baker, Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Desnoyers, Luc
 APPLICANT: Eaton, Dan L.
 APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, J. Christopher
 APPLICANT: Gurney, Austin L.
 APPLICANT: Kljavin, Ivar J.
 APPLICANT: Napier, Mary A.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Watanabe, Colin K.
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William I.
 APPLICANT: Zhang, Zemin
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 FILE OF INVENTION: Acids Encoding the Same
 FILE REFERENCE: P2730P1C4
 CURRENT APPLICATION NUMBER: US/09/993,667
 CURRENT FILING DATE: 2001-11-14
 PRIOR APPLICATION NUMBER: 60/049787
 PRIOR FILING DATE: 1997-06-16
 PRIOR APPLICATION NUMBER: 60/062250
 PRIOR FILING DATE: 1997-10-17
 PRIOR APPLICATION NUMBER: 60/065186
 PRIOR FILING DATE: 1997-11-12
 PRIOR APPLICATION NUMBER: 60/065311
 PRIOR FILING DATE: 1997-11-13
 PRIOR APPLICATION NUMBER: 60/066770
 PRIOR FILING DATE: 1997-11-24
 PRIOR APPLICATION NUMBER: 60/075945
 PRIOR FILING DATE: 1998-02-25
 PRIOR APPLICATION NUMBER: 60/078910
 PRIOR FILING DATE: 1998-03-20
 PRIOR APPLICATION NUMBER: 60/083322
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/084600
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/087106
 PRIOR FILING DATE: 1998-05-28
 PRIOR APPLICATION NUMBER: 60/087607
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087609
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087759
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087827
 PRIOR FILING DATE: 1998-06-03
 PRIOR APPLICATION NUMBER: 60/088021
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088025
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088026
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088028
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088029
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088030
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088033
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088326
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088167
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088202
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088212
 PRIOR FILING DATE: 1998-06-05

1	PRIOR APPLICATION NUMBER: 60/089217
2	PRIOR FILING DATE: 1998-06-05
3	PRIOR APPLICATION NUMBER: 60/089655
4	PRIOR FILING DATE: 1998-06-09
5	PRIOR APPLICATION NUMBER: 60/089734
6	PRIOR FILING DATE: 1998-06-10
7	PRIOR APPLICATION NUMBER: 60/089738
8	PRIOR FILING DATE: 1998-06-10
9	PRIOR APPLICATION NUMBER: 60/089742
10	PRIOR FILING DATE: 1998-06-10
11	PRIOR APPLICATION NUMBER: 60/088910
12	PRIOR FILING DATE: 1998-06-10
13	PRIOR APPLICATION NUMBER: 60/088924
14	PRIOR FILING DATE: 1998-06-10
15	PRIOR APPLICATION NUMBER: 60/088926
16	PRIOR FILING DATE: 1998-06-10
17	PRIOR APPLICATION NUMBER: 60/088958
18	PRIOR FILING DATE: 1998-06-11
19	PRIOR APPLICATION NUMBER: 60/088961
20	PRIOR FILING DATE: 1998-06-11
21	PRIOR APPLICATION NUMBER: 60/088976
22	PRIOR FILING DATE: 1998-06-11
23	PRIOR APPLICATION NUMBER: 60/089105
24	PRIOR FILING DATE: 1998-06-12
25	PRIOR APPLICATION NUMBER: 60/089440
26	PRIOR FILING DATE: 1998-06-16
27	PRIOR APPLICATION NUMBER: 60/089512
28	PRIOR FILING DATE: 1998-06-16
29	PRIOR APPLICATION NUMBER: 60/089514
30	PRIOR FILING DATE: 1998-06-16
31	PRIOR APPLICATION NUMBER: 60/089532
32	PRIOR FILING DATE: 1998-06-17
33	PRIOR APPLICATION NUMBER: 60/089538
34	PRIOR FILING DATE: 1998-06-17
35	PRIOR APPLICATION NUMBER: 60/089598
36	PRIOR FILING DATE: 1998-06-17
37	PRIOR APPLICATION NUMBER: 60/089599
38	PRIOR FILING DATE: 1998-06-17
39	PRIOR APPLICATION NUMBER: 60/089600
40	PRIOR FILING DATE: 1998-06-17
41	PRIOR APPLICATION NUMBER: 60/089653
42	PRIOR FILING DATE: 1998-06-17
43	PRIOR APPLICATION NUMBER: 60/089801
44	PRIOR FILING DATE: 1998-06-18
45	PRIOR APPLICATION NUMBER: 60/089907
46	PRIOR FILING DATE: 1998-06-18
47	PRIOR APPLICATION NUMBER: 60/089908
48	PRIOR FILING DATE: 1998-06-18
49	PRIOR APPLICATION NUMBER: 60/089947
50	PRIOR FILING DATE: 1998-06-19
51	PRIOR APPLICATION NUMBER: 60/089948
52	PRIOR FILING DATE: 1998-06-19
53	PRIOR APPLICATION NUMBER: 60/089952
54	PRIOR FILING DATE: 1998-06-19
55	PRIOR APPLICATION NUMBER: 60/090246
56	PRIOR FILING DATE: 1998-06-22
57	PRIOR APPLICATION NUMBER: 60/090252
58	PRIOR FILING DATE: 1998-06-22
59	PRIOR APPLICATION NUMBER: 60/090254
60	PRIOR FILING DATE: 1998-06-22
61	PRIOR APPLICATION NUMBER: 60/090349
62	PRIOR FILING DATE: 1998-06-23
63	PRIOR APPLICATION NUMBER: 60/090355
64	PRIOR FILING DATE: 1998-06-23
65	PRIOR APPLICATION NUMBER: 60/090429
66	PRIOR FILING DATE: 1998-06-24
67	PRIOR APPLICATION NUMBER: 60/090431
68	PRIOR FILING DATE: 1998-06-24
69	PRIOR APPLICATION NUMBER: 60/090435
70	PRIOR FILING DATE: 1998-06-24
71	PRIOR APPLICATION NUMBER: 60/090444
72	PRIOR FILING DATE: 1998-06-24
73	PRIOR APPLICATION NUMBER: 60/090445

1	PRIOR FILING DATE: 1998-06-24	
2	PRIOR APPLICATION NUMBER: 60/090472	
3	PRIOR FILING DATE: 1998-06-24	
4	PRIOR APPLICATION NUMBER: 60/090535	
5	PRIOR FILING DATE: 1998-06-24	
6	PRIOR APPLICATION NUMBER: 60/090540	
7	PRIOR FILING DATE: 1998-06-24	
8	PRIOR APPLICATION NUMBER: 60/090542	
9	PRIOR FILING DATE: 1998-06-24	
10	PRIOR APPLICATION NUMBER: 60/090557	
11	PRIOR FILING DATE: 1998-06-24	
12	PRIOR APPLICATION NUMBER: 60/090676	
13	PRIOR FILING DATE: 1998-06-25	
14	PRIOR APPLICATION NUMBER: 60/090678	
15	PRIOR FILING DATE: 1998-06-25	
16	PRIOR APPLICATION NUMBER: 60/090690	
17	PRIOR FILING DATE: 1998-06-25	
18	PRIOR APPLICATION NUMBER: 60/090694	
19	PRIOR FILING DATE: 1998-06-25	
20	PRIOR APPLICATION NUMBER: 60/090695	
21	PRIOR FILING DATE: 1998-06-25	
22	PRIOR APPLICATION NUMBER: 60/090696	
23	PRIOR FILING DATE: 1998-06-25	
24	PRIOR APPLICATION NUMBER: 60/090862	
25	PRIOR FILING DATE: 1998-06-26	
26	PRIOR APPLICATION NUMBER: 60/090863	
27	PRIOR FILING DATE: 1998-06-26	
28	PRIOR APPLICATION NUMBER: 60/091360	
29	PRIOR FILING DATE: 1998-07-01	
30	PRIOR APPLICATION NUMBER: 60/091478	
31	PRIOR FILING DATE: 1998-07-02	
32	PRIOR APPLICATION NUMBER: 60/091544	
33	PRIOR FILING DATE: 1998-07-01	
34	PRIOR APPLICATION NUMBER: 60/091519	
35	PRIOR FILING DATE: 1998-07-02	
36	PRIOR APPLICATION NUMBER: 60/091626	
37	PRIOR FILING DATE: 1998-07-02	
38	PRIOR APPLICATION NUMBER: 60/091633	
39	PRIOR FILING DATE: 1998-07-02	
40	PRIOR APPLICATION NUMBER: 60/091978	
41	PRIOR FILING DATE: 1998-07-07	
42	PRIOR APPLICATION NUMBER: 60/091982	
43	PRIOR FILING DATE: 1998-07-07	
44	PRIOR APPLICATION NUMBER: 60/092182	
45	PRIOR FILING DATE: 1998-07-09	

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0

Qy 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCASISLWRLGLRMCTPLGREGEEC 60

Qy 61 HPSSHVPFFRRKRKHHHTCPCLNLLCSRFPDGRYRCMDLKNINF 105

RESULT 26
US-09-997-428-371
Sequence 371, Application US/09997428
Publication No. US20030027162A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gartsen, Mary E.

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C44
CURRENT APPLICATION NUMBER: US/09/997,428
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24

```
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match          100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRRKHHTCPCLNLLCSRPDPDGRYCSMDLKNINF 105

RESULT 27
US-09-997-666-371
; Sequence 371, Application US/09997666
; Publication No. US20030027163A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
```

```
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C42
; CURRENT APPLICATION NUMBER: US/09/997,666
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
```

; PRIOR APPLICATION NUMBER: 60/088738
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088742
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088810
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088824
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088826
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088858
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088861
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088876
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/089105
 ; PRIOR FILING DATE: 1998-06-12
 ; PRIOR APPLICATION NUMBER: 60/089440
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089512
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089514
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089532
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089538
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089599
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089600
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089653
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089801
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089907
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089908
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089947
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540

; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCTCAISLWLRGRLMCTFLGREGGEC 60
 DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCTCAISLWLRGRLMCTFLGREGGEC 60
 QY 61 HPGSHKVPFFFRKRKHHTCTCPLNLLCSRFDPDGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFFRKRKHHTCTCPLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 28
 US-09-990-438-371
 ; Sequence 371, Application US/09990438
 ; Publication No. US2003002754A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.

APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730PIC3
CURRENT APPLICATION NUMBER: US/09/990,438
CURRENT FILING DATE: 2001-11-14
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24

us-10-027-603-2.rapb

Mon Aug 30 07:07:06 2004

PRIOR APPLICATION NUMBER: 60/090557
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090690
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090694
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred No. 2, 6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVOCGAGTCCALSLMLRGLRMCTPLGRGEEC 60
 Db 1 MRGATRVSIMLLLVTSVSDCAVITGACERDVOCGAGTCCALSLMLRGLRMCTPLGRGEEC 60
 QY 61 HPGSHKVPFFRRKHHTCPCLPNLLCSRFDPGRYRCSMDLKNINF 105
 Db 61 HPGSHKVPFFRRKHHTCPCLPNLLCSRFDPGRYRCSMDLKNINF 105

RESULT 29
 US-09-990-562-371
 Sequence 371, Application US/09990562
 Publication No. US20030027985A1
 GENERAL INFORMATION:
 APPLICANT: Ashkenazi, Avi J.
 APPLICANT: Baker, Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Desnoyers, Luc
 APPLICANT: Eaton, Dan L.
 APPLICANT: Ferrara, Napoleone
 APPLICANT: Fong, Sherman
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, J. Christopher
 APPLICANT: Gurney, Austin L.
 APPLICANT: Kljavin, Ivar J.
 APPLICANT: Napier, Mary A.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann

APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Watanabe, Colin K.
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William I.
 APPLICANT: Zhang, Zemin
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 FILE REFERENCE: P2730P1C18
 CURRENT APPLICATION NUMBER: US/09/990,562
 CURRENT FILING DATE: 2001-11-14
 PRIOR APPLICATION NUMBER: 60/049787
 PRIOR FILING DATE: 1997-06-16
 PRIOR APPLICATION NUMBER: 60/062250
 PRIOR FILING DATE: 1997-10-17
 PRIOR APPLICATION NUMBER: 60/065186
 PRIOR FILING DATE: 1997-11-12
 PRIOR APPLICATION NUMBER: 60/065311
 PRIOR FILING DATE: 1997-11-13
 PRIOR APPLICATION NUMBER: 60/066770
 PRIOR FILING DATE: 1997-11-24
 PRIOR APPLICATION NUMBER: 60/075945
 PRIOR FILING DATE: 1998-02-25
 PRIOR APPLICATION NUMBER: 60/078910
 PRIOR FILING DATE: 1998-03-20
 PRIOR APPLICATION NUMBER: 60/083322
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/084600
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/087106
 PRIOR FILING DATE: 1998-05-28
 PRIOR APPLICATION NUMBER: 60/087607
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087609
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087759
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087827
 PRIOR FILING DATE: 1998-06-03
 PRIOR APPLICATION NUMBER: 60/088021
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088025
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088026
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088028
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088029
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088030
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088033
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088326
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088167
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088202
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088212
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088217
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088655
 PRIOR FILING DATE: 1998-06-09
 PRIOR APPLICATION NUMBER: 60/088734
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088738
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088742
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088810
 PRIOR FILING DATE: 1998-06-10

```
/ PRIOR APPLICATION NUMBER: 60/088824
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088826
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088858
/ PRIOR FILING DATE: 1998-06-11
/ PRIOR APPLICATION NUMBER: 60/088861
/ PRIOR FILING DATE: 1998-06-11
/ PRIOR APPLICATION NUMBER: 60/088876
/ PRIOR FILING DATE: 1998-06-11
/ PRIOR APPLICATION NUMBER: 60/089105
/ PRIOR FILING DATE: 1998-06-12
/ PRIOR APPLICATION NUMBER: 60/089440
/ PRIOR FILING DATE: 1998-06-16
/ PRIOR APPLICATION NUMBER: 60/089512
/ PRIOR FILING DATE: 1998-06-16
/ PRIOR APPLICATION NUMBER: 60/089514
/ PRIOR FILING DATE: 1998-06-16
/ PRIOR APPLICATION NUMBER: 60/089532
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089538
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089598
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089599
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089600
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089653
/ PRIOR FILING DATE: 1998-06-17
/ PRIOR APPLICATION NUMBER: 60/089801
/ PRIOR FILING DATE: 1998-06-18
/ PRIOR APPLICATION NUMBER: 60/089907
/ PRIOR FILING DATE: 1998-06-18
/ PRIOR APPLICATION NUMBER: 60/089908
/ PRIOR FILING DATE: 1998-06-18
/ PRIOR APPLICATION NUMBER: 60/089947
/ PRIOR FILING DATE: 1998-06-19
/ PRIOR APPLICATION NUMBER: 60/089948
/ PRIOR FILING DATE: 1998-06-19
/ PRIOR APPLICATION NUMBER: 60/089952
/ PRIOR FILING DATE: 1998-06-19
/ PRIOR APPLICATION NUMBER: 60/090246
/ PRIOR FILING DATE: 1998-06-22
/ PRIOR APPLICATION NUMBER: 60/090252
/ PRIOR FILING DATE: 1998-06-22
/ PRIOR APPLICATION NUMBER: 60/090254
/ PRIOR FILING DATE: 1998-06-22
/ PRIOR APPLICATION NUMBER: 60/090349
/ PRIOR FILING DATE: 1998-06-23
/ PRIOR APPLICATION NUMBER: 60/090355
/ PRIOR FILING DATE: 1998-06-23
/ PRIOR APPLICATION NUMBER: 60/090429
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090431
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090435
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090444
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090445
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090472
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090535
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090540
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090542
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090557
/ PRIOR FILING DATE: 1998-06-24
/ PRIOR APPLICATION NUMBER: 60/090676

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLRGEGEC 60
Db 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLRGEGEC 60
Qy 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPGRYCSMDLKNINF 105

RESULT 30
US-09-796-753-64
; Sequence 64, Application US/09796753
; Publication No US20030027998A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Sean A.
; TITLE OF INVENTION: SECRETED PROTEINS AND USES THEREOF
; FILE REFERENCE: 7853-227-999
; CURRENT APPLICATION NUMBER: US/09/796,753
; CURRENT FILING DATE: 2001-03-01
; PRIOR APPLICATION NUMBER: 09/183,175
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 09/223,094
; PRIOR FILING DATE: 1998-12-30
; PRIOR APPLICATION NUMBER: 09/223,546
; PRIOR FILING DATE: 1998-12-30
; PRIOR APPLICATION NUMBER: 09/224,246
; PRIOR FILING DATE: 1998-12-30
; PRIOR APPLICATION NUMBER: 09/259,388
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 60/122,458
; PRIOR FILING DATE: 1999-03-01
; PRIOR APPLICATION NUMBER: 09/312,359
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 09/336,536
; PRIOR FILING DATE: 1999-06-18
```

us-10-027-603-2.rapb

Mon Aug 30 07:07:06 2004

```

PRIOR APPLICATION NUMBER: 09/342,687
PRIOR FILING DATE: 1999-06-29
PRIOR APPLICATION NUMBER: 09/345,464
PRIOR FILING DATE: 1999-06-30
PRIOR APPLICATION NUMBER: 09/365,164
PRIOR FILING DATE: 1999-07-30
PRIOR APPLICATION NUMBER: 09/399,723
PRIOR FILING DATE: 1999-09-20
PRIOR APPLICATION NUMBER: 09/409,634
PRIOR FILING DATE: 1999-09-30
PRIOR APPLICATION NUMBER: 09/471,179
PRIOR FILING DATE: 1999-12-23
PRIOR APPLICATION NUMBER: 09/474,071
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/474,072
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/514,010
PRIOR FILING DATE: 2000-02-25
PRIOR APPLICATION NUMBER: 09/516,745
PRIOR FILING DATE: 2000-03-01
PRIOR APPLICATION NUMBER: 09/572,002
PRIOR FILING DATE: 2000-05-14
PRIOR APPLICATION NUMBER: 09/597,993
PRIOR FILING DATE: 2000-06-19
PRIOR APPLICATION NUMBER: 09/599,596
PRIOR FILING DATE: 2000-06-22
PRIOR APPLICATION NUMBER: 09/630,334
PRIOR FILING DATE: 2000-07-31
PRIOR APPLICATION NUMBER: 09/606,565
PRIOR FILING DATE: 2000-06-29
PRIOR APPLICATION NUMBER: 09/606,317
PRIOR FILING DATE: 2000-06-29
PRIOR APPLICATION NUMBER: 09/665,666
PRIOR FILING DATE: 2000-09-20
PRIOR APPLICATION NUMBER: 09/677,751
PRIOR FILING DATE: 2000-09-30
NUMBER OF SEQ ID NOS: 162
SEQ ID NO 64
LENGTH: 105
TYPE: PRT
ORGANISM: Homo sapiens
US-09-796-753-64

Query Match      100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLMLRGLRMCTPLGREGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLMLRGLRMCTPLGREGEC 60

Qy 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGRYRCSMDLKNINF 105

RESULT 31
US-09-990-711-371
; Sequence 371, Application US/09990711
; Publication No. US20030032023A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Boctstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher

```

```

; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Tamas, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C2
; CURRENT APPLICATION NUMBER: US/09/990,711
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10

```

; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540

; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTSDDCAVITGACERDVQCGAGTCCCAISLWRLGRLMTPLRGEGEC 60
Db 1 MRGATRVSIMLLVTSDDCAVITGACERDVQCGAGTCCCAISLWRLGRLMTPLRGEGEC 60
Qy 61 HPGSHKVPFFRKXKHHTCPCLPNLLCSRFDPGRCMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHHTCPCLPNLLCSRFDPGRCMDLKNINF 105

RESULT 32
US-09-989-726-371
; Sequence 371, Application US/09989726
; Publication No. US20030040473A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.

us-10-027-603-2.rapb

Mon Aug 30 07:07:06 2004

APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C60
CURRENT APPLICATION NUMBER: US/09/989,726
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24

;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090696
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090862
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/090863
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/091360
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091478
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091544
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55; Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTPLGREGEC 60
DB 1 MEGATRVSIMLLVTVDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTPLGREGEC 60

QY 61 HPGSHKVPFFRRKHKHTCPCINLLCSRPDPGRYCSMDLKNINF 105

DB 61 HPGSHKVPFFRRKHKHTCPCINLLCSRPDPGRYCSMDLKNINF 105

RESULT 33

US-09-998-156-371
Sequence 371, Application US/09998156

Publication No. US20030044806A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, J. Christopher

APPLICANT: Gurney, Austin L.

APPLICANT: Kljavin, Ivar J.

APPLICANT: Napier, Mary A.

APPLICANT: Pan, James

APPLICANT: Paoni, Nicholas F.

APPLICANT: Roy, Margaret Ann

;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tamas, Daniel
;; APPLICANT: Watanabe, Colin K.
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William I.
;; APPLICANT: Zhang, Zemin
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2730P1C28
;; CURRENT APPLICATION NUMBER: US/09/998,156
;; CURRENT FILING DATE: 2001-11-15
;; PRIOR APPLICATION NUMBER: 60/049787
;; PRIOR FILING DATE: 1997-06-16
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/065186
;; PRIOR FILING DATE: 1997-11-12
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066770
;; PRIOR FILING DATE: 1997-11-24
;; PRIOR APPLICATION NUMBER: 60/075945
;; PRIOR FILING DATE: 1998-02-25
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/087106
;; PRIOR FILING DATE: 1998-05-28
;; PRIOR APPLICATION NUMBER: 60/087607
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087609
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087759
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087827
;; PRIOR FILING DATE: 1998-06-03
;; PRIOR APPLICATION NUMBER: 60/088021
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088025
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088026
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088028
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088029
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088030
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088033
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088326
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088167
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088202
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088212
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088217
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088655
;; PRIOR FILING DATE: 1998-06-09
;; PRIOR APPLICATION NUMBER: 60/088734
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088738
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088742
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088810
;; PRIOR FILING DATE: 1998-06-10

APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C49
CURRENT APPLICATION NUMBER: US/09/990,437
CURRENT FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25

PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVISIMLLTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGSEEC 60
Db 1 MRGATRVISIMLLTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGRGSEEC 60

Qy 61 HPGSHKVPFFFKRHHTCPCLNLLCSRFDPGRVRCSDMLKNINF 105
Db 61 HPGSHKVPFFFKRHHTCPCLNLLCSRFDPGRVRCSDMLKNINF 105

RESULT 35
US-09-991-157-371
Sequence 371, Application US/09991157
Publication No. US20030049638A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoli, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC51
CURRENT APPLICATION NUMBER: US/09/991,157
CURRENT FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11

;; PRIOR APPLICATION NUMBER: 60/088861
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088876
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/089105
;; PRIOR FILING DATE: 1998-06-12
;; PRIOR APPLICATION NUMBER: 60/089440
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089512
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089514
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089598
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089599
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089600
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089653
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089801
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089907
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089908
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694

;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090696
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090862
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/090863
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/091360
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091478
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091544
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09
;;
Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGGEC 60
Qy 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPDGRYRCSMDLKNINF 105
RESULT 36
US-09-997-514-371
; Sequence 371, Application US/09997514
; Publication No. US20030049681A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C46

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55; Mismatches 0; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCAISLWRLGRLMCTPLGREGGEC 60
|||||
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCAISLWRLGRLMCTPLGREGGEC 60
|||||

QY 61 HPGSHKVPFRKRKHHTCCLNLLCSRPDPGRYRCMDLNINF 105
|||||
Db 61 HPGSHKVPFRKRKHHTCCLNLLCSRPDPGRYRCMDLNINF 105
|||||

RESULT 37
US-09-997-573-371
; Sequence 371, Application US/09997573
; Publication No. US2003049682A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Vary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C45
; CURRENT APPLICATION NUMBER: US/09/997,573
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12

; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862

; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
Db 1 MEGATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRRKRKHTCTCLPPLLCSRFPPDGRVRCSDMLKNINF 105
Db 61 HPGSHKVPFFRRKRKHTCTCLPPLLCSRFPPDGRVRCSDMLKNINF 105

RESULT 38

US-09-991-172-371
; Sequence 371, Application US/0991172
; Publication No. US20030050457A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C50
; CURRENT APPLICATION NUMBER: US/09/991,172
; CURRENT FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17

/	PRIOR FILING DATE:	1998-06-16
/	PRIOR APPLICATION NUMBER:	60/089514
/	PRIOR FILING DATE:	1998-06-16
/	PRIOR APPLICATION NUMBER:	60/089532
/	PRIOR FILING DATE:	1998-06-17
/	PRIOR APPLICATION NUMBER:	60/089538
/	PRIOR FILING DATE:	1998-06-17
/	PRIOR APPLICATION NUMBER:	60/089598
/	PRIOR FILING DATE:	1998-06-17
/	PRIOR APPLICATION NUMBER:	60/089599
/	PRIOR FILING DATE:	1998-06-17
/	PRIOR APPLICATION NUMBER:	60/089600
/	PRIOR FILING DATE:	1998-06-17
/	PRIOR APPLICATION NUMBER:	60/089653
/	PRIOR FILING DATE:	1998-06-17
/	PRIOR APPLICATION NUMBER:	60/089801
/	PRIOR FILING DATE:	1998-06-18
/	PRIOR APPLICATION NUMBER:	60/089907
/	PRIOR FILING DATE:	1998-06-18
/	PRIOR APPLICATION NUMBER:	60/089908
/	PRIOR FILING DATE:	1998-06-18
/	PRIOR APPLICATION NUMBER:	60/089947
/	PRIOR FILING DATE:	1998-06-19
/	PRIOR APPLICATION NUMBER:	60/089948
/	PRIOR FILING DATE:	1998-06-19
/	PRIOR APPLICATION NUMBER:	60/089952
/	PRIOR FILING DATE:	1998-06-19
/	PRIOR APPLICATION NUMBER:	60/090246
/	PRIOR FILING DATE:	1998-06-22
/	PRIOR APPLICATION NUMBER:	60/090252
/	PRIOR FILING DATE:	1998-06-22
/	PRIOR APPLICATION NUMBER:	60/090254
/	PRIOR FILING DATE:	1998-06-22
/	PRIOR APPLICATION NUMBER:	60/090349
/	PRIOR FILING DATE:	1998-06-23
/	PRIOR APPLICATION NUMBER:	60/090355
/	PRIOR FILING DATE:	1998-06-23
/	PRIOR APPLICATION NUMBER:	60/090429
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090431
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090435
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090444
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090445
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090472
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090535
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090540
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090542
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090557
/	PRIOR FILING DATE:	1998-06-24
/	PRIOR APPLICATION NUMBER:	60/090676
/	PRIOR FILING DATE:	1998-06-25
/	PRIOR APPLICATION NUMBER:	60/090678
/	PRIOR FILING DATE:	1998-06-25
/	PRIOR APPLICATION NUMBER:	60/090690
/	PRIOR FILING DATE:	1998-06-25
/	PRIOR APPLICATION NUMBER:	60/090694
/	PRIOR FILING DATE:	1998-06-25
/	PRIOR APPLICATION NUMBER:	60/090695
/	PRIOR FILING DATE:	1998-06-25
/	PRIOR APPLICATION NUMBER:	60/090696
/	PRIOR FILING DATE:	1998-06-25
/	PRIOR APPLICATION NUMBER:	60/090862
/	PRIOR FILING DATE:	1998-06-26
/	PRIOR APPLICATION NUMBER:	60/090863
/	PRIOR FILING DATE:	1998-06-26

us-10-027-603-2.rapp

Mon Aug 30 07:07:06 2004

```

/ PRIOR APPLICATION NUMBER: 60/091360
/ PRIOR FILING DATE: 1998-07-01
/ PRIOR APPLICATION NUMBER: 60/091478
/ PRIOR FILING DATE: 1998-07-02
/ PRIOR APPLICATION NUMBER: 60/091544
/ PRIOR FILING DATE: 1998-07-01
/ PRIOR APPLICATION NUMBER: 60/091519
/ PRIOR FILING DATE: 1998-07-02
/ PRIOR APPLICATION NUMBER: 60/091626
/ PRIOR FILING DATE: 1998-07-02
/ PRIOR APPLICATION NUMBER: 60/091633
/ PRIOR FILING DATE: 1998-07-02
/ PRIOR APPLICATION NUMBER: 60/091978
/ PRIOR FILING DATE: 1998-07-07
/ PRIOR APPLICATION NUMBER: 60/091982
/ PRIOR FILING DATE: 1998-07-07
/ PRIOR APPLICATION NUMBER: 60/092182
/ PRIOR FILING DATE: 1998-07-09

Query Match      100.08; Score 589; DB 10; Length 105;
Best Local Similarity 100.08; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVISIMLLLVTSVCVITGACERDVCGAGTCCALSLWLRGRLMCTPLGREGEEC 60
DB 1 MRGATRVISIMLLLVTSVCVITGACERDVCGAGTCCALSLWLRGRLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKXKHTCPCLNLLCSFPDGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLNLLCSFPDGRVRCSDMLKNINF 105

RESULT 39
US-09-990-726-371
/ Sequence 371, Application US/09990726
/ Publication No. US20030054359A1
/ GENERAL INFORMATION:
/ APPLICANT: Ashkenazi, Avi J.
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, J. Christopher
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Kljavin, Ivar J.
/ APPLICANT: Napier, Mary A.
/ APPLICANT: Pan, James
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Watanabe, Colin K.
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William I.
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2730PIC16
/ CURRENT APPLICATION NUMBER: US/09/990.726
/ CURRENT FILING DATE: 2001-11-14
/ PRIOR APPLICATION NUMBER: 60/049787
/ PRIOR FILING DATE: 1997-06-16
/ PRIOR APPLICATION NUMBER: 60/062250
/ PRIOR FILING DATE: 1997-10-17
/ PRIOR APPLICATION NUMBER: 60/065186
/ PRIOR FILING DATE: 1997-11-12
/ PRIOR APPLICATION NUMBER: 60/065311

/ PRIOR FILING DATE: 1997-11-13
/ PRIOR APPLICATION NUMBER: 60/066770
/ PRIOR FILING DATE: 1997-11-24
/ PRIOR APPLICATION NUMBER: 60/075945
/ PRIOR FILING DATE: 1998-02-25
/ PRIOR APPLICATION NUMBER: 60/078910
/ PRIOR FILING DATE: 1998-03-20
/ PRIOR APPLICATION NUMBER: 60/083322
/ PRIOR FILING DATE: 1998-04-28
/ PRIOR APPLICATION NUMBER: 60/084600
/ PRIOR FILING DATE: 1998-05-07
/ PRIOR APPLICATION NUMBER: 60/087106
/ PRIOR FILING DATE: 1998-05-28
/ PRIOR APPLICATION NUMBER: 60/087607
/ PRIOR FILING DATE: 1998-06-02
/ PRIOR APPLICATION NUMBER: 60/087609
/ PRIOR FILING DATE: 1998-06-02
/ PRIOR APPLICATION NUMBER: 60/087759
/ PRIOR FILING DATE: 1998-06-02
/ PRIOR APPLICATION NUMBER: 60/087827
/ PRIOR FILING DATE: 1998-06-03
/ PRIOR APPLICATION NUMBER: 60/088021
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088025
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088026
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088028
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088029
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088030
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088033
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088326
/ PRIOR FILING DATE: 1998-06-04
/ PRIOR APPLICATION NUMBER: 60/088167
/ PRIOR FILING DATE: 1998-06-05
/ PRIOR APPLICATION NUMBER: 60/088202
/ PRIOR FILING DATE: 1998-06-05
/ PRIOR APPLICATION NUMBER: 60/088212
/ PRIOR FILING DATE: 1998-06-05
/ PRIOR APPLICATION NUMBER: 60/088217
/ PRIOR FILING DATE: 1998-06-05
/ PRIOR APPLICATION NUMBER: 60/088655
/ PRIOR FILING DATE: 1998-06-09
/ PRIOR APPLICATION NUMBER: 60/088734
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088738
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088742
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088810
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088824
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088826
/ PRIOR FILING DATE: 1998-06-10
/ PRIOR APPLICATION NUMBER: 60/088858
/ PRIOR FILING DATE: 1998-06-11
/ PRIOR APPLICATION NUMBER: 60/088861
/ PRIOR FILING DATE: 1998-06-11
/ PRIOR APPLICATION NUMBER: 60/088876
/ PRIOR FILING DATE: 1998-06-11
/ PRIOR APPLICATION NUMBER: 60/089105
/ PRIOR FILING DATE: 1998-06-12
/ PRIOR APPLICATION NUMBER: 60/089440
/ PRIOR FILING DATE: 1998-06-16
/ PRIOR APPLICATION NUMBER: 60/089512
/ PRIOR FILING DATE: 1998-06-16
/ PRIOR APPLICATION NUMBER: 60/089514
/ PRIOR FILING DATE: 1998-06-16

```


; PRIOR APPLICATION NUMBER: 60/089532
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089538
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089599
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089600
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089653
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089801
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089907
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089908
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089947
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478

; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMTPTLGRGEGEC 60
 Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCATSLWLRGLRMTPTLGRGEGEC 60
 QY 61 HPGSHKVPFFFRKHHTCPCLPNLCSRFPPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFFRKHHTCPCLPNLCSRFPPDGRYRCSDMLKNINF 105

RESULT 40

US-09-997-559-371
 ; Sequence 371, Application US/09997559
 ; Publication No. US20030054403A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Deanoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; TITLE OF INVENTION: Acids Encoding the Same
 ; FILE REFERENCE: P2730PLC40
 ; CURRENT APPLICATION NUMBER: US/09/997,559
 ; CURRENT FILING DATE: 2001-11-15
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/085186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24

[illegible]

;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLQREGSEC 60
DB 1 MEGATRVSIMLLVTVSCAVITGACERDVQCGAGTCCCAISLWLRGLRMCPTLQREGSEC 60

QY 61 HPGSHKVPFFRKHKHTCEPCINLLCSRPDPGRYCSMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCEPCINLLCSRPDPGRYCSMDLKNINF 105

RESULT 41

US-09-997-601-371
; Sequence 371, Application US/09997601
; Publication No. US20030054404A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Goddard, Audrey E.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PIC36
; CURRENT APPLICATION NUMBER: US/09/997,601
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910

;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/087106
;; PRIOR FILING DATE: 1998-05-28
;; PRIOR APPLICATION NUMBER: 60/087607
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087609
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087759
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087827
;; PRIOR FILING DATE: 1998-06-03
;; PRIOR APPLICATION NUMBER: 60/088021
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088025
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088026
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088028
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088029
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088030
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088033
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088326
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088167
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088202
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088212
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088217
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088655
;; PRIOR FILING DATE: 1998-06-09
;; PRIOR APPLICATION NUMBER: 60/088734
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088738
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088742
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088810
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088824
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088826
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088858
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088861
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088876
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/089105
;; PRIOR FILING DATE: 1998-06-12
;; PRIOR APPLICATION NUMBER: 60/089440
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089512
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089514
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089598
;; PRIOR FILING DATE: 1998-06-17

Sequence 371,	Application US/09990443
Publication No. US2003005498A1	
GENERAL INFORMATION:	
APPLICANT:	Athenazi, Avi J.
APPLICANT:	Baker, Kevin P.
APPLICANT:	Botstein, David
APPLICANT:	Desnoyers, Luc
APPLICANT:	Eaton, Dan L.
APPLICANT:	Ferrara, Napoleone
APPLICANT:	Fong, Sherman
APPLICANT:	Gerber, Hanspeter
APPLICANT:	Gerlitsen, Wary E.
APPLICANT:	Goddard, Audrey
APPLICANT:	Godowski, Paul J.
APPLICANT:	Grimaldi, J. Christopher
APPLICANT:	Gurney, Austin L.
APPLICANT:	Kljavin, Ivaz J.
APPLICANT:	Napier, Mary A.
APPLICANT:	Pan, James
APPLICANT:	Paoni, Nicholas F.
APPLICANT:	Roy, Margaret Ann
APPLICANT:	Stewart, Timothy A.
APPLICANT:	Tumas, Daniel
APPLICANT:	Watanabe, Colin K.
APPLICANT:	Williams, P. Wickey
APPLICANT:	Wood, William I.
APPLICANT:	Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmitted	
TITLE OF INVENTION: AGIDs Encoding the	
FILE REFERENCE: P2730PAC12	
CURRENT APPLICATION NUMBER: US/09/9990443	
CURRENT FILING DATE: 2001-11-14	
PRIOR APPLICATION NUMBER:	60/049787
PRIOR FILING DATE:	1997-06-16
PRIOR APPLICATION NUMBER:	60/062250
PRIOR FILING DATE:	1997-10-17
PRIOR APPLICATION NUMBER:	60/065186
PRIOR FILING DATE:	1997-11-12
PRIOR APPLICATION NUMBER:	60/065311
PRIOR FILING DATE:	1997-11-13
PRIOR APPLICATION NUMBER:	60/066770
PRIOR FILING DATE:	1997-11-24
PRIOR APPLICATION NUMBER:	60/075945
PRIOR FILING DATE:	1998-02-25
PRIOR APPLICATION NUMBER:	60/078910
PRIOR FILING DATE:	1998-03-20
PRIOR APPLICATION NUMBER:	60/083322
PRIOR FILING DATE:	1998-04-28

1	PRIOR FILING DATE: 1998-06-17	
2	PRIOR APPLICATION NUMBER: 60/089653	
3	PRIOR FILING DATE: 1998-06-17	
4	PRIOR APPLICATION NUMBER: 60/089601	
5	PRIOR FILING DATE: 1998-06-18	
6	PRIOR APPLICATION NUMBER: 60/089907	
7	PRIOR FILING DATE: 1998-06-18	
8	PRIOR APPLICATION NUMBER: 60/089908	
9	PRIOR FILING DATE: 1998-06-18	
10	PRIOR APPLICATION NUMBER: 60/089947	
11	PRIOR FILING DATE: 1998-06-19	
12	PRIOR APPLICATION NUMBER: 60/089948	
13	PRIOR FILING DATE: 1998-06-19	
14	PRIOR APPLICATION NUMBER: 60/089952	
15	PRIOR FILING DATE: 1998-06-19	
16	PRIOR APPLICATION NUMBER: 60/090246	
17	PRIOR FILING DATE: 1998-06-22	
18	PRIOR APPLICATION NUMBER: 60/090252	
19	PRIOR FILING DATE: 1998-06-22	
20	PRIOR APPLICATION NUMBER: 60/090254	
21	PRIOR FILING DATE: 1998-06-22	
22	PRIOR APPLICATION NUMBER: 60/090349	
23	PRIOR FILING DATE: 1998-06-23	
24	PRIOR APPLICATION NUMBER: 60/090355	
25	PRIOR FILING DATE: 1998-06-23	
26	PRIOR APPLICATION NUMBER: 60/090429	
27	PRIOR FILING DATE: 1998-06-24	
28	PRIOR APPLICATION NUMBER: 60/090431	
29	PRIOR FILING DATE: 1998-06-24	
30	PRIOR APPLICATION NUMBER: 60/090435	
31	PRIOR FILING DATE: 1998-06-24	
32	PRIOR APPLICATION NUMBER: 60/090444	
33	PRIOR FILING DATE: 1998-06-24	
34	PRIOR APPLICATION NUMBER: 60/090445	
35	PRIOR FILING DATE: 1998-06-24	
36	PRIOR APPLICATION NUMBER: 60/090472	
37	PRIOR FILING DATE: 1998-06-24	
38	PRIOR APPLICATION NUMBER: 60/090535	
39	PRIOR FILING DATE: 1998-06-24	
40	PRIOR APPLICATION NUMBER: 60/090540	
41	PRIOR FILING DATE: 1998-06-24	
42	PRIOR APPLICATION NUMBER: 60/090542	
43	PRIOR FILING DATE: 1998-06-24	
44	PRIOR APPLICATION NUMBER: 60/090557	
45	PRIOR FILING DATE: 1998-06-24	
46	PRIOR APPLICATION NUMBER: 60/090676	
47	PRIOR FILING DATE: 1998-06-25	
48	PRIOR APPLICATION NUMBER: 60/090678	
49	PRIOR FILING DATE: 1998-06-25	
50	PRIOR APPLICATION NUMBER: 60/090690	
51	PRIOR FILING DATE: 1998-06-25	
52	PRIOR APPLICATION NUMBER: 60/090696	
53	PRIOR FILING DATE: 1998-06-25	
54	PRIOR APPLICATION NUMBER: 60/090862	
55	PRIOR FILING DATE: 1998-06-26	
56	PRIOR APPLICATION NUMBER: 60/090863	
57	PRIOR FILING DATE: 1998-06-26	
58	PRIOR APPLICATION NUMBER: 60/091360	
59	PRIOR FILING DATE: 1998-07-01	
60	PRIOR APPLICATION NUMBER: 60/091478	
61	PRIOR FILING DATE: 1998-07-02	
62	PRIOR APPLICATION NUMBER: 60/091544	
63	PRIOR FILING DATE: 1998-07-01	
64	PRIOR APPLICATION NUMBER: 60/091519	
65	PRIOR FILING DATE: 1998-07-02	
66	PRIOR APPLICATION NUMBER: 60/091626	
67	PRIOR FILING DATE: 1998-07-02	
68	PRIOR APPLICATION NUMBER: 60/091633	
69	PRIOR FILING DATE: 1998-07-02	

```
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match      100.08; Score 589; DB 10; Length 105;
Best Local Similarity 100.08; Pred. No. 2.6e-55; Indels 0; Gaps 0;
Matches 105; Conservative 0; Mismatches 0;

QY 1 MRGATRVSIMLLLVTSVCVITGACERDVCGAGTCCATSLWLRGMRMCTPLGREGEC 60
    |||||
Db 1 MRGATRVSIMLLLVTSVCVITGACERDVCGAGTCCATSLWLRGMRMCTPLGREGEC 60
    |||||

QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSFPDGRVRCSDMLKNINF 105
    |||||
Db 61 HPGSHKVPFFRKXKHTCPCLPNLLCSFPDGRVRCSDMLKNINF 105
    |||||

RESULT 43
US-09-991-854-371
; Sequence 371, Application US/09991854
; Publication No. US20030059780A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730PIC24
; CURRENT APPLICATION NUMBER: US/09/991.854
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
```

;; PRIOR APPLICATION NUMBER: 60/089801
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089907
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089908
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090696
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090862
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/090863
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/091360
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091478
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091544
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982

;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09
Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred.No.2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRGATRVSIMLLLVSDCAVITGACERDVOCGAGTCCATSLMRLGRLMCTPLGRGEGEC 60
Db 1 MRGATRVSIMLLLVSDCAVITGACERDVOCGAGTCCATSLMRLGRLMCTPLGRGEGEC 60
Qy 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFDPDGRVRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFDPDGRVRCSDMLKNINF 105
RESULT 44
US-09-997-628-371
; Sequence 371, Application US/09997628
; Publication No. US20030059782A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PLC30
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02

[illegible]

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSMILLVTVDCAVITGACERDVQCGAGTCCCAISLWRLRMCPTPLGREGEC 60
DB |||||
1 MEGATRVSMILLVTVDCAVITGACERDVQCGAGTCCCAISLWRLRMCPTPLGREGEC 60
QY 61 HPGSHKVPFRKXKHTCPLNLLCSRPDPGRYRCSMDLKNINF 105
DB |||||
61 HPGSHKVPFRKXKHTCPLNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 45

US-09-997-683-371
Sequence 371, Application US/09997683
Publication No. US2003059783A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC32
CURRENT APPLICATION NUMBER: US/09/997,683
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759

PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948

; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLNCTPLGRGSEC 60

Db 1 MRGATRVIMLLLVTSVCANVTGACERDVCGAGTCCATLSLWLRGLRMCTPLGRGEGEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSFFPDGRYRCSDMLKXNIF 105

Db 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSFFPDGRYRCSDMLKXNIF 105

RESULT 47

US-09-997-349-371

; Sequence 371, Application US/09997349

; Publication No. US20030059832A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: P2730PIC37

; CURRENT APPLICATION NUMBER: US/09/997,349

; CURRENT FILING DATE: 2001-11-15

; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/075945

; PRIOR FILING DATE: 1998-02-25

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/084600

; PRIOR FILING DATE: 1998-05-07

; PRIOR APPLICATION NUMBER: 60/087106

; PRIOR FILING DATE: 1998-05-28

; PRIOR APPLICATION NUMBER: 60/087607

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087609

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087759

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087827

; PRIOR FILING DATE: 1998-06-03

; PRIOR APPLICATION NUMBER: 60/088021

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088025

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088026

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088028

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088029

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088030

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088033

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088326

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088167

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088202

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088212

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088217

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088655

; PRIOR FILING DATE: 1998-06-09

; PRIOR APPLICATION NUMBER: 60/088734

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088738

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088742

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088810

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088824

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088826

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088858

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/088861

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/088876

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/089105

; PRIOR FILING DATE: 1998-06-12

; PRIOR APPLICATION NUMBER: 60/089440

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089512

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089514

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089532

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089538

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089598

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089599

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089600

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089653

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089801

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089907

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089908

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089947

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/089948

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/089952

; PRIOR FILING DATE: 1998-06-19

1 PRIOR APPLICATION NUMBER: 60/090246
 1 PRIOR FILING DATE: 1998-06-22
 1 PRIOR APPLICATION NUMBER: 60/090252
 1 PRIOR FILING DATE: 1998-06-22
 1 PRIOR APPLICATION NUMBER: 60/090254
 1 PRIOR FILING DATE: 1998-06-22
 1 PRIOR APPLICATION NUMBER: 60/090349
 1 PRIOR FILING DATE: 1998-06-23
 1 PRIOR APPLICATION NUMBER: 60/090355
 1 PRIOR FILING DATE: 1998-06-23
 1 PRIOR APPLICATION NUMBER: 60/090429
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090431
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090435
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090444
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090445
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090472
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090535
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090540
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090542
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090557
 1 PRIOR FILING DATE: 1998-06-24
 1 PRIOR APPLICATION NUMBER: 60/090676
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090678
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090690
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090694
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090695
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090696
 1 PRIOR FILING DATE: 1998-06-25
 1 PRIOR APPLICATION NUMBER: 60/090862
 1 PRIOR FILING DATE: 1998-06-26
 1 PRIOR APPLICATION NUMBER: 60/090863
 1 PRIOR FILING DATE: 1998-06-26
 1 PRIOR APPLICATION NUMBER: 60/091360
 1 PRIOR FILING DATE: 1998-07-01
 1 PRIOR APPLICATION NUMBER: 60/091478
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091544
 1 PRIOR FILING DATE: 1998-07-01
 1 PRIOR APPLICATION NUMBER: 60/091519
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091626
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091633
 1 PRIOR FILING DATE: 1998-07-02
 1 PRIOR APPLICATION NUMBER: 60/091978
 1 PRIOR FILING DATE: 1998-07-07
 1 PRIOR APPLICATION NUMBER: 60/091982
 1 PRIOR FILING DATE: 1998-07-07
 1 PRIOR APPLICATION NUMBER: 60/092182
 1 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCITPLRGEGEC 60
 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCITPLRGEGEC 60

Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRRPDPGRYCSMDLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRRPDPGRYCSMDLKNINF 105
 RESULT 48
 US-09-997-440-371
 ; Sequence 371, Application US/09997440
 ; Publication No. US20030059833A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kijavini, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: P2730P1C31
 ; CURRENT FILING DATE: 2001-11-15
 ; PRIOR APPLICATION NUMBER: US/09/997,440
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/087106
 ; PRIOR FILING DATE: 1998-05-28
 ; PRIOR APPLICATION NUMBER: 60/087607
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087609
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087759
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087827
 ; PRIOR FILING DATE: 1998-06-03
 ; PRIOR APPLICATION NUMBER: 60/088021
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088025
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088026
 ; PRIOR FILING DATE: 1998-06-04

RESULT 49

US-09-990-440-371

; Sequence 371, Application US/09990440

; Publication No. US2003060407A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: P2730P/C21

; CURRENT APPLICATION NUMBER: US/09/990,440

; PRIOR FILING DATE: 2001-11-14

; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/075945

; PRIOR FILING DATE: 1998-02-25

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/084600

; PRIOR FILING DATE: 1998-05-07

; PRIOR APPLICATION NUMBER: 60/087106

; PRIOR FILING DATE: 1998-05-28

; PRIOR APPLICATION NUMBER: 60/087607

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087609

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087759

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087827

; PRIOR FILING DATE: 1998-06-03

; PRIOR APPLICATION NUMBER: 60/088021

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088025

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088026

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088028

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088029

; PRIOR FILING DATE: 1998-06-04

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088030

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088033

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088326

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088167

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088202

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088212

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088217

; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088655

; PRIOR FILING DATE: 1998-06-09

; PRIOR APPLICATION NUMBER: 60/088734

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088738

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088742

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088810

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088824

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088826

; PRIOR FILING DATE: 1998-06-10

; PRIOR APPLICATION NUMBER: 60/088858

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/088861

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/088876

; PRIOR FILING DATE: 1998-06-11

; PRIOR APPLICATION NUMBER: 60/089105

; PRIOR FILING DATE: 1998-06-12

; PRIOR APPLICATION NUMBER: 60/089440

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089512

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089514

; PRIOR FILING DATE: 1998-06-16

; PRIOR APPLICATION NUMBER: 60/089532

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089538

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089598

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089599

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089600

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089653

; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089801

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089907

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089908

; PRIOR FILING DATE: 1998-06-18

; PRIOR APPLICATION NUMBER: 60/089947

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/089948

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/089952

; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/090246

; PRIOR FILING DATE: 1998-06-22

; PRIOR APPLICATION NUMBER: 60/090252

; PRIOR FILING DATE: 1998-06-22

; PRIOR APPLICATION NUMBER: 60/090254

; PRIOR FILING DATE: 1998-06-22

PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTPLGREGEC 60

Db 1 MRGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTPLGREGEC 60

Qy 61 HPGSHKVPFPRKHKHTCPCLNLLCSRPFDGGRYCSMDLKNINF 105

Db 61 HPGSHKVPFPRKHKHTCPCLNLLCSRPFDGGRYCSMDLKNINF 105

RESULT 50

US-09-993-469-371
Sequence 371, Application US/09993469
Publication No. US2003006823A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C5
CURRENT APPLICATION NUMBER: US/09/993,469
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355

PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090852
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGDMCTPLGREGEBC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGDMCTPLGREGEBC 60
QY 61 HPGSHKVPFFPRKXHTCTCPLNLLCSRFDPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFPRKXHTCTCPLNLLCSRFDPDGRYRCSMDLKNINF 105

RESULT 51
US-09-997-542-371
; Sequence 371, Application US/09997542
; Publication No. US20030068647A1

; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090576
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGGATVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCCTPLGREGEC 60
Db 1 MGGATVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCCTPLGREGEC 60

QY 61 HPGSHKVPFRKKKHTCTCLNLLCSRPDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPFRKKKHTCTCLNLLCSRPDPGRYCSMDLKNINF 105

RESULT 52
US-09-993-748-371
; Sequence 371, Application US/09993748
; Publication No. US20030069403A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730F1C23
; CURRENT APPLICATION NUMBER: US/09/993,748
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05

; PRIOR APPLICATION NUMBER: 60/088202
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088212
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088217
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088655
 ; PRIOR FILING DATE: 1998-06-09
 ; PRIOR APPLICATION NUMBER: 60/088734
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088738
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088742
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088810
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088824
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088826
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088858
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088861
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088875
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/089105
 ; PRIOR FILING DATE: 1998-06-12
 ; PRIOR APPLICATION NUMBER: 60/089440
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089512
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089514
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089532
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089538
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089599
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089600
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089653
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089801
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089907
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089908
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089947
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435

; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCALISLWLRGLRMTCTPLGREGEEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCALISLWLRGLRMTCTPLGREGEEC 60

QY 61 HPGSHKVPFFFRKRKHTCTCPLNLLCSRFDPGRYRCMDLNINF 105
 Db 61 HPGSHKVPFFFRKRKHTCTCPLNLLCSRFDPGRYRCMDLNINF 105

RESULT 53
 US-09-990-439-371
 ; Sequence 371, Application US/09990439
 ; Publication No. US20030073090A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.

```

; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerzitsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PIC52
; CURRENT APPLICATION NUMBER: US/09/990,439
; CURRENT FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24

```

; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVISMLLVTSDDCAVITGACERDVQCCAGTGCCAISLWLRGKCTPLGREGGEC 60
 DB 1 MRGATRVISMLLVTSDDCAVITGACERDVQCCAGTGCCAISLWLRGKCTPLGREGGEC 60
 QY 61 HPGSHKVPFFRKHKHTCCPLNLLCSRPDPGRYCSMDLKNINF 105
 DB 61 HPGSHKVPFFRKHKHTCCPLNLLCSRPDPGRYCSMDLKNINF 105

RESULT 54

US-09-990-427-371
 ; Sequence 371, Application US/09990427
 ; Publication No. US20030073809A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: P2730PIC10
 ; CURRENT APPLICATION NUMBER: US/09/990,427
 ; CURRENT FILING DATE: 2001-11-14
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/087106
 ; PRIOR FILING DATE: 1998-05-28
 ; PRIOR APPLICATION NUMBER: 60/087607
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087609
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087759
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087827
 ; PRIOR FILING DATE: 1998-06-03
 ; PRIOR APPLICATION NUMBER: 60/088021
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088025
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088026
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088028
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088029
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088030
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088033
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088326
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088167
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088202
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088212
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088217
 ; PRIOR FILING DATE: 1998-06-05

1	PRIOR APPLICATION NUMBER: 60/089655	
2	PRIOR FILING DATE: 1998-06-09	
3	PRIOR APPLICATION NUMBER: 60/089734	
4	PRIOR FILING DATE: 1998-06-10	
5	PRIOR APPLICATION NUMBER: 60/089738	
6	PRIOR FILING DATE: 1998-06-10	
7	PRIOR APPLICATION NUMBER: 60/089742	
8	PRIOR FILING DATE: 1998-06-10	
9	PRIOR APPLICATION NUMBER: 60/089810	
10	PRIOR FILING DATE: 1998-06-10	
11	PRIOR APPLICATION NUMBER: 60/089824	
12	PRIOR FILING DATE: 1998-06-10	
13	PRIOR APPLICATION NUMBER: 60/089826	
14	PRIOR FILING DATE: 1998-06-10	
15	PRIOR APPLICATION NUMBER: 60/089858	
16	PRIOR FILING DATE: 1998-06-11	
17	PRIOR APPLICATION NUMBER: 60/089861	
18	PRIOR FILING DATE: 1998-06-11	
19	PRIOR APPLICATION NUMBER: 60/089876	
20	PRIOR FILING DATE: 1998-06-11	
21	PRIOR APPLICATION NUMBER: 60/089105	
22	PRIOR FILING DATE: 1998-06-12	
23	PRIOR APPLICATION NUMBER: 60/089440	
24	PRIOR FILING DATE: 1998-06-16	
25	PRIOR APPLICATION NUMBER: 60/089512	
26	PRIOR FILING DATE: 1998-06-16	
27	PRIOR APPLICATION NUMBER: 60/089514	
28	PRIOR FILING DATE: 1998-06-16	
29	PRIOR APPLICATION NUMBER: 60/089532	
30	PRIOR FILING DATE: 1998-06-17	
31	PRIOR APPLICATION NUMBER: 60/089538	
32	PRIOR FILING DATE: 1998-06-17	
33	PRIOR APPLICATION NUMBER: 60/089598	
34	PRIOR FILING DATE: 1998-06-17	
35	PRIOR APPLICATION NUMBER: 60/089599	
36	PRIOR FILING DATE: 1998-06-17	
37	PRIOR APPLICATION NUMBER: 60/089600	
38	PRIOR FILING DATE: 1998-06-17	
39	PRIOR APPLICATION NUMBER: 60/089653	
40	PRIOR FILING DATE: 1998-06-17	
41	PRIOR APPLICATION NUMBER: 60/089801	
42	PRIOR FILING DATE: 1998-06-18	
43	PRIOR APPLICATION NUMBER: 60/089907	
44	PRIOR FILING DATE: 1998-06-18	
45	PRIOR APPLICATION NUMBER: 60/089908	
46	PRIOR FILING DATE: 1998-06-18	
47	PRIOR APPLICATION NUMBER: 60/089947	
48	PRIOR FILING DATE: 1998-06-19	
49	PRIOR APPLICATION NUMBER: 60/089948	
50	PRIOR FILING DATE: 1998-06-19	
51	PRIOR APPLICATION NUMBER: 60/089952	
52	PRIOR FILING DATE: 1998-06-19	
53	PRIOR APPLICATION NUMBER: 60/090246	
54	PRIOR FILING DATE: 1998-06-22	
55	PRIOR APPLICATION NUMBER: 60/090252	
56	PRIOR FILING DATE: 1998-06-22	
57	PRIOR APPLICATION NUMBER: 60/090254	
58	PRIOR FILING DATE: 1998-06-22	
59	PRIOR APPLICATION NUMBER: 60/090349	
60	PRIOR FILING DATE: 1998-06-23	
61	PRIOR APPLICATION NUMBER: 60/090355	
62	PRIOR FILING DATE: 1998-06-23	
63	PRIOR APPLICATION NUMBER: 60/090429	
64	PRIOR FILING DATE: 1998-06-24	
65	PRIOR APPLICATION NUMBER: 60/090431	
66	PRIOR FILING DATE: 1998-06-24	
67	PRIOR APPLICATION NUMBER: 60/090435	
68	PRIOR FILING DATE: 1998-06-24	
69	PRIOR APPLICATION NUMBER: 60/090444	
70	PRIOR FILING DATE: 1998-06-24	
71	PRIOR APPLICATION NUMBER: 60/090445	
72	PRIOR FILING DATE: 1998-06-24	
73	PRIOR APPLICATION NUMBER: 60/090472	

1	PRIOR FILING DATE: 1998-06-24	
2	PRIOR APPLICATION NUMBER: 60/090535	
3	PRIOR FILING DATE: 1998-06-24	
4	PRIOR APPLICATION NUMBER: 60/090540	
5	PRIOR FILING DATE: 1998-06-24	
6	PRIOR APPLICATION NUMBER: 60/090542	
7	PRIOR FILING DATE: 1998-06-24	
8	PRIOR APPLICATION NUMBER: 60/090557	
9	PRIOR FILING DATE: 1998-06-24	
10	PRIOR APPLICATION NUMBER: 60/090676	
11	PRIOR FILING DATE: 1998-06-25	
12	PRIOR APPLICATION NUMBER: 60/090678	
13	PRIOR FILING DATE: 1998-06-25	
14	PRIOR APPLICATION NUMBER: 60/090690	
15	PRIOR FILING DATE: 1998-06-25	
16	PRIOR APPLICATION NUMBER: 60/090694	
17	PRIOR FILING DATE: 1998-06-25	
18	PRIOR APPLICATION NUMBER: 60/090695	
19	PRIOR FILING DATE: 1998-06-25	
20	PRIOR APPLICATION NUMBER: 60/090696	
21	PRIOR FILING DATE: 1998-06-25	
22	PRIOR APPLICATION NUMBER: 60/090862	
23	PRIOR FILING DATE: 1998-06-26	
24	PRIOR APPLICATION NUMBER: 60/090863	
25	PRIOR FILING DATE: 1998-06-26	
26	PRIOR APPLICATION NUMBER: 60/091360	
27	PRIOR FILING DATE: 1998-07-01	
28	PRIOR APPLICATION NUMBER: 60/091478	
29	PRIOR FILING DATE: 1998-07-02	
30	PRIOR APPLICATION NUMBER: 60/091544	
31	PRIOR FILING DATE: 1998-07-01	
32	PRIOR APPLICATION NUMBER: 60/091519	
33	PRIOR FILING DATE: 1998-07-02	
34	PRIOR APPLICATION NUMBER: 60/091626	
35	PRIOR FILING DATE: 1998-07-02	
36	PRIOR APPLICATION NUMBER: 60/091633	
37	PRIOR FILING DATE: 1998-07-02	
38	PRIOR APPLICATION NUMBER: 60/091978	
39	PRIOR FILING DATE: 1998-07-07	
40	PRIOR APPLICATION NUMBER: 60/091982	
41	PRIOR FILING DATE: 1998-07-07	
42	PRIOR APPLICATION NUMBER: 60/092182	
43	PRIOR FILING DATE: 1998-07-09	

Query Match	100.0%;	Score 589;	DB 10;	Length 105;
Best Local Similarity	100.0%;	Pred. No. 2.6e-55;		
Matches 105; Conservative	0;	Mismatches	0;	Indels

Q7 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCASISLWRLGRMCTPLGREGEEC 60
|||||

D6 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCASISLWRLGRMCTPLGREGEEC 60
|||||

QY 61 HPGSHKVFFFRKRKHHHTCPCLNLLCSRFDPDGRYRCSMDLKINF 105

61 HPGSHKVFFFRKRKHHHTCPCLNLLCSRFDPDGRYRCSMDLKINF 105

```

RESULT 55
US-09-589-328-371
; Sequence 371, Application US/09589328
; Publication No. US20030077593A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Garber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.

```

```

; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C54
; CURRENT APPLICATION NUMBER: US/09/989,328
; CURRENT FILING DATE: 2001-11-01
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 532
; SEQ ID NO 371
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-989-328-371

```

```

Query Match      100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTSVSDCAVITGACERDVQCGAGTCCALSLMLRGLMCTPLGRGEEC 60
Db 1 MRGATRVSIMLLVTSVSDCAVITGACERDVQCGAGTCCALSLMLRGLMCTPLGRGEEC 60

QY 61 HPGSHKVPFFKRRKHHKTCPLNLLCSRFDPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFKRRKHHKTCPLNLLCSRFDPDGRYRCSMDLKNINF 105

```

```

RESULT 56
US-09-993-583-371
; Sequence 371, Application US/09993583
; Publication No. US20030077594A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.

```

```

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C7
; CURRENT APPLICATION NUMBER: US/09/993,583
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655

```


;
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
;
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
;
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
;
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
;
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
;
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
;
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
;
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
;
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
;
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
;
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
;
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
;
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
;
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
;
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
;
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
;
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
;
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
;
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
;
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
;
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
;
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
;
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
;
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
;
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
;
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
;
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
;
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
;
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
;
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
;
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
;
; PRIOR FILING DATE: 1998-06-24

;
; PRIOR APPLICATION NUMBER: 60/090535
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
;
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
;
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
;
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
;
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
;
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
;
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
;
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
;
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
;
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
;
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
;
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
;
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
;
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
;
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
;
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
;
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
;
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
;
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.f6-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLMLRGLRMCTPLRGEGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLMLRGLRMCTPLRGEGEC 60
QY 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105

RESULT 57
US-09-941-992-371
; Sequence 371, Application US/09941992
; Publication No. US20030082546A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher

APPLICANT: Gurney, Austin L.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C1
CURRENT APPLICATION NUMBER: US/09/941,992
CURRENT FILING DATE: 2001-08-28
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-32
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089601
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540

APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: F2730PIC6
CURRENT APPLICATION NUMBER: US/09/992,521
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCITPLGREGGEC 60
Db 1 MEGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCITPLGREGGEC 60
QY 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFRKXKHTCPCLNLLCSRPDGRYCSMDLKNINF 105

RESULT 58
US-09-992-521-371
Sequence 371, Application US/09992521
Publication No. US20030083461A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.

APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C27
CURRENT APPLICATION NUMBER: US/09/997,333
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/043787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSMILLTVSDCAVITGACERDVCCAGTCCATSLWRLGRLMCTPLGRGEEC 60
Db 1 MRGATRVSMILLTVSDCAVITGACERDVCCAGTCCATSLWRLGRLMCTPLGRGEEC 60

Qy 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFDPGGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFDPGGRYRCSMDLKNINF 105

RESULT 60

US-09-997-384-371
Sequence 371, Application US/09997384
Publication No. US20030087305A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gershten, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.

APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC35
CURRENT APPLICATION NUMBER: US/09/997,384
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826

PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088858
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/088861
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/088876
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/089105
 PRIOR FILING DATE: 1998-06-12
 PRIOR APPLICATION NUMBER: 60/089440
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089512
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089514
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089532
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089538
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089598
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089599
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089600
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089653
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089801
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089907
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089908
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089947
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089948
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089952
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/090246
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090252
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090254
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090349
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090355
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090429
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090431
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090435
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090444
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090445
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090472
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090535
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090540
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090542
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090557
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25

Query Match 100.0%; Score 589; DB 10; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Indels 0; Gaps 0;

Qy 1 MEGATRVSIMLLVTVSDCAVITGACERDVCGAGTCAISLWLRGLRMTPLGREGEEC 60
 Db 1 MEGATRVSIMLLVTVSDCAVITGACERDVCGAGTCAISLWLRGLRMTPLGREGEEC 60
 Qy 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFDPGRYRCSMDLNINF 105
 Db 61 HPGSHKVPFFRKRKHHTCPCLPNLLCSRFDPGRYRCSMDLNINF 105

RESULT 61
 US-09-998-041-371
 ; Sequence 371, Application US/09998041
 ; Publication No. US20030119001A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Pong, Sherman
 ; APPLICANT: Garber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2730FIC34
;; CURRENT APPLICATION NUMBER: US/09/998,041
;; PRIOR FILING DATE: 2001-11-15
;; PRIOR APPLICATION NUMBER: 60/049787
;; PRIOR FILING DATE: 1997-06-16
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/065186
;; PRIOR FILING DATE: 1997-11-12
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066770
;; PRIOR FILING DATE: 1997-11-24
;; PRIOR APPLICATION NUMBER: 60/075945
;; PRIOR FILING DATE: 1998-02-25
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/087106
;; PRIOR FILING DATE: 1998-05-28
;; PRIOR APPLICATION NUMBER: 60/087607
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087609
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087759
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087827
;; PRIOR FILING DATE: 1998-06-03
;; PRIOR APPLICATION NUMBER: 60/088021
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088025
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088026
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088028
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088029
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088030
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088033
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088326
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088167
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088202
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088212
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088217
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088655
;; PRIOR FILING DATE: 1998-06-09
;; PRIOR APPLICATION NUMBER: 60/088734
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088738
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088742
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088810
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088824
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088826
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088858
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088861
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088876
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/089105
;; PRIOR FILING DATE: 1998-06-12
;; PRIOR APPLICATION NUMBER: 60/089440
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089512
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089514
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089598
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089599
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089600
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089653
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089801
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089907
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089908
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694


```

; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSTMLLVTSDDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MEGATRVSTMLLVTSDDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFPRKXKHTCTCLPNLLCSRPDPGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFPRKXKHTCTCLPNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 62
US-09-997-585-371
; Sequence 371, Application US/09997585
; Publication No. US20030119055A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C41
; CURRENT APPLICATION NUMBER: US/09/997,585
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088976

```

;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/089105
;; PRIOR FILING DATE: 1998-06-12
;; PRIOR APPLICATION NUMBER: 60/089440
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089512
;; PRIOR FILING DATE: 1998-06-15
;; PRIOR APPLICATION NUMBER: 60/089514
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089598
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089599
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089600
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089653
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089801
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089907
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089908
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25

;; PRIOR APPLICATION NUMBER: 60/090696
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090862
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/090863
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/091360
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091478
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091544
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09
Query Match 100.0%; Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
QY 61 HPGSHKVPPFFRKXKHTCPCLPNLLCSFPDGRYRCSDMLKXINF 105
Db 61 HPGSHKVPPFFRKXKHTCPCLPNLLCSFPDGRYRCSDMLKXINF 105
RESULT 63
US-09-997-614-371
; Sequence 371, Application US/09997614
; Publication No. US20030124531A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P27301C29
; CURRENT APPLICATION NUMBER: US/09/997,614
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787

[illegible]

```

; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0% Score 589; DB 10; Length 105;
Best Local Similarity 100.0%; Pred. No. 2, 6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCALSLMLRGLRMCTPLGREGEC 60
DB 1 MRGATRVSIMLLLVTSDCAVITGACERDVOCGAGTCCALSLMLRGLRMCTPLGREGEC 60
QY 61 HPGSHKVPFFRRKHHTCCPLNLLCSRFDPGRVRCMSMDLKNINF 105
DB 61 HPGSHKVPFFRRKHHTCCPLNLLCSRFDPGRVRCMSMDLKNINF 105

RESULT 64
US-09-989-862-371
; Sequence 371, Application US/09989862
; Publication No. US20030130182A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C58
; CURRENT APPLICATION NUMBER: US/09/989,862
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
```


, PRIOR FILING DATE: 1997-11-13
 , PRIOR APPLICATION NUMBER: 60/066770
 , PRIOR FILING DATE: 1997-11-24
 , PRIOR APPLICATION NUMBER: 60/075945
 , PRIOR FILING DATE: 1998-02-25
 , PRIOR APPLICATION NUMBER: 60/078910
 , PRIOR FILING DATE: 1998-03-20
 , PRIOR APPLICATION NUMBER: 60/083322
 , PRIOR FILING DATE: 1998-04-28
 , PRIOR APPLICATION NUMBER: 60/084600
 , PRIOR FILING DATE: 1998-05-07
 , PRIOR APPLICATION NUMBER: 60/087106
 , PRIOR FILING DATE: 1998-05-28
 , PRIOR APPLICATION NUMBER: 60/087607
 , PRIOR FILING DATE: 1998-06-02
 , PRIOR APPLICATION NUMBER: 60/087609
 , PRIOR FILING DATE: 1998-06-02
 , PRIOR APPLICATION NUMBER: 60/087759
 , PRIOR FILING DATE: 1998-06-02
 , PRIOR APPLICATION NUMBER: 60/087827
 , PRIOR FILING DATE: 1998-06-03
 , PRIOR APPLICATION NUMBER: 60/088021
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088025
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088026
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088028
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088029
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088030
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088033
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088326
 , PRIOR FILING DATE: 1998-06-04
 , PRIOR APPLICATION NUMBER: 60/088167
 , PRIOR FILING DATE: 1998-06-05
 , PRIOR APPLICATION NUMBER: 60/088202
 , PRIOR FILING DATE: 1998-06-05
 , PRIOR APPLICATION NUMBER: 60/088212
 , PRIOR FILING DATE: 1998-06-05
 , PRIOR APPLICATION NUMBER: 60/088217
 , PRIOR FILING DATE: 1998-06-05
 , PRIOR APPLICATION NUMBER: 60/088655
 , PRIOR FILING DATE: 1998-06-09
 , PRIOR APPLICATION NUMBER: 60/088734
 , PRIOR FILING DATE: 1998-06-10
 , PRIOR APPLICATION NUMBER: 60/088738
 , PRIOR FILING DATE: 1998-06-10
 , PRIOR APPLICATION NUMBER: 60/088742
 , PRIOR FILING DATE: 1998-06-10
 , PRIOR APPLICATION NUMBER: 60/088810
 , PRIOR FILING DATE: 1998-06-10
 , PRIOR APPLICATION NUMBER: 60/088824
 , PRIOR FILING DATE: 1998-06-10
 , PRIOR APPLICATION NUMBER: 60/088826
 , PRIOR FILING DATE: 1998-06-10
 , PRIOR APPLICATION NUMBER: 60/088858
 , PRIOR FILING DATE: 1998-06-11
 , PRIOR APPLICATION NUMBER: 60/088861
 , PRIOR FILING DATE: 1998-06-11
 , PRIOR APPLICATION NUMBER: 60/088876
 , PRIOR FILING DATE: 1998-06-11
 , PRIOR APPLICATION NUMBER: 60/089105
 , PRIOR FILING DATE: 1998-06-12
 , PRIOR APPLICATION NUMBER: 60/089440
 , PRIOR FILING DATE: 1998-06-16
 , PRIOR APPLICATION NUMBER: 60/089512
 , PRIOR FILING DATE: 1998-06-16
 , PRIOR APPLICATION NUMBER: 60/089514
 , PRIOR FILING DATE: 1998-06-16
 , PRIOR APPLICATION NUMBER: 60/091478

[illegible]

; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01

; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 10; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60

DB 1 MEGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60

QY 61 HPGSHKVPFFRKXKHTCTCLPNLLCSFRPDGRVRCSDMLKNINF 105

DB 61 HPGSHKVPFFRKXKHTCTCLPNLLCSFRPDGRVRCSDMLKNINF 105

RESULT 67

US-09-989-733-371

; Sequence 371, Application US/09989733

; Publication No. US20030228655A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zharg, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2730PLC68

; CURRENT FILING DATE: 2001-11-01

; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/075945

; PRIOR FILING DATE: 1998-02-25

; PRIOR APPLICATION NUMBER: 60/078910


```
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 532
; SEQ ID NO 371
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-989-733-371

Query Match      100.0%; Score 589; DB 11; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60

Qy 61 HPGSHKVPPFRKXKHTCPCLPNLLCSRPDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPPFRKXKHTCPCLPNLLCSRPDPGRYCSMDLKNINF 105

RESULT 68
US-09-992-643-371
; Sequence 371, Application US/09992643
; Publication No. US20030228656A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Daniel
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PIC13
; CURRENT APPLICATION NUMBER: US/09/992,643
; CURRENT FILING DATE: 2001-11-01
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
```

```
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 532
; SEQ ID NO 371
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-992-643-371

Query Match      100.0%; Score 589; DB 11; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60

Qy 61 HPGSHKVPPFRKXKHTCPCLPNLLCSRPDPGRYCSMDLKNINF 105
Db 61 HPGSHKVPPFRKXKHTCPCLPNLLCSRPDPGRYCSMDLKNINF 105

RESULT 69
US-10-147-493-470
; Sequence 470, Application US/10147493
; Publication No. US20040029217A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnovers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C345
; CURRENT APPLICATION NUMBER: US/10/147,493
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-493-470

Query Match      100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
```

Qy 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 70

US-10-145-127-470
; Sequence 470, Application US/10145127

; Publication No. US20040033558A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C252

; CURRENT APPLICATION NUMBER: US/10/145,127

; CURRENT FILING DATE: 2002-05-13

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-145-127-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

Qy 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 71

US-10-160-503-470

; Sequence 470, Application US/10160503

; Publication No. US20040033559A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C446

; CURRENT APPLICATION NUMBER: US/10/160,503

; CURRENT FILING DATE: 2002-05-30

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-160-503-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

Qy 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 72

US-10-143-118-470

; Sequence 470, Application US/10143118

; Publication No. US20040038335A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C228

; CURRENT APPLICATION NUMBER: US/10/143,118

; CURRENT FILING DATE: 2002-05-09

; Prior Application removed - See Palm or File Wrapper

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-143-118-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

Qy 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 73

US-10-144-993-470
; Sequence 470, Application US/10144993
; Publication No. US20040038336A1
; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C261
; CURRENT APPLICATION NUMBER: US/10/144,993
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-144-993-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60
|||||
Db 1 MEGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60
|||||

QY 61 HPGSHKVPPFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
|||||
Db 61 HPGSHKVPPFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
|||||

RESULT 74

US-10-158-787-470
; Sequence 470, Application US/10158787
; Publication No. US20040039164A1
; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C449
; CURRENT APPLICATION NUMBER: US/10/158,787
; CURRENT FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-158-787-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60
|||||
Db 1 MEGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60
|||||

QY 61 HPGSHKVPPFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
|||||
Db 61 HPGSHKVPPFRKRKHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
|||||

RESULT 75

US-10-081-056-172
; Sequence 172, Application US/10081056
; Publication No. US20040043927A1
; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Marsters, Scott A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Ye, Weilan
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; FILE REFERENCE: P3235P1C1
; CURRENT APPLICATION NUMBER: US/10/081,056
; CURRENT FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US01/21735
; PRIOR FILING DATE: 2001-07-09

; PRIOR APPLICATION NUMBER: US 60/219,556
 ; PRIOR FILING DATE: 2000-07-20
 ; PRIOR APPLICATION NUMBER: US 60/220,624
 ; PRIOR FILING DATE: 2000-07-25
 ; PRIOR APPLICATION NUMBER: US 60/220,664
 ; PRIOR FILING DATE: 2000-07-25
 ; PRIOR APPLICATION NUMBER: PCT/US00/20710
 ; PRIOR FILING DATE: 2000-07-28
 ; PRIOR APPLICATION NUMBER: US 60/222,695
 ; PRIOR FILING DATE: 2000-08-02
 ; PRIOR APPLICATION NUMBER: US 09/643,657
 ; PRIOR FILING DATE: 2000-08-17
 ; PRIOR APPLICATION NUMBER: PCT/US00/23522
 ; PRIOR FILING DATE: 2000-08-23
 ; PRIOR APPLICATION NUMBER: PCT/US00/23328
 ; PRIOR FILING DATE: 2000-08-24
 ; PRIOR APPLICATION NUMBER: US 60/230,978
 ; PRIOR FILING DATE: 2000-09-07
 ; PRIOR APPLICATION NUMBER: US 60/000,000
 ; PRIOR FILING DATE: 2000-09-15
 ; PRIOR APPLICATION NUMBER: US 09/664,610
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: US 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: US 60/242,922
 ; PRIOR FILING DATE: 2000-10-24
 ; PRIOR APPLICATION NUMBER: US 09/709,238
 ; PRIOR FILING DATE: 2000-11-08
 ; PRIOR APPLICATION NUMBER: PCT/US00/30952
 ; PRIOR FILING DATE: 2000-11-08
 ; PRIOR APPLICATION NUMBER: PCT/US00/30873
 ; PRIOR FILING DATE: 2000-11-10
 ; PRIOR APPLICATION NUMBER: PCT/US00/32678
 ; PRIOR FILING DATE: 2000-12-01
 ; PRIOR APPLICATION NUMBER: US 09/747,259
 ; PRIOR FILING DATE: 2000-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/34956
 ; PRIOR FILING DATE: 2000-12-20
 ; PRIOR APPLICATION NUMBER: US 09/767,609
 ; PRIOR FILING DATE: 2001-01-22
 ; PRIOR APPLICATION NUMBER: US 09/796,498
 ; PRIOR FILING DATE: 2001-02-28
 ; PRIOR APPLICATION NUMBER: PCT/US01/06520
 ; PRIOR FILING DATE: 2001-02-28
 ; PRIOR APPLICATION NUMBER: PCT/US01/06666
 ; PRIOR FILING DATE: 2001-03-01
 ; PRIOR APPLICATION NUMBER: US 09/802,706
 ; PRIOR FILING DATE: 2001-03-09
 ; PRIOR APPLICATION NUMBER: US 09/808,689
 ; PRIOR FILING DATE: 2001-03-14
 ; PRIOR APPLICATION NUMBER: US 09/816,744
 ; PRIOR FILING DATE: 2001-03-22
 ; PRIOR APPLICATION NUMBER: US 09/828,366
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: US 09/854,208
 ; PRIOR FILING DATE: 2001-05-10
 ; PRIOR APPLICATION NUMBER: US 09/854,280
 ; PRIOR FILING DATE: 2001-05-10
 ; PRIOR APPLICATION NUMBER: US 09/866,028
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 09/866,034
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: PCT/US01/17092
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 09/870,574
 ; PRIOR FILING DATE: 2001-05-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/17443
 ; PRIOR FILING DATE: 2001-05-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/17800
 ; PRIOR FILING DATE: 2001-06-01
 ; PRIOR APPLICATION NUMBER: PCT/US01/19692
 ; PRIOR FILING DATE: 2001-06-20
 ; PRIOR APPLICATION NUMBER: PCT/US01/00000

; PRIOR FILING DATE: 2001-06-28
 ; NUMBER OF SEQ ID NOS: 383
 ; SEQ ID NO 172
 ; LENGTH: 105
 ; TYPE: PRT
 ; ORGANISM: Homosapiens
 US-10-081-056-172

Query Match 100.0%; Score 589; DB 12; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGECC 60
 |||||
 Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGECC 60
 |||||
 QY 61 HPGSHKVPFFRRKRKHTCPCLPNNLLCSRFDPGRYRCSDMLKNINF 105
 |||||
 Db 61 HPGSHKVPFFRRKRKHTCPCLPNNLLCSRFDPGRYRCSDMLKNINF 105
 |||||

RESULT 76
 US-10-219-535-166
 ; Sequence 166, Application US/10219535
 ; Publication No. US20040044179A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Gerritsen, Mary
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stephan, Jean-Philippe F.
 ; APPLICANT: Watanabe, Colin L.
 ; APPLICANT: Wood, William I.
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3530PIC60
 ; CURRENT APPLICATION NUMBER: US/10/219,535
 ; CURRENT FILING DATE: 2002-08-14
 ; PRIOR APPLICATION NUMBER: 10/119,480
 ; PRIOR FILING DATE: 2002-04-09
 ; PRIOR APPLICATION NUMBER: 60/059113
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/062287
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/063549
 ; PRIOR FILING DATE: 1997-10-28
 ; PRIOR APPLICATION NUMBER: 60/064103
 ; PRIOR FILING DATE: 1997-10-31
 ; PRIOR APPLICATION NUMBER: 60/069873
 ; PRIOR FILING DATE: 1997-12-17
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/079294
 ; PRIOR FILING DATE: 1998-03-25
 ; PRIOR APPLICATION NUMBER: 60/079656
 ; PRIOR FILING DATE: 1998-03-26
 ; PRIOR APPLICATION NUMBER: 60/079728
 ; PRIOR FILING DATE: 1998-03-27
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 246
 ; SEQ ID NO 166
 ; LENGTH: 105
 ; TYPE: PRT
 ; ORGANISM: Homo Sapien
 US-10-219-535-166

Query Match 100.0%; Score 589; DB 12; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
QY 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFPDGRYCSMDLKNINF 105

RESULT 77

US-10-232-230-166
; Sequence 166, Application US/10232230
; Publication No. US20040044180A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerriksen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C103
; CURRENT APPLICATION NUMBER: US/10/232,230
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 166
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-230-166

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
QY 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFPDGRYCSMDLKNINF 105

RESULT 78

US-09-969-984-11
; Sequence 11, Application US/09969984
; Publication No. US20040048244A1
; GENERAL INFORMATION:
; APPLICANT: INCYTE GENOMICS, INC.
; APPLICANT: TANG, Y. Tom
; APPLICANT: YUE, Henry
; APPLICANT: LAL, Freeti
; APPLICANT: BURFORD, Neil
; APPLICANT: BANDMAN, Olga
; APPLICANT: BAUGHN, Mariah R.
; APPLICANT: AZIMZAI, Yalda
; APPLICANT: LU, Dyung Aina M.
; APPLICANT: PATTERSON, Chandra
; TITLE OF INVENTION: EXTRACELLULAR SIGNALING MOLECULES
; FILE REFERENCE: PF-0701-1 USA
; CURRENT APPLICATION NUMBER: US/09/969,984
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/134,949; 60/144,270; 60/146,700; 60/157,508
; PRIOR FILING DATE: 1999-05-19; 1999-07-15; 1999-07-30; 1999-10-04
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PERL Program
; SEQ ID NO 11
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: misc feature
; FEATURE:
; OTHER INFORMATION: Incyte ID No. US20040048244A1 2006548CD1
US-09-969-984-11

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEBC 60
QY 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKHKHTCPCPLNLLCSRFPDGRYCSMDLKNINF 105

RESULT 79

US-10-140-024-470
; Sequence 470, Application US/10140024
; Publication No. US20040058424A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerriksen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C69
; CURRENT APPLICATION NUMBER: US/10/140,024
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550

us-10-027-603-2.rapb

```
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-024-470

Query Match      100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 MRGATRVISIMLLTVSDCAVITGACERDVQCGAGTCCATSLWLRGVMCTPLGREGEC 60
        |||
Db      1 MRGATRVISIMLLTVSDCAVITGACERDVQCGAGTCCATSLWLRGVMCTPLGREGEC 60

Qy      61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
        |||
Db      61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 80
US-09-989-724-371
; Sequence 371, Application US/09989724
; Publication No. US20030017476A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin X.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730PLC67
; CURRENT APPLICATION NUMBER: US/09/989,724
; PRIOR FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
```



```
Query Match      100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MRGATVSIIMLLIVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEBC 60
      |||||
Db      1 MRGATVSIIMLLIVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLRGEGEBC 60
      |||||

QY      61 HPGSHKVPFFRKHKHTCTCLPNLLCSRPFDGGRYCSMDLKNINF 105
      |||||
Db      61 HPGSHKVPFFRKHKHTCTCLPNLLCSRPFDGGRYCSMDLKNINF 105
      |||||

RESULT 82
US-09-990-441-371
; Sequence 371, Application US/09990441
; Publication No. US20030017982A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Klijavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PIC47
; CURRENT APPLICATION NUMBER: US/09/990,441
; CURRENT FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
```

; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09
 ; PRIOR APPLICATION NUMBER: 60/092189
 ; PRIOR FILING DATE: 1998-07-09
 ; PRIOR APPLICATION NUMBER: 60/092189
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 12; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCTPLGREGESEC 60
 DB 1 MEGATRVSIMLLLVTSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCTPLGREGESEC 60
 QY 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFPDGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFPDGRYRCSDMLKNINF 105
 RESULT 83
 US-10-140-808-470
 ; Sequence 470, Application US/10140808
 ; Publication No. US20030017563A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: Deforge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Goddard, Paul J.
 ; APPLICANT: Godswski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C182
 ; CURRENT APPLICATION NUMBER: US/10/140,808
 ; CURRENT FILING DATE: 2002-05-07
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 470
 ; LENGTH: 105
 ; TYPE: PRT
 ; ORGANISM: Homo Sapien
 US-10-140-808-470

Query Match 100.0%; Score 589; DB 12; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCTPLGREGESEC 60
 DB 1 MEGATRVSIMLLLVTSDCAVITGACERDVOCAGTCCCAISLWLRGLRMCTPLGREGESEC 60
 QY 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFPDGRYRCSDMLKNINF 105
 DB 61 HPGSHKVPFFRRKRKHTCTCPLNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 84
 US-09-997-857-371
 ; Sequence 371, Application US/09997857
 ; Publication No. US20030064375A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tomas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC43
CURRENT APPLICATION NUMBER: US/09/997,857
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535

; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 12; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCALSILWRLGRLMCTPLGREGGEC 60

Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCALSILWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 85

US-10-232-224-166

; Sequence 166, Application US/10232224

; Publication No. US20030065147A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Desnoyers, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3530PIC111
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 166
; LENGTH: 105
; TYPE: PRM
; ORGANISM: Homo Sapien
US-10-232-224-166

Query Match

100.0%; Score 589; DB 12; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCALSILWRLGRLMCTPLGREGGEC 60

Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCALSILWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 86

US-09-997-641-371

; Sequence 371, Application US/09997641

; Publication No. US20030224358A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: P27301C39
;; CURRENT APPLICATION NUMBER: US/09/297,641
;; CURRENT FILING DATE: 2001-11-15
;; PRIOR APPLICATION NUMBER: 60/049787
;; PRIOR FILING DATE: 1997-06-16
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/065186
;; PRIOR FILING DATE: 1997-11-12
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066770
;; PRIOR FILING DATE: 1997-11-24
;; PRIOR APPLICATION NUMBER: 60/075945
;; PRIOR FILING DATE: 1998-02-25
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/087106
;; PRIOR FILING DATE: 1998-05-28
;; PRIOR APPLICATION NUMBER: 60/087607
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087609
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087759
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087827
;; PRIOR FILING DATE: 1998-06-03
;; PRIOR APPLICATION NUMBER: 60/088021
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088025
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088026
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088028
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088029
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088030
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088033
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088326
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088167
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088202
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088212
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088217
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088655
;; PRIOR FILING DATE: 1998-06-09
;; PRIOR APPLICATION NUMBER: 60/088734
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088738
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088742
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088810
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088824
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088826
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088858
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088861
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088876
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/089105
;; PRIOR FILING DATE: 1998-06-12
;; PRIOR APPLICATION NUMBER: 60/089440
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089512
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089514
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089598
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089599
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089600
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089653
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089801
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089907
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089908
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694

;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090696
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090862
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/090863
;; PRIOR FILING DATE: 1998-06-26
;; PRIOR APPLICATION NUMBER: 60/091360
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091478
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091544
;; PRIOR FILING DATE: 1998-07-01
;; PRIOR APPLICATION NUMBER: 60/091519
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091626
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091633
;; PRIOR FILING DATE: 1998-07-02
;; PRIOR APPLICATION NUMBER: 60/091978
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/092182
;; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 87

US-09-991-150-371
; Sequence 371, Application US/09991150
; Publication No. US20030194760A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Pao, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730P1C48

;; CURRENT APPLICATION NUMBER: US/09/991,150
;; CURRENT FILING DATE: 2001-11-16
;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 532
;; SEQ ID NO 371
;; LENGTH: 105
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-991-150-371

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 88

US-10-152-405-470
; Sequence 470, Application US/10152405
; Publication No. US20030211571A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C383
; CURRENT APPLICATION NUMBER: US/10/152,405
; CURRENT FILING DATE: 2002-05-20
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-152-405-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 89

US-10-127-852A-470

APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: F3330RIC81
CURRENT APPLICATION NUMBER: US/10/127,900A
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C116
CURRENT APPLICATION NUMBER: US/10/128,685A
CURRENT FILING DATE: 2002-04-23
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-128-685A-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSTMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMTCTPLGRGEEC 60
Db 1 MEGATRVSTMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMTCTPLGRGEEC 60

QY 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 92
US-10-131-820A-470
Sequence 470, Application US/10131820A
Publication No. US20030203431A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin

APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C144
CURRENT APPLICATION NUMBER: US/10/131,820A
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-131-820A-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSTMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMTCTPLGRGEEC 60
Db 1 MEGATRVSTMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMTCTPLGRGEEC 60

QY 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 93
US-10-142-886-470
Sequence 470, Application US/10142886
Publication No. US20030203432A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C326
; CURRENT APPLICATION NUMBER: US/10/142,886
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-142-886-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
QY 61 HPGSHKVPFFRKHKHTCPCLENLLCSRPDPGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLENLLCSRPDPGRYRCSMDLKNINF 105

RESULT 94
US-10-146-728-470
; Sequence 470, Application US/10146728
; Publication No. US2003020347A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C321
; CURRENT APPLICATION NUMBER: US/10/146,728
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-146-728-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
QY 61 HPGSHKVPFFRKHKHTCPCLENLLCSRPDPGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLENLLCSRPDPGRYRCSMDLKNINF 105

RESULT 95
US-10-146-786-470
; Sequence 470, Application US/10146786
; Publication No. US20030203438A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C313
; CURRENT APPLICATION NUMBER: US/10/146,786
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-146-786-470

Query Match 100.0%; Score 589; DB 12; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
QY 61 HPGSHKVPFFRKHKHTCPCLENLLCSRPDPGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLENLLCSRPDPGRYRCSMDLKNINF 105

RESULT 96
US-10-147-499-470
; Sequence 470, Application US/10147499
; Publication No. US20030203439A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C321
; CURRENT APPLICATION NUMBER: US/10/147,499
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-499-470

```
FILE REFERENCE: P3330R1C348
CURRENT APPLICATION NUMBER: US/10/147,499
CURRENT FILING DATE: 2002-05-17
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-147-499-470

Query Match
Best Local Similarity 100.0%; Score 589; DB 12; Length 105;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 97
US-10-157-798-470
Sequence 470, Application US/10157798
Publication No. US20030203440A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: Deforge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
TITLE OF INVENTION: ACIDS ENCODING THE SAME
FILE REFERENCE: P3330R1C443
CURRENT APPLICATION NUMBER: US/10/157,798
CURRENT FILING DATE: 2002-05-29
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-157-798-470

Query Match
Best Local Similarity 100.0%; Score 589; DB 12; Length 105;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 98
US-10-157-798-470

Query Match
Best Local Similarity 100.0%; Score 589; DB 13; Length 105;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

US-10-305-654-172
Sequence 172, Application US/10305654
Publication No. US20030224984A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Ferrara, Napoleone
APPLICANT: Gerber, Hans-Peter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Marsters, Scot A.
APPLICANT: Pan, J.
APPLICANT: Paoni, N. F.
APPLICANT: Stephan, J-P. F.
APPLICANT: Watanabe, C.K.
APPLICANT: Wood, W.I.
APPLICANT: Williams, P.M.
APPLICANT: Ye, Weilan
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
TITLE OF INVENTION: TREATMENT OF DISORDERS INVOLVING ANGIOGENESIS
FILE REFERENCE: P3235R1C
CURRENT APPLICATION NUMBER: US/10/305,654
CURRENT FILING DATE: 2002-11-26
NUMBER OF SEQ ID NOS: 383
SEQ ID NO 172
LENGTH: 105
TYPE: PRT
ORGANISM: Homosapiens
US-10-305-654-172

Query Match
Best Local Similarity 100.0%; Score 589; DB 12; Length 105;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 99
US-10-016-481-2
Sequence 2, Application US/10016481
Publication No. US20020115610A1
GENERAL INFORMATION:
APPLICANT: Zhou, Qun-Yong
APPLICANT: Ehler, Frederick
TITLE OF INVENTION: Prokineticin Polypeptides, Related
TITLE OF INVENTION: Compositions and Methods
FILE REFERENCE: P-UC 501g
CURRENT APPLICATION NUMBER: US/10/016,481
CURRENT FILING DATE: 2001-11-01
PRIOR APPLICATION NUMBER: 60/245,882
PRIOR FILING DATE: 2000-11-03
NUMBER OF SEQ ID NOS: 19
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 105
TYPE: PRT
ORGANISM: Homo sapiens
US-10-016-481-2

Query Match
Best Local Similarity 100.0%; Score 589; DB 13; Length 105;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
DB 1 MGRATRVSIMLLLVTSQCAVITGACERDVQCGAGTCCALSLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
```

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCATSLWLRGLRMCTPLGREGECC 60

Qy 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGGRYRCSDMLKNINF 105

RESULT 100

US-10-027-603-2
; Sequence 2, Application US/10027603
; Publication No. US20020192634A1
; GENERAL INFORMATION:
; APPLICANT: Pertara, Napoleone
; APPLICANT: Watanabe, Colin
; APPLICANT: Wood, William I.
; APPLICANT: Shek, Theresa
; TITLE OF INVENTION: EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES
; FILE OF INVENTION: AND METHODS OF USE
; FILE REFERENCE: GENENT.1516CPI
; CURRENT APPLICATION NUMBER: US/10/027,603
; PRIOR APPLICATION NUMBER: 09/886,242
; PRIOR FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: 60/230,978
; PRIOR FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: 60/213,637
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/096,146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: PCT/US00/32678
; PRIOR FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: PCT/US00/08439
; PRIOR FILING DATE: 2000-03-30
; PRIOR APPLICATION NUMBER: PCT/US00/04914
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; PRIOR APPLICATION NUMBER: PCT/US99/12252
; PRIOR FILING DATE: 1999-06-02
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
US-10-027-603-2

Query Match 100.0%; Score 589; DB 13; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCATSLWLRGLRMCTPLGREGECC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVOCGAGTCCATSLWLRGLRMCTPLGREGECC 60
Qy 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFPKRKHHTCPCLPNLLCSRFDPGGRYRCSDMLKNINF 105

RESULT 101
US-10-028-072-470
; Sequence 470, Application US/10028072
; Publication No. US20030004311A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen

APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang
FILE OF INVENTION:
FILE REFERENCE:
CURRENT APPLICATION NUMBER: US/10/028,072
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059836
PRIOR FILING DATE: 1997-09-24
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062285
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062287
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062814
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/062816
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063045
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063082
PRIOR FILING DATE: 1997-10-31
PRIOR APPLICATION NUMBER: 60/063127
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063327
PRIOR FILING DATE: 1997-10-27
PRIOR APPLICATION NUMBER: 60/063329
PRIOR FILING DATE: 1997-10-27
PRIOR APPLICATION NUMBER: 60/063550
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/063561
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/063704
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063733
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063735
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063738
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063755
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064248

; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081695
; PRIOR FILING DATE: 1998-04-14
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081818
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082999
; PRIOR FILING DATE: 1998-04-24
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/083545
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085149
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13

; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086414
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/086430
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088730
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088741
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 19/98-06-11
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090538
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMCTPIORGEEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCATSLWLRGLRMCTPIORGEEC 60

Qy 61 HPGSHKVPFFFKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFFKRKHHTCPCLPNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 102
US-10-121-049-470
; Sequence 470, Application US/10121049
; Publication No. US2003002239A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C17
CURRENT APPLICATION NUMBER: US/10/121,049
CURRENT FILING DATE: 2002-04-12
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-121-049-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60

Qy 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105

RESULT 103
US-10-123-904-470
Sequence 470, Application US/10123904
Publication No. US2003002238A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C54
CURRENT APPLICATION NUMBER: US/10/123,904
CURRENT FILING DATE: 2002-04-16
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-123-904-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60

Qy 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105

RESULT 104
US-10-140-470-470
Sequence 470, Application US/10140470
Publication No. US20030022331A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C160
CURRENT APPLICATION NUMBER: US/10/140,470
CURRENT FILING DATE: 2002-05-06
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-140-470-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEEC 60

Qy 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105
Db 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRFPDGRYRCMDLKNINF 105

RESULT 105
US-10-175-746-470
Sequence 470, Application US/10175746
Publication No. US20030027270A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.

```
/ APPLICANT: Sherwood,Steven
/ APPLICANT: Smith,Victoria
/ APPLICANT: Stewart,Timothy A.
/ APPLICANT: Tamas,Daniel
/ APPLICANT: Watanabe,Colin K
/ APPLICANT: Wood,William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ FILE REFERENCE: P3330R1C353
/ CURRENT APPLICATION NUMBER: US/10/175,746
/ CURRENT FILING DATE: 2002-06-19
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 550
/ SEQ ID NO 470
/ LENGTH: 105
/ TYPE: PRT
/ ORGANISM: Homo Sapien
US-10-175-746-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
Qy 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105

RESULT 106
US-10-176-918-470
/ Sequence 470, Application US/10176918
/ Publication No. US20030027275A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Beresini, Maureen
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Sherwood, Steven
/ APPLICANT: Smith, Victoria
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tamas, Daniel
/ APPLICANT: Watanabe, Colin K
/ APPLICANT: Wood, William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ FILE REFERENCE: P3330R1C388
/ CURRENT APPLICATION NUMBER: US/10/176,921
/ CURRENT FILING DATE: 2002-06-20
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 550
/ SEQ ID NO 470
/ LENGTH: 105
/ TYPE: PRT
/ ORGANISM: Homo Sapien
US-10-176-918-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
Qy 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105

RESULT 108
US-10-176-918-470
/ Sequence 470, Application US/10176918
/ Publication No. US20030027275A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Beresini, Maureen
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Sherwood, Steven
/ APPLICANT: Smith, Victoria
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tamas, Daniel
/ APPLICANT: Watanabe, Colin K
/ APPLICANT: Wood, William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ FILE REFERENCE: P3330R1C382
/ CURRENT APPLICATION NUMBER: US/10/176,918
/ CURRENT FILING DATE: 2002-06-20
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 550
/ SEQ ID NO 470
/ LENGTH: 105
/ TYPE: PRT
/ ORGANISM: Homo Sapien
US-10-176-918-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
```

```
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
Qy 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105

RESULT 107
US-10-176-921-470
/ Sequence 470, Application US/10176921
/ Publication No. US20030027276A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Beresini, Maureen
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Sherwood, Steven
/ APPLICANT: Smith, Victoria
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tamas, Daniel
/ APPLICANT: Watanabe, Colin K
/ APPLICANT: Wood, William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ FILE REFERENCE: P3330R1C288
/ CURRENT APPLICATION NUMBER: US/10/176,921
/ CURRENT FILING DATE: 2002-06-20
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 550
/ SEQ ID NO 470
/ LENGTH: 105
/ TYPE: PRT
/ ORGANISM: Homo Sapien
US-10-176-921-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGECC 60
Qy 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTKHTCPCPLNLLCSRFDPGGRYRCSMDLKNINF 105

RESULT 108
US-10-227-894-166
/ Sequence 166, Application US/10227884
/ Publication No. US20030027988A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Gerritsen, Mary
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, J. Christopher
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Smith, Victoria
/ APPLICANT: Stephan, Jean-Philippe F.
/ APPLICANT: Watanabe, Colin L.
/ APPLICANT: Wood, William I.
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
```

;; TITLE OF INVENTION: ACIDS ENCODING THE SAME
;; FILE REFERENCE: F5530PIC79
;; CURRENT APPLICATION NUMBER: US/10/227,884
;; CURRENT FILING DATE: 2002-08-26
;; PRIOR APPLICATION NUMBER: 10/119,480
;; PRIOR FILING DATE: 2002-04-09
;; PRIOR APPLICATION NUMBER: 60/059113
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/062287
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/063549
;; PRIOR FILING DATE: 1997-10-28
;; PRIOR APPLICATION NUMBER: 60/064103
;; PRIOR FILING DATE: 1997-10-31
;; PRIOR APPLICATION NUMBER: 60/069873
;; PRIOR FILING DATE: 1997-12-17
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/079294
;; PRIOR FILING DATE: 1998-03-25
;; PRIOR APPLICATION NUMBER: 60/079656
;; PRIOR FILING DATE: 1998-03-26
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/086392
;; PRIOR FILING DATE: 1998-05-22
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089905
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090691
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090695
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/091982
;; PRIOR FILING DATE: 1998-07-07
;; PRIOR APPLICATION NUMBER: 60/095302
;; PRIOR FILING DATE: 1998-08-04
;; PRIOR APPLICATION NUMBER: 60/095318
;; PRIOR FILING DATE: 1998-08-04
;; PRIOR APPLICATION NUMBER: 60/095916
;; PRIOR FILING DATE: 1998-08-10
;; PRIOR APPLICATION NUMBER: 60/096146
;; PRIOR FILING DATE: 1998-08-11
;; PRIOR APPLICATION NUMBER: 60/096791
;; PRIOR FILING DATE: 1998-08-17
;; PRIOR APPLICATION NUMBER: 60/097986
;; PRIOR FILING DATE: 1998-08-26
;; PRIOR APPLICATION NUMBER: 60/098544
;; PRIOR FILING DATE: 1998-08-31
;; PRIOR APPLICATION NUMBER: 60/099596
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099598
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099803
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099811
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099812
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099815
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/100038
;; PRIOR FILING DATE: 1998-09-11
;; PRIOR APPLICATION NUMBER: 60/100385
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100390
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100627
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101738
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101786
;; PRIOR FILING DATE: 1998-09-25
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101922
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/106178
;; PRIOR FILING DATE: 1998-10-28
;; PRIOR APPLICATION NUMBER: 60/106248
;; PRIOR FILING DATE: 1998-10-29
;; PRIOR APPLICATION NUMBER: 60/106464
;; PRIOR FILING DATE: 1998-10-30
;; PRIOR APPLICATION NUMBER: 60/106905
;; PRIOR FILING DATE: 1998-11-03
;; PRIOR APPLICATION NUMBER: 60/108787
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108801
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108849
;; PRIOR FILING DATE: 1998-11-18
;; PRIOR APPLICATION NUMBER: 60/112422
;; PRIOR FILING DATE: 1998-12-15
;; PRIOR APPLICATION NUMBER: 60/113296
;; PRIOR FILING DATE: 1998-12-22
;; PRIOR APPLICATION NUMBER: 60/113605
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/113621
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/115558
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115565
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115733
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/119549
;; PRIOR FILING DATE: 1999-02-10
;; PRIOR APPLICATION NUMBER: 60/123618
;; PRIOR FILING DATE: 1999-03-10
;; PRIOR APPLICATION NUMBER: 60/125259
;; PRIOR FILING DATE: 1999-03-19
;; PRIOR APPLICATION NUMBER: 60/125775
;; PRIOR FILING DATE: 1999-03-23
;; PRIOR APPLICATION NUMBER: 60/126773
;; PRIOR FILING DATE: 1999-03-29
;; PRIOR APPLICATION NUMBER: 60/127887
;; PRIOR FILING DATE: 1999-04-05
;; PRIOR APPLICATION NUMBER: 60/130232
;; PRIOR FILING DATE: 1999-04-21

PRIOR APPLICATION NUMBER: 60/131022
PRIOR FILING DATE: 1999-04-26
PRIOR APPLICATION NUMBER: 60/131270
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131291
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131445
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 60/134287
PRIOR FILING DATE: 1999-05-14
PRIOR APPLICATION NUMBER: 60/140650
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/140723
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/141037
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 60/144758
PRIOR FILING DATE: 1999-07-20
PRIOR APPLICATION NUMBER: 60/145698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: 60/146222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: 60/146963
PRIOR FILING DATE: 1999-08-03
PRIOR APPLICATION NUMBER: 60/149320
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/149638
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/151733
PRIOR FILING DATE: 1999-08-31
PRIOR APPLICATION NUMBER: 60/164418
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/166361
PRIOR FILING DATE: 1999-11-16
PRIOR APPLICATION NUMBER: 60/169445
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169495
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169835

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MEGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 109
US-10-137-865-470
Sequence 470, Application US/10137865
Publication No. US20030032155A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K

APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C154
CURRENT APPLICATION NUMBER: US/10/137,865
CURRENT FILING DATE: 2002-05-03
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-137-865-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MEGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 110
US-10-140-474-470
Sequence 470, Application US/10140474
Publication No. US20030032156A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C162
CURRENT APPLICATION NUMBER: US/10/140,474
CURRENT FILING DATE: 2002-05-06
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-140-474-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MEGATRVSIMLLLVTSVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFDPGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKXKHTCTCLPNNLLCSRPDPDGRYRCSMDLKNINF 105

RESULT 111

US-10-142-431-470
; Sequence 470, Application US/10142431
; Publication No. US20030036179A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C251

; CURRENT APPLICATION NUMBER: US/10/142,431

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-142-431-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSMLRGLRMCTPLGREGEEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSMLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKXKHTCTCLPNNLLCSRPDPDGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRKXKHTCTCLPNNLLCSRPDPDGRYRCSMDLKNINF 105

RESULT 112

US-10-143-114-470
; Sequence 470, Application US/10143114
; Publication No. US20030036180A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C211

; CURRENT APPLICATION NUMBER: US/10/143,114

; Prior Application removed - See Palm or File Wrapper

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-143-114-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSMLRGLRMCTPLGREGEEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCALSMLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKXKHTCTCLPNNLLCSRPDPDGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRKXKHTCTCLPNNLLCSRPDPDGRYRCSMDLKNINF 105

RESULT 113

US-10-230-163-166

; Sequence 166, Application US/10230163

; Publication No. US20030036635A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Desnoyers, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3530P1C96

; CURRENT APPLICATION NUMBER: US/10/230,163

; Prior Filing Date: 2002-08-28

; Prior Application Number: 10/119,480

; Prior Filing Date: 2002-04-09

; Prior Application Number: 60/059113

; Prior Filing Date: 1997-09-17

; Prior Application Number: 60/062287

; Prior Filing Date: 1997-10-17

; Prior Application Number: 60/063549

; Prior Filing Date: 1997-10-28

; Prior Application Number: 60/064103

; Prior Filing Date: 1997-10-31

; Prior Application Number: 60/069873

; Prior Filing Date: 1997-12-17

; Prior Application Number: 60/078910

; Prior Filing Date: 1998-03-20

; Prior Application Number: 60/079294

; Prior Filing Date: 1998-03-25

; Prior Application Number: 60/079656

; Prior Filing Date: 1998-03-26

; Prior Application Number: 60/079728

; Prior Filing Date: 1998-03-27

; Prior Application Number: 60/081819

; Prior Filing Date: 1998-04-15

; Prior Application Number: 60/081955

; Prior Filing Date: 1998-04-15

; Prior Application Number: 60/082804

; Prior Filing Date: 1998-04-22

; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60

Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60

QY 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 114

US-10-140-002-470

; Sequence 470, Application US/10140002

; Publication No. US20030037623A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P333031C59

; CURRENT APPLICATION NUMBER: US/10/140,002

; PRIOR FILING DATE: 2002-05-06

; PRIOR APPLICATION REMOVED - See Palm or File Wrapper

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-140-002-470

Query Match

100.0%; Score 589; DB 14; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60

Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60

QY 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 115

US-10-230-338-166

; Sequence 166, Application US/10230338

; Publication No. US20030044934A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Desnoyers, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe P.

; APPLICANT: Watanabe, Colin L.

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P35301C92

; CURRENT APPLICATION NUMBER: US/10/230,338

; PRIOR FILING DATE: 2002-08-28

; PRIOR APPLICATION NUMBER: 10/119,480

; PRIOR FILING DATE: 2002-04-09

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/062287

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/063549

; PRIOR FILING DATE: 1997-10-28

; PRIOR APPLICATION NUMBER: 60/064103

; PRIOR FILING DATE: 1997-10-31

; PRIOR APPLICATION NUMBER: 60/069873

; PRIOR FILING DATE: 1997-12-17

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/079294

; PRIOR FILING DATE: 1998-03-25

; PRIOR APPLICATION NUMBER: 60/079656

; PRIOR FILING DATE: 1998-03-26

; PRIOR APPLICATION NUMBER: 60/079728

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 246

; SEQ ID NO 166

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-230-338-166

Query Match 100.0%; Score 589; DB 14; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60

Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGECC 60

QY 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKHKHTCTCLNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 116

US-10-142-419-470

; Sequence 470, Application US/10142419

; Publication No. US20030044945A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

```
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C244
; CURRENT APPLICATION NUMBER: US/10/142.419
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-142-419-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGEEC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGEEC 60
QY 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 117
US-10-218-631-166
; Sequence 166, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218.631
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
```

```
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 166
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-166

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGEEC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGEEC 60
QY 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 118
US-10-123-262-470
; Sequence 470, Application US/10123262
; Publication No. US20030049816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C38
; CURRENT APPLICATION NUMBER: US/10/123.262
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-123-262-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGEEC 60
Db 1 MRGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGEEC 60
QY 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFFRKRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 119
```

```
US-10-142-423-470
; Sequence 470, Application US/10142423
; Publication No. US2003004981A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C249
; CURRENT APPLICATION NUMBER: US/10/142,423
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-142-423-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
OY 61 HPGSHKVPFFRKHKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 120
US-10-230-414-166
; Sequence 166, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
```

```
US-10-121-050-470
; Sequence 470, Application US/10121050
; Publication No. US20030054516A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C20
; CURRENT APPLICATION NUMBER: US/10/121,050
; CURRENT FILING DATE: 2002-04-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-121-050-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
OY 61 HPGSHKVPFFRKHKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105

RESULT 121
US-10-121-050-470
; Sequence 470, Application US/10121050
; Publication No. US20030054516A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C20
; CURRENT APPLICATION NUMBER: US/10/121,050
; CURRENT FILING DATE: 2002-04-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-121-050-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGGEC 60
OY 61 HPGSHKVPFFRKHKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLNLLCSRFDPGRYRCSDMLKNINF 105
```

	Matches	105;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1	MRGATRVISIMLLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGURNCTPLGREGEEC	60							
Db	1	MRGATRVISIMLLLVTVSDCAVITGACERDVQCGAGTCCALSLWRLGURNCTPLGREGEEC	60							
Qy	61	HPGSHKVPFFPRKXKHTTCPLPNLLCSRFDPDGRYRCSDMLKTNF	105							
Db	61	HPGSHKVPFFPRKXKHTTCPLPNLLCSRFDPDGRYRCSDMLKTNF	105							

```

RESULT 122
US-10-141-755-470
; Sequence 470, Application US/10141755
; Publication No. US20030054517A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeGeorge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C192
; CURRENT APPLICATION NUMBER: US/10/141,755
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-141-755-470

```

RESULT 123
US-10-132-812-16
; Sequence 16, Application US/10132812
; Publication No. US20030059856A1
; GENERAL INFORMATION:
; APPLICANT: Ames, Robert S.
; APPLICANT: Sarau, Henry M.
; APPLICANT: Siemmon, J. Randall
; APPLICANT: McNulty, Dean E.
; APPLICANT: Vawter, Lisa
; APPLICANT: Foley, James J.
; TITLE OF INVENTION: Methods Of Screening For Agonists And
; Agonists Of The Interaction Between The AXOR8 And AXOR52
; TITLE OF INVENTION: Receptors And Liqands Thereof

```

; FILE REFERENCE: P51256
; CURRENT APPLICATION NUMBER: US/10/132,812
; CURRENT FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: 60/286,234
; PRIOR FILING DATE: 2001-04-25
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-132-812-16

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps
Qy      1  MRGATRVSLMLLIVTSDCAVITGACERDVQCGAGTCCCAISLWLRLGLRMCTPLGREGSEC 60
Db      1  MRGATRVSLMLLIVTSDCAVITGACERDVQCGAGTCCCAISLWLRLGLRMCTPLGREGSEC 60
Qy      61  HPGSHKVPFFRRKXKHTCPCLPNLLCSRFPDGGRYCSDMLKNINF 105
Db      61  HPGSHKVPFFRRKXKHTCPCLPNLLCSRFPDGGRYCSDMLKNINF 105

```

```

RESULT 124
US-10-143-032-470
; Sequence 470, Application US/10143032
; Publication No. US20030059909A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C245
; CURRENT APPLICATION NUMBER: US/10/143,032
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See Palm or File wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-143-032-470

```

	Query Match	100.0%;	Score 589;	DB 14;	Length 105;
	Best Local Similarity	100.0%;	Pred. No. 2.6e-55;		
	Matches 105;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	MRGATRVISMLLTVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC	60		
Db	1	MRGATRVISMLLTVTSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGRGEEC	60		
Qy	61	HPGSHKVPRFRKKHHTCPCPLNLLCSRPFDGRYRCMDLKNF	105		
Db	61	HPGSHKVPRFRKKHHTCPCPLNLLCSRPFDGRYRCMDLKNF	105		

RESULT 125

US-10-123-108-470

; Sequence 470, Application US/10123108

; Publication No. US20030068793A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P33301C36

; CURRENT FILING DATE: 2002-04-15

; CURRENT FILING DATE: 2002-04-15

; PRIOR APPLICATION NUMBER: US/10/123,108

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059836

; PRIOR FILING DATE: 1997-09-24

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/062285

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/062287

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/062814

; PRIOR FILING DATE: 1997-10-24

; PRIOR APPLICATION NUMBER: 60/062816

; PRIOR FILING DATE: 1997-10-24

; PRIOR APPLICATION NUMBER: 60/053045

; PRIOR FILING DATE: 1997-10-24

; PRIOR APPLICATION NUMBER: 60/063082

; PRIOR FILING DATE: 1997-10-31

; PRIOR APPLICATION NUMBER: 60/063127

; PRIOR FILING DATE: 1997-10-24

; PRIOR APPLICATION NUMBER: 60/063327

; PRIOR FILING DATE: 1997-10-27

; PRIOR APPLICATION NUMBER: 60/063329

; PRIOR FILING DATE: 1997-10-27

; PRIOR APPLICATION NUMBER: 60/063550

; PRIOR FILING DATE: 1997-10-28

; PRIOR APPLICATION NUMBER: 60/063561

; PRIOR FILING DATE: 1997-10-28

; PRIOR FILING DATE: 1997-10-28

; PRIOR APPLICATION NUMBER: 60/063704

; PRIOR FILING DATE: 1997-10-29

; PRIOR APPLICATION NUMBER: 60/063733

; PRIOR FILING DATE: 1997-10-29

; PRIOR APPLICATION NUMBER: 60/063735

; PRIOR FILING DATE: 1997-10-29

; PRIOR APPLICATION NUMBER: 60/063738

; PRIOR FILING DATE: 1997-10-29

; PRIOR APPLICATION NUMBER: 60/063755

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/064248

; PRIOR FILING DATE: 1997-11-03

; PRIOR APPLICATION NUMBER: 60/064809

; PRIOR FILING DATE: 1997-11-07

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065846

; PRIOR FILING DATE: 1997-11-17

; PRIOR APPLICATION NUMBER: 60/066364

; PRIOR FILING DATE: 1997-11-21

; PRIOR APPLICATION NUMBER: 60/066453

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/066511

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/069212

; PRIOR FILING DATE: 1997-12-11

; PRIOR APPLICATION NUMBER: 60/069278

; PRIOR FILING DATE: 1997-12-11

; PRIOR APPLICATION NUMBER: 60/069334

; PRIOR FILING DATE: 1997-12-11

; PRIOR APPLICATION NUMBER: 60/069694

; PRIOR FILING DATE: 1997-12-16

; PRIOR APPLICATION NUMBER: 60/072320

; PRIOR FILING DATE: 1998-01-23

; PRIOR APPLICATION NUMBER: 60/073612

; PRIOR FILING DATE: 1998-02-04

; PRIOR APPLICATION NUMBER: 60/074086

; PRIOR FILING DATE: 1998-02-09

; PRIOR APPLICATION NUMBER: 60/074092

; PRIOR FILING DATE: 1998-02-09

; PRIOR APPLICATION NUMBER: 60/077791

; PRIOR FILING DATE: 1998-03-12

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/079294

; PRIOR FILING DATE: 1998-03-25

; PRIOR APPLICATION NUMBER: 60/079663

; PRIOR FILING DATE: 1998-02-27

; PRIOR APPLICATION NUMBER: 60/079728

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/080165

; PRIOR FILING DATE: 1998-03-31

; PRIOR APPLICATION NUMBER: 60/081203

; PRIOR FILING DATE: 1998-04-09

; PRIOR APPLICATION NUMBER: 60/081229

; PRIOR FILING DATE: 1998-04-09

; PRIOR APPLICATION NUMBER: 60/081695

; PRIOR FILING DATE: 1998-04-14

; PRIOR APPLICATION NUMBER: 60/081817

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/081818

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/082999

; PRIOR FILING DATE: 1998-04-24

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/083545

; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: 60/084600

; PRIOR FILING DATE: 1998-05-07

```

; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085149
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086414
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/086430
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088730
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088741
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090538
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091982

```

Query Match 100.0%; Score 589; DB 14; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRMCTPLGREGEBC 60
Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRMCTPLGREGEBC 60
QY 61 HPGSHKVPFFRRKHHHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRRKHHHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105

```

RESULT 126

US-10-123-236-470

```

; Sequence 470, Application US/10123236
; Publication No. US20030068795A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C33
; CURRENT APPLICATION NUMBER: US/10/123,236
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-123-236-470

```

Query Match 100.0%; Score 589; DB 14; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRMCTPLGREGEBC 60
Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRMCTPLGREGEBC 60
QY 61 HPGSHKVPFFRRKHHHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFRRKHHHTCPCLNLLCSRFDPDGRYRCSMDLKNINF 105

```

RESULT 127

US-10-123-261-470
 ; Sequence 470, Application US/10123261
 ; Publication No. US20030068796A1
 ; GENERAL INFORMATION:

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

```

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C42
 ; CURRENT APPLICATION NUMBER: US/10/123,261
 ; CURRENT FILING DATE: 2002-04-15


```
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-123-261-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGECC 60
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGECC 60
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 HPGSHKVPFFRKHKHTCPCLENLCSRPDGRYRCSMDLKNINF 105
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 HPGSHKVPFFRKHKHTCPCLENLCSRPDGRYRCSMDLKNINF 105
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 128
US-10-140-921-470
; Sequence 470, Application US/10140921
; Publication No. US20030068797A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C175
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-921-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGECC 60
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGECC 60
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 HPGSHKVPFFRKHKHTCPCLENLCSRPDGRYRCSMDLKNINF 105
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 HPGSHKVPFFRKHKHTCPCLENLCSRPDGRYRCSMDLKNINF 105
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 129
US-10-140-928-470
; Sequence 470, Application US/10140928
; Publication No. US20030068798A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C186
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-928-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGECC 60
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGRLMCTPLGREGECC 60
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

QY 61 HPGSHKVPFFRKHKHTCPCLENLCSRPDGRYRCSMDLKNINF 105
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 HPGSHKVPFFRKHKHTCPCLENLCSRPDGRYRCSMDLKNINF 105
   |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

RESULT 130
US-10-216-159A-166
; Sequence 166, Application US/10216159A
; Publication No. US2003006937A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C6
; CURRENT FILING DATE: 2002-08-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-166
```


APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C65
CURRENT APPLICATION NUMBER: US/10/123,903
CURRENT FILING DATE: 2002-04-16
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-123-903-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105

RESULT 134
US-10-124-819-470
Sequence 470, Application US/10124819
Publication No. US20030073213A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Gurney, Austin J.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C65
CURRENT APPLICATION NUMBER: US/10/124,819
CURRENT FILING DATE: 2002-04-17
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-124-819-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105

RESULT 135
US-10-124-822-470
Sequence 470, Application US/10124822
Publication No. US20030073214A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C64
CURRENT APPLICATION NUMBER: US/10/124,822
CURRENT FILING DATE: 2002-04-17
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-124-822-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105

RESULT 136
US-10-140-925-470
Sequence 470, Application US/10140925
Publication No. US20030073215A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105

RESULT 135
US-10-124-822-470
Sequence 470, Application US/10124822
Publication No. US20030073214A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C64
CURRENT APPLICATION NUMBER: US/10/124,822
CURRENT FILING DATE: 2002-04-17
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-124-822-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
DB 1 MEGATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRPDPDGRYRCMDLKNINF 105

RESULT 136
US-10-140-925-470
Sequence 470, Application US/10140925
Publication No. US20030073215A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel

```

; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C451
; CURRENT APPLICATION NUMBER: US/10/140,925
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-925-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
QY 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 137
US-10-160-498-470
; Sequence 470, Application US/10160498
; Publication No. US20030073216A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C451
; CURRENT APPLICATION NUMBER: US/10/160,498
; CURRENT FILING DATE: 2002-05-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-160-498-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
```

```

DB 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 138
US-10-218-849-166
; Sequence 166, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C11
; CURRENT APPLICATION NUMBER: US/10/218,849
; CURRENT FILING DATE: 2002-08-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 166
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-166

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
QY 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 139
US-10-227-873-166
; Sequence 166, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; Prior Application Number: 10/119,480
; Prior Filing Date: 2002-04-09
; Prior Application Number: 60/059113
; Prior Filing Date: 1997-09-17
; Prior Application Number: 60/062287
```

, PRIOR APPLICATION NUMBER: 60/063549
, PRIOR FILING DATE: 1997-10-28
, PRIOR APPLICATION NUMBER: 60/064103
, PRIOR FILING DATE: 1997-10-31
, PRIOR APPLICATION NUMBER: 60/069873
, PRIOR FILING DATE: 1997-12-17
, PRIOR APPLICATION NUMBER: 60/078910
, PRIOR FILING DATE: 1998-03-20
, PRIOR APPLICATION NUMBER: 60/079294
, PRIOR FILING DATE: 1998-03-25
, PRIOR APPLICATION NUMBER: 60/079656
, PRIOR FILING DATE: 1998-03-26
, PRIOR APPLICATION NUMBER: 60/079728
, PRIOR FILING DATE: 1998-03-27
, PRIOR APPLICATION NUMBER: 60/081819
, PRIOR FILING DATE: 1998-04-15
, PRIOR APPLICATION NUMBER: 60/081955
, PRIOR FILING DATE: 1998-04-15
, PRIOR APPLICATION NUMBER: 60/082804
, PRIOR FILING DATE: 1998-04-22
, PRIOR APPLICATION NUMBER: 60/084441
, PRIOR FILING DATE: 1998-05-06
, PRIOR APPLICATION NUMBER: 60/085323
, PRIOR FILING DATE: 1998-05-13
, PRIOR APPLICATION NUMBER: 60/085579
, PRIOR FILING DATE: 1998-05-15
, PRIOR APPLICATION NUMBER: 60/086392
, PRIOR FILING DATE: 1998-05-22
, PRIOR APPLICATION NUMBER: 60/089532
, PRIOR FILING DATE: 1998-06-17
, PRIOR APPLICATION NUMBER: 60/089538
, PRIOR FILING DATE: 1998-06-17
, PRIOR APPLICATION NUMBER: 60/089505
, PRIOR FILING DATE: 1998-06-18
, PRIOR APPLICATION NUMBER: 60/090472
, PRIOR FILING DATE: 1998-06-24
, PRIOR APPLICATION NUMBER: 60/090557
, PRIOR FILING DATE: 1998-06-24
, PRIOR APPLICATION NUMBER: 60/090691
, PRIOR FILING DATE: 1998-06-25
, PRIOR APPLICATION NUMBER: 60/090695
, PRIOR FILING DATE: 1998-06-25
, PRIOR APPLICATION NUMBER: 60/091982
, PRIOR FILING DATE: 1998-07-07
, PRIOR APPLICATION NUMBER: 60/095302
, PRIOR FILING DATE: 1998-08-04
, PRIOR APPLICATION NUMBER: 60/095318
, PRIOR FILING DATE: 1998-08-04
, PRIOR APPLICATION NUMBER: 60/095916
, PRIOR FILING DATE: 1998-08-10
, PRIOR APPLICATION NUMBER: 60/096146
, PRIOR FILING DATE: 1998-08-11
, PRIOR APPLICATION NUMBER: 60/096791
, PRIOR FILING DATE: 1998-08-17
, PRIOR APPLICATION NUMBER: 60/097986
, PRIOR FILING DATE: 1998-08-26
, PRIOR APPLICATION NUMBER: 60/098544
, PRIOR FILING DATE: 1998-08-31
, PRIOR APPLICATION NUMBER: 60/099596
, PRIOR FILING DATE: 1998-09-09
, PRIOR APPLICATION NUMBER: 60/099598
, PRIOR FILING DATE: 1998-09-09
, PRIOR APPLICATION NUMBER: 60/099803
, PRIOR FILING DATE: 1998-09-10
, PRIOR APPLICATION NUMBER: 60/099811
, PRIOR FILING DATE: 1998-09-10
, PRIOR APPLICATION NUMBER: 60/099812
, PRIOR FILING DATE: 1998-09-10
, PRIOR APPLICATION NUMBER: 60/099816
, PRIOR FILING DATE: 1998-09-10
, PRIOR APPLICATION NUMBER: 60/100038
, PRIOR FILING DATE: 1998-09-11
, PRIOR APPLICATION NUMBER: 60/100385
, PRIOR FILING DATE: 1998-09-15
, PRIOR APPLICATION NUMBER: 60/100390
, PRIOR FILING DATE: 1998-09-15
, PRIOR APPLICATION NUMBER: 60/100627
, PRIOR FILING DATE: 1998-09-16
, PRIOR APPLICATION NUMBER: 60/100848
, PRIOR FILING DATE: 1998-09-18
, PRIOR APPLICATION NUMBER: 60/100919
, PRIOR FILING DATE: 1998-09-17
, PRIOR APPLICATION NUMBER: 60/101477
, PRIOR FILING DATE: 1998-09-23
, PRIOR APPLICATION NUMBER: 60/101738
, PRIOR FILING DATE: 1998-09-24
, PRIOR APPLICATION NUMBER: 60/101741
, PRIOR FILING DATE: 1998-09-24
, PRIOR APPLICATION NUMBER: 60/101786
, PRIOR FILING DATE: 1998-09-25
, PRIOR APPLICATION NUMBER: 60/101916
, PRIOR FILING DATE: 1998-09-24
, PRIOR APPLICATION NUMBER: 60/101922
, PRIOR FILING DATE: 1998-09-24
, PRIOR APPLICATION NUMBER: 60/106178
, PRIOR FILING DATE: 1998-10-28
, PRIOR APPLICATION NUMBER: 60/106248
, PRIOR FILING DATE: 1998-10-29
, PRIOR APPLICATION NUMBER: 60/106464
, PRIOR FILING DATE: 1998-10-30
, PRIOR APPLICATION NUMBER: 60/106905
, PRIOR FILING DATE: 1998-11-03
, PRIOR APPLICATION NUMBER: 60/108787
, PRIOR FILING DATE: 1998-11-17
, PRIOR APPLICATION NUMBER: 60/108801
, PRIOR FILING DATE: 1998-11-17
, PRIOR APPLICATION NUMBER: 60/108849
, PRIOR FILING DATE: 1998-11-18
, PRIOR APPLICATION NUMBER: 60/112422
, PRIOR FILING DATE: 1998-12-15
, PRIOR APPLICATION NUMBER: 60/113296
, PRIOR FILING DATE: 1998-12-22
, PRIOR APPLICATION NUMBER: 60/113605
, PRIOR FILING DATE: 1998-12-23
, PRIOR APPLICATION NUMBER: 60/113621
, PRIOR FILING DATE: 1998-12-23
, PRIOR APPLICATION NUMBER: 60/115558
, PRIOR FILING DATE: 1999-01-12
, PRIOR APPLICATION NUMBER: 60/115565
, PRIOR FILING DATE: 1999-01-12
, PRIOR APPLICATION NUMBER: 60/115733
, PRIOR FILING DATE: 1999-01-12
, PRIOR APPLICATION NUMBER: 60/119549
, PRIOR FILING DATE: 1999-02-10
, PRIOR APPLICATION NUMBER: 60/123618
, PRIOR FILING DATE: 1999-03-10
, PRIOR APPLICATION NUMBER: 60/125259
, PRIOR FILING DATE: 1999-03-19
, PRIOR APPLICATION NUMBER: 60/125775
, PRIOR FILING DATE: 1999-03-23
, PRIOR APPLICATION NUMBER: 60/126773
, PRIOR FILING DATE: 1999-03-29
, PRIOR APPLICATION NUMBER: 60/127887
, PRIOR FILING DATE: 1999-04-05
, PRIOR APPLICATION NUMBER: 60/130232
, PRIOR FILING DATE: 1999-04-21
, PRIOR APPLICATION NUMBER: 60/131022
, PRIOR FILING DATE: 1999-04-26
, PRIOR APPLICATION NUMBER: 60/131270
, PRIOR FILING DATE: 1999-04-27
, PRIOR APPLICATION NUMBER: 60/131291
, PRIOR FILING DATE: 1999-04-27
, PRIOR APPLICATION NUMBER: 60/131445
, PRIOR FILING DATE: 1999-04-28
, PRIOR APPLICATION NUMBER: 60/134287
, PRIOR FILING DATE: 1999-05-14

PRIOR APPLICATION NUMBER: 60/140650
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/140723
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/141037
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 60/144758
PRIOR FILING DATE: 1999-07-20
PRIOR APPLICATION NUMBER: 60/145698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: 60/146222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: 60/146963
PRIOR FILING DATE: 1999-08-03
PRIOR APPLICATION NUMBER: 60/149320
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/149638
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/151733
PRIOR FILING DATE: 1999-08-31
PRIOR APPLICATION NUMBER: 60/164418
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/166361
PRIOR FILING DATE: 1999-11-16
PRIOR APPLICATION NUMBER: 60/169445
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169495
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169835

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGRATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCALSMLRLGRLMCTPLGRGEEC 60
Db |||||
Qy 1 MGRATRVSIMLLLVTSDDCAVITGACERDVQCGAGTCCALSMLRLGRLMCTPLGRGEEC 60
Db |||||

Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRRFPDGRYCSMDLKNINF 105
Db |||||

Qy 61 HPGSHKVPFFRKXKHTCPCLNLLCSRRFPDGRYCSMDLKNINF 105
Db |||||

RESULT 140
US-10-227-883-166
Sequence 166, Application US/10227883
Publication No. US20030073817A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Desnoyers, Luc
APPLICANT: Gerritsen, Mary
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Smith, Victoria
APPLICANT: Stephan, Jean-Philippe F.
APPLICANT: Watanabe, Colin L.
APPLICANT: Wood, William I.
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3530P1C78
CURRENT APPLICATION NUMBER: US/10/227,883
CURRENT FILING DATE: 2002-08-26
PRIOR APPLICATION NUMBER: 10/119,480
PRIOR FILING DATE: 2002-04-09
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/062287
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/063549
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/064103

PRIOR FILING DATE: 1997-10-31
PRIOR APPLICATION NUMBER: 60/069873
PRIOR FILING DATE: 1997-12-17
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/086392
PRIOR FILING DATE: 1998-05-22
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089905
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090691
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/095302
PRIOR FILING DATE: 1998-08-04
PRIOR APPLICATION NUMBER: 60/095318
PRIOR FILING DATE: 1998-08-04
PRIOR APPLICATION NUMBER: 60/095916
PRIOR FILING DATE: 1998-08-10
PRIOR APPLICATION NUMBER: 60/096146
PRIOR FILING DATE: 1998-08-11
PRIOR APPLICATION NUMBER: 60/096791
PRIOR FILING DATE: 1998-08-17
PRIOR APPLICATION NUMBER: 60/097986
PRIOR FILING DATE: 1998-08-26
PRIOR APPLICATION NUMBER: 60/098544
PRIOR FILING DATE: 1998-08-31
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099803
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099811
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100038
PRIOR FILING DATE: 1998-09-11
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15

[illegible]

US-10-124-824-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLPNNLLCSRFDPDGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLPNNLLCSRFDPDGRVRCSDMLKNINF 105

RESULT 142

US-10-127-825A-470
; Sequence 470, Application US/10127825A
; Publication No. US2003007710A1
; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C84

CURRENT APPLICATION NUMBER: US/10/127,825A

CURRENT FILING DATE: 2002-04-22

PRIOR APPLICATION NUMBER: 60/049911

PRIOR FILING DATE: 1997-06-18

PRIOR APPLICATION NUMBER: 60/056974

PRIOR FILING DATE: 1997-08-26

PRIOR APPLICATION NUMBER: 60/059113

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059115

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059117

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059122

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059184

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059263

PRIOR FILING DATE: 1997-09-18

PRIOR APPLICATION NUMBER: 60/059352

PRIOR FILING DATE: 1997-09-19

PRIOR APPLICATION NUMBER: 60/059588

PRIOR FILING DATE: 1997-09-19

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 550

SEQ ID NO 470

LENGTH: 105

TYPE: PRT

ORGANISM: Homo Sapien

US-10-127-825A-470

Query Match

Best Local Similarity 100.0%; Score 589; DB 14; Length 105;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-124-824-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLPNNLLCSRFDPDGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLPNNLLCSRFDPDGRVRCSDMLKNINF 105

RESULT 142

US-10-127-825A-470
; Sequence 470, Application US/10127825A
; Publication No. US2003007710A1
; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C84

CURRENT APPLICATION NUMBER: US/10/127,825A

CURRENT FILING DATE: 2002-04-22

PRIOR APPLICATION NUMBER: 60/049911

PRIOR FILING DATE: 1997-06-18

PRIOR APPLICATION NUMBER: 60/056974

PRIOR FILING DATE: 1997-08-26

PRIOR APPLICATION NUMBER: 60/059113

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059115

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059117

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059122

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059184

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059263

PRIOR FILING DATE: 1997-09-18

PRIOR APPLICATION NUMBER: 60/059352

PRIOR FILING DATE: 1997-09-19

PRIOR APPLICATION NUMBER: 60/059588

PRIOR FILING DATE: 1997-09-19

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 550

SEQ ID NO 470

LENGTH: 105

TYPE: PRT

ORGANISM: Homo Sapien

US-10-127-825A-470

Query Match

Best Local Similarity 100.0%; Score 589; DB 14; Length 105;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
QY 61 HPGSHKVPFFRKRKHHTCPCLPNNLLCSRFDPDGRVRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLPNNLLCSRFDPDGRVRCSDMLKNINF 105

RESULT 143

US-10-127-829A-470
; Sequence 470, Application US/10127829A
; Publication No. US2003007711A1
; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C85

CURRENT APPLICATION NUMBER: US/10/127,829A

CURRENT FILING DATE: 2002-10-15

PRIOR APPLICATION NUMBER: 60/049911

PRIOR FILING DATE: 1997-06-18

PRIOR APPLICATION NUMBER: 60/056974

PRIOR FILING DATE: 1997-08-26

PRIOR APPLICATION NUMBER: 60/059113

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059115

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059117

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059122

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059184

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059263

PRIOR FILING DATE: 1997-09-18

PRIOR APPLICATION NUMBER: 60/059352

PRIOR FILING DATE: 1997-09-19

PRIOR APPLICATION NUMBER: 60/059588

PRIOR FILING DATE: 1997-09-19

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 550

SEQ ID NO 470

LENGTH: 105

TYPE: PRT

ORGANISM: Homo Sapien

US-10-127-829A-470

Query Match

Best Local Similarity 100.0%; Score 589; DB 14; Length 105;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

/ APPLICANT: Baker, Kevin P.
 / APPLICANT: Beresini, Maureen
 / APPLICANT: DeForge, Laura
 / APPLICANT: Desnoyers, Luc
 / APPLICANT: Filvaroff, Ellen
 / APPLICANT: Gao, Wei-Qiang
 / APPLICANT: Gerritsen, Mary E.
 / APPLICANT: Goddard, Audrey
 / APPLICANT: Godowski, Paul J.
 / APPLICANT: Gurney, Austin L.
 / APPLICANT: Sherwood, Steven
 / APPLICANT: Smith, Victoria
 / APPLICANT: Stewart, Timothy A.
 / APPLICANT: Tamas, Daniel
 / APPLICANT: Watanabe, Colin K
 / APPLICANT: Wood, William
 / APPLICANT: Zhang, Zemin
 / TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 / FILE REFERENCE: P3330RLC86
 / CURRENT APPLICATION NUMBER: US/10/127,901A
 / CURRENT FILING DATE: 2002-10-15
 / PRIOR APPLICATION NUMBER: 60/049911
 / PRIOR FILING DATE: 1997-06-18
 / PRIOR APPLICATION NUMBER: 60/056974
 / PRIOR FILING DATE: 1997-08-26
 / PRIOR APPLICATION NUMBER: 60/059113
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059115
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059122
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059184
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059263
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059352
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059588
 / PRIOR FILING DATE: 1997-09-19
 / Remaining Prior Application data removed - See File Wrapper or PALM.
 / NUMBER OF SEQ ID NOS: 550
 / SEQ ID NO 470
 / LENGTH: 105
 / TYPE: PRT
 / ORGANISM: Homo Sapien
 / US-10-127-901A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWLRGLRMCTPLGRGEEC 60
 Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWLRGLRMCTPLGRGEEC 60
 QY 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 147
 US-10-128-693A-470
 / Sequence 470, Application US/10128693A
 / Publication No. US2003007715A1
 / GENERAL INFORMATION:
 / APPLICANT: Baker, Kevin P.
 / APPLICANT: Beresini, Maureen
 / APPLICANT: DeForge, Laura
 / APPLICANT: Desnoyers, Luc
 / APPLICANT: Filvaroff, Ellen

/ APPLICANT: Gao, Wei-Qiang
 / APPLICANT: Gerritsen, Mary E.
 / APPLICANT: Goddard, Audrey
 / APPLICANT: Godowski, Paul J.
 / APPLICANT: Gurney, Austin L.
 / APPLICANT: Sherwood, Steven
 / APPLICANT: Smith, Victoria
 / APPLICANT: Stewart, Timothy A.
 / APPLICANT: Tamas, Daniel
 / APPLICANT: Watanabe, Colin K
 / APPLICANT: Wood, William
 / APPLICANT: Zhang, Zemin
 / TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 / FILE REFERENCE: P3330RLC120
 / CURRENT APPLICATION NUMBER: US/10/128,693A
 / CURRENT FILING DATE: 2002-04-23
 / PRIOR APPLICATION NUMBER: 60/049911
 / PRIOR FILING DATE: 1997-06-18
 / PRIOR APPLICATION NUMBER: 60/056974
 / PRIOR FILING DATE: 1997-08-26
 / PRIOR APPLICATION NUMBER: 60/059113
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059115
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059117
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059122
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059184
 / PRIOR FILING DATE: 1997-09-17
 / PRIOR APPLICATION NUMBER: 60/059263
 / PRIOR FILING DATE: 1997-09-18
 / PRIOR APPLICATION NUMBER: 60/059352
 / PRIOR FILING DATE: 1997-09-19
 / PRIOR APPLICATION NUMBER: 60/059588
 / Remaining Prior Application data removed - See File Wrapper or PALM.
 / NUMBER OF SEQ ID NOS: 550
 / SEQ ID NO 470
 / LENGTH: 105
 / TYPE: PRT
 / ORGANISM: Homo Sapien
 / US-10-128-693A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWLRGLRMCTPLGRGEEC 60
 Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVQCGAGTCCALSLWLRGLRMCTPLGRGEEC 60
 QY 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRRKRKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 148
 US-10-131-813A-470
 / Sequence 470, Application US/10131813A
 / Publication No. US2003007716A1
 / GENERAL INFORMATION:
 / APPLICANT: Baker, Kevin P.
 / APPLICANT: Beresini, Maureen
 / APPLICANT: DeForge, Laura
 / APPLICANT: Desnoyers, Luc
 / APPLICANT: Filvaroff, Ellen
 / APPLICANT: Gao, Wei-Qiang
 / APPLICANT: Gerritsen, Mary E.
 / APPLICANT: Goddard, Audrey
 / APPLICANT: Godowski, Paul J.
 / APPLICANT: Gurney, Austin L.

```

/ APPLICANT: Wood,William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ TITLE OF INVENTION: ACIDS ENCODING THE SAME
/ FILE REFERENCE: P3330R1C141
/ CURRENT APPLICATION NUMBER: US/10/131,818A
/ CURRENT FILING DATE: 2002-10-17
/ PRIOR APPLICATION NUMBER: 60/049911
/ PRIOR FILING DATE: 1997-06-18
/ PRIOR APPLICATION NUMBER: 60/056974
/ PRIOR FILING DATE: 1997-08-26
/ PRIOR APPLICATION NUMBER: 60/059113
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059115
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059117
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059122
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059184
/ PRIOR FILING DATE: 1997-09-17
/ PRIOR APPLICATION NUMBER: 60/059263
/ PRIOR FILING DATE: 1997-09-18
/ PRIOR APPLICATION NUMBER: 60/059352
/ PRIOR FILING DATE: 1997-09-19
/ PRIOR APPLICATION NUMBER: 60/059588
/ PRIOR FILING DATE: 1997-09-19
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 550
/ SEQ ID NO 470
/ LENGTH: 105
/ TYPE: PRT
/ ORGANISM: Homo Sapien
US-10-131-818A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKRHHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKRHHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 150
US-10-131-823A-470
/ Sequence 470, Application US/10131823A
/ Publication No. US2003007718A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Beresini, Maureen
/ APPLICANT: DeForge, Laura
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Sherwood, Steven
/ APPLICANT: Smith, Victoria
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Watanabe, Colin K
/ APPLICANT: Wood, William
/ APPLICANT: Zhang, Zemin
/ TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
/ TITLE OF INVENTION: ACIDS ENCODING THE SAME
/ FILE REFERENCE: P3330R1C141

```

; CURRENT APPLICATION NUMBER: US/10/131.823A

; CURRENT FILING DATE: 2002-04-24

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-131-823A-470

Query Match

Best Local Similarity 100.0%; Score 589; DB 14; Length 105;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSMILLVTVSDCAVITGACERDVCCAGTCCCAISLWLRGMRCTPLGREGGEC 60

Db 1 MGRATRVSMILLVTVSDCAVITGACERDVCCAGTCCCAISLWLRGMRCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 151

US-10-131-824A-470

; Sequence 470, Application US/10/131.824A

; Publication No. US2003007719A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C126

; CURRENT APPLICATION NUMBER: US/10/131.824A

; CURRENT FILING DATE: 2002-04-24

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-131-824A-470

Query Match

Best Local Similarity 100.0%; Score 589; DB 14; Length 105;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSMILLVTVSDCAVITGACERDVCCAGTCCCAISLWLRGMRCTPLGREGGEC 60

Db 1 MGRATRVSMILLVTVSDCAVITGACERDVCCAGTCCCAISLWLRGMRCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

Db 61 HPGSHKVPFFRKRRKHTCPCLPNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 152

US-10-131-830A-470

; Sequence 470, Application US/10/131.830A

; Publication No. US2003007720A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C137

; CURRENT APPLICATION NUMBER: US/10/131.830A

; CURRENT FILING DATE: 2002-10-17

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

```
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
; US-10-131-830A-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MRGATRVSIMLLLVTSVDCAVITGACERDVOCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
Db      1 MRGATRVSIMLLLVTSVDCAVITGACERDVOCGAGTCCCAISLWRLGRLMCTPLGREGECC 60

QY      61 HPGSHKVPFPRKHKHTCPCLPNLLCSRFPDGYRCSDMLKNINF 105
Db      61 HPGSHKVPFPRKHKHTCPCLPNLLCSRFPDGYRCSDMLKNINF 105

RESULT 153
US-10-131-837A-470
; Sequence 470, Application US/10131837A
; Publication No. US2003007721A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C131
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059184
```

```
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
; US-10-131-837A-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MRGATRVSIMLLLVTSVDCAVITGACERDVOCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
Db      1 MRGATRVSIMLLLVTSVDCAVITGACERDVOCGAGTCCCAISLWRLGRLMCTPLGREGECC 60

QY      61 HPGSHKVPFPRKHKHTCPCLPNLLCSRFPDGYRCSDMLKNINF 105
Db      61 HPGSHKVPFPRKHKHTCPCLPNLLCSRFPDGYRCSDMLKNINF 105

RESULT 154
US-10-137-872A-470
; Sequence 470, Application US/10137872A
; Publication No. US2003007722A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C150
; CURRENT FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
```

;; PRIOR APPLICATION NUMBER: 60/059588
;; PRIOR FILING DATE: 1997-09-19
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 550
;; SEQ ID NO 470
;; LENGTH: 105
;; TYPE: PRT
;; ORGANISM: Homo Sapien
US-10-137-872A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPCLNLLCSRFDPDGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 155

US-10-147-500-470
;; Sequence 470, Application US/10147500
;; Publication No. US2003007723A1
;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Beresini, Maureen
;; APPLICANT: DeForge, Laura
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Sherwood, Steven
;; APPLICANT: Smith, Victoria
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tamas, Daniel
;; APPLICANT: Watanabe, Colin K
;; APPLICANT: Wood, William
;; APPLICANT: Zhang, Zemin
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

;; FILE REFERENCE: P3330R1C325
;; CURRENT APPLICATION NUMBER: US/10/147,500
;; CURRENT FILING DATE: 2002-05-16

;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 550
;; SEQ ID NO 470
;; LENGTH: 105
;; TYPE: PRT
;; ORGANISM: Homo Sapien
US-10-147-500-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPCLNLLCSRFDPDGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 156

US-10-147-502-470

;; Sequence 470, Application US/10147502
;; Publication No. US2003007724A1
;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Beresini, Maureen
;; APPLICANT: DeForge, Laura
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Sherwood, Steven
;; APPLICANT: Smith, Victoria
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tamas, Daniel
;; APPLICANT: Watanabe, Colin K
;; APPLICANT: Wood, William
;; APPLICANT: Zhang, Zemin
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

;; FILE REFERENCE: P3330R1C326
;; CURRENT APPLICATION NUMBER: US/10/147,502
;; CURRENT FILING DATE: 2002-05-16
;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 550
;; SEQ ID NO 470
;; LENGTH: 105
;; TYPE: PRT
;; ORGANISM: Homo Sapien
US-10-147-502-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKXKHTCPCLPCLNLLCSRFDPDGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKXKHTCPCLPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 157

US-10-147-515-470

;; Sequence 470, Application US/10147515
;; Publication No. US2003007725A1
;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Beresini, Maureen
;; APPLICANT: DeForge, Laura
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Sherwood, Steven
;; APPLICANT: Smith, Victoria
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tamas, Daniel
;; APPLICANT: Watanabe, Colin K
;; APPLICANT: Wood, William
;; APPLICANT: Zhang, Zemin
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

;; FILE REFERENCE: P3330R1C342
;; CURRENT APPLICATION NUMBER: US/10/147,515
;; CURRENT FILING DATE: 2002-05-17

; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-515-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKXKHTCTCPLNLLCSRFDPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCTCPLNLLCSRFDPDGRYCSMDLKNINF 105

RESULT 158

US-10-147-517-470
; Sequence 470, Application US/10147517
; Publication No. US2003007726A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330RIC337

; CURRENT APPLICATION NUMBER: US/10/147,517

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-147-517-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKXKHTCTCPLNLLCSRFDPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCTCPLNLLCSRFDPDGRYCSMDLKNINF 105

RESULT 159

US-10-147-526-470

; Sequence 470, Application US/10147526

; Publication No. US2003007727A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC343
; CURRENT APPLICATION NUMBER: US/10/147,526
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-526-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
QY 61 HPGSHKVPFFRKXKHTCTCPLNLLCSRFDPDGRYCSMDLKNINF 105
Db 61 HPGSHKVPFFRKXKHTCTCPLNLLCSRFDPDGRYCSMDLKNINF 105

RESULT 160

US-10-147-527-470

; Sequence 470, Application US/10147527

; Publication No. US2003007728A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC353
; CURRENT APPLICATION NUMBER: US/10/147,527
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550

```
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-527-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 161
US-10-121-041-470
; Sequence 470, Application US/10121041
; Publication No. US2003007776A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C15
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-121-043-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 162
US-10-121-043-470
; Sequence 470, Application US/10121043
; Publication No. US2003007776A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C15
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-121-041-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 163
US-10-121-047-470
; Sequence 470, Application US/10121047
; Publication No. US2003007778A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C4
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
```



```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-121-047-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105
Db 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105

RESULT 164
US-10-123-215-470
; Sequence 470, Application US/10123215
; Publication No. US2003007780A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C41
; CURRENT APPLICATION NUMBER: US/10/123,215
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-123-215-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105
Db 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105

RESULT 165
US-10-123-902-470
; Sequence 470, Application US/10123902
; Publication No. US2003007778A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C44
; CURRENT APPLICATION NUMBER: US/10/123,908
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-123-902-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105
Db 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105

RESULT 166
US-10-123-908-470
; Sequence 470, Application US/10123908
; Publication No. US20030077782A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C44
; CURRENT APPLICATION NUMBER: US/10/123,908
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-123-908-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105
Db 61 HPGSHKVPFFRKRKHHTCPCLNLLCSRFPDGRYRCSDMLKKNINF 105
```

US-10-123-908-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
DB 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105

RESULT 167

US-10-123-909-470
; Sequence 470, Application US/10123909
; Publication No. US2003007783A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C49

; CURRENT APPLICATION NUMBER: US/10/123,909

; CURRENT FILING DATE: 2002-04-16

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-123-909-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60

DB 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105

DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105

RESULT 168

US-10-123-910-470
; Sequence 470, Application US/10123910
; Publication No. US2003007784A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C45

; CURRENT APPLICATION NUMBER: US/10/123,910

; CURRENT FILING DATE: 2002-04-16

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-123-910-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60
DB 1 MEGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGSEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRFPPDGRYRCSMDLKNINF 105

RESULT 169

US-10-124-813-470

; Sequence 470, Application US/10124813

; Publication No. US2003007785A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C67

; CURRENT APPLICATION NUMBER: US/10/124,813

; CURRENT FILING DATE: 2002-04-17

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-124-813-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60

QY 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 170
US-10-124-817-470
; Sequence 470, Application US/10124817
; Publication No. US2003007786A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C56
; CURRENT APPLICATION NUMBER: US/10/124,817
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-124-817-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60

QY 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 171
US-10-125-922-470
; Sequence 470, Application US/10125922
; Publication No. US2003007787A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C75
; CURRENT APPLICATION NUMBER: US/10/125,924
; CURRENT FILING DATE: 2002-04-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-125-922-470

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C73
CURRENT APPLICATION NUMBER: US/10/125,922
CURRENT FILING DATE: 2002-04-19
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-125-922-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGECC 60

QY 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFPRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF 105

RESULT 172
US-10-125-924-470
; Sequence 470, Application US/10125924
; Publication No. US2003007788A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C75
; CURRENT APPLICATION NUMBER: US/10/125,924
; CURRENT FILING DATE: 2002-04-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-125-924-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;

```
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGGEC 60
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGGEC 60
QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105

RESULT 173
US-10-140-860-470
; Sequence 470, Application US/10140860
; Publication No. US20030077789A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C189
; CURRENT APPLICATION NUMBER: US/10/140.860
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-860-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGGEC 60
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGGEC 60
QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105

RESULT 174
US-10-142-417-470
; Sequence 470, Application US/10142417
; Publication No. US2003007790A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C346
; CURRENT APPLICATION NUMBER: US/10/147.519
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-142-417-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C232
; CURRENT APPLICATION NUMBER: US/10/142.417
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-142-417-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGGEC 60
Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMTCTPLGREGGEC 60
QY 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105
Db 61 HPGSHKVPFFFRKRKHHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105

RESULT 175
US-10-147-519-470
; Sequence 470, Application US/10147519
; Publication No. US20030077791A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C346
; CURRENT APPLICATION NUMBER: US/10/147.519
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-147-519-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 176

US-10-157-782-470
 ; Sequence 470, Application US/10157782
 ; Publication No. US2003007792A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C431
 ; CURRENT FILING DATE: 2002-05-29
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 470
 ; LENGTH: 105
 ; TYPE: PRT
 ; ORGANISM: Homo Sapien
 US-10-157-782-470

Query Match 100.0%; Score 589; DB 14; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 177

US-10-152-395-470
 ; Sequence 470, Application US/10152395
 ; Publication No. US2003007837A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C405
 ; CURRENT APPLICATION NUMBER: US/10/152,395
 ; CURRENT FILING DATE: 2002-05-21
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 470
 ; LENGTH: 105
 ; TYPE: PRT
 ; ORGANISM: Homo Sapien
 US-10-152-395-470

Query Match 100.0%; Score 589; DB 14; Length 105;
 Best Local Similarity 100.0%; Pred. No. 2.6e-55;
 Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLRMCTPLGREGEC 60
 QY 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
 Db 61 HPGSHKVPFFRKXKHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 178

US-10-219-076-166
 ; Sequence 166, Application US/10219076
 ; Publication No. US20030078379A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Gerritsen, Mary
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stephan, Jean-Philippe F.
 ; APPLICANT: Watanabe, Colin L.
 ; APPLICANT: Wood, William I.
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330P1C82
 ; CURRENT APPLICATION NUMBER: US/10/219,076
 ; CURRENT FILING DATE: 2002-08-14
 ; Prior Application Number: 10/119,480
 ; Prior Filing Date: 2002-04-09
 ; Prior Application Number: 60/059113
 ; Prior Filing Date: 1997-09-17
 ; Prior Application Number: 60/062287
 ; Prior Filing Date: 1997-10-17
 ; Prior Application Number: 60/063549
 ; Prior Filing Date: 1997-10-28
 ; Prior Application Number: 60/064103
 ; Prior Filing Date: 1997-10-31
 ; Prior Application Number: 60/069873
 ; Prior Filing Date: 1997-12-17
 ; Prior Application Number: 60/078910
 ; Prior Filing Date: 1998-03-20
 ; Prior Application Number: 60/079294
 ; Prior Filing Date: 1998-03-25
 ; Prior Application Number: 60/079656
 ; Prior Filing Date: 1998-03-26
 ; Prior Application Number: 60/079728
 ; Prior Filing Date: 1998-03-27

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 246

; SEQ ID NO 166

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-219-076-166

Query Match

Best Local Similarity 100.0%; Score 589; DB 14; Length 105;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLGREGEEC 60

Db 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSFPDGRYRCSMDLKNINF 105

RESULT 179

US-10-230-434-166

; Sequence 166, Application US/10230434

; Publication No. US20030078380A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Desnoyers, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3530P1C82

; CURRENT APPLICATION NUMBER: US/10/230,434

; PRIOR FILING DATE: 2002-08-28

; PRIOR FILING DATE: 2002-04-09

; PRIOR FILING DATE: 1997-09-17

; PRIOR FILING DATE: 1997-10-17

; PRIOR FILING DATE: 1997-10-28

; PRIOR FILING DATE: 1997-10-31

; PRIOR FILING DATE: 1997-12-17

; PRIOR FILING DATE: 1998-03-20

; PRIOR FILING DATE: 1998-03-25

; PRIOR FILING DATE: 1998-03-26

; PRIOR FILING DATE: 1998-03-27

; PRIOR FILING DATE: 1998-04-15

; PRIOR FILING DATE: 1998-04-15

; PRIOR FILING DATE: 1998-04-22

; PRIOR FILING DATE: 1998-05-06

; PRIOR FILING DATE: 1998-05-13

; PRIOR FILING DATE: 1998-05-19

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

; PRIOR FILING DATE: 1998-05-25

```

; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MRGATRVSMLLLVTVSDCAVITGACERDVQCAGTCCCAISLWRLGRLMCTPLGREGEEC 60
Db      1 MRGATRVSMLLLVTVSDCAVITGACERDVQCAGTCCCAISLWRLGRLMCTPLGREGEEC 60

QY      61 HPGSHKVPFRFKKHTTCCLPNLLCSRFPDGRYRCMDLKNINF 105
Db      61 HPGSHKVPFRFKKHTTCCLPNLLCSRFPDGRYRCMDLKNINF 105

RESULT 180
US-10-125-926A-470
; Sequence 470, Application US/10125926A
; Publication No. US20030082686A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3330RIC80
; CURRENT APPLICATION NUMBER: US/10/125,926A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-125-926A-470

```

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLRGEGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLNLLCSFPPDGRYRCSMDLNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLNLLCSFPPDGRYRCSMDLNINF 105

RESULT 181

US-10-125-930A-470
; Sequence 470, Application US/10125930A
; Publication No. US20030082687A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C78

; CURRENT APPLICATION NUMBER: US/10/125, 930A
; CURRENT FILING DATE: 2002-04-19

; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-125-930A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLRGEGEC 60

DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLNLLCSFPPDGRYRCSMDLNINF 105

DB 61 HPGSHKVPFFRKRKHHTCPCLNLLCSFPPDGRYRCSMDLNINF 105

RESULT 182

US-10-127-831A-470

; Sequence 470, Application US/10127831A

; Publication No. US20030082689A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C107

; CURRENT APPLICATION NUMBER: US/10/127, 831A
; CURRENT FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-127-831A-470

Query Match 100.0%; Score 589; DB 14; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLRGEGEC 60

DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWLRGLMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLNLLCSFPPDGRYRCSMDLNINF 105

Db 61 HPGSHKVPFFRKRKHHTCCPLNLLCSRFDPGRYRCMDLKNINF 105

RESULT 183

US-10-127-837A-470

; Sequence 470, Application US/10127837A

; Publication No. US20030082690A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P330R1C96

; CURRENT APPLICATION NUMBER: US/10/127,837A

; CURRENT FILING DATE: 2002-10-17

; PRIOR APPLICATION NUMBER: 60/045911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-127-837A-470

Query Match 100.0%; Score 589; DB 14; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

Db 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKRKHHTCCPLNLLCSRFDPGRYRCMDLKNINF 105

Db 61 HPGSHKVPFFRKRKHHTCCPLNLLCSRFDPGRYRCMDLKNINF 105

RESULT 184

US-10-127-838B-470

; Sequence 470, Application US/10127838B

; Publication No. US20030082691A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P330R1C98

; CURRENT APPLICATION NUMBER: US/10/127,838B

; CURRENT FILING DATE: 2002-04-22

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-127-838B-470

Query Match 100.0%; Score 589; DB 14; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

Db 1 MGRATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKRKHHTCCPLNLLCSRFDPGRYRCMDLKNINF 105

Db 61 HPGSHKVPFFRKRKHHTCCPLNLLCSRFDPGRYRCMDLKNINF 105

RESULT 185

US-10-127-842A-470

; Sequence 470, Application US/10127842A

; Publication No. US20030082692A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

APPLICANT: DeForge,Laura
APPLICANT: Desnoyers,Luc
APPLICANT: Filvaroff,Ellen
APPLICANT: Gao,Wei-Qiang
APPLICANT: Gerritsen,Mary E.
APPLICANT: Goddard,Audrey
APPLICANT: Godowski,Paul J.
APPLICANT: Gurney,Austin L.
APPLICANT: Sherwood,Steven
APPLICANT: Smith,Victoria
APPLICANT: Stewart,Timothy A.
APPLICANT: Tamas,Daniel
APPLICANT: Watanabe,Colin K
APPLICANT: Wood,William
APPLICANT: Zhang,Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330RIC100
CURRENT APPLICATION NUMBER: US/10/127,842A
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-127-842A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60
Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60

Qy 61 HPGSHKVPFFFRKRKHHTCPCLPNNLLCSRFDPDGRYRCMDLNINF 105
Db 61 HPGSHKVPFFFRKRKHHTCPCLPNNLLCSRFDPDGRYRCMDLNINF 105

RESULT 186
US-10-127-843A-470
Sequence 470, Application US/10127843A
Publication No. US20030082693A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria

APPLICANT: Goddard,Audrey
APPLICANT: Godowski,Paul J.
APPLICANT: Gurney,Austin L.
APPLICANT: Sherwood,Steven
APPLICANT: Smith,Victoria
APPLICANT: Stewart,Timothy A.
APPLICANT: Tamas,Daniel
APPLICANT: Watanabe,Colin K
APPLICANT: Wood,William
APPLICANT: Zhang,Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330RIC99
CURRENT APPLICATION NUMBER: US/10/127,843A
CURRENT FILING DATE: 2002-04-22
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-127-843A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60
Db 1 MEGATRVSIMLLLVTSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLGRGEEC 60

Qy 61 HPGSHKVPFFFRKRKHHTCPCLPNNLLCSRFDPDGRYRCMDLNINF 105
Db 61 HPGSHKVPFFFRKRKHHTCPCLPNNLLCSRFDPDGRYRCMDLNINF 105

RESULT 187
US-10-127-845A-470
Sequence 470, Application US/10127845A
Publication No. US20030082694A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria

APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C93
CURRENT APPLICATION NUMBER: US/10/127,845A
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-127-845A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

RESULT 189
US-10-127-848A-470
Sequence 470, Application US/10127848A
Publication No. US20030082696A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C106
CURRENT APPLICATION NUMBER: US/10/127,848A
CURRENT FILING DATE: 2002-10-15

APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C93
CURRENT APPLICATION NUMBER: US/10/127,845A
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 470
LENGTH: 105
TYPE: PRT
ORGANISM: Homo Sapien
US-10-127-845A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60
DB 1 MRGATRVSIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGGEC 60

QY 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105
DB 61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFDPDGRYRCMDLKNINF 105

RESULT 188
US-10-127-846A-470
Sequence 470, Application US/10127846A
Publication No. US20030082695A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin

;; PRIOR APPLICATION NUMBER: 60/049911
;; PRIOR FILING DATE: 1997-06-18
;; PRIOR APPLICATION NUMBER: 60/056974
;; PRIOR FILING DATE: 1997-08-26
;; PRIOR APPLICATION NUMBER: 60/059113
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059115
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059117
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059122
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059184
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059263
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059352
;; PRIOR FILING DATE: 1997-09-18
;; PRIOR APPLICATION NUMBER: 60/059358
;; PRIOR FILING DATE: 1997-09-19
;; PRIOR APPLICATION NUMBER: 60/059588
;; PRIOR FILING DATE: 1997-09-19
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 550
;; SEQ ID NO 470
;; LENGTH: 105
;; TYPE: PRT
;; ORGANISM: Homo Sapien
US-10-127-848A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
DB 1 MGGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLPNULLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLPNULLCSRFPDGRYRCSMDLKNINF 105

RESULT 190
US-10-127-849A-470
;; Sequence 470, Application US/10127849A
;; Publication No. US20030082697A1
;; GENERAL INFORMATION:
;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Beresini, Maureen
;; APPLICANT: DeForge, Laura
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Sherwood, Steven
;; APPLICANT: Smith, Victoria
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Watanabe, Colin K
;; APPLICANT: Wood, William
;; APPLICANT: Zhang, Zemin
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;; FILE REFERENCE: P3330R1C103
;; CURRENT APPLICATION NUMBER: US/10/127,849A
;; CURRENT FILING DATE: 2002-04-23
;; PRIOR APPLICATION NUMBER: 60/049911
;; PRIOR FILING DATE: 1997-06-18
;; PRIOR APPLICATION NUMBER: 60/056974
;; PRIOR FILING DATE: 1997-08-26
;; PRIOR APPLICATION NUMBER: 60/059113

;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059115
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059117
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059122
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059184
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059263
;; PRIOR FILING DATE: 1997-09-18
;; PRIOR APPLICATION NUMBER: 60/059352
;; PRIOR FILING DATE: 1997-09-19
;; PRIOR APPLICATION NUMBER: 60/059588
;; PRIOR FILING DATE: 1997-09-19
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 550
;; SEQ ID NO 470
;; LENGTH: 105
;; TYPE: PRT
;; ORGANISM: Homo Sapien
US-10-127-849A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
DB 1 MGGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60

QY 61 HPGSHKVPFFRKRKHHTCPCLPNULLCSRFPDGRYRCSMDLKNINF 105
DB 61 HPGSHKVPFFRKRKHHTCPCLPNULLCSRFPDGRYRCSMDLKNINF 105

RESULT 191
US-10-127-850A-470
;; Sequence 470, Application US/10127850A
;; Publication No. US20030082698A1
;; GENERAL INFORMATION:
;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Beresini, Maureen
;; APPLICANT: DeForge, Laura
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Filvaroff, Ellen
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Sherwood, Steven
;; APPLICANT: Smith, Victoria
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Watanabe, Colin K
;; APPLICANT: Wood, William
;; APPLICANT: Zhang, Zemin
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;; FILE REFERENCE: P3330R1C110
;; CURRENT APPLICATION NUMBER: US/10/127,850A
;; CURRENT FILING DATE: 2002-10-15
;; PRIOR APPLICATION NUMBER: 60/049911
;; PRIOR FILING DATE: 1997-06-18
;; PRIOR APPLICATION NUMBER: 60/056974
;; PRIOR FILING DATE: 1997-08-26
;; PRIOR APPLICATION NUMBER: 60/059113
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059115
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-127-851A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MGRATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKRRKHHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKRRKHHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 192

US-10-127-851A-470
; Sequence 470, Application US/10127851A
; Publication No. US20030082699A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C87
; CURRENT APPLICATION NUMBER: US/10/127,851A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-17

; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-127-851A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGRATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60
Db 1 MGRATRVSIIMLLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGLRMCTPLGREGEEC 60

QY 61 HPGSHKVPFFRKRRKHHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKRRKHHTCPCLNLLCSRFDPDGRYRCSDMLKNINF 105

RESULT 193

US-10-128-684A-470
; Sequence 470, Application US/10128684A
; Publication No. US20030082700A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C118
; CURRENT APPLICATION NUMBER: US/10/128,684A
; CURRENT FILING DATE: 2002-04-23
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19

Remaining Prior Application data removed - See File Wrapper or PALM.

US-10-128-686A-470
; ORGANISM: Homo Sapien
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
; US-10-128-684A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60
DB 1 MRGATRVSMILLVTVSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEBC 60

QY 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRPDPGRYRCSDMLKNINF 105
DB 61 HPGSHKVPFFRKRKHTCPCLPNLLCSRPDPGRYRCSDMLKNINF 105

RESULT 194

US-10-128-686A-470
; Sequence 470, Application US/10128686A
; Publication No. US20030082701A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C119

; CURRENT FILING DATE: 2002-04-23

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

; PRIOR FILING DATE: 1997-06-18

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 196

US-10-128-691A-470

; Sequence 470, Application US/10128691A

; Publication No. US20030082703A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C123

; CURRENT APPLICATION NUMBER: US/10/128,691A

; CURRENT FILING DATE: 2002-04-23

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-128-691A-470

Query Match 100.0%; Score 589; DB 14; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

RESULT 197

US-10-131-819A-470

; Sequence 470, Application US/10131819A

; Publication No. US20030082704A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C134

; CURRENT APPLICATION NUMBER: US/10/131,819A

; CURRENT FILING DATE: 2002-04-24

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 470

; LENGTH: 105

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-131-819A-470

Query Match 100.0%; Score 589; DB 14; Length 105;

Best Local Similarity 100.0%; Pred. No. 2.6e-55;

Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

Db 1 MRGATRVSIMLLVTVSDCAVITGACERDVCGAGTCCCAISLWLRGLRMCTPLRGEGEC 60

QY 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

Db 61 HPGSHKVPFFRRKRKHTCPCLPNLLCSRPDPGRYRCSMDLKNINF 105

```
RESULT 198
US-10-131-829A-470
; Sequence 470, Application US/10131829A
; Publication No. US20030082705A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC138
; CURRENT APPLICATION NUMBER: US/10/131,829A
; CURRENT FILING DATE: 2002-04-27
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-131-829A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKRRKHTCPCLPRLNLLCSRFPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKRRKHTCPCLPRLNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 199
US-10-131-836A-470
; Sequence 470, Application US/10131836A
; Publication No. US20030082706A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC135
; CURRENT APPLICATION NUMBER: US/10/131,836A
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-131-836A-470

Query Match 100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. No. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
Db 1 MRGATRVSIMLLVTSDCAVITGACERDVQCGAGTCCCAISLWRLGRLMCTPLGREGEC 60
QY 61 HPGSHKVPFFRKRRKHTCPCLPRLNLLCSRFPDGRYRCSDMLKNINF 105
Db 61 HPGSHKVPFFRKRRKHTCPCLPRLNLLCSRFPDGRYRCSDMLKNINF 105

RESULT 199
US-10-131-836A-470
; Sequence 470, Application US/10131836A
; Publication No. US20030082706A1
```



```

; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C318
; CURRENT APPLICATION NUMBER: US/10/146,729
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 470
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-146-729-470

Query Match      100.0%; Score 589; DB 14; Length 105;
Best Local Similarity 100.0%; Pred. NO. 2.6e-55;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MRGATRVSIMLLLVTSDCAVITGACERDVCCGAGTCCALSLWRLGRLMCTPLRGEGEC 60
Db      1 MRGATRVSIMLLLVTSDCAVITGACERDVCCGAGTCCALSLWRLGRLMCTPLRGEGEC 60

QY      61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFPDGRYCSMDLKNINF 105
Db      61 HPGSHKVPFFRKHKHTCPCLPNLLCSRFPDGRYCSMDLKNINF 105

```

Search completed: August 30, 2004, 07:06:38
Job time : 60 secs

